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Background: Bony metastatic castration-refractory prostate cancer is associated with a poor prognosis
and high morbidity. TRAPEZE was a two-by-two factorial randomised controlled trial of zoledronic acid (ZA)
and strontium-89 (Sr-89), each combined with docetaxel. All have palliative benefits, are used to control
bone symptoms and are used with docetaxel to prolong survival. ZA, approved on the basis of reducing
skeletal-related events (SREs), is commonly combined with docetaxel in practice, although evidence of
efficacy and cost-effectiveness is lacking. Sr-89, approved for controlling metastatic pain and reducing
need for subsequent bone treatments, is generally palliatively used in patients unfit for chemotherapy.
Phase II analysis confirmed the safety and feasibility of combining these agents. TRAPEZE aimed to
determine the clinical effectiveness and cost-effectiveness of each agent.
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Methods: Patients were randomised to receive six cycles of docetaxel plus prednisolone: alone, with ZA,
with a single Sr-89 dose after cycle 6, or with both. Primary outcomes were clinical progression-free
survival (CPFS: time to pain progression, SRE or death) and cost-effectiveness. Secondary outcomes were
SRE-free interval (SREFI), total SREs, overall survival (OS) and quality of life (QoL). Log-rank test and Cox
regression modelling were used to determine clinical effectiveness. Cost-effectiveness was assessed from
the NHS perspective and expressed as cost per additional quality-adjusted life-year (QALY). An additional
analysis was carried out for ZA to reflect the availability of generic ZA.
Results: Patients: 757 randomised (median age 68.7 years; Eastern Cooperative Oncology Group scale
score 0, 40%; 1, 52%; 2, 8%; prior radiotherapy, 45%); median prostate-specific antigen 143.78 ng/ml
(interquartile range 50.8–353.9 ng/ml). Stratified log-rank analysis of CPFS was statistically non-significant
for either agent (Sr-89, p= 0.11; ZA, p= 0.45). Cox regression analysis adjusted for stratification variables
showed CPFS benefit for Sr-89 [hazard ratio (HR) 0.845, 95% confidence interval (CI) 0.72 to 0.99;
p= 0.036] and confirmed no effect of ZA (p= 0.46). ZA showed a significant SREFI effect (HR 0.76;
95% CI 0.63 to 0.93; p= 0.008). Neither agent affected OS (Sr-89, p= 0.74; ZA, p= 0.91), but both
increased total cost (vs. no ZA and no Sr-89, respectively); decreased post-trial therapies partly offset costs
[net difference: Sr-89 £1341; proprietary ZA (Zometa®, East Hanover, NJ, USA) £1319; generic ZA £251].
QoL was maintained in all trial arms; Sr-89 (0.08 additional QALYs) and ZA (0.03 additional QALYs)
showed slight improvements. The resulting incremental cost-effectiveness ratio (ICER) for Sr-89 was
£16,590, with £42,047 per QALY for Zometa and £8005 per QALY for generic ZA.
Conclusion: Strontium-89 improved CPFS, but not OS. ZA did not improve CPFS or OS but significantly
improved SREFI, mostly post progression, suggesting a role as post-chemotherapy maintenance therapy.
QoL was well maintained in all treatment arms, with differing patterns of care resulting from the effects of
Sr-89 on time to progression and ZA on SREFI and total SREs. The addition of Sr-89 resulted in additional
cost and a small positive increase in QALYs, with an ICER below the £20,000 ceiling per QALY. The
additional costs and small positive QALY changes in favour of ZA resulted in ICERs of £42,047 (Zometa)
and £8005 for the generic alternative; thus, generic ZA represents a cost-effective option. Additional
analyses on the basis of data from the Hospital Episode Statistics data set would allow corroborating the
findings of this study. Further research into the use of ZA (and other bone-targeting therapies) with newer
prostate cancer therapies would be desirable.
Study registration: Current Controlled Trials ISRCTN12808747.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 20, No. 53. See the NIHR Journals Library website
for further project information.
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Plain English summary
TRAPEZE evaluated the use of two bone-targeting therapies, strontium-89 (Sr-89) and zoledronic acid(ZA), in men receiving docetaxel chemotherapy for relapsing prostate cancer involving the skeleton.
Bony disease can cause pain, fractures and other serious complications. Docetaxel has been shown to
increase survival and improve quality of life (QoL) in this setting. Intravenous ZA has been shown to reduce
skeletal complications in prostate cancer, but is not recommended for general use because of doubts over
its cost-effectiveness. Sr-89 is a radioactive drug taken up by bone cancer deposits and is recommended by
the National Institute for Health and Care Excellence when chemotherapy is unsuitable.
TRAPEZE showed that adding Sr-89 to docetaxel delayed deterioration by around a month, but did not
result in any improvement in overall survival. Adding ZA did not delay deterioration but did reduce
subsequent serious bone complications by around one-third, with a 50% reduction in the most serious
events such as fracture and spinal cord compression. QoL was well maintained. Both drugs increased
treatment costs but decreased post-trial therapy costs because of delayed deterioration and, for ZA,
decreased surgery and radiotherapy for bone complications.
Incremental costs per quality-adjusted life-year (QALY) for branded ZA and Sr-89 were calculated at
£42,047 and £16,590, respectively. Sr-89 net acquisition was £1341 with modest gains in QoL and cost
per QALY gained, a measure of the effectiveness of drug treatments. For ZA, net acquisition was £1319,
but this cost was reduced to £251 by using the generic drug. The cost per QALY for the generic drug fell
to £8005, making ZA both cost-effective and clinically effective as a therapy.
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Scientific summary
Prostate cancer is a major health problem worldwide and accounts for nearly one-fifth of all newlydiagnosed male cancers. In the UK, approximately 35,000 men are diagnosed with prostate cancer
each year, and in 2008 almost 10,000 men died from the disease. The disease is mostly one of older age,
but significant numbers of men of working age will develop the disease.
Although prostate cancer most often presents as local disease, a significant proportion of patients progress
despite initial treatment with ablative surgery or radiotherapy, often in combination with hormonal
therapy. A minority of patients present with de novo metastatic disease.
Hormone therapy has been the mainstay of treatment for relapsed prostate cancer since the seminal studies
of Huggins and Hodges, published in 1941, demonstrating substantial and prolonged remissions from
prostate cancer with the use of either surgical castration or oestrogen therapy (Huggins C, Hodges CV.
Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum
phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7). Responses to hormone
therapy typically last 18–24 months, depending on disease stage. This period after failure of initial androgen
deprivation therapy was previously known as hormone-refractory prostate cancer. However, with the
recognition that relapsing tumours remain dependent on androgen receptor-mediated pathways
and the recent licensing in relapsing disease of abiraterone, a steroid synthesis inhibitor, and enzalutamide,
an androgen receptor-targeting agent, the term castration-refractory prostate cancer (CRPC) is increasingly
used and will be the preferred term in this report.
Chemotherapy with docetaxel is also a mainstay of therapy for metastatic castration-refractory prostate
cancer (mCRPC) following two landmark trials published in the New England Journal of Medicine in 2004
(Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisolone or
mitoxantrone plus prednisolone for advanced prostate cancer. N Engl J Med 2004;351:1502–12; and
Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine
compared with mitoxantrone and prednisolone for advanced refractory prostate cancer. N Engl J Med
2004;351:1513–20). Both trials showed improved palliative outcomes compared with mitoxantrone and,
very importantly, an overall survival advantage for 3-weekly docetaxel and the docetaxel–estramustine
combination with hazard ratios (HRs) of 0.76 and 0.8, respectively. On the basis of these trials, a 3-weekly
schedule of docetaxel plus prednisolone for up to 10 cycles has emerged as the standard of care for
mCRPC/CRPC and was approved by the National Institute for Health and Care Excellence (NICE) for this
purpose in 2006. A number of post-chemotherapy treatments have been licensed on the basis of
improvements in overall survival since 2010, including cabazitaxel, abiraterone and enzalutamide.
In patients with mCRPC, one of the most common sites of spread is bone, and bone metastases are a
major cause of morbidity in men with CRPC. Bone morbidity is often quantified in clinical trials via
a composite end point termed the skeletal-related events (SREs):
l pathological fracture
l spinal cord compression
l radiotherapy to bone
l hypercalcaemia
l change in anticancer treatment to treat bone pain.
Bisphosphonates inhibit bone catabolism by reducing the numbers of functioning osteoclasts and have been
used to manage bone metastases. Zoledronic acid (ZA), but not some older bisphosphonates, also arrests cell
proliferation, induces apoptosis and inhibits the growth factor stimulation of cultured prostate cancer cells.
In trials in relapsing mCRPC, ZA reduced the time to SREs, as well as the frequency of subsequent SREs. The ZA
licensing trials have proved very controversial, as the fracture end point was assessed by regular skeletal survey
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with blinded radiological assessment. Hence, there is significant doubt as to whether many of the small
fractures detected were precursors of a subsequent real ‘clinical’ SRE or radiological features of no significance.
ZA is not currently recommended for use in the UK by NICE because of doubts as to its cost-effectiveness.
Radioisotopes have been used to palliate bone pain for over 20 years. A variety of radioisotopes are available;
the most commonly used during the trial recruitment era were strontium-89 (Sr-89) and samarium-153. Both
accumulate selectively in bone metastases compared with non-involved bone. There is some evidence that
Sr-89 may reduce overall health-care costs compared with standard methods of delivering radiotherapy.
There are a number of previous studies of combined use of chemotherapy with radioisotopes. Of particular
note, Tu et al. combined combination chemotherapy with Sr-89 in a small randomised trial with promising
results, suggesting a survival advantage in chemotherapy responders allocated to Sr-89 (Tu SM, Millikan RE,
Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therpay for advanced androgen-
independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357:336–41).
This study sought to assess whether or not the addition of Sr-89 or ZA offers a significant benefit in
combination with docetaxel and prednisolone in CRPC metastatic to bone. The primary research questions
of the study are as follows:
l Does upfront use of bone-targeting agents with chemotherapy improve clinical outcomes?
l Is it more cost-effective to prevent bone complications or to treat them as they arise?
Design
This is a randomised controlled Phase III trial with a two-by-two factorial design which proceeded
seamlessly from a randomised controlled four-arm Phase II trial. The Phase II trial objectives were to
compare the four trial arms with respect to feasibility, tolerability and safety. The Phase III trial objectives
were to assess treatments with respect to efficacy within a two-by-two factorial design framework; that is,
the trial compared ZA with no ZA (stratified for Sr-89 use) and Sr-89 with no Sr-89 (stratified for ZA use).
The primary outcome measures for the Phase III trial were both clinical progression-free survival (CPFS)
(defined in relation to bone) and cost-effectiveness.
The Phase II end points of feasibility, tolerability and safety are subsumed within Phase III of the trial as
secondary outcomes. The funding for Phase II was not provided by the Health Technology Assessment (HTA)
programme of the National Institute for Health Research, and the preliminary Phase II analysis formed the basis
of the HTA programme application for funding. We do not propose to present detailed analysis of the Phase II
subset of patients in this report, as feasibility is confirmed by the successful completion of the Phase III trial.
Setting
UK oncology departments.
Participants
Men with CRPC metastatic to bone who are eligible for treatment with first-line chemotherapy.
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Interventions
Arm A: docetaxel 75-mg/m2 intravenously 3-weekly for up to 10 cycles.
Arm B: docetaxel as above plus ZA 4-mg intravenously 3-weekly during chemotherapy, then 4-weekly until
disease progression.
Arm C: docetaxel as above for six cycles, Sr-89 150MBq, then further docetaxel up to total of 10 cycles.
Arm D: docetaxel plus both Sr-89 and ZA as above.
Main outcome measures
Phase II
Primary: feasibility, tolerability and safety in terms of cycles of docetaxel and ZA and Sr-89, cycle delays,
dose reductions and toxicity.
Secondary: CPFS, SRE-free survival, pain progression-free interval, overall survival (OS), costs, quality of
life (QoL).
Phase III
Primary: CPFS, costs and cost-effectiveness.
Secondary: SRE-free survival, pain progression-free interval, OS.
All phases: additional substudies not part of this report
Changes in bone mineral density, biological profiling for prognostic and predictive indicators, prostate-
specific antigen-related outcomes, patient-reported pain-related outcomes.
Data sources (if applicable)
Data were collected by research staff in the treating hospitals on standard case report forms.
Statistical methods
The trial examined the clinical efficacy of adding bone-targeting treatment to standard chemotherapy.
Assuming that clinically worthwhile differences were seen, the costs associated with the extra therapy
were analysed and used to estimate the clinical cost-effectiveness of the trial interventions. If no significant
differences were seen, or if the trial interventions worsened outcomes, then the health economic analysis
was clearly considered redundant.
The clinical analysis was conducted under a two-by-two factorial design; as such, we can consider the results
of Sr-89 and ZA comparisons separately. In addition, in the interests of clarity, we shall also present the
results of the health economic evaluation separately.
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Clinical analysis
Strontium-89 comparison
In the control arm, median time to CPFS was 8.8 months from randomisation. This increased to 9.8 months
with the addition of Sr-89 after cycle 6 [HR for benefit of 0.85 on multivariable analysis, 95% confidence
interval (CI) 0.77 to 0.99; p= 0.036]. As some patients did not complete six cycles of chemotherapy, they
did not get to the point of receiving Sr-89; we therefore did a second analysis restricted to those patients
completing six cycles of chemotherapy. Resetting the time to progression from the sixth chemotherapy
cycle makes the time to progression 4.3 months and 5.3 months, respectively, to give a HR for benefit of
0.8 on multivariable analysis (95% CI 0.66 to 0.97; p= 0.024). There was no improvement in overall survival
(HR 0.97, 95% CI 0.82 to 1.15).
Zoledronic acid comparison
In the ZA arm, median control time to CPFS was, again, 8.8 months from randomisation. This also
increased to 9.7 months, but the difference was not statistically significant (HR 0.94, 95% CI 0.81 to 1.10;
p= 0.457). There was also no improvement in overall survival (HR 1.01, 95% CI 0.85 to 1.20). ZA did,
however, show a highly significant effect on skeletal-related event-free interval (HR 0.76, 95% CI 0.63 to
0.93; p= 0.008). There was no improvement in overall survival (HR 1.01, 95% CI 0.85 to 1.20).
Economic evaluation
Strontium-89 comparison
The most prominent difference in mean patient costs between the Sr-89 and no Sr-89 groups is a result of
the cost of the Sr-89 radioisotope itself. Apart from higher cost of Sr-89, the Sr-89 group was associated
with a greater cost for docetaxel and ZA given as protocol treatments, higher cost of cabazitaxel and
docetaxel provided as concomitant medications and increased cost because of surgery. On the other hand,
this group was associated with a lower use of radiotherapies, abiraterone, ZA and Sr-89 as concomitant
medications, as well as fewer inpatient days, outpatient appointments and GP visits. This resulted in a
mean cost difference of £1341 (95% bias-corrected and accelerated bootstrap method 95% CI –£66 to
£2748). In terms of quality-adjusted life-years (QALYs), patients receiving Sr-89 presented a slightly greater
number (0.08) of QALYs than those not receiving Sr-89. The point estimate incremental cost-effectiveness
ratio (ICER) for Sr-89 compared with that for no Sr-89 was calculated at £16,590 per additional QALY.
For prices of an administration of Sr-89 up to £2120, the ICER for Sr-89 remains below the £20,000 per
QALY mark.
Zoledronic acid comparison
The difference in mean patient costs between the ZA and no ZA groups was, to a great extent, because of
the use of ZA (mean difference £2197). Excluding the use of ZA, patients in the ZA group presented lower
resource use and costs than those in the no ZA group. In particular, there were significant differences in
the use of radiotherapy and surgery for skeletal-related problems. If ZA is considered as a branded product
with an acquisition cost of £174 for a 4-mg dose, the difference in total cost between ZA and no ZA is
£1319. On the other hand, taking into account the availability of generic ZA at a significantly lower cost
reduced the difference in total cost to £251. In terms of QALYs, ZA appeared to be slightly more effective
than no ZA, resulting in a gain of 0.03 QALYs. The additional costs and the small but positive change in
QALYs in favour of ZA resulted in ICERs of £8005 for the generic-based price and £42,047 for the
proprietary product. Whether or not the addition of ZA to chemotherapy represents a cost-effective use of
resources depends largely on the acquisition cost of a 4-mg dose of ZA. If this acquisition cost is up to
£98, which is the most likely scenario because of the availability of generic ZA, the ICER for ZA is below
£20,000 per QALY and, thus, this option is cost-effective at this ceiling ratio.
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Conclusions
In terms of impact on the primary outcome measure of bony progression-free survival, the Sr-89 arm was
positive but with a relatively modest absolute benefit and no improvement in OS. In contrast, there was no
evidence that the ZA arm was of benefit for the primary outcome measure and OS, but there was evidence
of a benefit in terms of impact on SRE-free interval and total SRE numbers. On the basis of the positive
effects seen, undertaking the health economic evaluation for both agents was considered worthwhile.
The impact of the trial therapies on the primary outcome measure of cost-effectiveness is interesting.
Although associated with relatively modest benefits, Sr-89 met the cost-to-QALY ratio of less than £20,000
that is considered to represent effective use of NHS resources. In contrast, ZA had more tangible clinical
benefits in the form of a substantial reduction in SREs and increased time to first SRE. These did not
translate into sizeable QoL benefits, as QoL was maintained by increased use of other therapies,
particularly surgery and radiotherapy. Hence, patients traded attendance for a predictable preventative
therapy for attendances for needs-driven palliative therapies. The ICER for proprietary ZA is high, at
£42,047, largely because of the lack of impact on QoL. As noted above, taking into account the recent
availability of generic ZA at low prices, ZA resulted in an additional cost of £251 and an ICER of £8005.
Given the pressure on NHS emergency resources, trusts may consider this cost to be good value for
money, as it converts unpredictable events such as fracture or spinal cord compression into predictable
outpatient workload. Additional analyses on the basis of data from the Hospital Episode Statistics data set
would allow corroborating the findings of this study. Further research into the use of ZA (and other
bone-targeting therapies) with newer prostate cancer therapies would be desirable.
Study registration
This trial is registered as ISRCTN12808747.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Prostate cancer
Prostate cancer is a major worldwide health problem which accounts for nearly one-fifth of all newly
diagnosed male cancers. In the UK, approximately 35,000 men are diagnosed with prostate cancer each
year, and in 2008 almost 10,000 men died from the disease.1 The disease is mostly one of older age, but
significant numbers of men of working age will develop the disease. Figure 1 summarises the age
distribution of incident cases and deaths.
Although adenocarcinoma of the prostate most often presents as local (stage T1 or T2) disease, in which
the malignancy is confined to the prostate, a significant proportion of patients progress despite initial
treatment with ablative surgery or radiotherapy, often in combination with hormonal therapy. A minority
of patients present with de novo metastatic disease. Figure 2 summarises the treatment options across the
disease spectrum.
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FIGURE 1 Prostate cancer incidence and mortality in the UK.2–4
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FIGURE 2 Prostate cancer treatment paradigm. Cancer has spread to the pelvic lymph nodes (N+) or to lymph nodes,
organs, or bones distant from the prostate (M+). CRPC, castration-refractory prostate cancer; Ra223, Radium-223.
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Hormone therapy
A hormone (from the Greek ὁρμή, meaning ‘impetus’) is a chemical released by a cell in one part of the
body to affect cells in other parts of the organism. Cells respond to a hormone when they express a
specific receptor for that hormone. The hormone binds to the receptor protein, resulting in the activation
of a signal transduction mechanism that ultimately leads to cell type-specific responses. Hormone therapies
can thus work on a number of points in this pathway and there are examples of all of these in prostate
cancer, which are summarised in Table 1.
Hormone therapy has been a mainstay of prostate cancer since the seminal studies of Huggins and
Hodges,5 published in 1941, demonstrating substantial and prolonged remissions from prostate cancer
with the use of either surgical castration or oestrogen therapy. Diethylstilboestrol is the first example of a
successful drug treatment for advanced cancer, and, while now supplanted in this role, it remains in use
70 years later. As is now well known, while responses to hormone therapy may be dramatic, with
durations running into many years, they are rarely curative and typically last 18–24 months depending on
disease stage. This period after failure of initial androgen deprivation therapy has been known by many
terms over the years, including androgen-independent prostate cancer and castration-refractory prostate
cancer (CRPC). However, with the recognition that relapsing tumours remain dependent on androgen
receptor-mediated pathways and the licensing in relapsing disease of abiraterone,6–8 a steroid synthesis
inhibitor, and enzalutamide,9 an androgen receptor-targeting agent, the term castration-refractory prostate
cancer is increasingly used. This term is, however, unpopular with patient groups and, while accurate, may
yet also be supplanted if anyone can think of a term with less pejorative overtones.
Broadly speaking, there are two routes into long-term hormone therapy: via localised disease, radical
therapy and relapse, and de novo advanced disease (Figure 3).
TABLE 1 Hormone therapy targets
Target Example in prostate cancer therapy
Block synthesis of regulator of hormone Gonadotropin-releasing hormone analogues and antagonists,
e.g. goserelin, leuprorelin, triptorelin
Block binding of secreted hormone to receptor Bicalutamide, enzalutamide, cyproterone acetate
Block post-receptor effects Enzalutamide
Block synthesis of hormone Cyp17 inhibitors, e.g. abiraterone
Add alternative hormones to alter environment Diethylstilboestrol, dexamethasone
PSA
Initial diagnosis
and ADT
Death
?
Second-line
hormone therapy
Chemotherapy 
CRPC (PSA relapse under ADT) 
Clinical
progression
≈ 2 years ≈ 1.5 years 
FIGURE 3 Pathways to advanced disease. Natural history for metastatic patients. ADT, androgen deprivation
therapy; PSA, prostate-specific antigen.
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Figure 3 shows disease burden expressed via the prostate-specific antigen (PSA) level on the vertical axis.
For most purposes, however, PSA does equate with disease burden. In particular, in late-stage disease
managed with non-hormonal therapies the relationship is not that close and PSA is not recognised as
a surrogate end point for clinical trials. In early hormone-sensitive disease, the concordance between PSA
changes and clinical ones is close. One consequence of the use of the PSA test is that managment tends
to be PSA-driven rather than clinically-driven. In the case of patients relapsing after failed local therapy,
clinicians are faced with a rising PSA but often no radiological evidence of disease for many years – termed
a biochemical relapse. Patients in this situation will often be started on hormone therapy many years
before any clinical consequences of relapse. Randomised trials in this setting have shown that intermittent
therapy is as good as continuous therapy and probably should be regarded as the standard of care.
Management of metastatic disease
Initial management of men with locally advanced or metastatic prostate cancer is some form of androgen
deprivation therapy. This will generally control disease for 1–3 years, following which progressive clinical
failure will ensue – CRPC. In patients with metastatic CRPC (mCRPC), one of the most common sites
of spread is bone. The development of bone metastasis, and the associated pain, results in a high level of
mobility problems, leading to a loss of functional independence in men, and is a major cause of mortality
[bone marrow failure, pathological fractures, spinal cord compression (SCC) and other bone-related
complications]. Bone morbidity is often quantified in clinical trials via a composite end point termed the
skeletal-related events (SREs). The elements that make up this end point are summarised as:
l pathological fracture
l SCC
l radiotherapy to bone
l hypercalcaemia
l change in anticancer treatment to treat bone pain.
The reduction in the frequency or severity of SREs that any particular patient experiences during the
individual disease pathway may provide additional health-related quality-of-life (HRQoL) benefits. The true
benefit in terms of HRQoL is not yet completely known, although recent data from clinical trials have
begun to show the HRQoL benefits of bisphosphonates.10,11 In addition to the potential quality-of-life (QoL)
benefits, patients may also gain actual survival benefit from either mono or combination therapy.
Although bisphosphonates therapy and/or chemotherapy may be considered as central to the treatment
of patients with bone metastases, other therapies such as radioisotopes are available and are widely used
for patients with mCRPC.
Chemotherapy
For many years chemotherapy was considered too toxic to be of value in men with advanced prostate
cancer. There were a number of reasons for this, including later diagnosis in the pre-PSA era, difficulty in
assessing responses and problems in managing toxicity, such as nausea and vomiting. The advent of
PSA-driven diagnosis and management, while remaining controversial in terms of use as a screening test,
has undoubtedly resulted in a strong trend to earlier diagnosis now dating back several decades. This in turn
has meant that men are diagnosed younger with advanced disease. Secondly, the use of PSA monitoring
post-primary treatment has meant that men relapsing after failed radical therapy are picked up early and so,
when mCRPC does develop, treatment can be instigated when men remain fit enough to cope with it.
Definitive proof of benefit from palliative chemotherapy came from a landmark National Cancer Institute
of Canada trial led by Ian Tannock from Toronto. The trial compared prednisone alone with prednisolone
plus mitoxantrone given 3-weekly for up to 10 cycles. This relatively small study of 161 patients published in
1996 set out to compare palliative end points rather than survival-based ones.12
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A palliative response was observed in 23 out of 80 patients who received mitoxantrone plus prednisone,
compared with 10 out of 81 patients who received prednisone alone. In an additional seven patients in
each group, analgesic medication was reduced without an increase in pain. The duration of palliation was
longer in patients who received chemotherapy (with a median of 43 weeks to symptom worsening) than in
those treated with prednisone alone (median of 18 weeks to symptom worsening). There was significant
crossover from the prednisone arm to the chemotherapy arm and no difference in overall survival. Thus,
this study clearly established the principle that chemotherapy could provide palliative benefit but did not
show a survival benefit. Subsequent mitoxantrone trials produced similar results, although the crossover
between the chemotherapy and no-chemotherapy arms means that, essentially, it is not known whether or
not chemotherapy with this agent produces a survival benefit.
In the late 1990s, a variety of agents started to be evaluated in what was then called hormone-refractory
prostate cancer (HRPC). Docetaxel emerged as the lead candidate for evaluation in large phase trials,
and two landmark studies were published in the New England Journal of Medicine in 2004.13,14 One trial,
the TAX327 study,13 compared weekly or 3-weekly docetaxel with the Tannock mitoxantrone regimen. The
second trial (SWOG 991614) compared a combination of docetaxel and estramustine with the same control
arm. Both trials showed improved palliative outcomes compared with mitoxantrone and, very importantly,
an overall survival (OS) advantage for 3-weekly docetaxel and the docetaxel–estramustine combination
with hazard ratios (HRs) of 0.76 and 0.8, respectively, despite significant crossover to docetaxel in the
mitoxantrone arms of both studies. All patients in both trials received prednisone as per the original
Tannock paper. These trials confirmed unequivocally that chemotherapy could both prolong survival and
give worthwhile palliation without undue toxicity. They also established that docetaxel is a superior agent
to mitoxantrone. On the basis of these trials, a 3-weekly schedule of docetaxel plus prednisolone for up to
10 cycles has emerged as the standard of care for mCRPC and was approved by the National Institute for
Health and Care Excellence (NICE) for this purpose in 2006 (Figure 4).
A number of agents have been studied in the second-line chemotherapy setting. Of these, to date only
cabazitaxel has shown a survival advantage and obtained a licence. The key trial, TROPIC, compared
cabazitaxel with mitoxantrone given on the standard Tannock trial schedule and showed an improvement
in median survival from 12.7 to 15.1 months.16 Cabazitaxel was licensed in 2010 ahead of abiraterone,
which obtained a licence in 2011 in the same post-docetaxel setting. As both drugs improve survival,
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although they have completely different modes of action, there is clearly an unresolved issue over choice
and sequencing (or indeed combination) of agents. The position has now been further complicated by
the licensing of enzalutamide post chemotherapy based on the AFFIRM trial,9 plus the extension of the
abiraterone licence to chemo-naive patients.6 The licence for enzalutamide was also expanded to cover
pre-chemotherapy patients following the PREVAIL trial.17
Additionally, the recent publication of the results of the ALSYMPCA trial of radium-22318 demonstrated
both improved OS and reduced skeletal complications with six injections, one every 28 days, of
radioisotope compared with placebo.18 How chemotherapy should best be integrated with other
therapeutic options for patients with bone metastasis is at present not defined.
Bisphosphonates
Bisphosphonates inhibit bone catabolism by reducing the numbers of functioning osteoclasts and have
been used to manage bone metastases. Zoledronic acid (ZA), but not some older bisphosphonates, also
arrest cell proliferation, induce apoptosis, and inhibit the growth factor stimulation of cultured prostate
cancer cells.14 In trials in relapsing mCRPC, ZA reduced the time to SRE as well as the frequency of
subsequent SREs.19,20 The ZA licensing trials19,20 have proved very controversial, as the fracture end point
was assessed by regular skeletal survey with blinded radiological assessment. Hence, there is significant
doubt as to whether many of the small fractures detected were precursors of a subsequent real ‘clinical’
SRE or radiological features of no significance. ZA is not currently recommended for use in the UK by NICE
because of doubts as to its cost-effectiveness.
Radioisotopes have been used to palliate bone pain for over 20 years. A variety of radioisotopes are
available; the most commonly used during the trial recruitment era were strontium-89 (Sr-89)21,22 and
samarium-153.23 Both accumulate selectively in bone metastases compared with non-involved bone. There
is some evidence that Sr-89 may reduce overall health-care costs compared with standard methods of
delivering radiotherapy.24 There are a number of previous studies of combined use of chemotherapy with
radioisotopes. Of particular note, Tu et al.25 combined combination chemotherapy with Sr-89 in a small
randomised trial with promising results suggesting a survival advantage in chemotherapy responders
allocated to Sr-89.
Since the publication of the MRC PR05 study,26,27 more potent bisphosphonates have been evaluated in
mCRPC. The most widely studied has been zoledronate, which has a 40- to 850-fold higher potency than
clodronate in pre-clinical models of bone resorption.28 It has also been shown to be more effective
than pamidronate (90mg) in controlling malignant hypercalcaemia29,30 In addition, zoledronate has
demonstrated direct anticancer activity, including inhibition of proliferation of breast cancer and prostate
cancer cells in vitro.31,32
In prostate cancer trials in relapsing mCRPC, ZA reduced the time to SREs as well as the frequency of
subsequent SREs.19,20 However, it is clear from looking at the components that make up the SREs that
these vary hugely in clinical significance and, in addition, are to a degree subjective. In particular, the ZA
licensing trials19,20 have proved very controversial as the fracture end point was assessed by regular skeletal
survey with blinded radiological assessment. As such there is significant doubt about whether many of the
small fractures detected were precursors of a subsequent real ‘clinical’ SRE or radiological features of no
significance. The subsequent trials comparing ZA with denusomab33 used the same methodology and
so can be subject to the same criticism. As a result, neither agent is recommended for use in the UK by
NICE. The impact of ZA on SREs is illustrated in Figure 5; the bisphosphonate showing decreases in skeletal
complications in both lytic and blastic lesions in a comparison with pamidonate.20
DOI: 10.3310/hta20530 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 53
© Queen’s Printer and Controller of HMSO 2016. This work was produced by James et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
In vitro evidence suggests synergistic killing of breast and prostate cancer cells when combined with
chemotherapy.32 Furthermore, ZA was licensed in the ‘pre-docetaxel’ era; hence, whatever the merits of
SRE prevention, the role of zoledronate in the chemotherapy era was effectively undefined. It was
therefore logical to evaluate docetaxel with ZA in men with mCRPC affecting bone. In view of the
controversy over the SRE as an end point, we did not undertake routine skeletal evaluations as in the
zoledronate and denosumab licensing trials but collected data only on ‘clinical’ SREs; that is, those reported
by the patient or diagnosed on the basis of symptoms such as those from SCC. We combined this clinically
orientated approach to the SRE with a health economic assessment of the impact of the various trial
interventions, the intention being that, if the clinical utility of combination therapy were confirmed,
we should be able to produce robust estimates of the cost-effectiveness at the same time.
Radioisotopes
A variety of radioisotopes are available, the most commonly used during the trial recruitment era being
Sr-89 and samarium-153. Both accumulate selectively in bone metastases compared with uptake rates in
non-involved bone. Sr-89, a bone-seeking radionuclide, is a pure β-emitter with a half-life of 50 days, has a
high uptake in osteoblastic metastases, and remains in tumour sites for up to 100 days. Sr-89 provides
pain relief in up to 80% of patients, and complete freedom from pain in approximately 10%, for periods
that can exceed 3 months.21,34 In a randomised controlled Phase III trial, the combination of Sr-89 injection
and external beam radiotherapy improved pain relief, delayed disease progression and enhanced
some QoL measures compared with external beam radiotherapy alone.21 However, another Phase III
randomised controlled trial has suggested that, in some patients, systemic Sr-89 may be inferior to
local-field radiotherapy in terms of survival (7.2 months vs. 11.0 months; p= 0.0457).22 The selection
of patients has a significant impact on outcome, response and duration of response to radionuclide
therapy, as bone pain palliation is reduced in those who have widespread metastatic disease or a short life
expectancy.35–38 Consequently, the use of radionuclides appears to be optimal at an early stage in disease
management. However, their efficacy is reduced or lost with repeated use, and overtreatment can also
lead to irreversible pancytopenia. As noted above (see Bisphosphonates), there is some evidence that Sr-89
may reduce overall health-care costs compared with standard methods of delivering radiotherapy.39
There are a number of previous studies of combined use of chemotherapy with radioisotopes. Tu et al.
combined combination chemotherapy with Sr-89 in a small randomised trial with promising results suggesting
a survival advantage in chemotherapy responders allocated to Sr-89.25 More recently, Fizazi et al.,40 Tu et al.41
and Morris et al.42 have combined docetaxel with samarium-153 in Phase I/II trials, confirming safety for the
combination. No published randomised trials have addressed the safety or efficacy of docetaxel with either
Sr-89 or samarium-53.
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As new treatments have appeared for CRPC, these treatments have been less frequently used. However,
recent data with a new radioisotope radium-223 seem set to change this picture. Like Sr-89, radium-223 is
a calcium mimetic. Recently completed placebo-controlled Phase III trials in symptomatic CRPC patients
showed a prolongation of survival and also a delay and reduction in symptomatic (as opposed to
radiological) SREs.18 Levels of adverse reactions reported in the trial were low. The agent was licensed in
2013 and is an important new therapeutic option for men with CRPC, especially as the trial included men
both pre and post chemotherapy, as well as those deemed unfit to ever receive chemotherapy.
Osteoporosis
Patients eligible for the study are at risk of osteoporosis in view of their previous therapy (androgen
deprivation, possible steroid exposure, age) as well as from some on-study therapies (steroids, docetaxel).
Osteoporosis was therefore considered in the causality of any SRE. A bone density substudy formed part of
this trial.
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Chapter 2 Methods
Trial design
This was originally a four-arm randomised controlled Phase II trial, which proceeded seamlessly to a Phase III
trial. In order to increase efficiency and reduce the trial duration, the Phase III design was switched from a
four-arm comparison to a two-by-two factorial design. The end points changed as the trial progressed from
Phase II to Phase III, as summarised in Table 2.
The Phase II objectives were to compare the four trial arms with respect to feasibility, tolerability and
safety. The Phase III objectives were to assess treatments with respect to efficacy within a two-by-two
factorial design framework; that is, the trial compared ZA versus no ZA (stratified for Sr-89 use) and Sr-89
versus no Sr-89 (stratified for ZA use). The Phase III trial had dual primary end points of effect of each
treatment on time to bony disease progression and cost and cost-effectiveness.
During the chemotherapy treatment period, participants were assessed at 3-weekly intervals. Irrespective of
treatment arm, all patients were assessed at the end of the sixth cycle of chemotherapy to ensure their
fitness to receive Sr-89.
Phase II participants ceased primary trial treatment after cycle 6 of Sr-89 administration, where relevant.
Clinicians were encouraged to give further docetaxel off-trial up to a total of 10 cycles in keeping with
NICE guidance, where appropriate. In order to streamline data collection, cycles 7 to 10 of docetaxel were
designated as trial therapy for Phase III of the study.
TABLE 2 Summary of study end points
Phase Primary Secondary Tertiary
II l Feasibility, tolerability and
safety in terms of cycles of
docetaxel and ZA and Sr-89,
cycle delays, dose reductions
and toxicity
l CPFS
l SRE-free survival
l Pain progression-free interval
l OS
l Costs
l QoL
l Changes in bone mineral density
(substudy)
l Biological profiling for prognostic
and predictive indicators (substudy)
l PSA-related outcomes
l Patient-reported pain-related
outcomes
III l Clinical progression-free
survival
l Costs and cost-effectiveness
l SRE-free interval
l Pain progression-free survival
l OS
l QoL
l Toxicity
l Changes in bone mineral density
(substudy)
l Biological profiling for prognostic
and predictive indicators (substudy)
l PSA-related outcomes
l Patient-reported pain-related
outcomes
CPFS, clinical progression-free survival.
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Participants
Male patients over the age of 18 years were recruited into the trial. The trial recruited sufficient patients to
ensure that at least 618 participants reached the primary end points. The entry criteria primarily included
proven mCRPC, with one or more of progressive sclerotic bone metastases, progression of measurable
malignant lesions or elevated and rising PSA levels on blood analysis. Consenting participants had to have
had an Eastern Cooperative Oncology Group (ECOG) scale score of up to 2, be fit enough to receive trial
treatment and have adequate haematological, renal and hepatic function.
Exclusion criteria included prior chemotherapy or radionuclide therapy for CRPC, prior radiotherapy to
more than 25% of bone marrow or whole-pelvic irradiation, prior bisphosphonate therapy within
2 months of trial entry, other malignant disease within the previous 5 years (excluding adequately treated
basal cell carcinoma), known brain metastases, symptomatic peripheral neuropathy of National Institutes of
Health National Cancer Institute’s Common Terminology for the Criteria for Adverse Events grade 2 or
more, concurrent participation in any other clinical trial involving an investigational therapeutic compound
or treatment with other investigational compound within the 30 days prior to trial entry.
Owing to the nature of the treatments under investigation, this was not a blinded trial for patients
or caregivers.
Interventions
Arm A: control – docetaxel plus prednisolone
Docetaxel 75mg/m2 (up to a maximum dose of 165mg) was administered intravenously at 3-weekly
intervals (21 days). Participants also received oral prednisolone 10mg daily throughout trial treatment or
until disease progression or associated treatment toxicity.
Trial chemotherapy ceased after cycle 6 for Phase II participants but continued for up to 10 cycles for Phase III
participants, ceasing for pain or tumour disease progression, or other cause decided by the treating clinician
or patient choice. As noted above (see Trial design) patients could receive further chemotherapy off-trial in
keeping with NICE guidance.
Arm B: docetaxel, prednisolone plus zoledronic acid
Docetaxel and prednisolone were administered as per the control arm. ZA was administered intravenously
after completion of docetaxel administration at a dose of 4mg, subject to pre-treatment creatinine
clearance being greater than 60ml/minute; creatinine clearance of < 60ml/minute would incrementally
reduce the dose given, as detailed in section 6.1.3 of the protocol (see Appendix 1). Following the
completion of chemotherapy, participants received continuing ZA at 4-weekly intervals, as clinically
indicated, until pain or tumour disease progression or withdrawal. It was recommended that patients
treated with ZA also receive vitamin D and calcium supplements throughout treatment.
Arm C: docetaxel, prednisolone plus strontium-89
Docetaxel and prednisolone were administered as per the control arm, for six cycles. Subject to satisfactory
haematological and clinical parameters on clinical assessment 21 days after the sixth docetaxel treatment,
participants received a single 150-MBq dose of Sr-89 on the 28th day after the sixth cycle.
Chemotherapy ceased after cycle 6 for Phase II participants, but for Phase III participants continued for up
to 10 cycles after a period of between 28 and 56 days of Sr-89 administration, allowing for bone marrow
function to be adequately recovered.
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Arm D: docetaxel, prednisolone, zoledronic acid plus strontium-89
Patients in this arm received docetaxel, prednisolone and ZA for six cycles, as per arm B participants, plus
clinical and haematological assessment and Sr-89 administration, as per arm C participants. Following a
recovery period of between 28 and 56 days, chemotherapy, prednisolone and ZA treatment resumed until
disease progression, associated treatment toxicity or patient withdrawal. As per the arm B treatment regime,
following the end of chemotherapy, patients received continuing ZA administrations at 4-weekly intervals,
as clinically indicated, until disease progression or until other discontinuation criteria were met. It was
again recommended that patients treated with ZA also receive vitamin D and calcium supplements
throughout treatment.
Further off-study treatment
All further off-study treatment, for example chemotherapy, bisphosphonate and radioisotope therapy, as
well as newer drugs, such as abiraterone, enzalutamide and radium-223, received after study treatment
were captured on the Concomitant Medication Running Form. The choice of further treatment was at the
discretion of the participant’s clinician.
Objectives
The primary objective of the Phase II component was to assess the feasibility, tolerability and safety of the
four treatment arms.
Phase III assessed treatments within a two-by-two factorial design framework; that is, ZA versus no ZA
(stratified for Sr-89 use) and Sr-89 versus no Sr-89 (stratified for ZA use). Each of these treatment
comparisons was made in terms of clinical efficacy, with primary outcome clinical progression-free survival
(CPFS) interval and health economic outcomes. In addition, the trial assessed the presence of any
association between biomarkers and clinical outcomes.
Data collection
Case report forms
Data collected on each subject were recorded by the investigator or his/her designee on case report forms
(CRFs). Originals of the CRF were returned to the trial management office, whereas photocopies were
retained by the site.
Quality-of-life data
All eligible participants were asked to consider taking part in the QoL part of the study. QoL was assessed
using patient-completed questionnaires, i.e. the European Quality of Life 5-Dimensions (EQ-5D) and
Functional Assessment of Cancer Therapy – Prostate (FACT-P), while pain and analgesic use diaries were
used to facilitate changes in participants’ pain perception and management. An example of both the
QoL booklet and pain diary are part of the protocol in Appendix 1. A QoL booklet and pain diary were
completed at baseline and subsequently prior to each treatment and follow-up visit. Completion of these
documents remained voluntary and continued throughout patient follow-up (pre and post clinical
progression), irrespective of any further therapy a patient may have received.
Monitoring
The study was conducted under the auspices of the Cancer Research Clinical Trials Unit (CRCTU) according
to current guidelines for good clinical practice. Participating centres were monitored by CRCTU staff to
confirm compliance with the protocol and the protection of patients’ rights as detailed in the Declaration
of Helsinki.
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Participating centres were monitored by checking incoming forms for compliance against the protocol,
consistent data, missing data and timing. CRCTU onsite monitoring was carried out as detailed by the
trial’s risk assessment, primarily of all sites that had enrolled four or more patients into the trial. Patients’
records to be audited at such visits were selected randomly from the different treatment arms.
Sample size
Sample size calculations were based on the primary outcome measure of CPFS. The calculations were the
same for both the comparison of ZA with no ZA and that of Sr-89 with no Sr-89. The trial aimed to detect
a HR of 0.76, which would be equivalent to 1-year CPFS rates of 30% versus 40%, assuming that CPFS
follows an exponential distribution. The number of events required to detect this difference in each group
for either treatment comparison, using a two-sided 5% significance level and 80% power, was 206. It was
estimated that approximately 294 participants would be required in each group, that is 588 patients in
total, to observe this number of events at 1 year’s follow-up. We aimed to recruit a minimum of
618 evaluable patients, which allowed for 5% dropout.
The analysis of the Phase II component of the trial was entirely descriptive and did not involve any
statistical hypothesis testing. The primary outcomes were feasibility, tolerability and safety, and these will
be measured as proportions or means, as appropriate. Recruitment of 50 patients into each arm ensured
that percentages could be estimated with a precision of at least 15% and provided sufficient data to be
able to assess the arms in terms of their suitability for progression into the Phase III component of the trial.
Randomisation
Stratified randomisation
Stratification was used to ensure the balance of participant characteristics as well as numbers within each
treatment group. Patients were randomised to treatment arms in a 1 : 1 : 1 : 1 allocation ratio using a
computerised minimisation algorithm. If the minimisation is balanced, then allocation is random with
equal chance of allocation to all arms. Randomisation was stratified by centre and ECOG performance
score (0, 1 or 2) to avoid imbalance.
Implementation
Prior to randomisation, patients gave their informed consent to take part in the trial and the clinician or
research nurse completed a pre-randomisation checklist to ascertain that the patient met all the
entry criteria.
The process of entering a patient into the trial was conducted by telephone with the CRCTU randomisation
office. Using either a computerised randomisation program or a paper equivalent should the computer
system be out of commission, the CRCTU randomisation officer re-ascertained the patient’s eligibility, after
which the computer program allocated the next available trial number and randomised treatment arm
for the participant. When the randomisation was conducted while the computer was out of commission,
systems were in place to allocate the next available trial number and random treatment.
The allocated trial number and treatment arm were communicated to the site by telephone and confirmed
by fax.
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Follow-up
Patients were assessed every 3 weeks during the study treatment period. After treatment completion or
withdrawal for any reason except disease progression (pain or tumour growth), participants were followed
up monthly for 3 months and subsequently every 3 months until either patient death or withdrawal of the
patient’s consent for further follow-up.
Patients progressed to 3-monthly follow-up following clinical progression; that is, increasing pain, tumour
growth or SREs.
Trial management
Trial Management Group
The Trial Management Group comprised the chief investigator, a few co-investigators and members of the
CRCTU, as detailed in the front sleeve of the protocol (see Appendix 1). The Trial Management Group was
responsible for the day-to-day running and management of the trial and met by teleconference or in
person, as required.
Data Monitoring Committee
An independent Data Monitoring Committee (DMC; see Appendix 2), comprising an independent
statistician, oncologist and urologist, met approximately annually to review the accumulating confidential
trial data. Their main objective was to advise the Trial Steering Committee (TSC) whether or not there was
any evidence or reason to amend or terminate the trial based on the recruitment rate or safety. Reports to
the DMC were produced by the CRCTU.
Trial Steering Committee
An independent TSC (see Appendix 2) provided overall supervision for the trial and advised the trial
management group. Members included an independent statistician, oncologist and two urologists. The
ultimate decision regarding continuation of the trial lay with the TSC, based on the advice received from
the DMC. The TSC met approximately annually, shortly after the DMC met.
Outcomes
Primary end points
Phase II: feasibility, tolerability and safety
The primary end points of the Phase II study were feasibility, tolerability and the safety of each treatment arm.
Analysis was purely descriptive, while the control arm data acted as a benchmark against which to assess
the experimental treatment arms. Percentages and means were calculated, and 95% confidence intervals
(CIs) constructed as appropriate.
Phase III: clinical progression-free survival
The primary Phase III analysis compared ZA versus no ZA (stratified for Sr-89 use) and Sr-89 versus no Sr-89
(stratified for ZA use) in terms of CPFS. CPFS was defined as the number of whole days from the date of
randomisation to the first occurrence of SRE, pain progression or death. Patients not experiencing clinical
progression were censored at the date last known to be progression free.
Economic analyses
Economic evaluations were carried out to assess the cost-effectiveness of the relevant comparisons – ZA
versus no ZA and Sr-89 versus no Sr-89 – for patients with mCRPC. The analyses were carried out from the
perspective of the NHS and Personal Social Services and involved calculating estimates of mean per-patient
costs and health outcomes for each of the compared treatment options. Costs were calculated on the
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basis of treatment acquisition and administration costs, cost of concomitant medications and use of NHS
primary and secondary care resources. Outcomes were expressed as quality-adjusted life-years (QALYs),
calculated on the basis of patients’ responses to the EQ-5D (three-level) instrument. Mean values were
reported together with their 95% CIs. To account for the skewed distributions of costs and QALYs,
CIs were obtained through bias-corrected and accelerated bootstrap methods. In line with current
recommendations, costs and QALYs accruing in the future were discounted at an annual rate of 3.5%.
Incremental analysis was undertaken to obtain a ratio of the difference in costs over the difference in
QALYs for each comparison. Results were presented in the form of incremental cost-effectiveness ratios
(ICERs), reflecting the extra cost for an additional QALY.43 To account for the inherent uncertainty as a
result of sampling variation, the joint distribution of differences in cost and QALYs was derived by carrying
out a large number of non-parametric bootstrap simulations.44,45 The simulated cost and effect pairs were
depicted on a cost-effectiveness plane46 and were plotted as cost-effectiveness acceptability curves
(CEACs).47,48 A series of sensitivity analyses was carried out to assess the impact of key assumptions on the
obtained results. Given the short expected survival time of mCRPC patients and the long-term follow-up of
patients in the trial, lifetime costs and effects were largely observed and so extrapolation beyond the trial
was not necessary.
Secondary end points
Skeletal-related event-free interval
A skeletal-related event-free interval (SREFI) was defined as the time in whole days from the date of
randomisation to the date of the first occurrence of a SRE. A SRE was defined as any one of the following:
l symptomatic pathological bone fracture
l spinal cord or nerve root compression likely to be related to cancer or treatment
l cancer related surgery to bone
l radiation therapy to bone (including use of radioisotopes)
l change of antineoplastic therapy to treat bone pain due to prostate cancer
l hypercalcaemia.
Patients who did not experience a SRE were censored at death or the date last known to be alive.
Pain progression-free interval
Pain progression-free interval (PPFI) was defined as the time in whole days from the date of randomisation
to the date of clinician-determined pain progression. Patients not experiencing pain progression were
censored at the date of death or the date last known to be alive.
Overall survival
Overall survival was defined as the number of whole days from the date of randomisation to the date of
death from any cause. Patients alive at the date of analysis were censored at the date last known to be alive.
Quality of life
Quality-of-life questionnaires included the EQ-5D, which consisted of the health-state scale, the descriptive
three-level system and the visual analogue scale (VAS); the FACT-P version 4; and a health-problems
questionnaire focusing predominantly on resource use. The QoL form was collected 3-weekly during
treatment and then monthly for 3 months and, finally, 3-monthly until death.
The EQ-5D is a generic preference-based measure of HRQoL. The instrument was designed to be
self-completed and so, where possible, data were provided by the patient. Responses to the descriptive
system of the EQ-5D were translated into a single summary utility index ranging from –0.59 to 1 by using
a UK-relevant value set. Patients’ rating of their QoL was also collected through a vertical 20-cm VAS
with the bottom end point representing the worst imaginable health state and the top end point showing
the best imaginable health state. The VAS resembles a thermometer and takes values between 0 (worst
imaginable state) and 100 (best imaginable state).
METHODS
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The FACT-P is a 40-item self-reported cancer therapy questionnaire with an additional 12-item prostate
cancer subscale. Six measures were generated by this questionnaire: social well-being, personal well-being,
emotional well-being, functional well-being, prostate cancer-specific score and an overall FACT-P score
ranging from zero to 156.
Toxicity
The analysis of toxicity was purely descriptive. Proportions and means were calculated and 95% CIs
constructed as appropriate.
Ancillary end points
Bone mineral density changes and biomarker substudies are detailed in the protocol (see Appendix 1);
tertiary end points will not be presented at this time in this report.
Statistical methods
The definitive study analysis was conducted on an intention-to-treat basis. All tests of statistical
significance were conducted at the 5% two-sided significance level. All analysis was carried out using
Stata version 12.1 (StataCorp LP, College Station, TX, USA).
Descriptive comparisons not involving hypothesis testing will be presented as medians, interquartile ranges
(IQRs) and ranges for numerical variables, and percentages will be given for categorical variables. Percentages
will not always total exactly 100% due to rounding errors associated with reporting results to one decimal
place. Percentage totals have been rounded to the nearest integer. Time-to-event analysis, multiple event
analysis and QoL analysis are detailed at the start of the appropriate section. No direct statistical analysis of
between randomisation arms has been conducted. The factorial design of the study assumes there is no
interaction between the two agents and any treatment effects are assumed to be additive; therefore, the trial
was not powered for this analysis.
Summary of changes to the trial protocol
Phase II treatment consisted of six cycles of docetaxel chemotherapy plus an additional four cycles off-study
at the discretion of the treating physician. NICE, however, recommended that up to 10 cycles of docetaxel
chemotherapy should be administered in one treatment block. This was not stated clearly in the Phase II
protocol and the previous trial design had the inadvertent effect of preventing some patients from
receiving cycles 7 to 10 at a later stage because of local policy. Adopting the NICE recommendation formally
into the clinical trial design ensured that all patients had access to the NICE-recommended schedule of
chemotherapy and that the control treatment arm was considered the true ‘standard of care’ (Tables 3 and 4).
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TABLE 4 A summary of Phase III approved protocol versions
TRAPEZE, Phase III: version 8
(24 September 2008)
l The majority of the changes related to the transition from a Phase II to a
Phase III clinical trial, covering trial infrastructure, data collection procedures
and statistical considerations. These changes had no direct impact on
patient participation or safety but did increase the maximum number of
chemotherapy cycles from 6 to 10, according to NICE guidelines for
docetaxel chemotherapy
Version 9 (12 April 2011) l This amendment concerns a statistical redesign of the Phase III trial from
a four-arm comparison to a two-by-two factorial design to assess
treatment efficacy
l Reduction of target recruitment from 1240 (as per version 8 amendment) to
618 evaluable patients. The trial will close to recruitment at the end of
February 2012
Version 10 (25 May 2011) l This amendment concerns a correction in section 12.2.3 on timing of
analysis. We intend to conduct initial analysis once all patients have at least
1 year’s follow-up, not 2 years as previously stated
Version 11 (17 February 2012) Substantial amendments:
l Changing the requirement for both ALT and AST to be tested – only one of
them needs to have been performed
l Change of definition for SRE-free interval and PPFI, and removal of the event
of death as a SRE and element of pain progression criteria
Non-substantial amendments:
l Clarification of prophylactic antiemetic for nausea/vomiting because of
chemotherapy and permission to use local protocols that coincide with
off-study practice
l Updating of deputy clinical co-ordinator’s details
l Additional safety information for ZA administration
Various typographical corrections and clarifications of existing text
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
TABLE 3 A summary of developmental and Phase II approved protocol versions
Protocol version no./date Brief description of previous amendments
Versions 1–3 (12 July 2004,
2 August 2004, 16 August 2004)
l Developmental protocols not submitted for ethical or regulatory approval
TRAPEZE, Phase II: version 4
(1 September 2004)
l First approved and implemented version
Version 5 (23 March 2005) l Change to the eligibility criteria to enable patients to enter the study without
the need for a confirmation prostate biopsy if they have confirmed bone
disease with a PSA value of ≥ 100 ng/ml
l Change to wording of baseline and post-chemotherapy assessment
requirements to allow centres to take part in the study without the need to
perform clinical procedures if local facilities are not available
Version 6 (7 June 2005) l Safety amendment to clarification of ZA dose procedures to comply with the
manufacturer’s summary of product characteristics
Version 7 (4 May 2007) l Changes to the inclusion criteria clarified patient eligibility regarding
abnormal ALT and AST levels
l The requirement for a confirmed serum testosterone blood test was removed
from the screening procedures
l A new entry criterion question was added to ensure that at time of study
entry all patients were fit enough to receive any of the trial treatments, in the
opinion of the investigator
l Clarification of administration sequence of trial treatments
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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Chapter 3 Results
Consolidated Standards of Reporting Trials diagram
A Consolidated Standards of Reporting Trials (CONSORT) diagram summarising trial participation figures
and analysis is included as Figure 6.
Recruitment
Figure 7 shows trial recruitment both by monthly randomisation periods and cumulatively over the course
of the trial. Table 78 (see Appendix 5) shows recruitment by centre.
Losses and exclusions
Ineligible
In total, 27 patients were found to be ineligible following randomisation. Five were randomised to
docetaxel alone, 10 to docetaxel+ ZA, seven to docetaxel+ Sr-89 and five to docetaxel, ZA and Sr-89.
All ineligible patients are included in intention-to-treat analysis.
There were three main categories of ineligibilities. These were (1) pre-randomisation blood pressure and
blood tests were missed or performed outside of the allowed time frame, (2) progression on trial entry
was not appropriately documented and (3) hormone therapies were not stopped at the appropriate time
point, for example if bicalutamide had been stopped within 4 weeks of starting trial treatment rather than
within 4 weeks of randomisation as stipulated in the eligibility criteria.
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Protocol deviations
In total, 71 protocol deviations were reported: 15 in the docetaxel arm, 17 in the docetaxel and ZA arm,
18 in the docetaxel and Sr-89 arm and 21in the docetaxel, ZA and Sr-89 arm.
Table 5 provides a complete summary of all protocol deviations reported during the course of the trial.
Patient withdrawal of consent
Full consent for any further participation in the trial, including follow-up, has been withdrawn by 21 patients.
In addition, 28 patients have withdrawn from one or more of the trial substudies. Table 6 contains a
breakdown of all non-treatment withdrawals by randomisation arm and Table 7 by comparison group;
a complete list of all patients who have withdrawn full consent can be found in Appendix 5.
Withdrawal of trial treatment
Docetaxel
In total, 408 (54%) patients received fewer than the protocol-defined number of treatment cycles, which
was originally six and then increased to 10. In total, 220 (29%) patients received only six cycles because
of the original protocol limitation. Table 8 shows the reasons for withdrawal from docetaxel by
randomisation arm and Table 9 shows the reasons by comparison group.
Strontium-89
Of the 378 patients randomised to receive Sr-89, 253 (67%) did so. The reasons for not receiving Sr-89
are reported in Table 10.
Lost to follow-up
Six patients in total have been reported as being lost to follow-up by site: three randomised to docetaxel
alone, one randomised to docetaxel and Sr-89 and two randomised to docetaxel, ZA and Sr-89. Two of
these reached the primary end point prior to being lost, one subsequently died and, although some
follow-up information remains missing, the death information was obtained.
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FIGURE 7 Recruitment from January 2005 to February 2012.
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TABLE 5 Reasons for deviations
Deviation reason n (N= 71)
Administrative error 2
Blood pressure consistently not done 2
Blood pressure not done at baseline 10
Bloods not done before chemotherapy 1
Calcium supplements not given with ZA 1
Calcium supplements stopped at incorrect time for Sr-89 1
Chemotherapy capped at wrong BSA 9
Clinician chose to give lower dose of docetaxel because of patient’s age and comorbidities 1
Cycle delayed over 14 days 6
Docetaxel dose capped at BSA of 2m2 by medical decision to prevent possible excess toxicity 1
Docetaxel dose escalated 1
Docetaxel dose reduction not per protocol 7
Dose not recalculated to BSA at cycle 5: 160mg given instead of 150mg 1
Incorrect dose of strontium 1
Patient did not receive scheduled ZA 1
Patient received intended dose of 67.2mg/m2 because of diarrhoea 1
Patient received different trial arm 5
Patient recommenced bicalutamide while on study 1
Patient sensitive to prednisolone, therefore commenced on 1.5mg of dexamethasone 1
Patient stopped taking LHRH agonist 1
Post-docetaxel assessment not done prior to Sr-89 6
Post-docetaxel assessment performed late 1
Pre-ZA creatinine not done 2
Premature discontinuation 2
Sr-89 given at wrong time point 5
Sr-89 given prior to post-docetaxel assessment 1
Total 71
BSA, body surface area; LHRH, luteinising hormone-releasing hormone.
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TABLE 7 Withdrawal: by comparison group
Withdrawal
No ZA (N= 381) ZA (N= 376) No Sr-89 (N= 379) Sr-89 (N= 378)
n % n % n % n %
Full withdrawal of consent 12 3.1 16 4.3 19 5 9 2.4
No withdrawal 355 93.2 342 91 346 91.3 351 92.9
Partial withdrawal: blocks 0 0.0 1 0.3 0 0.0 1 0.3
Partial withdrawal: proteomics 0 0.0 2 0.5 1 0.3 1 0.3
Partial withdrawal: Qol 14 3.7 10 2.7 12 3.2 12 3.2
Partial withdrawal: Qol+ blocks 0 0.0 1 0.3 1 0.3 0 0.0
Partial withdrawal: Qol+ proteomics 0 0.0 4 1.1 0 0.0 4 1.1
Total 381 100 376 100 379 100 378 100
TABLE 6 Withdrawal: by randomisation arm
Withdrawal
Docetaxel
(N= 191)
Docetaxel+ ZA
(N= 188)
Docetaxel+ Sr-89
(N= 190)
Docetaxel+ ZA+
Sr-89 (N= 188)
Overall
(N= 757)
n % n % n % n % n %
Full withdrawal of
consent
6 3.1 13 6.9 6 3.2 3 1.6 28 3.7
No withdrawal 178 93.2 168 89.4 177 93.2 174 92.6 697 92.1
Partial withdrawal:
blocks
0 0.0 0 0.0 0 0.0 1 0.5 1 0.1
Partial withdrawal:
proteomics
0 0.0 1 0.5 0 0.0 1 0.5 2 0.3
Partial withdrawal:
Qol
7 3.7 5 2.7 7 3.7 5 2.7 24 3.2
Partial withdrawal:
Qol+ blocks
0 0.0 1 0.5 0 0.0 0 0.0 1 0.1
Partial withdrawal:
Qol+ proteomics
0 0.0 0 0.0 0 0.0 4 2.1 4 0.5
Total 191 100 188 100 190 100 188 100 757 100
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TABLE 10 Reasons for Sr-89 omission
Withdrawal reason
Docetaxel+ Sr-89
(N= 67)
Docetaxel+ ZA+ Sr-89
(N= 58) Overall (N= 125)
n % n % n %
Administration error 0 0.0 1 1.7 1 0.8
Change in treatment 2 3.0 3 5.2 5 4.0
Clinician decision 0 0.0 2 3.4 2 1.6
Death 6 9.0 7 12.1 13 10.4
Disease progression 22 32.8 12 20.7 34 27.2
Other condition 19 28.4 14 24.1 33 26.4
Patient choice 3 4.5 2 3.4 5 4.0
Toxicity 5 7.5 6 10.3 11 8.8
Unknown 10 14.9 11 19.0 21 16.8
Total 67 100.0 58 100.0 125 100.0
TABLE 9 Docetaxel withdrawal by comparison groups
Withdrawal reason
No ZA ZA No Sr-89 Sr-89
n % n % n % n %
Administration error 0 0.0 2 1.0 1 0.5 1 0.5
Change in treatment 7 3.3 5 2.6 5 2.4 7 3.5
Clinician decision 7 3.3 11 5.6 5 2.4 13 6.5
Death 14 6.6 10 5.1 8 3.9 16 8.0
Disease progression 68 32.0 50 25.6 62 29.9 56 27.9
Other condition 67 31.4 54 27.7 66 31.9 55 27.4
Patient choice 15 7.0 13 6.7 14 6.8 14 6.9
Toxicity 20 9.4 30 15.4 29 14.0 21 10.4
Unknown 15 7.0 20 10.3 17 8.2 18 8.9
Total 213 100.0 195 100.0 207 100.0 201 100.0
TABLE 8 Docetaxel withdrawal by randomisation arms
Withdrawal reason
Docetaxel
(N= 107)
Docetaxel+ ZA
(N= 100)
Docetaxel+ Sr-89
(N= 106)
Docetaxel+ ZA+
Sr-89 (N= 95)
Overall
(N= 408)
n % n % n % n % n %
Administration error 0 0.0 1 1.0 0 0.0 1 1.1 2 0.5
Change in treatment 4 3.7 1 1.0 3 2.8 4 4.2 12 2.9
Clinician decision 2 1.9 3 3.0 5 4.7 8 8.4 18 4.4
Death 5 4.7 3 3.0 9 8.5 7 7.4 24 5.9
Disease progression 35 32.7 27 27.0 33 31.1 23 24.2 118 28.9
Other condition 36 33.6 30 30.0 31 29.2 24 25.3 121 29.7
Patient choice 7 6.5 7 7.0 8 7.5 6 6.3 28 6.9
Toxicity 11 10.3 18 18.0 9 8.5 12 12.6 50 12.3
Unknown 7 6.5 10 10.0 8 7.5 10 10.5 35 8.6
Total 107 100.0 100 100.0 106 100.0 95 100.0 408 100.0
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Data maturity
In total, 618 patients have been followed up until death. Of the remaining 139 patients, 78 have reached
the primary CPFS end point, leaving 61 patients alive without having reached the primary end point.
The average follow-up of alive patients was 1.84 years (IQR 1.4–2.4 years), and the average follow-up
of the 61 patients who have not reached the primary end point was 1.7 years (IQR 1.4–2.1 years). Table 11
shows the average follow-up of the surviving patients split by randomisation arm.
Figure 8 shows the time between the date of randomisation and the date when the patient was last seen
and the time from that date to the date of the analysis. Each point represents a patient, and the solid
black dots are patients who have not reached the primary end point of the trial. The solid black line
indicates where the patients would appear on the graph if they were seen on the date of the analysis.
The dashed line represents 6 months before the analysis and the dotted line represents 12 months prior
to the analysis.
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FIGURE 8 Duration of follow-up. Pain, pain progression.
TABLE 11 Follow-up of alive patients
Duration of
follow-up (years)
Docetaxel
(N= 37)
Docetaxel+ ZA
(N= 32)
Docetaxel+ Sr-89
(N= 35)
Docetaxel+ ZA+ Sr-89
(N= 35)
Overall
(N= 139)
n 37 32 35 35 139
Median 1.7 1.8 1.9 1.9 1.8
IQR 1.4–2.3 1.4–2.3 1.6–2.6 1.5–2.4 1.4–2.4
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Stratification variables
Two stratification factors were used during the randomisation process: centre and ECOG performance
status. These can be seen in Tables 12 and 13.
TABLE 12 Stratification variables by randomisation arm
Stratification variable
Docetaxel
(N= 191)
Docetaxel+ ZA
(N= 188)
Docetaxel+ Sr-89
(N= 190)
Docetaxel+ ZA+
Sr-89 (N= 188)
Overall
(N= 757)
n % n % n % n % n %
ECOG performance status score
0 77 40.3 76 40.4 76 40.0 76 40.4 305 40.3
1 98 51.3 97 51.6 97 51.1 97 51.6 389 51.4
2 16 8.4 15 8.0 17 8.9 15 8.0 63 8.3
Randomisation centre
Aberdeen Royal Infirmary 5 2.6 5 2.7 5 2.6 6 3.2 21 2.8
Ayr Hospital 5 2.6 6 3.2 5 2.6 5 2.7 21 2.8
Beatson West of Scotland
Cancer Centre
15 7.9 15 8.0 15 7.9 16 8.5 61 8.1
Bradford Royal Infirmary 3 1.6 4 2.1 4 2.1 2 1.1 13 1.7
Cheltenham General Hospital 4 2.1 4 2.1 4 2.1 4 2.1 16 2.1
Christie Hospital 30 15.7 31 16.5 30 15.8 31 16.5 122 16.1
Dorset County Hospital 2 1.0 1 0.5 1 0.5 1 0.5 5 0.7
Forth Valley Royal Hospital 2 1.0 1 0.5 2 1.1 1 0.5 6 0.8
Gloucester Royal Hospital 0 0.0 0 0.0 1 0.5 0 0.0 1 0.1
Huddersfield Royal Infirmary 2 1.0 2 1.1 3 1.6 2 1.1 9 1.2
Ipswich Hospital 5 2.6 4 2.1 4 2.1 4 2.1 17 2.2
Maidstone Hospital 7 3.7 7 3.7 7 3.7 8 4.3 29 3.8
Poole Hospital 0 0.0 5 0.0 0 0.0 1 0.5 1 0.1
Queen Alexandra Hospital 4 2.1 6 2.7 4 2.1 4 2.1 17 2.2
Queen Elizabeth Hospital 32 16.8 15 16.5 32 16.8 31 16.5 126 16.6
Royal Albert Edward Infirmary 2 1.0 4 0.5 2 1.1 2 1.1 7 0.9
Royal Bournemouth Hospital 2 1.0 4 0.5 1 0.5 1 0.5 5 0.7
Royal Derby Hospital 6 3.1 31 3.2 7 3.7 7 3.7 26 3.4
Royal Free Hospital 3 1.6 1 2.1 2 1.1 3 1.6 12 1.6
Royal Marsden Hospital London 1 0.5 1 0.0 0 0.0 0 0.0 1 0.1
Royal Marsden Hospital Sutton 7 3.7 0 4.3 7 3.7 8 4.3 30 4.0
Royal Preston Hospital 9 4.7 2 4.8 8 4.2 8 4.3 34 4.5
Southampton General Hospital 4 2.1 4 1.6 4 2.1 3 1.6 14 1.8
St James’s University Hospital 7 3.7 7 3.7 7 3.7 6 3.2 27 3.6
Velindre Hospital 1 0.5 5 1.1 2 1.1 2 1.1 7 0.9
Western General Hospital 28 14.7 6 14.4 28 14.7 28 14.9 111 14.7
Weston General Hospital 3 1.6 15 1.6 4 2.1 3 1.6 13 1.7
Wishaw General Hospital 2 1.0 4 0.5 1 0.5 1 0.5 5 0.7
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TABLE 13 Stratification variables by comparison group
Stratification variable
No ZA (N= 381) ZA (N= 376) No Sr-89 (N= 379) Sr-89 (N= 378)
n % n % n % n %
ECOG performance status score
0 153 40.2 152 40.4 153 40.4 152 40.2
1 195 51.2 194 51.6 195 51.5 194 51.3
2 33 8.7 30 8.0 31 8.2 32 8.5
Randomisation centre
Aberdeen Royal Infirmary 10 2.6 11 2.9 10 2.6 11 2.9
Ayr Hospital 10 2.6 11 2.9 11 2.9 10 2.6
Beatson West of Scotland Cancer Centre 30 7.9 31 8.2 30 7.9 31 8.2
Bradford Royal Infirmary 7 1.8 6 1.6 7 1.8 6 1.6
Cheltenham General Hospital 8 2.1 8 2.1 8 2.1 8 2.1
Christie Hospital 60 15.7 62 16.5 61 16.1 61 16.1
Dorset County Hospital 3 0.8 2 0.5 3 0.8 2 0.5
Forth Valley Royal Hospital 4 1.0 2 0.5 3 0.8 3 0.8
Gloucester Royal Hospital 1 0.3 0 0.0 0 0.0 1 0.3
Huddersfield Royal Infirmary 5 1.3 4 1.1 4 1.1 5 1.3
Ipswich Hospital 9 2.4 8 2.1 9 2.4 8 2.1
Maidstone Hospital 14 3.7 15 4.0 14 3.7 15 4.0
Poole Hospital 0 0.0 1 0.3 0 0.0 1 0.3
Queen Alexandra Hospital 8 2.1 9 2.4 9 2.4 8 2.1
Queen Elizabeth Hospital 64 16.8 62 16.5 63 16.6 63 16.7
Royal Albert Edward Infirmary 4 1.0 3 0.8 3 0.8 4 1.1
Royal Bournemouth Hospital 3 0.8 2 0.5 3 0.8 2 0.5
Royal Derby Hospital 13 3.4 13 3.5 12 3.2 14 3.7
Royal Free Hospital 5 1.3 7 1.9 7 1.8 5 1.3
Royal Marsden Hospital London 1 0.3 0 0.0 1 0.3 0 0.0
Royal Marsden Hospital Sutton 14 3.7 16 4.3 15 4.0 15 4.0
Royal Preston Hospital 17 4.5 17 4.5 18 4.7 16 4.2
Southampton General Hospital 8 2.1 6 1.6 7 1.8 7 1.9
St James’s University Hospital 14 3.7 13 3.5 14 3.7 13 3.4
Velindre Hospital 3 0.8 4 1.1 3 0.8 4 1.1
Western General Hospital 56 14.7 55 14.6 55 14.5 56 14.8
Weston General Hospital 7 1.8 6 1.6 6 1.6 7 1.9
Wishaw General Hospital 3 0.8 2 0.5 3 0.8 2 0.5
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Baseline data
In total, 752 (99%) baseline forms were returned. Table 14 shows the baseline information recorded on
the on-study form by randomisation arm.
Table 15 repeats the baseline characteristics reported above but split by comparison groups.
TABLE 14 Patient characteristics by randomisation arm
Patient characteristic
Randomisation arm
Docetaxel
(N= 191)
Docetaxel+ ZA
(N= 187)
Docetaxel+ Sr-89
(N= 188)
Docetaxel+ ZA+
Sr-89 (N= 186)
Overall
(N= 752)
n % n % n % n % n %
ECOG performance status score
0 76 43.4 71 40.8 70 39.3 64 37.0 281 40.1
1 83 47.4 88 50.6 90 50.6 95 54.9 356 50.9
2 15 8.6 15 8.6 18 10.1 14 8.1 62 8.9
3 1 0.6 0 0.0 0 0.0 0 0.0 1 0.1
Missing 16 – 13 – 10 – 13 – 52 –
Diagnostic indicator
Adenocarcinoma 156 81.7 146 78.9 150 80.2 149 81.0 601 80.5
PSA only 35 18.3 39 21.1 37 19.8 35 19.0 146 19.5
Missing 0 – 2 – 1 – 2 – 5 –
Staging: T
T1 2 1.4 5 3.8 2 1.7 1 0.7 10 1.9
T1b 1 0.7 0 0.0 1 0.8 0 0.0 2 0.4
T1c 0 0.0 1 0.8 2 1.7 1 0.7 4 0.7
T2 19 13.3 16 12.2 11 9.1 17 12.1 63 11.8
T2a 2 1.4 2 1.5 0 0.0 0 0.0 4 0.7
T2b 4 2.8 1 0.8 1 0.8 2 1.4 8 1.5
T3 54 37.8 53 40.5 49 40.5 63 44.7 219 40.9
T3a 4 2.8 3 2.3 5 4.1 4 2.8 16 3.0
T3b 12 8.4 10 7.6 10 8.3 9 6.4 41 7.6
T4 28 19.6 22 16.8 20 16.5 25 17.7 95 17.7
TX 16 11.2 18 13.7 20 16.5 18 12.8 72 13.4
T2c 1 0.7 0 0.0 0 0.0 1 0.7 2 0.4
Missing 48 – 56 – 67 – 45 – 216 –
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TABLE 14 Patient characteristics by randomisation arm (continued )
Patient characteristic
Randomisation arm
Docetaxel
(N= 191)
Docetaxel+ ZA
(N= 187)
Docetaxel+ Sr-89
(N= 188)
Docetaxel+ ZA+
Sr-89 (N= 186)
Overall
(N= 752)
n % n % n % n % n %
Staging: M
M0 44 30.8 41 31.3 33 27.3 40 28.4 158 29.5
M1a 20 14.0 20 15.3 22 18.2 21 14.9 83 15.5
M1b 8 5.6 7 5.3 3 2.5 2 1.4 20 3.7
M1c 4 2.8 10 7.6 6 5.0 5 3.5 25 4.7
MX 26 18.2 14 10.7 17 14.0 26 18.4 83 15.5
M1 41 28.7 39 29.8 40 33.1 47 33.3 167 31.2
Missing 48 – 56 – 67 – 45 – 216 –
Staging: N
N0 59 41.3 57 43.5 46 38.0 58 41.1 220 41.0
N1 42 29.4 28 21.4 32 26.4 39 27.7 141 26.3
NX 42 29.4 46 35.1 43 35.5 44 31.2 175 32.6
Missing 48 – 56 – 67 – 45 – 216 –
Gleason score
3 0 0.0 0 0.0 0 0.0 1 0.7 1 0.2
4 2 1.4 0 0.0 1 0.7 0 0.0 3 0.5
5 2 1.4 3 2.1 2 1.4 3 2.2 10 1.8
6 9 6.3 12 8.4 12 8.7 6 4.5 39 7.0
7 43 29.9 48 33.6 39 28.3 41 30.6 171 30.6
8 30 20.8 24 16.8 35 25.4 25 18.7 114 20.4
9 57 39.6 55 38.5 41 29.7 54 40.3 207 37.0
10 1 0.7 1 0.7 8 5.8 4 3.0 14 2.5
Missing 47 – 44 – 50 – 52 – 193 –
Prior radiotherapy received?
No 114 59.7 107 57.2 95 50.8 98 52.7 414 55.1
Yes 77 40.3 80 42.8 92 49.2 88 47.3 337 44.9
Missing 0 – 0 – 1 – 0 – 1 –
Method of castration
Surgery 5 2.6 4 2.1 3 1.6 2 1.1 14 1.9
Ongoing LHRH agonists 186 97.4 183 97.9 185 98.4 184 98.9 738 98.1
Anti-androgen received?
No 10 5.2 19 10.2 17 9.1 14 7.6 60 8.0
Yes 181 94.8 168 89.8 170 90.9 171 92.4 690 92.0
Missing 0 – 0 – 1 – 1 – 2 –
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TABLE 14 Patient characteristics by randomisation arm (continued )
Patient characteristic
Randomisation arm
Docetaxel
(N= 191)
Docetaxel+ ZA
(N= 187)
Docetaxel+ Sr-89
(N= 188)
Docetaxel+ ZA+
Sr-89 (N= 186)
Overall
(N= 752)
n % n % n % n % n %
Flutamide, nilutamide or cyproterone acetate received?
No 151 83.9 141 83.9 142 84.0 133 77.8 567 82.4
Yes 29 16.1 27 16.1 27 16.0 38 22.2 121 17.6
Missing 11 – 19 – 19 – 15 – 64 –
Bicalutamide received?
No 11 6.1 14 8.3 8 4.7 15 8.8 48 7.0
Yes 170 93.9 154 91.7 162 95.3 156 91.2 642 93.0
Missing 10 – 19 – 18 – 15 – 62 –
Method of progression at study entry
All 26 13.7 27 14.6 27 14.4 27 14.5 107 14.3
Elevated PSA 42 22.1 48 25.9 42 22.3 44 23.7 176 23.5
New lesion 15 7.9 16 8.6 21 11.2 19 10.2 71 9.5
Objective 5 2.6 1 0.5 1 0.5 1 0.5 8 1.1
Objective+ new lesion 3 1.6 4 2.2 7 3.7 5 2.7 19 2.5
PSA+ new lesion 94 49.5 85 45.9 82 43.6 88 47.3 349 46.6
PSA+ objective 5 2.6 4 2.2 8 4.3 2 1.1 19 2.5
Missing 1 – 2 – 0 – 0 – 3 –
Baseline pain diary completed?
No 30 15.7 37 19.8 42 22.3 34 18.3 143 19.0
Yes 161 84.3 150 80.2 146 77.7 152 81.7 609 81.0
Baseline QoL booklet completed?
No 22 11.6 19 10.3 28 14.9 25 13.7 94 12.6
Yes 168 88.4 165 89.7 160 85.1 158 86.3 651 87.4
Missing 1 – 3 – 0 – 3 – 7 –
LHRH, luteinising hormone-releasing hormone.
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TABLE 15 Patient characteristics by comparison group
Patient characteristic
Comparison group
No ZA (N= 379) ZA (N= 373) No Sr-89 (N= 378) Sr-89 (N= 374)
n % n % n % n %
ECOG performance status score
0 146 41.4 135 38.9 147 42.1 134 38.2
1 173 49.0 183 52.7 171 49.0 185 52.7
2 33 9.3 29 8.4 30 8.6 32 9.1
3 1 0.3 0 0.0 1 0.3 0 0.0
Missing 26 – 26 – 29 – 23 –
Diagnostic indicator
Adenocarcinoma 306 81.0 295 79.9 302 80.3 299 80.6
PSA only 72 19.0 74 20.1 74 19.7 72 19.4
Missing 1 – 4 – 2 – 3 –
Staging: T
T1 4 1.5 6 2.2 7 2.6 3 1.1
T1b 2 0.8 0 0.0 1 0.4 1 0.4
T1c 2 0.8 2 0.7 1 0.4 3 1.1
T2 30 11.4 33 12.1 35 12.8 28 10.7
T2a 2 0.8 2 0.7 4 1.5 0 0.0
T2b 5 1.9 3 1.1 5 1.8 3 1.1
T3 103 39.0 116 42.6 107 39.1 112 42.7
T3a 9 3.4 7 2.6 7 2.6 9 3.4
T3b 22 8.3 19 7 22 8.0 19 7.3
T4 48 18.2 47 17.3 50 18.2 45 17.2
TX 36 13.6 36 13.2 34 12.4 38 14.5
T2c 1 0.4 1 0.4 1 0.4 1 0.4
Missing 115 – 101 – 104 – 112 –
Staging: M
M0 77 29.2 81 29.8 85 31.0 73 27.9
M1a 42 15.9 41 15.1 40 14.6 43 16.4
M1b 11 4.2 9 3.3 15 5.5 5 1.9
M1c 10 3.8 15 5.5 14 5.1 11 4.2
MX 43 16.3 40 14.7 40 14.6 43 16.4
M1 81 30.7 86 31.6 80 29.2 87 33.2
Missing 115 – 101 – 104 – 112 –
Staging: N
N0 105 39.8 115 42.3 116 42.3 104 39.7
N1 74 28.0 67 24.6 70 25.5 71 27.1
NX 85 32.2 90 33.1 88 32.1 87 33.2
Missing 115 – 101 – 104 – 112 –
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TABLE 15 Patient characteristics by comparison group (continued )
Patient characteristic
Comparison group
No ZA (N= 379) ZA (N= 373) No Sr-89 (N= 378) Sr-89 (N= 374)
n % n % n % n %
Gleason score
3 0 0.0 1 0.4 0 0.0 1 0.4
4 3 1.1 0 0.0 2 0.7 1 0.4
5 4 1.4 6 2.2 5 1.7 5 1.8
6 21 7.4 18 6.5 21 7.3 18 6.6
7 82 29.1 89 32.1 91 31.7 80 29.4
8 65 23.0 49 17.7 54 18.8 60 22.1
9 98 34.8 109 39.4 112 39.0 95 34.9
10 9 3.2 5 1.8 2 0.7 12 4.4
Missing 97 – 96 – 91 – 102 –
Prior radiotherapy received?
No 209 55.3 205 55.0 221 58.5 193 51.7
Yes 169 44.7 168 45.0 157 41.5 180 48.3
Missing 1 – – – – – 1 –
Method of castration
Surgery 8 2.1 6 1.6 9 2.4 5 1.3
Ongoing LHRH agonists 371 97.9 367 98.4 369 97.6 369 98.7
Anti-androgen received?
No 27 7.1 33 8.9 29 7.7 31 8.3
Yes 351 92.9 339 91.1 349 92.3 341 91.7
Flutamide, nilutamide or cyproterone acetate received?
No 293 84.0 274 80.8 292 83.9 275 80.9
Yes 56 16.0 65 19.2 56 16.1 65 19.1
Missing 30 – 34 – 30 – 34 –
Bicalutamide received?
No 19 5.4 29 8.6 25 7.2 23 6.7
Yes 332 94.6 310 91.4 324 92.8 318 93.3
Missing 28 – 34 – 29 – 33 –
Method of progression at study entry
All 53 14.0 54 14.6 53 14.1 54 14.4
Elevated PSA 84 22.2 92 24.8 90 24.0 86 23.0
New lesion 36 9.5 35 9.4 31 8.3 40 10.7
Objective 6 1.6 2 0.5 6 1.6 2 0.5
Objective+ new lesion 10 2.6 9 2.4 7 1.9 12 3.2
PSA+ new lesion 176 46.6 173 46.6 179 47.7 170 45.5
PSA+ objective 13 3.4 6 1.6 9 2.4 10 2.7
Missing 1 – 2 – 3 – 0 –
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Treatment
In total, 4488 treatment forms were returned. Table 16 shows the treatment information split by cycle for
each of the randomisation arms and Table 17 shows the same details split by comparison groups. The data
show that only 17% of patients received 10 cycles of docetaxel, with 45% stopping at cycle 6. It is
important to take into account that 29% of patients were only ever intended to receive six cycles of
treatment, as previously detailed in Withdrawal of trial treatment, docetaxel.
The 47 reasons for discontinuation of ZA which are reported as ‘other’ in Table 16 are summarised in
Table 18.
TABLE 15 Patient characteristics by comparison group (continued )
Patient characteristic
Comparison group
No ZA (N= 379) ZA (N= 373) No Sr-89 (N= 378) Sr-89 (N= 374)
n % n % n % n %
Baseline pain diary completed?
No 72 19.0 71 19.0 67 17.7 76 20.3
Yes 307 81.0 302 81.0 311 82.3 298 79.7
Baseline QoL booklet completed?
No 50 13.2 44 12.0 41 11.0 53 14.3
Yes 328 86.8 323 88.0 333 89.0 318 85.7
Missing 1 – 6 – 4 – 3 –
n n n n
Age at randomisation (years)
N 379 373 378 374
Median 68.4 69.0 68.9 68.6
IQR 63.6–73.6 64.1–73.4 64.3–73.8 63.2–73.1
Range 45.9–83.8 45.0–83.7 45.0–83.8 49.4–82.0
Days from baseline ECOG to randomisation
N 349 339 341 347
Median 2.0 2.0 2.0 2.0
IQR 0.0–8.0 0.0–8.0 0.0–8.0 0.0–7.0
Range 0.0–367.0 0.0–73.0 0.0–51.0 0.0–367.0
Months from diagnosis to randomisation
N 379 373 378 374
Median 30.1 37.8 34.0 33.3
IQR 18.7–61.6 20.2–62.1 19.2–57.0 19.0–70.1
Range 1.3–246.2 0.3–190.3 0.3–246.2 0.4–187.2
LHRH, luteinising hormone-releasing hormone.
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Delivery of strontium-89
Table 19 shows the timings of delivery and dose of Sr-89 administered for the 253 patients who received
Sr-89 split firstly by randomisation arm and then by comparison groups. Reasons for not receiving Sr-89
are detailed in withdrawal Sr-89 section.
Tables 20 and 21 show that most patients who were able to receive Sr-89 received the total dose,
independent of whether or not they were randomised to also receive ZA.
TABLE 18 Other reasons for ZA discontinuation
Other reasons Number of patients
Hypocalcaemia 6
Breathlessness 1
Clinical decision 6
Dental treatment 10
Raised creatinine 3
Anaemia 1
Osteonecrosis 1
Patient choice 1
Unspecified side effects 2
Toxicities 9
Ulcer on gums 1
Omitted in error 4
Hypophosphataemia 1
Investigation of jaw pain 1
TABLE 19 Strontium-89 administration by randomisation arm
Sr-89
details
Randomisation arm Comparison group
Docetaxel+ Sr-89 (N= 123) Docetaxel+ ZA+ Sr-89 (N= 130) All patients receiving Sr-89 (N= 253)
Days from randomisation to Sr-89
n 123 130 253
Median 144.0 145.5 145.0
IQR 140.0–149.0 140.0–152.0 140.0–151.0
Range 132.0–203.0 133.0–182.0 132.0–203.0
Sr-89 dose (MBq)
n 123 130 253
Median 150.0 150.0 150.0
IQR 150.0–150.0 149.0–150.0 150.0–150.0
Range 89.0–165.0 89.0–169.0 89.0–169.0
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
TABLE 20 Docetaxel dose reductions cycles 1–5
Dose reduction details
C1 (N= 729) C2 (N= 692) C3 (N= 665) C4 (N= 623) C5 (N= 588)
n % n % n % n % n %
Did the patient have a dose reduction?
No 723 99.2 627 90.6 625 94.0 579 92.9 550 93.9
Yes 6 0.8 65 9.4 40 6.0 44 7.1 36 6.1
Missing 0 – 0 – 0 – 0 – 2 –
Split by randomisation arm
Docetaxel: was the dose reduced?
No 184 98.9 164 91.6 161 94.7 142 89.9 136 92.5
Yes 2 1.1 15 8.4 9 5.3 16 10.1 11 7.5
Docetaxel+ ZA: was the dose reduced?
No 180 100.0 148 88.6 153 93.9 147 94.2 139 94.6
Yes 0 0.0 19 11.4 10 6.1 9 5.8 8 5.4
Docetaxel+ Sr-89: was the dose reduced?
No 178 98.3 157 89.7 156 94.0 145 95.4 136 94.4
Yes 3 1.7 18 10.3 10 6.0 7 4.6 8 5.6
Docetaxel+ ZA+ Sr-89: was the dose reduced?
No 181 99.5 158 92.4 155 93.4 145 92.4 139 93.9
Yes 1 0.5 13 7.6 11 6.6 12 7.6 9 6.1
Docetaxel: reasons for reduction
Non-study drug related 0 0.0 2 13.3 0 0.0 1 6.3 0 0.0
Study drug-related haematological toxicity 1 50.0 9 60.0 6 66.7 8 50.0 5 45.5
Study drug-related non-haematological toxicity 0 0.0 2 13.3 0 0.0 2 12.5 5 45.5
Study drug-related both 0 0.0 1 6.7 0 0.0 0 0.0 1 9.1
Study drug-related other, specify 1 50.0 1 6.7 3 33.3 5 31.3 0 0.0
Docetaxel+ ZA: reasons for reduction
Non-study drug related 0 0.0 1 5.3 1 10.0 1 11.1 0 0.0
Study drug-related haematological toxicity 0 0.0 8 42.1 5 50.0 5 55.6 1 12.5
Study drug-related non-haematological toxicity 0 0.0 2 10.5 2 20.0 1 11.1 5 62.5
Study drug-related both 0 0.0 4 21.1 1 10.0 1 11.1 1 12.5
Study drug-related other, specify 0 0.0 4 21.1 1 10.0 1 11.1 1 12.5
Docetaxel+ Sr-89: reasons for reduction
Non-study drug related 0 0.0 1 5.6 0 0.0 0 0.0 0 0.0
Study drug-related haematological toxicity 0 0.0 10 55.6 5 50.0 3 42.9 4 50.0
Study drug-related non-haematological toxicity 0 0.0 3 16.7 3 30.0 3 42.9 1 12.5
Study drug-related both 1 33.3 3 16.7 1 10.0 1 14.3 1 12.5
Study drug-related other, specify 2 66.7 1 5.6 1 10.0 0 0.0 2 25.0
Docetaxel+ ZA+ Sr-89: reasons for reduction
Non-study drug related 0 0.0 1 7.7 1 9.1 2 16.7 1 11.1
Study drug-related haematological toxicity 1 100.0 9 69.2 7 63.6 5 41.7 4 44.4
Study drug-related non-haematological toxicity 0 0.0 2 15.4 2 18.2 2 16.7 2 22.2
Study drug-related other, specify 0 0.0 1 7.7 1 9.1 3 25.0 2 22.2
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TABLE 21 Docetaxel dose reductions cycles 6–10
Dose reduction details
C6 (N= 527) C7 (N= 202) C8 (N= 179) C9 (N= 154) C10 (N= 129)
n % n % n % n % n %
Did the patient have a dose reduction?
No 493 93.7 191 94.6 162 90.5 147 95.5 120 93.8
Yes 33 6.3 11 5.4 17 9.5 7 4.5 8 6.3
Missing 1 0 0 0 1
Split by randomisation arms
Docetaxel: was the dose reduced
No 121 94.5 42 93.3 32 84.2 32 94.1 23 88.5
Yes 7 5.5 3 6.7 6 15.8 2 5.9 3 11.5
Docetaxel+ ZA: was the dose reduced?
No 123 93.9 53 93.0 51 96.2 42 97.7 31 91.2
Yes 8 6.1 4 7.0 2 3.8 1 2.3 3 8.8
Docetaxel+ Sr-89: was the dose reduced?
No 123 94.6 46 93.9 40 90.9 38 95.0 34 100.0
Yes 7 5.4 3 6.1 4 9.1 2 5.0 0 0.0
Docetaxel+ ZA+ Sr-89: was the dose reduced?
No 126 92.0 50 98.0 39 88.6 35 94.6 32 94.1
Yes 11 8.0 1 2 5 11.4 2 5.4 2 5.9
Docetaxel: reasons for reduction
Study drug-related haematological toxicity 4 57.1 2 66.7 2 33.3 0 0.0 0 0.0
Study drug-related non-haematological toxicity 1 14.3 1 33.3 4 66.7 2 100.0 3 100.0
Study drug-related both 2 28.6 0 0.0 0 0.0 0 0.0 0 0.0
Docetaxel+ ZA: reasons for reduction
Non-study drug related 1 14.3 0 0.0 0 0.0 0 0.0 0 0.0
Study drug-related haematological toxicity 3 42.9 1 25.0 1 50.0 0 0.0 2 66.7
Study drug-related non-haematological toxicity 2 28.6 2 50.0 0 0.0 1 100.0 1 33.3
Study drug-related other, specify 1 14.3 1 25.0 1 50.0 0 0.0 0 0.0
Docetaxel+ Sr-89: reasons for reduction
Non-study drug related 0 0.0 1 33.3 0 0.0 0 0.0 0 0.0
Study drug-related haematological toxicity 3 42.9 0 0.0 1 25.0 1 50.0 0 0.0
Study drug-related non-haematological toxicity 2 28.6 1 33.3 1 25.0 1 50.0 0 0.0
Study drug-related both 1 14.3 1 33.3 1 25.0 0 0.0 0 0.0
Study drug-related other, specify 1 14.3 0 0.0 1 25.0 0 0.0 0 0.0
Docetaxel+ ZA+ Sr-89: reasons for reduction
Non-study drug related 2 18.2 0 0.0 0 0.0 0 0.0 0 0.0
Study drug-related haematological toxicity 4 36.4 1 100.0 3 60.0 1 50.0 1 50.0
Study drug-related non-haematological toxicity 4 36.4 0 0.0 2 40.0 1 50.0 1 50.0
Study drug-related other, specify 1 9.1 0 0.0 0 0.0 0 0.0 0 0.0
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
Dose intensity
The protocol-defined starting dose of docetaxel was 75mg/m2 (up to a maximum dose of 165mg).
Figures 9 and 10, split by comparisons, show the actual dose of docetaxel received (lines) and the
numbers of patients off-treatment (bar) over the 10 cycles of the trial.
The graphs show that there were only minimal changes in the total doses of docetaxel given during the
course of the trial.
Dose reductions and delays
Reductions
Table 20 shows the number of and reasons for dose reductions by randomisation arm over time for
cycles 1–5 and Table 21 for cycles 6–10. In total, 267 dose reductions were reported across all 10 cycles,
which equated to 6% of all for docetaxel cycles given being reduced.
Delays
Table 22 shows the numbers of docetaxel delays over time and by randomisation arm for cycles 1–5
and Table 23 for cycles 6–10. In total, there were 297 delays reported, equating to delays in 7% of all
docetaxel cycles received.
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FIGURE 10 Docetaxel administration by Sr-89 comparison.
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FIGURE 9 Docetaxel administration by ZA comparison.
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TABLE 22 Docetaxel dose delays for cycles 1–5
Dose delay details
C1 (N= 729) C2 (N= 692) C3 (N= 665) C4 (N= 623) C5 (N= 588)
n % n % n % n % n %
Did the patient have a dose delay?
No 712 97.7 637 92.1 617 92.8 571 91.7 545 92.8
Yes 17 2.3 55 7.9 48 7.2 52 8.3 42 7.2
Missing 0 0 0 0 1
Split by randomisation arm
Docetaxel: was cycle delayed?
No 183 98.4 163 91.1 158 92.9 144 91.1 134 90.5
Yes 3 1.6 16 8.9 12 7.1 14 8.9 14 9.5
Docetaxel+ ZA: was cycle delayed?
No 177 98.3 154 92.2 152 93.3 140 89.7 136 92.5
Yes 3 1.7 13 7.8 11 6.7 16 10.3 11 7.5
Docetaxel+ Sr-89: was cycle delayed?
No 173 95.6 162 92.6 155 93.4 142 93.4 133 92.4
Yes 8 4.4 13 7.4 11 6.6 10 6.6 11 7.6
Docetaxel+ ZA+ Sr-89: was cycle delayed?
No 179 98.4 158 92.4 152 91.6 145 92.4 142 95.9
Yes 3 1.6 13 7.6 14 8.4 12 7.6 6 4.1
Docetaxel: reasons for delay
Non-study drug related 0 0.0 4 25.0 3 27.3 2 14.3 7 50.0
Study drug-related haematological toxicity 0 0.0 4 25.0 1 9.1 2 14.3 0 0.0
Study drug-related non-haematological toxicity 0 0.0 1 6.3 1 9.1 2 14.3 2 14.3
Study drug-related other, specify 3 100.0 7 43.8 6 54.5 8 57.1 5 35.7
Docetaxel+ ZA: reasons for delay
Non-study drug related 2 66.7 0 0.0 1 9.1 6 37.5 2 18.2
Study drug-related haematological toxicity 0 0.0 3 23.1 3 27.3 3 18.8 1 9.1
Study drug-related non-haematological toxicity 0 0.0 3 23.1 3 27.3 1 6.3 3 27.3
Study drug-related both 0 0.0 2 15.4 0 0.0 0 0.0 0 0.0
Study drug-related other, specify 1 33.3 5 38.5 4 36.4 6 37.5 5 45.5
Docetaxel+ Sr-89: reasons for delay
Non-study drug related 3 37.5 0 0.0 0 0.0 2 20.0 2 18.2
Study drug-related haematological toxicity 0 0.0 5 38.5 2 18.2 0 0.0 2 18.2
Study drug-related non-haematological toxicity 0 0.0 0 0.0 3 27.3 3 30.0 1 9.1
Study drug-related both 0 0.0 2 15.4 1 9.1 1 10.0 0 0.0
Study drug-related other, specify 5 62.5 6 46.2 5 45.5 4 40.0 6 54.5
Docetaxel+ ZA+ Sr-89: reasons for delay
Non-study drug related 2 66.7 2 15.4 1 7.1 2 16.7 2 33.3
Study drug-related haematological toxicity 0 0.0 5 38.5 1 7.1 1 8.3 0 0.0
Study drug-related non-haematological toxicity 0 0.0 3 23.1 3 21.4 4 33.3 0 0.0
Study drug-related both 0 0.0 0 0.0 0 0.0 0 0.0 1 16.7
Study drug-related other, specify 1 33.3 3 23.1 9 64.3 5 41.7 3 50.0
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TABLE 23 Docetaxel dose delays for cycles 6–10
Dose delay details
C6 (N= 527) C7 (N= 202) C8 (N= 179) C9 (N= 154) C10 (N= 129)
n % n % n % n % n %
Did the patient have a dose delay?
No 493 93.5 182 90.1 162 90.5 145 94.2 125 97.7
Yes 34 6.5 20 9.9 17 9.5 9 5.8 3 2.3
Missing 0 0 0 0 1
Split by randomisation arm
Docetaxel: was cycle delayed?
No 125 97.7 43 95.6 35 92.1 34 100.0 25 96.2
Yes 3 2.3 2 4.4 3 7.9 0 0.0 1 3.8
Docetaxel+ ZA: was cycle delayed?
No 121 91.7 52 91.2 49 92.5 40 93.0 33 97.1
Yes 11 8.3 5 8.8 4 7.5 3 7.0 1 2.9
Docetaxel+ Sr-89: was cycle delayed?
No 118 90.8 43 87.8 39 88.6 35 87.5 33 97.1
Yes 12 9.2 6 12.2 5 11.4 5 12.5 1 2.9
Docetaxel+ ZA+ Sr-89: was cycle delayed?
No 129 94.2 44 86.3 39 88.6 36 97.3 34 100.0
Yes 8 5.8 7 13.7 5 11.4 1 2.7 0 0.0
Docetaxel: reasons for delay
Non-study drug related 1 33.3 1 50.0 1 33.3 0 0.0 0 0.0
Study drug-related non-haematological toxicity 0 0.0 0 0.0 1 33.3 0 0.0 0 0.0
Study drug-related other, specify 2 66.7 1 50.0 1 33.3 0 0.0 1 100.0
Docetaxel+ ZA: reasons for delay
Non-study drug related 3 27.3 2 40.0 0 0.0 0 0.0 0 0.0
Study drug-related haematological toxicity 2 18.2 0 0.0 0 0.0 0 0.0 0 0.0
Study drug-related non-haematological toxicity 0 0.0 2 40.0 2 50.0 0 0.0 0 0.0
Study drug-related other, specify 6 54.5 1 20.0 2 50.0 3 100.0 1 100.0
Docetaxel+ Sr-89: reasons for delay
Non-study drug related 2 16.7 1 16.7 0 0.0 1 20.0 0 0.0
Study drug-related haematological toxicity 0 0.0 0 0.0 1 20.0 0 0.0 0 0.0
Study drug-related non-haematological toxicity 4 33.3 0 0.0 0 0.0 0 0.0 0 0.0
Study drug-related both 0 0.0 0 0.0 1 20.0 0 0.0 0 0.0
Study drug-related other, specify 6 50.0 5 83.3 3 60.0 4 80.0 1 100.0
Docetaxel+ ZA+ Sr-89: reasons for delay
Non-study drug related 3 37.5 1 14.3 2 40.0 0 0.0 0 0.0
Study drug-related haematological toxicity 0 0.0 0 0.0 1 20.0 0 0.0 0 0.0
Study drug-related non-haematological toxicity 1 12.5 0 0.0 1 20.0 0 0.0 0 0.0
Study drug-related both 1 12.5 0 0.0 0 0.0 0 0.0 0 0.0
Study drug-related other, specify 3 37.5 6 85.7 1 20.0 1 100.0 0 0.0
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Figures 11 and 12 show the overall (line) dose reductions and delays, and the reasons (bar) for these, as a
percentage of the number of patients who received each cycle. Figure 11 was split by Sr-89 and Figure 12
by ZA.
It is clear in both figures that study drug-related haematological toxicities tended to result in dose
reductions rather than delays. For patients receiving Sr-89 there appeared to be a peak in delays to cycle 7
following Sr-89 admission, this fits with a drop in the percentage of patients needing dose reductions at
that cycle.
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FIGURE 11 Reasons for docetaxel reductions and delays by Sr-89. SDR, study-related drug. (a) No Sr-89: delays;
(b) no Sr-89: reductions; (c) Sr-89:delays; and (d) Sr-89: reductions.
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FIGURE 12 Reasons for docetaxel reductions and delays by ZA. SDR, study-related drug. (a) No ZA: delays;
(b) no ZA: reductions; (c) ZA: delays; and (d) ZA: reductions.
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Concomitant medications
Concomitant medications were collected at randomisation and during treatment visits. In addition,
all concomitant medications given in response to serious adverse events (SAEs) were recorded on the SAE
form. At the point of tumour, pain or PSA progression, sites were specifically asked about radiotherapy,
radioisotopes and bisphosphonates and given the option to record any other treatments provided at
that time.
In total, 9637 concomitant medications were reported, of which 2152 (22%) were related to concomitant
medications that were already being taken at randomisation. The majority, 5233 (54%), were taken prior
to the patient experiencing CPFS, and 1969 (20%) were taken following CPFS. In addition to this, in the
case of 304 (3%) concomitant medications, the date on which they were taken was unavailable.
Details of all concomitant medications reported by more than 20 patients can be found in Appendix 5,
Tables 82–87, split by both randomisation arm and comparison groups. The data within these tables are
also split by whether the concomitant medications were administered at baseline, post baseline but prior
to CPFS or following CPFS.
Analgesic concomitant medications
Patients were asked to complete pain diaries for the 7 days prior to each visit. Patients were asked to list
all pain medication taken during these days. This does not give a complete overview of analgesic use;
however, as recording was the same in all arms, any difference should be representative of overall use.
In total, 40,029 instances of receiving analgesic medications were reported by 575 patients; 19,494 (79%)
were opioid analgesics and 20,535 (51%) non-opioid. These were evenly distributed both between
randomisation arms and across comparison groups; details are presented in Tables 24 and 25.
Details of the types of analgesic medications being taken can be found in Appendix 5, Tables 88–93,
split by both randomisation arm and comparison groups. The data within these tables are also split by
whether the concomitant medication was administered at baseline, post baseline but prior to CPFS or
following CPFS.
TABLE 24 Opioid vs. non-opioid analgesic medications split by randomisation arms
Analgesic Docetaxel Docetaxel+ ZA Docetaxel+ Sr-89 Docetaxel+ ZA+ Sr-89 Overall
Number of patients
Non-opioid 87 82 88 90 347
Opioid 59 64 5 44 225
Missing 1 1 1 0 3
Number of instances
Non-opioid 5203 5106 5188 5038 20,535
Opioid 5016 4742 5081 4493 19,332
Missing 53 55 25 29 162
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Clinical progression-free survival
Statistical methods
Descriptive analysis of CPFS events is presented as percentages. Kaplan–Meier curves were created and
used to calculate CPFS percentages at 6, 12, 18 and 24 months. Analysis of CPFS has been carried
out using both an unadjusted approach and an adjusted approach. The first analysis of the primary
outcome was an unadjusted stratified log-rank test comparing ZA with no ZA, stratified by Sr-89, and
comparing Sr-89 with no Sr-89, stratified by ZA. Conclusions were based on a two-sided 5% significance
level. No adjustments for multiple testing were made.
The second analysis of the primary end point used an adjusted Cox regression model, including both
treatment comparisons and stratification factors (ECOG and randomising centre). The use of stratification
factors within the design leads to correlation between the treatment groups. These correlations, when not
adjusted for, can lead to upwards biased standard error rates for treatment effects, CIs which are too
wide, type 1 error rates which are too low and a subsequent reduction in power.49,50 Owing to these
potential implications, our primary outcome conclusions have been based on the adjusted Cox regression
analysis. The use of both log-rank and Cox regression models was pre-specified in the trial protocol.
Further analysis included all prognostic factors recorded at baseline that were either statistically
(stratification factors: ECOG, centre) or clinically (age, histology, prior radiotherapy use, anti-androgen use,
presence of measurable lesions on bone scan, baseline alkaline phosphatase levels and baseline PSA levels)
important. No optimal model-building techniques were employed. All factors listed were adjusted for in
the model.
Clinical progression-free survival results
Tables 26 and 27 show a breakdown of the first CPFS event split by randomisation arms and
comparison groups.
Thirty per cent of patients did not experience a SRE or pain progression prior to death. An audit was
conducted of patients in this study which checked to see whether or not SREs or pain progression had
gone unreported. The audit concluded that this was not the case and confirmed that approximately 30%
of patients died without experiencing a preceding event.
In total, 696 of the 757 patients (92%) randomised experienced clinical progression. The median follow-up
time of the 61 surviving patients who had not yet progressed is 20.9 months (IQR 16.3–24.8 months).
TABLE 25 Opioid vs. non-opioid analgesic medications split by comparison groups
Analgesic No ZA ZA No Sr-89 Sr-89
Number of patients
Non-opioid 175 172 169 178
Opioid 112 113 123 102
Missing 2 1 2 1
Number of instances
Non-opioid 10,391 10,144 10,309 10,225
Opioid 10,097 9235 9758 9574
Missing 78 84 108 54
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Zoledronic acid versus no zoledronic acid
In total, there were 696 events; 352 (51%) occurred in the ZA group and 344 (49%) in the no ZA group.
A stratified log-rank test was performed comparing ZA and no ZA. No difference in CPFS between the
two groups was observed (χ2= 0.10; p= 0.7553). The median survival time in the ZA group was 9.43 months
(95% CI 8.51 to 9.89 months), compared with 8.57 months (95% CI 7.36 to 9.33 months) in the no ZA
group. A Cox proportional hazards model was used to estimate the HR (0.98, 95% CI 0.84 to 1.13; p= 0.762).
Table 28 shows the estimated clinical-related progression-free survival percentages at 6-monthly intervals,
with 95% CIs.
It can be clearly seen that the estimated survival percentage is almost exactly the same at 12 and 18 months.
Figure 13 shows the Kaplan–Meier survival estimates split by comparison ZA. The Kaplan–Meier curve
shows very clearly that there was virtually no difference between the ZA and no ZA groups.
TABLE 26 Breakdown of CPFS by type of first event
Type of first CPFS event
Docetaxel
(N= 173)
Docetaxel+ ZA
(N= 174)
Docetaxel+ Sr-89
(N= 171)
Docetaxel+ ZA+
Sr-89 (N= 178)
Overall
(N= 696)
n % n % n % n % n %
Death 45 26.0 61 35.1 42 24.6 61 34.3 209 30.0
SRE 34 19.7 27 15.5 39 22.8 29 16.3 129 18.5
Pain 73 42.2 71 40.8 59 34.5 61 34.3 264 37.9
Death SRE 0 0.0 1 0.6 0 0.0 0 0.0 1 0.1
SRE pain 21 12.1 14 8.0 31 18.1 27 15.2 93 13.4
Total 173 100.0 174 100.0 171 100.0 178 100.0 696 100.0
TABLE 27 Breakdown of CPFS by type of first event analysis arm
Type of first CPFS event
No ZA (N= 344) ZA (N= 352) No Sr-89 (N= 347) Sr-89 (N= 349)
n % n % n % n %
Death 87 25.3 122 34.7 106 30.5 103 29.5
SRE 73 21.2 56 15.9 61 17.6 68 19.5
Pain 132 38.4 132 37.5 144 41.5 120 34.4
Death SRE 0 0.0 1 0.3 1 0.3 0 0.0
SRE pain 52 15.1 41 11.6 35 10.1 58 16.6
Total 344 100.0 352 100.0 347 100.0 349 100.0
TABLE 28 Estimated clinical-related progression-free survival percentages
Time point % survival (95% CI), no ZA % survival (95% CI), ZA
6 months 68 (64 to 73) 74 (69 to 78)
12 months 34 (29 to 39) 34 (30 to 39)
18 months 20 (16 to 24) 20 (16 to 24)
24 months 14 (10 to 18) 11 (8 to 15)
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Strontium-89 versus no strontium-89
In total, there were 696 events: 349 (50%) in the Sr-89 group and 347 (50%) in the no Sr-89 group.
A stratified log-rank test comparing Sr-89 and no Sr-89 revealed no difference in CPFS between the two
groups (χ2= 2.38; p= 0.1230). The median survival time in the Sr-89 arm was 9.56 months (95% CI 8.74
to 10.25 months), compared with 8.38 months (95% CI 7.36 to 9.07 months) in the no Sr-89 arm. A Cox
proportional hazards model was used to estimate the HR (0.88, 95% CI 0.76 to 1.03; p= 0.108).
Table 29 shows the estimated CPFS survival percentages at 6-monthly intervals with 95% CIs.
Figure 14 shows the Kaplan–Meier survival estimates split by comparison of Sr-89 treatment. A small
difference from approximately 6 months to 3 years is visible, although this is not statistically significant
according to the log-rank test.
TABLE 29 Estimated clinical-related progression-free survival percentages for Sr-89
Time point % survival (95% CI), no Sr-89 % survival (95% CI), Sr-89
6 months 71 (66 to 75) 71 (67 to 76)
12 months 31 (26 to 35) 38 (33 to 42)
18 months 18 (14 to 22) 21 (17 to 25)
24 months 11 (8 to 15) 14 (10 to 18)
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FIGURE 13 Kaplan–Meier survival estimates of CPFS by ZA comparison. Reproduced with permission from JAMA
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Interaction
The two-by-two factorial design assumed no interaction between Sr-89 and ZA. This assumption was
investigated both graphically and by inclusion of interaction terms within a Cox model, which revealed
no evidence of an interaction between the two treatments (χ2= 0.70; p= 0.4035).
Secondary analysis adjusting for stratification factors
The secondary analyses of the primary outcome used a Cox multivariable proportional hazards model,
including both treatment comparisons, ECOG performance status (fixed effect) and randomising centre
(random effect).
Cox model
Table 30 shows the HRs, p-values and the 95% CIs for the HRs from the Cox model.
A Cox proportional hazards model looking at treatment effects while controlling for important covariates
demonstrated a statistically significant effect of Sr-89, albeit with only a moderate HR (0.85, 95% CI
0.73 to 0.99; p= 0.03); however, there was no statistically significant effect of ZA (HR 0.98, 95% CI 0.84
to 1.14; p= 0.80).
Analysis adjusting for all potential prognostic factors
Table 31 shows the results of Cox proportional hazards model analysis adjusting for all statistically and
clinically significant factors.
A Cox proportional hazards model looking at treatment effects while controlling for important covariates
demonstrated a statistically significant effect of Sr-89 (HR 0.81, 95% CI 0.70 to 0.95; p= 0.01), but no
statistically significant effect of ZA (HR 0.99, 95% CI 0.85 to 1.16; p= 0.93). Other factors shown to
be associated with reduced risk of CPFS were good performance status, increased age, no previous
radiotherapy, low PSA and low alkaline phosphatase levels. The proportionality assumption was assessed
and found to be upheld.
TABLE 30 Cox proportional hazards model including stratification factors
Variable HR p-value
95% CI
Lower limit Upper limit
Sr-89 (ref.: no Sr-89)
Sr-89 0.847 0.031 0.729 0.985
ZA (ref.: no ZA)
ZA 0.982 0.808 0.845 1.141
ECOG (ref.: ECOG 0)
ECOG 1 1.547 < 0.001 1.315 1.821
ECOG 2 2.136 < 0.001 1.603 2.847
Random effect of centre
Centre – < 0.001 – –
Ref., reference.
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Skeletal-related events
Statistical methods
Descriptive analysis of types of SREs is presented as percentages, progression between different types of
SREs and the time between them diagrammatically and Kaplan–Meier curves were used to present SREFIs.
The primary analysis was a stratified log-rank comparing ZA with no ZA, stratified by Sr-89 and Sr-89, with
no Sr-89 stratified by ZA. Conclusions were based on a two-sided 5% significance level. No adjustments
for multiple testing were made.
Sensitivity analysis
Owing to the high proportion of patients who were randomised to Sr-89 but unable to receive it, a
per-protocol analysis was conducted on a per-protocol population. The per-protocol population is defined
as all eligible patients who received six cycles of docetaxel and did not experience pain progression or a
SRE prior to 21 days following the sixth administration of docetaxel and therefore would have been able to
TABLE 31 Cox proportional hazards model including important covariates
Variable HR p-value
95% CI
Lower limit Upper limit
Sr-89 (ref.: no Sr-89)
Sr-89 0.814 0.010 0.696 0.952
ZA (ref.: no ZA)
ZA 0.993 0.933 0.851 1.160
ECOG (ref.: ECOG 0)
ECOG 1 1.605 < 0.001 1.350 1.909
ECOG 2 1.895 < 0.001 1.397 2.570
Age (years)
1-year increase 0.977 < 0.001 0.965 0.988
Histology (ref.: adenocarcinoma)
Elevated PSA 0.970 0.771 0.791 1.190
Prior radiotherapy (ref.: no)
Yes 1.221 0.016 1.039 1.436
Anti-androgens (ref.: no)
Yes 0.773 0.084 0.578 1.035
Measurable lesions on bone scan (ref.: no)
Yes 1.181 0.058 0.994 1.403
Baseline alkaline phosphatase
100-unit increase 1.025 < 0.001 1.016 1.033
Baseline PSA
100-unit increase 1.016 0.019 1.003 1.030
Random effect of centre
Centre – < 0.001 – –
Ref., reference.
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receive Sr-89. The definition of SREFIs will remain the same as detailed above, as will the Kaplan–Meier
method and stratified log-rank test used.
Multiple failure model
The previously defined log-rank time-to-event analysis took into account only the time-to-first SRE, although
patients were at risk of experiencing multiple SREs throughout the course of the trial. It was, therefore,
conceivable that a medication may have had little or no effect on the time-to-first event but could prevent
patients experiencing multiple events. To take account of this, a multiple failure model was employed.
There were three factors to consider when deciding on the appropriate multiple failure methodology. First,
a patient could experience multiple SREs on the same day. Second, SREs were ordered in the sense that a
second event could not occur without a first event having been experienced. Finally, for subsequent SREs
the time-to-event needed to be measured from the date of the previous SRE and not from randomisation.
For example, once a patient had experienced a first SRE, his risk of having a subsequent event changed,
as it was considered feasible to assume that having the first SRE would change the underlying hazard in
this disease setting. To take account of all of these factors, a multiple failure model was used, specifically
the conditional risk set model proposed by Prentice et al.52 Once the model was set up to account for the
multiple events, Kaplan–Meier stratified log-rank methods were employed as previously described.
Descriptive statistics of skeletal-related events
Tables 32 and 33 show the breakdown of the types of SREs that occurred, split by randomisation arm and
comparison groups. The occurrence of more serious SREs, that is fracture, SCC and surgery, was consistently
higher in the no ZA group than the ZA group, although the overall distribution of SREs within groups was similar.
Table 34 shows number of patients experiencing SREs by comparison group. The numbers of patients
experiencing multiple SREs is lower in the ZA group.
Diagrams showing the order in which different types of SREs occurred and the time between these events can
be found in Appendix 5, Figures 55–74. These show that the overall time to the first SRE is longer in the no ZA
group than in the ZA group. The difference is approximately 1.5 months if radiation, fracture or change of
therapy was the first SRE and approximately 5.5 months if the first SRE was SCC. In both ZA and no ZA
groups, radiation was by far the most common first SRE, with change in therapy being the second most
common, followed by SCC. The proportion of first SREs which were SCCs in the no ZA arm was almost double
that in the ZA arm. The ZA group also saw fewer instances of subsequent SREs being for surgery or SCC.
In terms of the Sr-89 comparison, there were fewer differences, with both the no Sr-89 and the Sr-89
groups having similar distributions of the type of events and times to the first events. The only exception
was when SCC was the first event, in which case the time to first event was 2.5 months longer for those
receiving Sr-89 than for those who were not.
TABLE 32 Type of SRE by randomisation arm
Type of SRE
Docetaxel Docetaxel+ ZA Docetaxel+ Sr-89 Docetaxel+ ZA+ Sr-89 Overall
n % n % n % n % n %
Fractures 12 3.8 5 2.3 18 6.3 7 3.4 42 4.1
SCC 31 9.8 13 6 30 10.4 21 10.2 95 9.2
Surgery 7 2.2 4 1.8 14 4.9 2 1 27 2.6
Radiation 221 69.7 158 72.5 171 59.4 140 68 690 67.1
Change of therapy 46 14.5 38 17.4 53 18.4 36 17.5 173 16.8
Hypercalcaemia 0 0 0 0 2 0.7 0 0 2 0.2
Total 317 100.0 218 100.0 288 100.0 206 100.0 1029 100.0
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Skeletal-related event-free interval
Zoledronic acid versus no zoledronic acid
In total, there were 437 events: 234 (54%) in the no ZA group and 203 (46%) in the ZA group.
A stratified log-rank test was performed comparing ZA with no ZA. A statistically significant difference in
SREFIs between the two groups was observed (χ2= 6.49, p= 0.011). The median survival time in the ZA
group was 13.60 months (95% CI 11.76 to 16.62 months), compared with 11.17 months (95% CI 9.76
to 13.01 months) in the no ZA group.
A Cox proportional hazards model was used to estimate the HR (0.78, 95% CI 0.65 to 0.95; p= 0.011).
Figure 15 shows the Kaplan–Meier survival estimates split by comparison group: ZA.
Strontium-89 versus no strontium-89
In total, there were 437 events: 222 (51%) in the no Sr-89 group and 215 (49%) in the Sr-89 group.
A stratified log-rank test was performed comparing Sr-89 with no Sr-89. No difference in SREFI between
the two groups was observed (χ2= 1.89; p= 0.169). The median survival time in the Sr-89 group was
13.04 months (95% CI 11.14 to 14.69 months), compared with 11.70 months (95% CI 10.58 to
13.60 months) in the no Sr-89 group.
TABLE 33 Type of SRE by ZA and Sr-89 comparison group
Type of SRE
No ZA ZA No Sr-89 Sr-89
n % n % n % n %
Fractures 30 5 12 2.8 17 3.2 25 5.1
SCC 61 10.1 34 8 44 8.2 51 10.3
Surgery 21 3.5 6 1.4 11 2.1 16 3.2
Radiation 392 64.8 298 70.3 379 70.8 311 63
Change of therapy 99 16.4 74 17.5 84 15.7 89 18
Hypercalcaemia 2 0.3 0 0 0 0 2 0.4
Total 605 100.0 424 100.0 535 100.0 494 100.0
TABLE 34 Number of patients experiencing multiple SREs by comparison group
Number of SREs
ZA comparison Sr-89 comparison
No ZA ZA No Sr-89 Sr-89
n (%) n (%) n (%) n (%)
None 147 (39) 173 (46) 157 (41) 163 (43)
1 80 (21) 100 (27) 90 (24) 90 (24)
2 57 (15) 45 (12) 52 (14) 50 (13)
3 40 (10) 29 (8) 35 (9) 34 (9)
4 21 (5) 13 (3) 15 (4) 19 (5)
5 22 (6) 10 (2) 17 (5) 15 (4)
≥ 6 14 (4) 6 (2) 13 (3) 7 (2)
Total number of patients 381 (100) 376 (100) 379 (100) 378 (100)
Number reporting at least one SRE 234 (61) 203 (54) 222 (59) 215 (57)
Reproduced with permission from JAMA Oncol, 2016;2(4):493–9. Copyright © (2016) American Medical Association.
All rights reserved.51
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A Cox proportional hazards model was used to estimate the hazard ratio (HR 0.88, 95% CI 0.73 to 1.06;
p= 0.170). Figure 16 shows the Kaplan–Meier survival estimates split by Sr-89 comparison.
Landmark analysis for strontium-89
In total, 531 (70%) patients received six cycles of docetaxel and were therefore eligible to receive Sr-89.
Of a total of 321 events, 162 (50%) occurred in the no Sr-89 group and 159 (50%) in the Sr-89 group.
A stratified log-rank test was performed comparing Sr-89 with no Sr-89. No difference in SREFI between
the two groups was observed (χ2= 2.27; p= 0.132). The median survival time in the Sr-89 arm was
14.16 months (95% CI 12.52 to 17.74 months), compared with 12.75 months (95% CI 11.43 to
15.38 months) in the no Sr-89 arm.
A Cox proportional hazards model was used to estimate the HR (HR 0.85, 95% CI 0.68 to 1.05;
p= 0.170). Figure 17 shows the Kaplan–Meier survival estimates split by comparison Sr-89.
Multiple failure model
As seen in the Descriptive statistics of skeletal-related events, patients experience multiple SREs. The
previous time-to-event analysis looks at only time-to-first event, not taking multiple SREs into account.
The following section takes the multiple events into account, as detailed in this section’s statistical methods.
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FIGURE 15 Kaplan–Meier survival estimates of SREFIs by comparison group: ZA. Reproduced with permission from
JAMA Oncol, 2016;2(4):493–9. Copyright © (2016) American Medical Association. All rights reserved.51
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FIGURE 16 Kaplan–Meier survival estimates of SREFI by comparison group: Sr-89. Reproduced with permission from
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There were 33 instances where patients experienced multiple SREs on the same day; for the purposes of
this analysis such events were counted as a single event.
Zoledronic acid versus no zoledronic acid
In total, there were 996 events: 584 (59%) in the no ZA group and 412 (41%) in the ZA group. A stratified
log-rank test comparing ZA with no ZA demonstrated a statistically significant difference in SREFIs between
the two groups (χ2= 31.39; p< 0.001). The median survival time in the ZA group was 11.5 months (95% CI
10.61 to 12.65 months), compared with 8.87 months (95% CI 7.85 to 9.66 months) in the no ZA group.
A Cox proportional hazards model was used to estimate the HR (HR 0.70, 95% CI 0.62 to 0.79; p< 0.001).
Figure 18 shows the Kaplan–Meier survival estimates split by comparison ZA.
Strontium-89 versus no strontium-89
In total, there were 996 events: 518 (52%) in the no Sr-89 group and 478 (48%) in the Sr-89 group. A
stratified log-rank test performed to compare Sr-89 with no Sr-89 observed no difference in SREFI between
the two groups (χ2= 3.11; p= 0.078). The median survival time in the Sr-89 group was 10.41 months (95% CI
9.69 to 11.14 months), compared with 9.86 months (95% CI 9.13 to 10.81 months) in the no Sr-89 group.
A Cox proportional hazards model was used to estimate the HR (HR 0.89, 95% CI 0.79 to 1.01;
p= 0.078). Figure 19 shows the Kaplan–Meier survival estimates split by Sr-89 comparison.
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FIGURE 17 Kaplan–Meier survival estimates of SREFIs by Sr-89.
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FIGURE 18 Kaplan–Meier survival estimates for SREFI multiple failure model by ZA comparison.
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Pain progression-free interval
Statistical methods
The primary analysis was a stratified log-rank test comparing ZA with no ZA, stratified by Sr-89, and Sr-89
with no Sr-89, stratified by ZA. Conclusions were based on a two-sided 5% significance level. No
adjustments for multiple testing were made.
Zoledronic acid versus no zoledronic acid
In total, there were 432 events: 225 (52%) in the no ZA group and 207 (48%) in the ZA group.
A stratified log-rank test was performed comparing ZA with no ZA. No difference in PPFI between the
two groups was observed (χ2= 1.02; p= 0.3127). The median progression-free survival time in the ZA
group was 12.19 months (95% CI 10.78 to 15.38 months), compared with 11.76 months (95% CI
10.55 to 13.37 months) in the no ZA group.
A Cox proportional hazards model was used to estimate the HR (HR 0.91, 95% CI 0.75 to 1.10; p= 0.313).
Figure 20 shows the Kaplan–Meier survival estimates split by ZA comparison.
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FIGURE 19 Kaplan–Meier survival estimates for SREFI multiple failure model by Sr-89 comparison.
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FIGURE 20 Kaplan–Meier survival estimates for PPFI by ZA.
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Strontium-89 versus no strontium-89
In total, there were 432 events: 215 (50%) in the no Sr-89 group and 217 (50%) in the Sr-89 group.
A stratified log-rank test was performed comparing Sr-89 with no Sr-89. No difference in PPFI between the
two groups was observed (χ2= 0.40; p= 0.3991). The median PPFI time in the Sr-89 group was 12.22 months
(95% CI 10.94 to 14.09 months), compared with 11.76 months (95% CI 10.32 to 13.54 months) in the
no Sr-89 group.
A Cox proportional hazards model was used to estimate the HR (HR 0.92, 95% CI 0.76 to 1.11; p= 0.387).
Figure 21 shows the Kaplan–Meier survival estimates split by Sr-89 comparison.
Overall survival
Statistical methods
The primary analysis was a stratified log-rank comparing ZA with no ZA, stratified by Sr-89, and Sr-89
versus no Sr-89, stratified by ZA. Conclusions were based on a two-sided 5% significance level.
No adjustments for multiple testing were made.
Descriptive statistics of deaths
In total, 618 patients died. Tables 35 and 36 list the reported causes of death split by randomisation arm
and comparison groups.
Overall survival: zoledronic acid versus no zoledronic acid
In total, there were 618 events: 309 (50%) occurred in each group. A stratified log-rank test performed to
compare ZA with no ZA demonstrated no difference in OS between the two groups (χ2= 0.01; p= 0.909).
The median survival time in the ZA group was 16.99 months (95% CI 16.07 to 19.23 months), compared
with 17.61 months (95% CI 16.10 to 18.96 months) in the no ZA group.
A Cox proportional hazards model was used to estimate the HR (HR 0.99, 95% CI 0.84 to 1.16; p= 0.870).
Figure 22 shows the Kaplan–Meier survival estimates split by ZA comparison.
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FIGURE 21 Kaplan–Meier survival estimates for PPFI by Sr-89.
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TABLE 35 Cause of death by randomisation arm
Cause of death
Docetaxel
(N= 154)
Docetaxel+ ZA
(N= 156)
Docetaxel+ Sr-89
(N=155)
Docetaxel+ZA+
Sr-89 (N=153)
Overall
(N= 618)
n % n % n % n % n %
Disease related 122 91.0 118 84.9 128 92.1 122 89.1 490 89.3
Trial treatment related 0 0.0 4 2.9 0 0.0 0 0.0 4 0.7
Disease and trial treatment
related
0 0.0 1 0.7 0 0.0 1 0.7 2 0.4
Other cancer 0 0.0 0 0.0 0 0.0 1 0.7 1 0.2
Other non-cancer 11 8.2 15 10.8 10 7.2 12 8.8 48 8.7
Non-trial treatment related 1 0.7 1 0.7 1 0.7 1 0.7 4 0.7
Unknown 20 – 17 – 16 – 16 – 69 –
Total 134 100.0 139 100.0 139 100.0 137 100.0 549 100.0
TABLE 36 Cause of death by comparison group
Cause of death
No ZA (N= 309) ZA (N= 309) No Sr-89 (N= 310) Sr-89 (N= 308)
n % n % n % n %
Disease related 250 91.6 240 87 240 87.9 250 90.6
Trial treatment related 0 0 4 1.4 4 1.5 0 0
Disease and trial treatment related 0 0 2 0.7 1 0.4 1 0.4
Other cancer 0 0 1 0.4 0 0 1 0.4
Other non-cancer 21 7.7 27 9.8 26 9.5 22 8
Non-trial treatment related 2 0.7 2 0.7 2 0.7 2 0.7
Unknown 36 – 33 – 37 – 32 –
Total 273 100 276 100 273 100 276 100
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FIGURE 22 Kaplan–Meier estimates of OS by ZA.
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Strontium-89 versus no strontium-89
In total, there were 618 events: 310 (50%) in the no Sr-89 group and 308 in the Sr-89 (50%) group.
A stratified log-rank test performed to compare Sr-89 with no Sr-89 demonstrated no difference in OS
between the two groups (χ2= 0.93; p= 0.3359). The median survival time in the Sr-89 group was
18.17 months (95% CI 16.66 to 19.12 months), compared with 16.59 months (95% CI 15.61
to 18.27 months) in the no Sr-89 group.
A Cox proportional hazards model was used to estimate the HR (HR 0.92, 95% CI 0.79 to 1.08; p= 0.323).
Figure 23 shows the Kaplan–Meier survival estimates split by Sr-89 comparison.
Quality of life
Statistical methods
The EQ-5D, VAS and FACT-P are presented descriptively using means, standard deviations and ranges for
the comparison groups. In addition, all are presented graphically to look for patterns emerging over time.
It was also considered that SREs may have an effect on patients’ QoL; therefore, patients were categorised
as having no SREs, mild SREs or severe SREs, and these were investigated descriptively. In all cases, missing
data for single items on questionnaires were dealt with in accordance with the manuals provided.
Quality-adjusted life-year analysis using subject-based approaches
Quality-adjusted life-years were utilised in two ways: subject- and group-based approaches. The first
approach to QALY analysis was area-under-the-curve analysis, which was employed to investigate whether
or not there were any differences between the comparison groups. As is usual with QoL data, there are
more missing data towards the end of life. Therefore, three different methods were used to calculate
QALYs to assess the impact of different assumptions, which can be seen in Figure 24. All deceased
patients were treated in the same way. As only minimal changes in EQ-5D scores over time had been
observed, the last QoL score was carried forward to the date the patient was last known to be alive and
then a diagonal line was imputed from that date to date of death (see Figure 24a). For those patients still
alive at the time of analysis, three separate approaches were taken. The first (see Figure 24b) made no
imputation and the curve was dropped straight down at the date of the last EQ-5D score. This is a
conservative approach, as it makes the inference that the patient died on the day his last EQ-5D
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FIGURE 23 Kaplan–Meier estimates of OS by Sr-89.
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FIGURE 24 Method of calculating QALYs. (a) Deceased patients; (b) alive patients: conservative approach; (c) alive
patients: standard approach; and (d) alive patients: optimistic approach. (continued )
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questionnaire was collected. The other extreme of this was termed the optimistic approach (see Figure 24d);
this approach carried the last EQ-5D score forward to the date last seen and then assumed that the patient
survived for the same amount of time as the longest-surviving patient in the study and a diagonal line was
imputed to that point. The third approach (see Figure 24c) is a middle ground between the conservative
and optimistic approaches. The EQ-5D score is carried forward to the date last seen and drops to zero at
that point, therefore imputing EQ-5D scores up to the date that the patient was known to be alive but not
beyond this point.
Quality-adjusted life-year analysis using group-based approaches
The second approach to QALY analysis was a pre-specified group-based quality-adjusted survival analysis
conducted to assess the balance between QoL and survival. This approach takes account of dropout due
to death and censoring. As the median overall survival in the trial was 1.4 years, 2 years was deemed the
appropriate cut-off point for the quality-adjusted survival. The integrated quality survival product is the
product of the survival53 and EQ-5D QoL measures over the 2-year time period of interest. It is calculated
using the following equation:
QAS(24) =∫ 24
0
Q(t)S(t)dt, (1)
where S(t) is the proportion of patients who survive to time t and Q(t) is the mean EQ-5D QoL associated with
those survivors. This methodology of integrating QoL and survival was carried out at a group level for both the
ZA and Sr-89 comparisons. The area under the curve at 2 years gave the mean QALY for each group. Standard
errors were calculated and 95% CIs constructed using bootstrapping techniques with 1000 replications.
Results
In total, 6100 QoL booklets were returned: 5802 (95%) had complete EQ-5D data, 5806 (95%) had
complete EQ-5D VAS data and 5573 (91%) had complete FACT-P data.
The 6100 forms were completed by 707 patients, leaving 50 patients for whom no QoL data were
available. These patients are therefore excluded from this section of the report.
Patients returned, on average, six questionnaires: 40 patients returned only one form and one patient
returned 22 forms.
EQ
-5
D
 s
co
re
(d)
Time
Date last seen Longest
survival
in trial
EQ-5D score
FIGURE 24 Method of calculating QALYs. (a) Deceased patients; (b) alive patients: conservative approach; (c) alive
patients: standard approach; and (d) alive patients: optimistic approach.
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Of the 707 patients, 572 had died at the time of analysis and 135 remained alive and on follow-up. The
median time from completing the last QoL form to death was 193 days (IQR 86–381 days), meaning that,
on average, two questionnaires are missing at the end of a patient’s life. For those patients alive, the
median time from last QoL form to date last seen was 231 days (IQR 59–434 days). Again, there were, on
average, two missing questionnaires. Figure 25 shows the points at which each questionnaire was returned.
Six distinct lines can be seen at the start of the graph; these relate to the first six cycles of treatment.
Subsequently, among those patients receiving Sr-89, there would be a longer gap between cycles 6 and 7.
At this point, a large number of patients also started to progress and, thus, were withdrawn from
treatment. As a result, their schedule of completion of QoL questionnaires changed, which explains why
there was no discernible pattern after the first six chemotherapy cycles.
Health state thermometer
As mentioned previously, the EQ-5D VAS is a self-completed measure resembling a thermometer ranging
from 0 to 100, on which patients mark how well they feel on any specific day. Table 37 shows the average
EQ-5D VAS scores for each of the comparison groups throughout the trial.
There is no discernible difference in health state overall. Figure 26 shows the health state by ZA comparison
over time and the number of deaths over time; it also shows this split by SRE severity.
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FIGURE 25 Quality-of-life questionnaire timings. TNO, trial number.
TABLE 37 Visual analogue scale split by ZA and Sr-89
Health state (score range: 0–100) No ZA (N= 2905) ZA (N= 2996) No Sr-89 (N= 2920) Sr-89 (N= 2981)
n 2905 2996 2920 2981
Mean (SD) 70.4 (19.5) 72.4 (17.6) 70.9 (18.4) 71.9 (18.7)
Range 0.0–100.0 0.0–100.0 0.0–100.0 0.0–100.0
SD, standard deviation.
N= number of QoL questionnaires returned.
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Once the treatment period is complete, at about 6 months, the QoL of patients not receiving ZA seems
to be consistently lower, particularly among those experiencing severe SREs, as would be expected.
Figure 27 below shows the health state by Sr-89 comparison over time and the number of deaths
over time; it also shows this split by SRE severity.
Again, the QoL of those receiving Sr-89 appears to be consistently lower following the completion
of treatment.
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FIGURE 26 Visual analogue scale scores over time (lines) and number of deaths (boxes) by ZA comparison.
(a) VAS score by ZA; and (b) VAS score by worst SRE and ZA.
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FIGURE 27 Visual analogue scale scores over time (lines) and number of deaths (boxes) by Sr-89 comparison.
(a) VAS score by Sr-89; and (b) VAS score by worst SRE and Sr-89.
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Functional Assessment of Cancer Therapy – Prostate
Table 38 shows the average score over the whole trial for each of the FACT-P subscales split by
comparison groups.
As with health state scales, there are very few differences across the comparison groups overall. Figure 28
shows a series of six graphs of the FACT-P subscale score over time split by ZA groups. Figure 28f also
includes a bar chart of the numbers of deaths over time.
Each of the curves appears to show an increase in QoL within the first 2 months. It is most pronounced in
the prostate cancer subscale and perhaps shows the positive effect of treatment in this patient population.
The scales level off relatively quickly and remain constant and there is no visible decline in QoL; this is almost
certainly at least in part due to missing data at the end of patients lives. The ZA line is very slightly higher in
all of the graphs, and this is particularly apparent on the FACT-P graph, which is a summation of all of the
subscales combined. Figure 29 shows the same series of graphs for Sr-89.
TABLE 38 Average scores for FACT-P subscales by comparison groups
FACT-P No ZA (N= 3005) ZA (N= 3095) No Sr-89 (N= 3022) Sr-89 (N= 3078)
Physical well-being (score range: 0–28)
n 2901 2993 2913 2981
Mean (SD) 21.7 (5.0) 22.1 (4.7) 21.7 (5.0) 22.1 (4.8)
Range 0.0–28.0 0.0–28.0 0.0–28.0 0.0–28.0
Social well-being (score range: 0–28)
n 2914 3000 2921 2993
Mean (SD) 22.7 (4.5) 23.2 (4.3) 23.1 (4.5) 22.8 (4.2)
Range 0.0–28.0 0.0–28.0 0.0–28.0 0.0–28.0
Emotional well-being (score range: 0–24)
n 2866 2970 2885 2951
Mean (SD) 18.9 (4.4) 19.3 (4.0) 18.9 (4.4) 19.2 (4.0)
Range 0.0–24.0 2.0–24.0 0.0–24.0 0.0–24.0
Functional well-being (score range: 0–28)
n 2897 3004 2923 2978
Mean (SD) 18.4 (6.5) 18.9 (6.2) 18.5 (6.4) 18.8 (6.3)
Range 0.0–28.0 0.0–28.0 0.0–28.0 0.0–28.0
Prostate cancer (score range: 0–48)
n 2901 3012 2916 2997
Mean (SD) 32.9 (7.7) 33.2 (7.4) 32.9 (7.5) 33.2 (7.6)
Range 3.0–48.0 6.5–48.0 3.0–48.0 3.0–48.0
FACT-P (score range: 0–156)
n 2729 2844 2746 2827
Mean (SD) 114.6 (22.2) 116.9 (20.8) 115.2 (21.8) 116.3 (21.2)
Range 29.0–156.0 44.0–156.0 44.0–156.0 29.0–156.0
SD, standard deviation.
N= number of QoL forms.
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FIGURE 28 Functional Assessment of Cancer Therapy – Prostate subscales over time by ZA. (a) Physical well-being;
(b) social well-being; (c) emotional well-being; (d) functional well-being; (e) prostate cancer; and (f) FACT-P. (continued)
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FIGURE 28 Functional Assessment of Cancer Therapy – Prostate subscales over time by ZA. (a) Physical well-being;
(b) social well-being; (c) emotional well-being; (d) functional well-being; (e) prostate cancer; and (f) FACT-P.
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FIGURE 29 Functional Assessment of Cancer Therapy – Prostate subscale over time by Sr-89. (a) Physical well-being;
(b) social well-being; (c) emotional well-being; (d) functional well-being; (e) prostate cancer; and (f) FACT-P. (continued)
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FIGURE 29 Functional Assessment of Cancer Therapy – Prostate subscale over time by Sr-89. (a) Physical well-being;
(b) social well-being; (c) emotional well-being; (d) functional well-being; (e) prostate cancer; and (f) FACT-P.
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As seen previously, there is an increased QoL in the first 2 months. However, there appears to be no
difference between the Sr-89 comparison groups in terms of social well-being, and this has contributed to
the much reduced differences observed in the overall FACT-P scale. Figures 30 and 31 show the same
six graphs, but they also split by SRE severity.
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FIGURE 30 Functional Assessment of Cancer Therapy – Prostate subscale over time by SRE severity and ZA.
(a) Physical well-being; (b) social well-being; (c) emotional well-being; (d) functional well-being; (e) prostate cancer;
and (f) FACT-P. (continued )
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FIGURE 30 Functional Assessment of Cancer Therapy – Prostate subscale over time by SRE severity and ZA.
(a) Physical well-being; (b) social well-being; (c) emotional well-being; (d) functional well-being; (e) prostate cancer;
and (f) FACT-P.
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FIGURE 31 Functional Assessment of Cancer Therapy – Prostate subscale over time by SRE severity and Sr-89.
(a) Physical well-being; (b) social well-being; (c) emotional well-being; (d) functional well-being; (e) prostate cancer;
and (f) FACT-P. (continued )
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FIGURE 31 Functional Assessment of Cancer Therapy – Prostate subscale over time by SRE severity and Sr-89.
(a) Physical well-being; (b) social well-being; (c) emotional well-being; (d) functional well-being; (e) prostate cancer;
and (f) FACT-P.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
European Quality of Life 5-Dimensions
Gains in QALYS measured using the three methods are detailed in Table 39, split by Sr-89 and ZA.
These findings again support the previous QoL investigations in that no difference between comparison
groups is apparent. The three different methods of calculating QALYs do affect the estimates, but the
differences between the groups remained consistent. Figure 32 shows the actual returned values of the
EQ-5D over time split by SRE severity and ZA.
The increase in QoL in the first 2 months is again present. Figure 33 is the same as Figure 32, but split by Sr-89.
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FIGURE 32 European Quality of Life 5-Dimensions over time by ZA and SRE Severity. (a) EQ-5D by ZA; and
(b) EQ-5D by worst SRE and ZA.
TABLE 39 Quality-adjusted life-years by comparison groups
QALYs No ZA (N= 357) ZA (N= 350) No Sr-89 (N= 357) Sr-89 (N= 350)
Conservative
n 357 350 357 350
Mean QALYs gained (SD) 0.8 (0.6) 0.8 (0.6) 0.8 (0.6) 0.8 (0.6)
Range –0.2 to 4.2 –0.1 to 3.6 –0.1 to 4.2 –0.2 to 4.1
Standard
n 357 350 357 350
Mean QALYs gained (SD) 0.9 (0.7) 0.9 (0.7) 0.9 (0.7) 0.9 (0.7)
Range –0.2 to 4.3 –0.1 to 3.6 –0.1 to 4.3 –0.2 to 4.1
Optimistic
n 357 350 357 350
Mean QALYs gained (SD) 1.2 (1.1) 1.2 (1.1) 1.1 (1.1) 1.2 (1.1)
Range –0.2 to 5.2 –0.4 to 4.6 –0.1 to 5.2 –0.4 to 4.7
SD, standard deviation.
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Quality-adjusted survival
Quality-adjusted survival within 2 years split by the comparison groups is detailed in Table 40.
Adjusting for QoL does not change the conclusions of the overall survival analysis alone. There were no
statistically or clinically meaningful differences between either comparison group. The 2-year quality-adjusted
survival is approximately 1 year in all comparison arms, which is 4 to 6 months shorter than the survival
analysis alone. Figures 34 and 35 illustrate the QoL function, the survival function and the integrated quality
survival product for the two comparison groups.
The Sr-89 integrated survival product does show a slight difference, with those receiving Sr-89 gaining
approximately one additional quality-adjusted survival month.
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FIGURE 33 European Quality of Life 5-Dimensions over time by Sr-89 and SRE severity. (a) EQ-5D by Sr-89;
and (b) EQ-5D by worst SRE and Sr-89.
TABLE 40 Quality-adjusted survival at 2 years by comparison groups
Comparitor
No ZA ZA No Sr-89 Sr-89
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
Mean life-years gained
(within 2 years)
1.47 (1.34 to 1.58) 1.42 (1.34 to 1.59) 1.38 (1.30 to 1.52) 1.51 (1.39 to 1.59)
Quality-adjusted survival
(within 2 years)
1.00 (0.93 to 1.10) 1.04 (0.98 to 1.10) 0.97 (0.991 to 1.03) 1.05 (0.99 to 1.12)
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FIGURE 34 Quality-adjusted survival split by ZA group. (a) EQ-5D QoL function, Q(t); (b) survival function, S(t);
and (c) integrated quality survival product.
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FIGURE 35 Quality-adjusted survival split by Sr-89 group. (a) EQ-5D QoL function, Q(t); (b) survival function,
S(t); and (c) integrated quality survival product.
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Adverse events
Timing of events
In total, 493 grade 3 or 4 adverse events (AEs) were reported. In addition, 313 events without a grade
were reported and 161 without a start date were reported, making it impossible to determine whether
these events occurred on- or off-treatment.
Additionally, there were 178 (24%) patients who reported no grade 3 or 4 AEs, while 27 patients reported
experiencing AEs but did not receive any treatment. Table 41 shows the grading and timing of all AEs.
Tables 42 and 43 show the percentages of patients at each time point who reported at least one grade 3
or 4 event, split by randomisation arm and comparison group.
Tables 41–43 indicate that there was a peak in adverse events at cycle 6. This may have been a function
of increased scrutiny at this time point to ensure that patients were well enough to receive additional
treatment, which was particularly important for those randomised to receive Sr-89.
TABLE 41 Adverse event timings
Time point
Grade 3 (N= 447) Grade 4 (N= 46) Missing (N= 313) Overall (N= 806)
n % n % n % n %
Pre-treatment 13 2.9 4 8.7 8 2.6 25 3.1
Cycle 1 101 22.6 11 23.9 38 12.1 150 18.6
Cycle 2 55 12.3 10 21.7 23 7.3 88 10.9
Cycle 3 52 11.6 5 10.9 18 5.8 75 9.3
Cycle 4 31 6.9 5 10.9 16 5.1 52 6.5
Cycle 5 38 8.5 3 6.5 7 2.2 48 6.0
Cycle 6 81 18.1 4 8.7 54 17.3 139 17.2
Cycle 7 18 4.0 2 4.3 2 0.6 22 2.7
Cycle 8 10 2.2 0 0.0 1 0.3 11 1.4
Cycle 9 5 1.1 0 0.0 4 1.3 9 1.1
Cycle 10 3 0.7 1 2.2 0 0.0 4 0.5
Follow-up 1 6 1.3 0 0.0 5 1.6 11 1.4
Follow-up 2 1 0.2 1 2.2 0 0.0 2 0.2
Follow-up 3 3 0.7 0 0.0 1 0.3 4 0.5
Follow-up 4 5 1.1 0 0.0 0 0.0 5 0.6
Unknown 25 5.6 0 0.0 136 43.5 161 20.0
Total 447 100.0 46 100.0 313 100.0 806 100.0
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TABLE 42 Percentages of patients experiencing grade 3 or 4 AEs
Time point
Docetaxel
(%)
Docetaxel+ ZA
(%)
Docetaxel+ Sr-89
(%)
Docetaxel+ ZA+ Sr-89
(%)
Overall
(%)
Cycle 1 14.0 17.2 12.7 17.6 15.4
Cycle 2 12.8 4.8 8.6 11.1 9.4
Cycle 3 7.1 8.6 11.4 7.2 8.6
Cycle 4 4.4 5.1 10.5 3.2 5.8
Cycle 5 7.4 6.1 6.3 8.1 7.0
Cycle 6 10.2 13.6 17.7 22.6 16.1
Cycle 7 20.0 10.5 6.1 3.9 9.9
Cycle 8 2.6 3.8 4.5 11.4 5.6
Cycle 9 2.9 9.3 0 0 3.2
Cycle 10 3.8 5.9 2.9 0 3.1
Follow-up 1 0 3.2 0.7 0 1.0
Follow-up 2 0.7 0 0.7 0 0.3
Follow-up 3 0 0.7 1.6 0 0.6
Follow-up 4 0.9 3.4 0 0 1.1
TABLE 43 Percentage of patients with grade 3 or 4 AEs
Time point No ZA (%) ZA (%) No Sr-89 (%) Sr-89 (%)
Cycle 1 13.4 17.4 15.6 15.2
Cycle 2 10.7 8.0 9.0 9.8
Cycle 3 9.2 8.0 7.8 9.3
Cycle 4 7.4 4.2 4.8 6.8
Cycle 5 6.8 7.1 6.8 7.2
Cycle 6 14.0 18.2 11.9 20.2
Cycle 7 12.8 7.4 14.7 5.0
Cycle 8 3.7 7.2 3.3 8.0
Cycle 9 1.4 5.0 6.5 0
Cycle 10 3.3 2.9 5.0 1.4
Follow-up 1 0.3 1.6 1.6 0.3
Follow-up 2 0.7 0 0.3 0.4
Follow-up 3 0.8 0.4 0.4 0.8
Follow-up 4 0.5 1.7 2.2 0
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Grade and number of adverse events
Figures 36 and 37 show the grade and number of AEs over time, split by comparisons. The graphs show
that grade 3 and 4 AEs peak at cycle 1 and cycle 6. There appear to be additional events associated with
Sr-89 at cycle 6, which makes sense, as this would include the time during which Sr-89 is administered,
but there is no evidence to suggest that these effects are long-lasting. In terms of ZA, increased numbers
of events are seen at both peaks. However, it is worth noting that the magnitude of these differences is
only 10 individual events.
Figure 38 shows the time and type of any AE where at least five or more instances were observed at one
time point. This is split by comparison groups.
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FIGURE 36 Grade and number of AEs over time by ZA comparison. (a) No ZA; and (b) ZA.
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FIGURE 37 Grade and number of AEs over time by Sr-89 comparison. (a) No Sr-89; and (b) Sr-89.
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FIGURE 38 Frequency of AEs over time. (a) No ZA; (b) no Sr-89; (c) ZA; and (d) Sr-89.
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Adverse event symptoms
Tables 44–46 show the adverse event symptoms reported by randomisation arm separately for grades 3
and 4 and missing grades.
The most common grade 4 events were infection- and blood/bone marrow-related. However, it did not
appear to be the case that the combined arm containing both ZA and Sr-89 was experiencing more
grade 4 AEs.
TABLE 44 Symptoms of grade 3 AEs
Category as defined in
Common Terminology
Criteria for Adverse
Events, version 354
Docetaxel
(N= 106)
Docetaxel+ ZA
(N= 109)
Docetaxel+ Sr-89
(N= 117)
Docetaxel+ ZA+
Sr-89 (N= 115)
Overall
(N= 447)
n % n % n % n % n %
Pulmonary/upper respiratory 8 7.5 3 2.8 0 0.0 0 0.0 11 2.5
Pain 16 15.1 10 9.2 16 13.7 11 9.6 53 11.9
Haemorrhage/bleeding 0 0.0 0 0.0 1 0.9 1 0.9 2 0.4
Ocular/visual 0 0.0 0 0.0 0 0.0 1 0.9 1 0.2
Constitutional symptoms 13 12.3 10 9.2 20 17.1 12 10.4 55 12.3
Allergy/immunology 3 2.8 1 0.9 0 0.0 0 0.0 4 0.9
Musculoskeletal/soft tissue 1 0.9 4 3.7 5 4.3 2 1.7 12 2.7
Neurology 7 6.6 10 9.2 8 6.8 5 4.3 30 6.7
Lymphatics 4 3.8 2 1.8 2 1.7 9 7.8 17 3.8
Renal/genitourinary 0 0.0 5 4.6 2 1.7 7 6.1 14 3.1
Dermatology/skin 6 5.7 7 6.4 6 5.1 2 1.7 21 4.7
Vascular 0 0.0 1 0.9 1 0.9 4 3.5 6 1.3
Infection 16 15.1 15 13.8 12 10.3 12 10.4 55 12.3
Metabolic/laboratory 9 8.5 12 11.0 11 9.4 15 13.0 47 10.5
Blood/bone marrow 13 12.3 20 18.3 21 17.9 17 14.8 71 15.9
Cardiac general 0 0.0 0 0.0 2 1.7 0 0.0 2 0.4
Sexual/reproductive
function
0 0.0 1 0.9 0 0.0 0 0.0 1 0.2
Cardiac arrhythmia 0 0.0 0 0.0 0 0.0 2 1.7 2 0.4
Syndromes 0 0.0 0 0.0 1 0.9 1 0.9 2 0.4
Endocrine 0 0.0 0 0.0 0 0.0 1 0.9 1 0.2
Gastrointestinal 10 9.4 8 7.3 9 7.7 13 11.3 40 8.9
Total 106 100.0 109 100.0 117 100.0 115 100.0 447 100.0
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TABLE 45 Symptoms of grade 4 AEs
Category as defined in
Common Terminology
Criteria for Adverse
Events, version 354
Docetaxel
(N= 15)
Docetaxel+ ZA
(N= 9)
Docetaxel+ Sr-89
(N= 12)
Docetaxel+ ZA+
Sr-89 (N= 10)
Overall
(N= 46)
n % n % n % n % n %
Pulmonary/upper respiratory 1 6.7 0 0.0 0 0.0 0 0.0 1 2.2
Pain 0 0.0 0 0.0 0 0.0 1 10.0 1 2.2
Neurology 0 0.0 0 0.0 1 8.3 1 10.0 2 4.3
Vascular 1 6.7 3 33.3 0 0.0 0 0.0 4 8.7
Infection 5 33.3 1 11.1 4 33.3 2 20.0 12 26.1
Metabolic/laboratory 1 6.7 2 22.2 1 8.3 0 0.0 4 8.7
Blood/bone marrow 5 33.3 3 33.3 6 50.0 6 60.0 20 43.5
Cardiac general 2 13.3 0 0.0 0 0.0 0 0.0 2 4.3
Total 15 100.0 9 100.0 12 100.0 10 100.0 46 100.0
TABLE 46 Symptoms of AEs of unknown grade
Category as defined in
Common Terminology
Criteria for Adverse
Events, version 354
Docetaxel
(N= 91)
Docetaxel+ ZA
(N= 73)
Docetaxel+ Sr-89
(N= 78)
Docetaxel+ ZA+
Sr-89 (N= 71)
Overall
(N= 313)
n % n % n % n % n %
Pulmonary/upper respiratory 2 2.5 1 1.8 2 3.2 3 5.5 8 3.1
Pain 22 27.5 14 25.0 15 23.8 14 25.5 65 25.6
Haemorrhage/bleeding 1 1.3 0 0.0 0 0.0 0 0.0 1 0.4
Ocular/visual 0 0.0 0 0.0 1 1.6 0 0.0 1 0.4
Constitutional symptoms 6 7.5 9 16.1 5 7.9 3 5.5 23 9.1
Allergy/immunology 1 1.3 0 0.0 0 0.0 0 0.0 1 0.4
Musculoskeletal/soft tissue 4 5.0 5 8.9 2 3.2 3 5.5 14 5.5
Neurology 2 2.5 1 1.8 5 7.9 3 5.5 11 4.3
Lymphatics 4 5.0 4 7.1 4 6.3 2 3.6 14 5.5
Renal/genitourinary 0 0.0 2 3.6 2 3.2 2 3.6 6 2.4
Dermatology/skin 2 2.5 5 8.9 8 12.7 4 7.3 19 7.5
Infection 5 6.3 3 5.4 2 3.2 2 3.6 12 4.7
Metabolic/laboratory 0 0.0 0 0.0 0 0.0 2 3.6 2 0.8
Blood/bone marrow 4 5.0 3 5.4 2 3.2 4 7.3 13 5.1
Cardiac general 1 1.3 0 0.0 0 0.0 0 0.0 1 0.4
Cardiac arrhythmia 0 0.0 0 0.0 1 1.6 0 0.0 1 0.4
Syndromes 3 3.8 0 0.0 0 0.0 0 0.0 3 1.2
Endocrine 0 0.0 0 0.0 2 3.2 0 0.0 2 0.8
Gastrointestinal 22 27.5 9 16.1 12 19.0 13 23.6 56 22.0
Secondary malignancy 1 1.3 0 0.0 0 0.0 0 0.0 1 0.4
Missing 11 – 17 – 15 – 16 – 59 –
Total 80 100.0 56 100.0 63 100.0 55 100.0 254 100.0
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Serious adverse events
In total, 583 SAEs were reported, with 1064 associated symptoms, relating to 373 (49%) patients. Tables 47
and 48 show the categorisation of the 583 SAEs by both randomisation arm and comparison group.
Tables 49 and 50 show the number of SAEs experienced per patient, split by randomisation arm and
comparison group.
Approximately 50% of patients in each comparison group experienced at least one SAE, with approximately
20% going on to have multiple SAEs.
TABLE 47 Serious adverse event categorisations by randomisation arm
SAE categorisation
Docetaxel
(N= 133)
Docetaxel+ ZA
(N= 164)
Docetaxel+
Sr-89 (N= 146)
Docetaxel+ZA+
Sr-89 (N=140)
Overall
(N= 583)
n % n % n % n % n %
Unrelated SAE 56 42.1 96 58.5 67 45.9 67 47.9 286 49.1
SAR 73 54.9 65 39.6 73 50.0 65 46.4 276 47.3
Non-fatal/life-threatening
SUSAR
1 0.8 1 0.6 3 2.1 1 0.7 6 1.0
Fatal/life-threatening SUSAR 3 2.3 2 1.2 3 2.1 7 5.0 15 2.6
Total 133 100.0 164 100.0 146 100.0 140 100.0 583 100.0
SAR, serious adverse reaction; SUSAR, suspected unexpected serious adverse reaction.
TABLE 48 Serious adverse event categorisations by ZA and Sr-89 comparison
SAE categorisation
No ZA (N= 279) ZA (N= 304) No Sr-89 (N= 297) Sr-89 (N= 286)
n % n % n % n %
Unrelated SAE 123 44.1 163 53.6 152 51.2 134 46.9
SAR 146 52.3 130 42.8 138 46.5 138 48.3
Non-fatal/life-threatening SUSAR 4 1.4 2 0.7 2 0.7 4 1.4
Fatal/life-threatening SUSAR 6 2.2 9 3.0 5 1.7 10 3.5
Total 279 100.0 304 100.0 297 100.0 286 100.0
SAR, serious adverse reaction; SUSAR, suspected unexpected serious adverse reaction.
TABLE 49 Number of SAEs per patient by randomisation arm
Number of SAEs per patient
Docetaxel
(N= 191)
Docetaxel+ ZA
(N= 188)
Docetaxel+ Sr-89
(N= 190)
Docetaxel+ ZA+
Sr-89 (N= 188)
Overall
(N= 757)
n % n % n % n % n %
1 48 25 72 38 64 34 49 26 233 31
2 24 13 17 9 23 12 24 13 88 12
3 11 6 11 6 5 3 11 6 38 5
4 1 0 5 3 4 2 1 < 1 11 1
5 0 0 1 < 1 1 < 1 0 0 2 < 1
6 0 0 0 0 0 0 1 < 1 1 < 1
Patients with ≥ 1 SAE 84 44 106 56 97 51 86 46 373 49
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Reasons for serious adverse events
Tables 51 and 52 show the reasons for SAEs split by both randomisation arm and comparison groups.
By far the most common reason for reporting an SAE was hospitalisation, which alone accounted for
80% of all SAEs.
TABLE 50 Number of SAEs per patient by ZA and Sr-89 comparison group
Number of SAEs per patient
No ZA (N= 381) ZA (N= 376) No Sr-89 (N= 379) Sr-89 (N= 378)
n % n % n % n %
1 112 30 121 32 120 32 113 30
2 47 12 41 11 41 11 47 12
3 16 4 22 6 22 6 16 4
4 5 1 6 2 6 1 5 1
5 1 < 1 1 < 1 1 < 1 1 < 1
6 0 0 1 < 1 0 0 1 < 1
Patients with ≥ 1 SAE 181 47 192 51 190 50 183 48
TABLE 51 Serious adverse event reasons by randomisation arm
New reason
Docetaxel
(N= 133)
Docetaxel+ ZA
(N= 164)
Docetaxel+ Sr-89
(N= 146)
Docetaxel+ ZA+
Sr-89 (N= 140)
Overall
(N= 583)
n % n % n % n % n %
Death 1 0.8 7 4.3 8 5.5 9 6.4 25 4.3
Death and disability 0 0.0 1 0.6 0 0.0 0 0.0 1 0.2
Death and hospitalisation 4 3.0 5 3.0 7 4.8 9 6.4 25 4.3
Death and other 0 0.0 0 0.0 0 0.0 1 0.7 1 0.2
Death, hospitalisation and
disability
1 0.8 0 0.0 0 0.0 0 0.0 1 0.2
Death, life-threatening and
hospitalisation
1 0.8 2 1.2 0 0.0 2 1.4 5 0.9
Death, life-threatening,
hospitalisation and other
0 0.0 0 0.0 0 0.0 1 0.7 1 0.2
Disability 0 0.0 2 1.2 1 0.7 1 0.7 4 0.7
Hospitalisation 115 86.5 124 75.6 117 80.1 111 79.3 467 80.1
Hospitalisation and disability 3 2.3 4 2.4 1 0.7 3 2.1 11 1.9
Hospitalisation and other 2 1.5 2 1.2 2 1.4 0 0.0 6 1.0
Hospitalisation, disability
and other
1 0.8 1 0.6 0 0.0 0 0.0 2 0.3
Life-threatening 0 0.0 1 0.6 1 0.7 0 0.0 2 0.3
Life-threatening and
hospitalisation
3 2.3 12 7.3 4 2.7 3 2.1 22 3.8
New primary cancer 1 0.8 0 0.0 0 0.0 0 0.0 1 0.2
Other 1 0.8 3 1.8 5 3.4 0 0.0 9 1.5
Total 133 100.0 164 100.0 146 100.0 140 100.0 583 100.0
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TABLE 52 Serious adverse event reasons by ZA and Sr-89 comparison group
Reason
No ZA
(N= 279)
ZA
(N= 304)
No Sr-89
(N= 297)
Sr-89
(N= 286)
n % n % n % n %
Death 9 3.2 16 5.3 8 2.7 17 5.9
Death and disability 0 0.0 1 0.3 1 0.3 0 0.0
Death and hospitalisation 11 3.9 14 4.6 9 3.0 16 5.6
Death and other 0 0.0 1 0.3 0 0.0 1 0.3
Death, hospitalisation and disability 1 0.4 0 0.0 1 0.3 0 0.0
Death, life-threatening and hospitalisation 1 0.4 4 1.3 3 1.0 2 0.7
Death, life-threatening, hospitalisation and other 0 0.0 1 0.3 0 0.0 1 0.3
Disability 1 0.4 3 1.0 2 0.7 2 0.7
Hospitalisation 232 83.2 235 77.3 239 80.5 228 79.7
Hospitalisation and disability 4 1.4 7 2.3 7 2.4 4 1.4
Hospitalisation and other 4 1.4 2 0.7 4 1.3 2 0.7
Hospitalisation, disability and other 1 0.4 1 0.3 2 0.7 0 0.0
Life-threatening 1 0.4 1 0.3 1 0.3 1 0.3
Life-threatening and hospitalisation 7 2.5 15 4.9 15 5.1 7 2.4
New primary cancer 1 0.4 0 0.0 1 0.3 0 0.0
Other 6 2.2 3 1.0 4 1.3 5 1.7
Total 279 100.0 304 100.0 297 100.0 286 100.0
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Serious adverse event symptoms by serious adverse event categorisation by
randomisation arm
Multiple symptoms were associated with each SAE in a total of 1064 reported symptoms. Tables 53 and 54
split these symptoms by type of SAE and randomisation arm.
Tables 55 and 56 split the symptoms associated with SAE by category of SAE and comparison groups.
TABLE 53 Symptoms of unrelated SAEs
Category as defined in
Common Terminology
Criteria for Adverse
Events, version 354
Docetaxel
(N= 87)
Docetaxel+ ZA
(N= 154)
Docetaxel+ Sr-89
(N= 103)
Docetaxel+ ZA+
Sr-89 (N= 120)
Overall
(N= 464)
n % n % n % n % n %
Pulmonary/upper respiratory 8 9.2 3 1.9 5 4.9 10 8.3 26 5.6
Pain 18 20.7 20 13.0 19 18.6 15 12.5 72 15.6
Haemorrhage/bleeding 1 1.1 7 4.5 3 2.9 3 2.5 14 3.0
Ocular/visual 0 0.0 4 2.6 1 1.0 0 0.0 5 1.1
Constitutional symptoms 10 11.5 10 6.5 7 6.9 6 5.0 33 7.1
Musculoskeletal/soft tissue 8 9.2 14 9.1 14 13.7 10 8.3 46 9.9
Neurology 10 11.5 13 8.4 8 7.8 9 7.5 40 8.6
Lymphatics 1 1.1 3 1.9 2 2.0 3 2.5 9 1.9
Auditory/ear 0 0.0 1 0.6 0 0.0 0 0.0 1 0.2
Renal/genitourinary 3 3.4 23 14.9 11 10.8 8 6.7 45 9.7
Dermatology/skin 0 0 1 0.6 0 0.0 1 0.8 2 0.4
Vascular 2 2.3 2 1.3 2 2.0 9 7.5 15 3.2
Surgery/intraoperative injury 0 0.0 1 0.6 0 0.0 0 0.0 1 0.2
Infection 3 3.4 8 5.2 2 2.0 10 8.3 23 5.0
Metabolic/laboratory 3 3.4 4 2.6 4 3.9 3 2.5 14 3.0
Blood/bone marrow 5 5.7 8 5.2 1 1.0 7 5.8 21 4.5
Cardiac general 2 2.3 4 2.6 3 2.9 2 1.7 11 2.4
Death 2 2.3 9 5.8 7 6.9 5 4.2 23 5.0
Cardiac arrhythmia 1 1.1 0 0.0 2 2.0 3 2.5 6 1.3
Syndromes 0 0.0 1 0.6 1 1.0 0 0.0 2 0.4
Gastrointestinal 9 10.3 18 11.7 10 9.8 16 13.3 53 11.4
Secondary malignancy 1 1.1 0 0.0 0 0.0 0 0.0 1 0.2
Missing 0 – 0 – 1 – 0 – 1 –
Total 87 100 154 100 102 100 120 100 463 100
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TABLE 54 Symptoms of SAEs
Category as defined in
Common Terminology
Criteria for Adverse
Events, version 354
Docetaxel
(N= 142)
Docetaxel+ ZA
(N= 133)
Docetaxel+ Sr-89
(N= 142)
Docetaxel+ ZA+
Sr-89 (N= 131)
Overall
(N= 548)
n % n % n % n % n %
Pulmonary/upper respiratory 11 8.1 11 8.4 4 2.8 6 4.6 32 5.9
Pain 4 2.9 4 3.1 8 5.7 7 5.4 23 4.3
Haemorrhage/bleeding 2 1.5 2 1.5 6 4.3 2 1.5 12 2.2
Ocular/visual 0 0.0 1 0.8 0 0.0 0 0.0 1 0.2
Constitutional symptoms 23 16.9 12 9.2 19 13.5 12 9.2 66 12.3
Allergy/immunology 0 0.0 0 0.0 1 0.7 0 0.0 1 0.2
Musculoskeletal/soft tissue 2 1.5 0 0.0 1 0.7 3 2.3 6 1.1
Neurology 6 4.4 10 7.6 4 2.8 3 2.3 23 4.3
Lymphatics 2 1.5 0 0.0 0 0.0 0 0.0 2 0.4
Renal/genitourinary 2 1.5 8 6.1 2 1.4 4 3.1 16 3.0
Dermatology/skin 2 1.5 0 0.0 1 0.7 0 0.0 3 0.6
Vascular 2 1.5 4 3.1 2 1.4 2 1.5 10 1.9
Infection 27 19.9 29 22.1 35 24.8 23 17.7 114 21.2
Metabolic/laboratory 3 2.2 8 6.1 1 0.7 11 8.5 23 4.3
Blood/bone marrow 18 13.2 20 15.3 26 18.4 23 17.7 87 16.2
Cardiac general 1 0.7 1 0.8 2 1.4 2 1.5 6 1.1
Death 0 0.0 0 0.0 1 0.7 1 0.8 2 0.4
Cardiac arrhythmia 3 2.2 2 1.5 3 2.1 2 1.5 10 1.9
Gastrointestinal 28 20.6 19 14.5 25 17.7 29 22.3 101 18.8
Missing 6 – 2 – 1 – 1 – 10 –
Total 136 100 131 100 141 100 130 100 538 100
TABLE 55 Symptoms of non-fatal/life-threatening suspected unexpected serious adverse reactions
Category as defined in
Common Terminology
Criteria for Adverse
Events, version 354
Docetaxel
(N= 2)
Docetaxel+ ZA
(N= 1)
Docetaxel+ Sr-89
(N= 6)
Docetaxel+ ZA+
Sr-89 (N= 1)
Overall
(N= 10)
n % n % n % n % n %
Ocular/visual 0 0.0 0 0.0 1 16.7 0 0.0 1 10.0
Coagulation 0 0.0 0 0.0 1 16.7 0 0.0 1 10.0
Neurology 0 0.0 0 0.0 1 16.7 0 0.0 1 10.0
Dermatology/skin 0 0.0 1 100.0 0 0.0 0 0.0 1 10.0
Vascular 0 0.0 0 0.0 1 16.7 0 0.0 1 10.0
Infection 1 50.0 0 0.0 1 16.7 0 0.0 2 20.0
Cardiac arrhythmia 0 0.0 0 0.0 1 16.7 1 100.0 2 20.0
Gastrointestinal 1 50.0 0 0.0 0 0.0 0 0.0 1 10.0
Total 2 100 1 100 6 100 1 100 10 100
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TABLE 56 Symptoms of fatal/life-threatening suspected unexpected serious adverse reactions
Category as defined in
Common Terminology
Criteria for Adverse
Events, version 354
Docetaxel
(N= 7)
Docetaxel+ ZA
(N= 8)
Docetaxel+Sr-89
(N=6)
Docetaxel+ ZA+
Sr-89 (N= 21)
Overall
(N= 42)
n % n % n % n % n %
Pulmonary/upper respiratory 3 42.9 2 25.0 1 16.7 2 10.0 8 19.5
Pain 0 0.0 1 12.5 0 0.0 1 5.0 2 4.9
Haemorrhage/bleeding 1 14.3 0 0.0 0 0.0 1 5.0 2 4.9
Constitutional symptoms 0 0.0 1 12.5 0 0.0 0 0.0 1 2.4
Neurology 0 0.0 0 0.0 0 0.0 1 5.0 1 2.4
Hepatobiliary/pancreas 0 0.0 0 0.0 1 16.7 0 0.0 1 2.4
Renal/genitourinary 0 0.0 1 12.5 1 16.7 2 10.0 4 9.8
Vascular 1 14.3 0 0.0 1 16.7 1 5.0 3 7.3
Infection 1 14.3 3 37.5 1 16.7 4 20.0 9 22.0
Blood/bone marrow 0 0.0 0 0.0 0 0.0 3 15.0 3 7.3
Cardiac general 1 14.3 0 0.0 0 0 3 15.0 4 9.8
Death 0 0.0 0 0.0 1 16.7 0 0.0 1 2.4
Gastrointestinal 0 0.0 0 0.0 0 0.0 2 10.0 2 4.9
Missing 0 – 0 – 0 – 1 – 1 –
Total 7 100 8 100 6 100 20 100 41 100
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Chapter 4 Economic evaluation
Parts of this chapter are based on the study by Andronis et al.55
There is considerable uncertainty whether or not the addition of ZA and/or Sr-89 to standard chemotherapy
for advanced CRPC patients would represent a cost-effective use of resources. In particular, it is unclear
whether or not the extra cost of treatments seeking to alleviate bone-related problems would be balanced
out by reduced use of resources – for example, because of a possible reduction in SREs – and improved
outcomes. As such, an economic analysis was undertaken on the basis of patient-level data collected
alongside the factorial TRAPEZE trial, to assess the cost-effectiveness of two relevant comparisons:
1. ZA versus no ZA
2. Sr-89 versus no Sr-89.
The results of these analyses are expressed in terms of additional cost per QALY gained. The comparison
was conducted on the basis of findings suggesting no significant interactions between ZA and Sr-89 in
terms of costs (p-value= 0.12) or QALYs (p-value= 0.2). The economic evaluation was based on 707
patients (93% of the total number of 757 patients) for whom the calculation of QALYs was possible, as
detailed previously. Two separate analyses are reported for the comparison between ZA and no ZA; the
first analysis considers ZA as a branded pharmaceutical, while the second analysis reflects the availability
of ZA as a generic product. The ZA patent in the EU expired in May 2013 after completion of the trial.
As this exploration aims to inform clinical practice and resource allocation decisions within the NHS, the
methods followed are in agreement with recent recommendations for conducting health technology
appraisals.46 On this basis, the analyses were undertaken from the perspective of the NHS and Personal
Social Services, while costs and outcomes occurring in the future were discounted at a rate of 3.5%.
Monetary values throughout the study are expressed in UK pounds sterling in 2011–12 prices, when ZA
was available only as a proprietary medication. We have recalculated the impact of generic pricing
available since May 2013 as a further analysis.
Methods
This section describes the methods followed in estimating the mean per-patient costs and QALYs and the
ICERs for the compared options.
Resource use and cost
NHS resource use was captured through CRFs and patient-completed questionnaires and falls into
three overarching categories:
1. trial treatment
2. use of related concomitant treatments
3. use of hospital and primary care services.
Trial treatments comprised combinations of docetaxel and prednisolone with (1) ZA (docetaxel,
prednisolone and ZA), (2) Sr-89 (docetaxel, prednisolone and Sr-89) or (3) ZA and Sr-89 (docetaxel,
prednisolone, ZA and Sr-89). Data on trial treatments provided were obtained from CRFs completed by
research nurses. Information on use of treatments or care provided concomitantly with the trial treatments
was also obtained from CRFs. Data on duration of inpatient stay and number of outpatient visits were
obtained from CRFs for care that were completed during the treatment period, and from patient
questionnaires for services provided after the treatment period.
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Trial treatment acquisition and administration
The acquisition cost of trial treatments (docetaxel, prednisolone, ZA and Sr-89) was calculated by
multiplying patient-specific doses and numbers of cycles received by published unit cost estimates obtained
from the British National Formulary (BNF).56 An alternative unit cost estimate was used to reflect the lower
acquisition price for ZA owing to the drug being available as a generic product (Table 57). With regards to
docetaxel, patients received different doses according to their body surface area, which resulted in the use
of vials of different volumes. For example, a patient who was administered a dose of docetaxel between
80mg and 100mg would require one 4-ml vial and one 1-ml vial at a total cost of £663, whereas a
patient administered a dose between 100mg and 140mg would require one 7-ml vial at a cost of £720
(see Table 57). Prednisolone at a dose of 10mg per day was given orally together with docetaxel. The daily
cost of prednisolone was calculated at £0.64 (approximately £13.50 per 21-day treatment cycle). ZA was
provided in doses of up to 4mg per cycle at a cost of £174 for the branded product or £58 for the generic
alternative in additional analyses. Finally, Sr-89 was given as a single fraction of 150MBq. As the cost of
Sr-89 is not available from the BNF, a value was obtained from the Nuclear Medicine Department of the
University Hospital Birmingham, Birmingham, UK. This value was varied in sensitivity analyses.
The cost of a chemotherapy administration was taken from the National Schedule of Reference
Costs 2011–12,15 with the exception of Sr-89 administrations, the cost of which was obtained from the
Nuclear Medicine Department of the University Hospital Birmingham, Birmingham, UK (Table 58).
TABLE 57 Constituent parts and unit costs of protocol treatments
Drugs Dose Constituent parts Cost (£) Source
Docetaxel 1–20mg One 1-ml (20-mg) vial 155 BNF54
21–40mg Two 1-ml (40-mg) vials 309 BNF54
41–80mg One 4-ml (80-mg) vial 508 BNF54
81–100mg One 4-ml (80-mg) vial
and one 1-ml (20-mg) vial
663 BNF54
101–140mg One 7-ml (140-mg) vial 720 BNF54
141–160mg One 16-ml (160-mg) viala 1070 BNF54
161–180mg One 16-ml (160-mg) viala
and one 1-ml (20-mg) vial
1224 BNF54
Prednisolone 10mg daily 30-tablet pack of 5mg 0.64 a day BNF54
ZA (branded product) Range of doses
up to 3.5mg
One 5-ml (4-mg) vial 174 BNF54
ZA (generic alternative) One 4mg/100 ml infusion
bottle
58 Department of Health’s electronic
market information tool
Sr-89 150MBq N/A 1710 Nuclear Medicine Department,
University Hospital Birmingham,
Birmingham, UK
N/A, not applicable.
a Docetaxel vials of 16ml provide 160mg of the required chemotherapy infusion (10mg per 1ml).
TABLE 58 Unit costs of administration of protocol treatments
Administration Cost (£) Source
Docetaxel and prednisolone 245 National Schedule of Reference Costs 2011–1215
ZA (stand-alone) 245 National Schedule of Reference Costs 2011–1215
Sr-89 (stand-alone) 443 Nuclear Medicine Department, University Hospital Birmingham, Birmingham, UK
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No administration cost was incurred for prednisolone, as the drug is taken orally. When ZA was administered
together with docetaxel, no additional cost on top of the administration cost of docetaxel was incurred.
However, when ZA was administered as a stand-alone follow-up treatment, it incurred the cost of an
outpatient appointment for chemotherapy administration.
Concomitant treatments
Castration-refractory prostate cancer patients received further care or medications provided concomitantly
with their trial treatment. Examples include radiotherapy, abiraterone, cabazitaxel, mitoxantrone, blood
transfusions, as well as docetaxel, Sr-89 and ZA. The cost of each of these treatments was obtained by
multiplying their use, obtained from CRFs, by unit cost estimates available from various sources (Table 59).
The cost of docetaxel, ZA and Sr-89 given as concomitant medications is the same as in Table 57. As
information on specific doses for concomitant medications was not available from CRFs, the cost of such
medications was calculated on the basis of their recommended dosage as detailed in the BNF.56
The cost of administration of concomitant medications given intravenously was obtained from the National
Schedule of Reference Costs 2011–1215 and is given in Table 60. No administration cost was accounted for
abiraterone, which is provided as an oral treatment. The administration cost for docetaxel, Sr-89 and ZA
given as second-line treatments is the same as the cost of administration shown in Table 58.
Patients who experienced SREs, such as SCC and fractures, would typically receive surgery and/or radiotherapy.
Each of the undertaken surgical procedures was matched with a Healthcare Resources Group code and was
assigned a cost using the NHS reference cost schedules15 (Table 61). It was assumed that these services
were provided on a non-elective basis. Typically, a course of radiotherapy would be on consecutive days and
would include a single planning session. Where the gap between fractions was more than 2 weeks, it was
assumed that this represented treatment to a different site and a further planning session was added to the
model for this separate course of treatment. On this basis, the cost of a radiotherapy session consisted of
the cost of the planning visit and the cost of the radiotherapy fraction itself.
TABLE 59 Unit costs of additional concomitant treatments
Drugs Unit cost Source
Radiotherapy £813 cost of radiotherapy preparation
plus £118 cost of radiotherapy fraction
National Schedule of Reference Costs 2011–1215
Abiraterone £98 per day BNF54
Cabazitaxel £3696 per cycle BNF54
Mitoxantrone £100 per cycle BNF54
Blood £123 per unit plus intravenous cannula (£1)
and blood-giving set (£4)
NHS Blood and Transplant57
TABLE 60 Unit costs of administration of concomitant treatments
Administration Unit cost (£) Source
Cabazitaxel 144 National Schedule of Reference Costs 2011–1215
Mitoxantrone 245 National Schedule of Reference Costs 2011–1215
Blood transfusion 172 National Schedule of Reference Costs 2011–1215
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As NHS reference cost estimates for surgeries include the cost of an average length of inpatient stay, to
avoid double-counting of inpatient stay, the average length of stay specific to each surgery was deducted
from the total length of inpatient stay recorded for the patient. The cost of inpatient stay was calculated
separately, as described in the next section.
Use of hospital and primary care services
Outpatient appointments, inpatient stays and GP visits which took place during the trial treatment period were
obtained from CRFs, while post-treatment stays and visits were obtained from patient-completed questionnaires.
The former were filled in by health-care professionals and were complete for 707 patients, 100% of the
available sample for the economic evaluation, whereas the latter presented missing data for 126 patients
(approximately 18% of the sample). Multiple imputation by chained equations was used to impute the
missing observations.58 The imputation model made use of predictive mean matching to ensure that the
imputed values were consistent with the range of observed values in the trial.59 Predictor variables used in
the model included patient characteristics (age, survival after randomisation, treatment arm allocation),
resource use (number of cycles of trial treatment received, use of concomitant medications, number of
radiotherapy sessions received, surgeries), as well observed (non-missing) data on outpatient appointments,
inpatient stay and GP visits. Unit costs for outpatient appointments, inpatient stay and GP visits were
obtained from the NHS reference cost schedules and the Personal Social Services Research Unit’s Unit Cost
of Health and Social Care 2012 report60 (Table 62).
TABLE 61 Unit cost of surgical procedures carried out to address skeletal-related problems
Intervention Unit cost (£) Source
Decompression for SCC 9573 National Schedule of Reference Costs 2011–1215
Laminectomy 6893 National Schedule of Reference Costs 2011–1215
Intramedullary nailing 4995 National Schedule of Reference Costs 2011–1215
Hip replacement 8038 National Schedule of Reference Costs 2011–1215
Pathological fractures with
complications
3888 National Schedule of Reference Costs 2011–1215
SCC 7816 National Schedule of Reference Costs 2011–1215
TABLE 62 Unit costs of outpatient appointments, inpatient stay and general practice appointments
Service Unit cost (£) Source
Inpatient stay 680 National Schedule of Reference Costs 2011–1215
Outpatient appointment 139 PSSRU’s Unit Cost of Health and Social Care 2012 report60
GP consultation 63 PSSRU’s Unit Cost of Health and Social Care 2012 report60
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Health-related quality of life and quality-adjusted life-years
A QALY score was derived for each patient on the basis of his responses to the three-level EQ-5D
instrument, a generic preference-based measure commonly used in valuing HRQoL. Responses to the
instrument’s health status classification system were translated into a single preference-based (utility) score
using a UK-specific value set.61 QALYs were calculated as the area under the curve connecting utility
scores reported at different time points from baseline to death, at which point utility was assigned
a value of zero.62 Details on the analysis of QoL data and the calculation of QALYs are given in Chapter 3,
Quality of life. For missing questionnaires, no multiple imputation was conducted. The reason for this was
that observed responses at time t could not be used as predictors of missing responses at time t as they
corresponded to different time points in patients’ treatment and follow-up trajectory.
Analysis
A total NHS cost and a total number of QALYs were calculated for each of the 707 patients for whom
information on costs and preference-based QoL (EQ-5D) was available. The base-case analysis, in which
the unit cost of ZA was obtained from the BNF, was supplemented by an additional analysis reflecting the
availability of generic ZA at a considerably lower price than the proprietary product. The mean total cost
and mean total QALYs across all patients under a given treatment were then calculated. As the distribution
of costs and QALYs are typically skewed, 95% CIs around mean values were obtained on the basis of
1000 replications using the bias-corrected and accelerated (BCa) bootstrap method.
Incremental analysis was carried out to determine the difference in mean total costs and QALYs between the
compared options. These differences were summarised in the form of an ICER, a measure that reflects the extra
cost associated with a gain of one additional QALY.43 To account for the inherent uncertainty in the results
because of sampling variation, non-parametric bootstrapping was used to replicate the joint distribution of
the differences in cost and QALYs.63 This generated 5000 paired estimates of incremental costs and QALYs,
which were subsequently represented graphically on a cost-effectiveness plane and plotted on CEACs.47,48
Cost-effectiveness planes show the bootstrap estimates on a four-quadrant plane. Depending on the quadrant
in which cost-effectiveness results are located, a treatment may be more effective and more costly (north-east
quadrant), more effective and less costly (south-east quadrant), less effective and less costly (south-west quadrant)
or less effective and more costly (north-west quadrant) than an alternative treatment. CEACs show the probability
of each option being cost-effective across a range of possible values of willingness to pay for an additional QALY.
Data management tasks were undertaken in Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA)
and statistical analyses, including multiple imputation for missing values, were carried out in Stata version 12.
The impact of different assumptions employed in the cost-effectiveness analysis was assessed in a series
of sensitivity analyses. In line with recommendations, and to avoid biased estimates of QALY scores,
the analysis controlled for any possible between-group imbalance in baseline EQ-5D QoL scores, using
multivariate ordinary least squares regression.64 Additional sensitivity analyses explored the impact of
different plausible values of uncertain parameters in the results, including alternative unit costs for Sr-89,
docetaxel and mitoxantrone. As per NICE recommendations, discount rates were varied to no discounting
and discounting at 6% for both costs and benefits.46
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Results of comparison between zoledronic acid and no
zoledronic acid
The following section reports the results of the comparison between the ZA and no ZA options in terms
of resource use and costs, QALYs and ICERs. Two analyses are reported; the first is based on ZA being a
branded product, while the second takes into account the availability of ZA as a generic alternative.
Resource use and cost
The number and proportion of patients that received a trial treatment, concomitant treatment and inpatient,
outpatient and primary care services are given in Chapter 3 and Appendix 6. The mean cost for main
resource use items are given in Table 63.
As expected, the most substantial difference in costs between the ZA and no ZA groups was as a result
of the use of ZA (as protocol and follow-up treatment) in the ZA arm. The mean difference in cost
between groups associated with the use of ZA was £2197 (BCa 95% CIs £1971 to £2422). With the
exception of ZA, patients in the ZA arm presented lower resource use and costs compared with those in
the no ZA arm. In particular, there were significant differences in the use of radiotherapies and surgeries.
As such care is provided in response to SREs, the lower use and cost of radiotherapy and surgeries is
representative of the fact that people in the ZA arm experienced significantly fewer skeletal-related problems.
TABLE 63 Mean per-patient cost for different cost items by treatment group
ZA (n= 350) No ZA (n= 357) Difference (ZA vs. no ZA)
Mean (£) SD (£) Mean (£) SD (£) Cost difference (£) Lower CI (£) Upper CI (£)
Trial treatments
Docetaxel+ prednisolone 2502 760 2441 749 60 –49 169
ZA 1044 456 0 0 1044 1091 996
Sr-89 769 1033 724 1018 45 –107 197
ZA as follow-up treatment 1157 1886 4 67 1153 955 1351
Concomitant medications and treatments
Radiotherapy 764 1093 1021 1264 –257 –429 –85
Abiraterone 1811 4198 2150 4478 –339 –993 316
ZA as concomitant medication 326 1109 141 681 185 45 324
Sr-89 as concomitant medication 98 476 132 539 –34 –109 41
Blood units 23 150 19 125 4 –16 24
Cabazitaxel 301 1710 293 2230 8 –288 304
Docetaxel as concomitant
medication
372 1543 433 2049 –61 –338 216
Mitoxantrone 51 245 26 179 25 –6 56
Surgery 116 988 377 1974 –261 –495 –27
Outpatient appointments and inpatient stay
Hospital outpatient appointment 672 1015 591 804 81 –51 213
Hospital inpatient stay 3494 6216 3786 6562 –292 –1217 632
GP appointments 278 319 319 384 –42 –95 12
Source: reproduced and amended with permission from Andronis et al.55
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Patients in the ZA arm also showed lower, although not significantly different, costs because of abiraterone,
Sr-89 and docetaxel as concomitant medication and lower costs as a result of fewer hospital stays and GP
appointments. On the other hand, ZA was associated with higher, although non-significantly different,
costs for docetaxel and prednisolone – because of patients in ZA receiving on average more cycles of
docetaxel, prednisolone – Sr-89 as trial treatment, blood units, cabazitaxel, mitoxantrone and hospital
outpatient appointments.
The estimated mean total cost per patient was £13,776 (BCa 95% CIs £12,824 to £14,728) for ZA and
£12,457 (BCa 95% CIs £11,465 to £13,449) for no ZA. This resulted in a mean cost difference of £1319
(BCa 95% CIs –£34 to £2671) (Table 64).
The distribution of the total cost can be seen in the box plot in Figure 39 and histogram in Figure 40.
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FIGURE 39 Box plot summarising the distribution of total per-patient cost for ZA and no ZA.
TABLE 64 Mean total per-patient cost for ZA and no ZA
Treatment Mean (£) SD (£)
BCa 95% CIs (£)
Difference in cost
(ZA vs. no ZA) (£)
BCa 95% CIs of difference (£)
Lower CI Upper CI Lower CI Upper CI
ZA 13,776 9118 12,824 14,728 1319 –34 2671
No ZA 12,457 9453 11,465 13,449
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Quality-adjusted life-years
Figure 41 depicts the mean EQ-5D scores across treatment groups at three points in time (date of
randomisation, 6 and 12 months after randomisation). Mean EQ-5D scores between randomisation and
6 months after randomisation increased in the no ZA group and decreased in the ZA group. This trend
was reversed in the period between 6 and 12 months after randomisation, when the mean QoL score for
patients in the ZA group increased, while the equivalent value for the no ZA group decreased. It must be
noted that caution is needed in comparing EQ-5D scores across time points, as patients returning a
questionnaire at the same point in time after randomisations may be at different stages along their
treatment and follow-up trajectories (i.e., at 6 months, some patients were still on treatment while others
had completed or discontinued their treatment).
Mean numbers of QALYs gained for each treatment are given in Table 65. In total, patients in the ZA group
gained an average of 0.91 QALYs, suggesting an improvement of 0.03 QALYs over their counterparts in the
no ZA group. The distribution of the discounted QALYs is illustrated in Figure 42.
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FIGURE 41 Box plot showing the distribution of EQ-5D scores across different time points, for the ZA and
no ZA groups.
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FIGURE 40 Histogram depicting the distribution of the mean total cost for the ZA and no ZA arms. (a) no ZA;
and (b) ZA.
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Cost-effectiveness results
Summary cost and effectiveness results, expressed in terms of a point estimate ICER, are shown in Table 66.
ZA appeared to be more costly than no ZA, resulting in an estimated incremental cost of £1319. This
difference is mainly driven by the additional cost of ZA in the ZA group. In terms of QALYs gained, ZA
appeared to be slightly more effective than no ZA, resulting in a gain of 0.03 QALYs. Given the above, the
point estimate ICER for ZA compared with no ZA is £42,047 per additional QALY. This value is considerably
greater that the ratio of £20,000 to £30,000 per QALY which is perceived to represent a cost-effective use
of resources by NICE.46
Figure 43 depicts the results of 5000 bootstrap replications plotted on the cost-effectiveness plane. Each
point represents a pair of incremental cost and incremental effectiveness estimates for the comparison
between ZA and no ZA. Approximately 71% of the simulated pairs are located in the north-east quadrant,
indicating that ZA is likely to be more costly and more effective than no ZA. About 26% of the points
appear in the north-west quadrant, which indicates that ZA is more costly and less effective than no ZA.
There are also a small number of points located in the southern half of the plane, indicating that ZA may
be less costly and more effective than no ZA (south-east quadrant; 1% of all points) or less costly and less
effective than no ZA (south-west quadrant; 2% of all points).
Figure 44 depicts the CEACs for ZA and no ZA, showing the probability of each of the option being
cost-effective at different values of a decision-maker’s willingness to pay for a QALY (ceiling ratio). In a
situation in which the decision-maker is not prepared to pay any amount for additional health benefits
(i.e. the ceiling ratio is zero), the probabilities of ZA and no ZA being cost-effective are 3% and 97%,
respectively. At values of the ceiling ratio between £20,000 and £30,000 per QALY, the probability of ZA
being cost-effective rises from 26% to 40%; it exceeds 50% (i.e. appears to be the most cost-effective
treatment) for ceiling ratios over £42,000 per QALY.
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FIGURE 42 Box plot summarising the distribution of discounted QALYs gained for ZA and no ZA.
TABLE 65 Mean per-patient QALYs for ZA and no ZA
ZA (n= 350) No ZA (n= 357)
Difference
BCa 95% CI
Mean SD Mean SD Lower CI Upper CI
QALYs gained (undiscounted) 0.915 0.697 0.884 0.712 0.031 –0.073 0.134
QALYs gained (discounted) 0.908 0.683 0.876 0.693 0.031 –0.07 0.133
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FIGURE 44 Cost-effectiveness acceptability curves showing the probability of ZA and no ZA being cost-effective at
different values of the ceiling ratio.
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FIGURE 43 Cost-effectiveness plane showing incremental cost and effect (QALYs) pairs for the comparison between
ZA and no ZA.
TABLE 66 Point estimate ICER for the comparison between ZA and no ZA
Treatment Total cost (£) Total QALYs
Difference in cost
(ZA vs. no ZA) (£)
Difference in QALYs
(ZA vs. no ZA) ICER (£)
ZA £13,776 0.908 1319 0.031 42,047
No ZA £12,457 0.876
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Additional analysis to account for the availability of generic zoledronic acid
Generic alternatives to ZA have now become available and are in use in NHS hospitals, at a significantly
lower price than the proprietary alternatives (Zometa®, East Hanover, NJ, USA, or Aclasta®, Surrey, UK).
Given this, additional analysis was undertaken to reflect the fact that NHS hospitals are likely to face a
lower acquisition cost for ZA.
An estimate of the average price paid by NHS hospitals for ZA in 2013 (£58 per 4mg/100ml infusion
bottle) was obtained from the electronic market information tool (eMIT) of the Department of Health
Commercial Medicines Unit.65
The use of this unit cost estimate resulted in a marked decrease in the cost of ZA when given as trial
treatment, follow-up treatment and concomitant medication (Table 67). As expected, the cost associated
with the use of ZA in the ZA group was still higher than the equivalent cost in the no ZA group;
nonetheless, the difference between groups is now considerably smaller.
As the cost of ZA itself is a main driver of the total cost of ZA, the use of lower prices for ZA led to a
decrease in the total per-patient cost for ZA and, consequently, the difference in total costs between
ZA and no ZA was reduced to £251 (BCa 95% CI £–1099 to £1602) (Table 68).
The reduced incremental cost combined with the observed change in QALYs gave a point estimate ICER
of £8005 per additional QALY (Table 69).
TABLE 69 Point estimate ICER for the comparison between ZA and no ZA, using generic prices for ZA
Treatment Total cost (£) Total QALYs
Difference in cost
(ZA vs. no ZA) (£)
Difference in QALYs
(ZA vs. no ZA) ICER (£)
ZA 12,667 0.908 251 0.031 8005
No ZA 12,417 0.876
TABLE 68 Mean total per-patient cost for ZA and no ZA using generic prices for ZA
Treatment Mean (£) SD (£)
BCa 95% CIs (£)
Difference in cost
(ZA vs. no ZA) (£)
BCa 95% CIs of difference (£)
Lower CI Upper CI Lower CI Upper CI
ZA 12,667 8795 11,724 13,612 251 –1099 1602
No ZA 12,417 9433 11,436 13,397
TABLE 67 Mean per-patient cost for different cost items on the basis of generic ZA
Treatment
ZA (n= 350) No ZA (n= 357) Difference (ZA vs. no ZA)
Mean (£) SD (£) Mean (£) SD (£) Cost difference (£)
Lower
95% CI (£)
Upper
95% CI (£)
ZA 346 151 0 0 346 330 361
ZA as follow-up
treatment
837 1358 3 48 834 692 977
ZA as concomitant
medication
235 801 101 492 134 36 230
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Uncertainty around incremental costs and QALYs, propagated through 5000 bootstrap replications, is
plotted on the cost-effectiveness plane in Figure 45. Approximately half (51%) of the simulated pairs are
located in the north-east quadrant, indicating that ZA is likely to be more costly and more effective than
no ZA. About 14% of the pairs appear in the north-west quadrant (i.e. ZA is more costly and less effective
than no ZA), while 21% of the pairs are located in the south-east quadrant (i.e. ZA is less costly and more
effective than no ZA). The remaining 14% of the pairs are located in the south-west quadrant (i.e. ZA is
less costly and less effective than no ZA).
Cost-effectiveness acceptability curves showing the probability of ZA and no ZA being cost-effective at
different ceiling ratios are depicted in Figure 46. In a situation in which the decision-maker is not prepared
to pay any amount for additional health benefits (i.e. the ceiling ratio is zero), the probabilities of ZA and
no ZA being cost-effective are 35% and 65%, respectively. ZA appears to be the most cost-effective
option at ceiling ratios over £8000 per QALY, and at £20,000 and £30,000 per QALY the probability of
ZA being cost-effective is 64% and 68%, respectively.
Figure 47 depicts ICER values for ZA as a function of possible prices of ZA. For prices of ZA between
£0 and £31, the total per-patient cost of ZA is lower than that of no ZA and, given the fact that ZA is
associated with additional QALYs, this treatment option dominates its comparator. For prices between
£31 and £98, ZA results in ICERs up to £20,000 per QALY, and it is thus cost-effective at this ceiling ratio.
For prices of ZA higher than £98, the resulting ICER exceeds £20,000 per QALY.
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FIGURE 45 Cost-effectiveness plane showing incremental cost and effect (QALYs) pairs for the comparison between
ZA and no ZA, based on the availability of generic ZA.
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Sensitivity analysis
Most of the alternative assumptions explored in sensitivity analyses appeared to have a small effect on the
magnitude of cost and benefits and, consequently, a limited impact on the resulting ICER. First, when
future costs and benefits were not discounted, there was a small increase in both costs and QALYs, giving
a slightly increased ICER value for ZA of £42,500 per additional QALY. On the other hand, discounting
at a higher rate of 6% per annum led to a small decrease in the ICER, which, under this scenario, assumed
a value of £41,851. Using alternative unit cost estimates for docetaxel and mitoxantrone from the NHS
Commercial Medicines Unit65 had a small effect on the total mean cost per patient, with lower prices
of docetaxel and mitoxantrone compared with the base-case values from BNF resulting in ICERs of £43,250
and £41,950, respectively. Sensitivity analyses around the price of Sr-89 had no significant effect on the
differences in costs between the ZA and no ZA arms, and gave ICERs close to the £42,000 per QALY mark.
A different pattern was observed when adjusting QALYs for baseline imbalances in EQ-5D scores. Such an
adjustment had a significant impact on the difference in QALYs between the compared groups, with no
ZA appearing to be slightly more effective than ZA (difference of –0.001 QALYs, 95% CI –0.096 to 0.094).
Under this scenario, the ZA group appears to be more expensive and less effective than no ZA, and thus it
is extendedly dominated by the latter (Table 70).
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FIGURE 47 Incremental cost-effectiveness ratio for ZA vs. no ZA for different prices of ZA.
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FIGURE 46 Cost-effectiveness acceptability curves showing the probability of generic ZA and no ZA being
cost-effective at different values of the ceiling ratio. Reproduced and amended with permission from Andronis
et al.55 In the source figure, only the ZA CEAC was plotted; a CEAC for No ZA has been added here.
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Results of comparison between strontium-89 and no strontium-89
The following section reports the results of the comparison between Sr-89 and no Sr-89 in terms of
resource use and costs, QALYs and ICERs.
Resource use and cost
The number and proportion of patients who received a trial treatment, concomitant treatment and
inpatient, outpatient and primary care are given in Appendix 5. The mean costs for main resource use
items are given in Table 71.
As expected, the most prominent difference in mean costs between the Sr-89 and no Sr-89 groups is a
result of the cost of Sr-89 itself. Apart from higher cost of Sr-89, the Sr-89 group was associated with
greater cost for docetaxel and ZA given as protocol treatments, higher cost of cabazitaxel and docetaxel
provided as concomitant medications and increased cost as a result of surgeries. On the other hand,
the Sr-89 group was associated with lower use of radiotherapies, abiraterone, ZA and Sr-89 as
concomitant medications, as well as fewer inpatient days, outpatient appointments and GP visits.
The estimated mean total cost per patient was £13,787 (BCa 95% CI £12,862 to £14,713) for Sr-89 and
£12,446 (BCa 95% CI £11,489 to £13,403) for no Sr-89. This resulted in a mean cost difference of £1341
(BCa 95% CI –£66 to £2748) (Table 72).
The distribution of the total cost can be seen in the box plot Figure 48 and histogram Figure 49.
TABLE 70 Results of sensitivity analysis for ZA and no ZA
ZA No ZA
ICER (£)Mean cost (£) Mean QALYs Mean cost (£) Mean QALYs
Base-case results 13,776 0.908 12,457 0.876 42,047
No discounting 13,897 0.915 12,592 0.884 42,449
Discounting at 0.06 per annum
for both costs and benefits
13,695 0.903 12,366 0.871 41,851
QALYs adjusted for baseline
imbalances in EQ-5D
13,776 0.875 12,457 0.876 ZA dominated
Unit cost of docetaxel from eMIT
(£34.29 for 140mg)
12,618 0.908 11,261 0.876 43,251
Unit cost of mitoxantrone from
eMIT (£60.36 for 25mg)
13,770 0.908 12,454 0.876 41,956
Unit cost of Sr-89 (75% of
available estimate)
13,757 0.908 12,431 0.876 42,261
Unit cost of Sr-89 (125% of
available estimate)
13,795 0.908 12,483 0.876 41,832
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TABLE 71 Mean per-patient cost for different cost items by treatment group
Sr-89 (n= 350) No Sr-89 (n=357) Difference (Sr-89 vs. no Sr-89)
Mean (£) SD (£) Mean (£) SD (£) Cost difference (£)
Lower
95% CI (£)
Upper
95% CI (£)
Trial treatments
Docetaxel+ prednisolone 2497 738 2445 771 52 –61 165
ZA 525 613 508 613 18 –71 107
Sr-89 1507 988 0 0 1507 1407 1608
ZA as follow-up treatment 539 1337 609 1549 –69 –279 141
Concomitant medications
Radiotherapy 803 1033 983 1318 –180 –349 –11
Abiraterone 1905 4279 2058 4408 –153 –814 508
ZA as concomitant medication 205 866 259 975 –54 –192 84
Sr-89 as concomitant medication 110 527 120 492 –9 –85 66
Blood units 21 150 21 124 0 –20 21
Cabazitaxel 375 2192 221 1765 154 –134 443
Docetaxel as concomitant
medication
415 2057 390 1545 25 –233 283
Mitoxantrone 39 218 39 211 0 –32 31
Surgery 325 1954 172 1064 153 –84 390
Outpatient appointments and inpatient stay
Hospital outpatient appointment 609 889 653 940 –44 –178 89
Hospital inpatient stay 3630 6294 3653 6491 –23 –950 903
GP appointments 281 350 316 357 –35 –86 16
Source: reproduced and amended with permission from Andronis et al.55
TABLE 72 Mean total per-patient cost for Sr-89 and no Sr-89
Treatment Mean SD
Bootstrapped 95% CIs
Difference
Bootstrapped 95% CIs of difference
Lower CI Upper CI Lower CI Upper CI
Sr-89 £13,787 £9295 £12,862 £14,713 £1341 –£66 £2748
No Sr-89 £12,446 £9281 £11,489 £13,403
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FIGURE 48 Box plot summarising the distribution of total per-patient cost for Sr-89 and no Sr-89.
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FIGURE 49 Histogram depicting the distribution of the mean total cost for the Sr-89 and no Sr-89 groups.
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Quality-adjusted life-years
Figure 50 shows the distribution of EQ-5D scores at baseline and at 6 and 12 months after randomisation
for the Sr-89 and no Sr-89 groups. Throughout the first year after randomisation, both groups presented
approximately the same average increase in QoL. Again, it must be noted that, while responses relate
to a specific point in time (e.g. 6 months), patients at this point in time may be at different stages of their
treatment and follow-up pathways.
The mean and standard deviation of the distribution of discounted and undiscounted QALYs for each
treatment are given in Table 73. These distributions are depicted as box plots in Figure 51.
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FIGURE 51 Box plot summarising the distribution of QALYs for Sr-89 and no Sr-89.
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FIGURE 50 Box plot showing the distribution of EQ-5D scores across different time points, for the Sr-89 and
no Sr-89 groups.
TABLE 73 Quality-adjusted life-years for Sr-89 and no Sr-89
Sr-89 (n= 350) No Sr-89 (n= 357)
Difference
BCa 95% CI
Mean SD Mean SD Lower CI Upper CI
QALYs (undiscounted) 0.941 0.741 0.859 0.665 0.082 –0.021 0.184
QALYs (discounted) 0.933 0.725 0.852 0.648 0.081 –0.019 0.181
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Cost-effectiveness results
Differences in mean total per-patient cost and mean overall QALYs between the Sr-89 and no Sr-89
groups can be seen in Table 74. Sr-89 appears to be more costly than no Sr-89, resulting in a
between-group difference of approximately £1350. In terms of QALYs, Sr-89 is slightly more effective,
indicating a gain of 0.08 QALYs over no Sr-89. Given these differences in costs and QALYs, the point
estimate ICER for Sr-89 compared with no Sr-89 was calculated at £16,590 per additional QALY.
This value is well below the £20,000 per QALY ratio which NICE considers to represent effective use
of the NHS resources.46
Pairs of differences in costs and QALYs between the two groups, generated through 5000 bootstrap
replications, are depicted on the cost-effectiveness plane (Figure 52). Approximately 91% of the simulated
pairs are located in the north-east quadrant, pointing to a substantial likelihood that Sr-89 is more costly
and at the same time more effective than no Sr-89. About 6% of the points appear in the north-west
quadrant, which indicates that Sr-89 may be more costly and less effective than no Sr-89. The rest of the
points – approximately 3% of the 5000 estimates – fall in the southern half of the plane, indicating that
Sr-89 may be less costly and more effective than no Sr-89 (south-east quadrant; 2% of all points) or less
costly and less effective than no Sr-89 (south-west quadrant; 1% of all points).
The CEAC for Sr-89 and no Sr-89 is given in Figure 53. In the situation that the decision-maker is not
prepared to pay any amount for additional QALYs – that is, the ceiling ratio is zero – the likelihoods of Sr-89
and no Sr-89 being cost-effective are 97% and 3%, respectively. As the value of the ceiling ratio rises, the
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FIGURE 52 Cost-effectiveness plane showing incremental cost and effect (QALYs) pairs for the comparison between
Sr-89 and no Sr-89.
TABLE 74 Point estimate ICER for the comparison between Sr-89 and no Sr-89
Treatment Total cost (£) Total QALYs
Difference in costs (£)
(Sr-89 vs. no Sr-89)
Difference in QALYs
(Sr-89 vs. no Sr-89) ICER (£)
Sr-89 13,787 0.933 1341 0.081 16,590
No Sr-89 12,446 0.852
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likelihood of Sr-89 being the most cost-effective option increases steadily and reaches 50% at about
£16,600 per QALY. For ceiling ratios between £20,000 and £30,000 per QALY gained, the probability that
Sr-89 is more cost-effective than no Sr-89 ranges from 61% to 76%. If society is willing to pay more than
£20,000 for an additional QALY, the chance that Sr-89 is the most cost-effective option is in excess of 61%.
Sensitivity analysis
Different scenarios were explored in the sensitivity analysis and are presented in Table 75. Most scenarios
appeared to have a limited impact on the resulting ICER. In particular, not discounting costs and QALYs and
discounting costs and benefits at 0.06% per year resulted in ICERs for Sr-89 of £16,520 and £16,650 per
QALY, respectively. After adjusting for baseline utility, the calculated QALYs for the Sr-89 group remained
greater than the QALYs of the no Sr-89 group (difference of 0.073 QALYs, 95% CI –0.019 to 0.166).
This resulted in an ICER of £18,325. Using alternative unit cost estimates for docetaxel and mitoxantrone
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FIGURE 53 Cost-effectiveness acceptability curve showing the probability of Sr-89 and no Sr-89 being cost-effective
at different values of the ceiling ratio. Reproduced and amended with permission from Andronis et al.55 In the
source figure, only the Sr-89 CEAC was plotted; a CEAC for No Sr-89 has been added here.
TABLE 75 Results of sensitivity analysis for Sr-89 and no Sr-89
Sr-89 No Sr-89
ICER (£)Mean cost Mean QALYs Mean cost (£) Mean QALYs
Base-case results 13,787 0.933 12,446 0.852 16,590
No discounting 13,920 0.941 12,570 0.859 16,517
Discounting at 0.6 per annum for both
costs and benefits
13,698 0.927 12,363 0.847 16,646
QALYs adjusted for baseline imbalances in
EQ-5D
13,787 0.925 12,446 0.852 18,325
Unit cost of docetaxel from eMIT (£34.29
for 140mg)
12,592 0.933 11,287 0.852 16,151
Unit cost of mitoxantrone from eMIT
(£60.36 for 25mg)
13,783 0.933 12,442 0.852 16,591
Unit cost of ZA (50% lower than BNF price) 13,371 0.933 12,012 0.852 16,777
Unit cost of ZA (90% lower than BNF price) 13,038 0.933 11,665 0.852 16,952
Unit cost of ZA (£57.71 for 4mg) 13,230 0.933 11,865 0.852 16,851
Unit cost of Sr-89 (75% of available estimate) 13,488 0.933 12,446 0.852 12,889
Unit cost of Sr-89 (125% of available estimate) 14,086 0.933 12,446 0.852 20,292
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from the NHS Commercial Medicines Unit65 had a minimal effect on the total mean per-patient cost, with
prices of docetaxel and mitoxantrone lower than the base-case values from BNF, resulting in ICERs of
£16,150 and £16,590 per QALY, respectively. The use of lower acquisition cost for ZA to reflect the
availability of generic alternatives had a limited effect on the difference in cost between Sr-89 and no
Sr-89 and, thus, it had a minimal impact on the resulting ICER.
As expected, sensitivity analyses around the price of Sr-89 had a more profound effect on the differences
in costs between Sr-89 and no Sr-89; a lower price of Sr-89 showed Sr-89 to be associated with an ICER
of £12,900 per QALY, whereas a higher price for this radioisotope resulted in an ICER for Sr-89 slightly
over £20,000 per QALY. The relationship between the price of Sr-89 and the resulting ICER for Sr-89,
as compared with no Sr-89, is depicted in Figure 54; it can be seen that for prices of Sr-89 up to £2120,
the ICER for ZA is below £20,000 per QALY and, thus, Sr-89 is cost-effective at the ceiling ratio of
£20,000 per QALY.
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FIGURE 54 Incremental cost-effectiveness ratio for Sr-89 vs. no Sr-89 for different prices of Sr-89.
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Chapter 5 Discussion
Interpretation
There are two strands to the discussion: the clinical effectiveness of the two treatments and the health
economic aspects. As there was no interaction between the effects of the two therapies, Sr-89 and ZA, the
effects can be considered separately.
Strontium-89
The addition of Sr-89 to chemotherapy did favourably affect time to bony disease progression and had a
modest effect on QoL, but no effect on OS. Surprisingly, given the previous data for Sr-89, there was no
impact on SREs in terms of time to first SRE, total numbers or distribution. Given the lack of impact on
events such as SREs, there was little impact on downstream costs. However, the observed QoL gain
and modest additional cost (£1341) translated into an ICER of £16,590 per additional QALY.
Despite these positive outcomes, it is less clear whether or not findings will significantly alter the use of Sr-89,
for a number of reasons. First, the gain in CPFS is modest – about 1 month – while, at the same time, there
was no impact on SRE frequency or time to first event. At the time of study inception, this gain in CPFS,
coupled with a QoL gain, would certainly have been practice-changing at an ICER well below £20,000 per
QALY. However, we have seen a number of new treatments licensed in the last few years that improve OS
after chemotherapy and bring improvements in QoL and SREs. These include abiraterone,8 enzalutamide,9
cabazitaxel16 and, of particular relevance to this study, radium-223.18 Radium-223 is a radioisotope with a
similar uptake mechanism of action to Sr-89, being a calcium-mimetic agent. However, it is more intensely
radioactive and the key ALSYMPCA trial18 shows improvements in both OS and symptomatic SREs. In addition,
the SRE benefit appears to be potentiated by concurrent use of bisphosphonates.
Zoledronic acid
The addition of ZA to docetaxel did not impact on OS or affect CPFS after chemotherapy. There was, however,
a substantial impact on symptomatic SREs. As indicated in Chapter 1, Bisphosphonates, SREs are controversial
as they are a composite end point, and in the ZA licensing trials a key component, pathological fracture,
was assessed repeatedly by a blinded radiologist. The consequence was that many SREs in the trials were of
uncertain clinical significance. In contrast, in TRAPEZE and in some other recent trials in CRPC such as the
ALSYMPCA study with radium-223,18 only symptomatic SREs have been collected; hence the clinical and
economic consequences are much clearer. The US Food and Drug Administration now refers to symptomatic
SREs as ‘symptomatic skeletal events’, which is probably a helpful and relevant distinction. We shall continue
to use the term SRE in this report, as this is the terminology used throughout the study. In the trial, ZA
produced a substantial increase in time to first SRE (13.6 months vs. 11.17 months; HR 0.78), a substantial
decrease in SREs (total SREs 605 vs. 424), as well as a decrease in SREs per patient (see Figure 15).
Furthermore, when the distribution of SREs by type is considered, the biggest effect of ZA was on the SREs
that may be considered the most severe (fracture, SCC and surgery to bone), with a near 50% reduction,
compared with radiotherapy, which reduced these SREs by about one-third (see Table 34).
With this background of clinical effect, the QoL data are of considerable interest. The first feature to note
is that QoL is well preserved across the course of the illness. This accords with clinical impression, which is
that patients remain well in the majority of cases until the final terminal period. The data collected are
undoubtedly incomplete, because the final terminal phase does not seem to be well captured as patients
are generally not attending trials clinics in that period. The second feature is that ZA had a positive, albeit
minimal, effect on QoL, despite a marked change in distribution of SREs in particular. How may we explain
this, as events such as pain leading to radiotherapy, fracture and SCC must certainly impair QoL? There are
a number of possibilities. The first relates to the fact that the timing of completion of forms was variable
DOI: 10.3310/hta20530 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 53
© Queen’s Printer and Controller of HMSO 2016. This work was produced by James et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
115
and hence may well have occurred only in the stable outpatient environment of the trials clinic, once
problems were resolved. The second is that, after a serious event such as a fracture, patients cease to
attend the trial clinic and so the detriment to QoL from a SRE is not well captured. The third is that as the
serious SREs are a minority, any effect is drowned by the QoL impact of radiotherapy, which, it could be
postulated, is as good a way of maintaining QoL as regular ZA infusions. In truth it is likely that all of these
explanations are partially true.
From an economic viewpoint, our cost-effectiveness analysis showed the ZA group to be associated with
an additional cost of £1319 compared with no ZA, on the premise that ZA is purchased as a branded
product at the price reported in the BNF. Combined with the small increase in QoL, ZA appeared to be
more costly and more effective than no ZA, resulting in an ICER near the £42,000 per QALY mark.
However, since the completion of the TRAPEZE trial, ZA has become available as a generic product at a
significantly lower price – less than one-third of the price of the branded Zometa. Indeed, according to the
NHS Commercial Medicines Unit, the average price that hospitals across England pay for ZA is one-third of
the price of proprietary products listed in BNF. As the cost of adding ZA to chemotherapy is a main driver
of the difference in total cost between ZA and no ZA, accounting for this showed lower additional costs
associated with ZA (£251) and a markedly lower ICER of £8005 per QALY. In addition, prevention of
serious events, such as fracture, surgery and cord compression (all associated with frequent and prolonged
admissions), is a high priority for NHS trusts with great pressures on beds. Therefore, a predictable outpatient
therapy with modest net acquisition costs may well be attractive to trusts if it prevents emergency,
unpredictable visits. We did not carry out a patient preference study; however, it may well be the case that
patients would prefer a preventative treatment such as ZA to a reactive approach.
Limitations
The main limitations of the data presented are largely discussed above. Specifically, the development of
new treatments for CRPC makes Sr-89 in particular less relevant, with the advent of better radioisotope
therapy such as radium-223. The limitations on the ZA data are more complex, as the effects on SREs are
substantial and result in reduced costs associated with surgery and radiotherapy at a modest additional
cost. It is likely that these benefits are complementary to those achieved with other post-docetaxel
therapies. In particular, there are data available showing that the benefit of radium-223 on SREs may be
increased by ZA. Improved bone-protecting agents that prevent hospital visits may also alter the potential
benefits of these agents.
A further problem with the QoL data is the effect of missing data, which we have attempted to model but
which could clearly influence outcomes, as it is likely that we are missing data, in particular relating to QoL
around SREs and in the terminal phases. In line with recommendations, health benefits accruing from the
compared treatments were measured in terms of QALYs on the basis of patient responses to the EQ-5D
(three-level) preference-based QoL instrument. However, it must be noted that, in such terminal phases,
benefits perceived to be relevant by patients may not be fully captured by instruments such as the EQ-5D
and they may be inadequately reflected on QALYs. As Gomes et al.66 point out, this is largely because,
at the end-of-life stage, patients deem improvements in survival and QoL as secondary considerations.
Despite this, no instruments are available to measure benefits of end-of-life care for the purposes of
economic evaluations. Costs in this paper have been derived from patient-reported resource use data and,
thus, may be subject to recall bias.
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Generalisablity
Docetaxel remains a mainstay of therapy for CRPC despite the development of new treatments for the
disease. Of note is the fact that, although all patients recruited to the study had relapsing bone mCRPC,
around 40% of patients died without experiencing a single SRE in the docetaxel arm (fewer with the
addition of ZA). Hence, docetaxel itself can be imputed to effectively prevent SREs, as it is highly likely that
the majority of patients managed without this agent (in the era prior to the new therapies listed previously)
would have had many SREs. The data on QoL are striking for the way that QoL is maintained in a highly
disease-burdened population. QoL also rose on commencement of chemotherapy, underlining its value as
a palliative treatment.
As noted, Sr-89 has probably been superseded by radium-223, as well as by other treatments of higher
effectiveness for CRPC. On the other hand, bone-protecting agents such as ZA may offer complementary
benefits via their impact on SREs, particularly serious ones.
Overall evidence
Strontium-89 after six cycles of docetaxel improved CPFS but not OS. ZA did not improve CPFS or OS but
did significantly improve median SREFI, mostly after progression, suggesting a role as post-chemotherapy
maintenance therapy. QoL was well maintained in all treatment arms but with differing patterns of care
resulting from the effects of Sr-89 on time to progression and ZA on SREFI and total SREs.
The addition of Sr-89 to docetaxel chemotherapy resulted in an additional cost of £1341, mainly because
of the cost of the Sr-89 acquisition and administration. Combined with a positive, although small, increase
in QALYs, this option resulted in an ICER of £16,590 per QALY compared with no use of Sr-89. This value
is below the commonly cited willingness-to-pay value of £20,000 per additional QALY.
The addition of ZA to docetaxel resulted in an extra cost of about £1320 (for proprietary ZA) or £251
(given the availability of generic alternatives). These additional costs and the small but positive change
in QALYs in favour of ZA resulted in ICERs of £42,047 for the proprietary product or £8005 for the
alternative generic-based price. Whether or not the addition of ZA to chemotherapy represents a
cost-effective use of resources depends largely on the acquisition cost of a 4-mg dose of ZA. In the likely
case that NHS trusts pay less than £98 for 4mg of ZA, the ICER for ZA is below £20,000 per QALY, and
thus ZA represents a cost-effective option at this ceiling ratio.
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Chapter 6 Conclusion
Implications for health care
Docetaxel appears to prevent patients with relapsing bone disease from developing skeletal complications.
Its use improves QoL and it should remain a component of the treatment options for men with mCRPC.
Sr-89 showed modest benefits at a modest cost, resulting in an ICER lower than £20,000 per QALY,
though it is likely that this radioisotope has now been superseded, in particular by the recently licensed
radium-223. ZA reduced serious skeletal complications at a modest additional cost and showed a small
gain in QALYs. Analysis using generic ZA resulted in a low additional cost of £251 and, coupled with
the gain in QALYs, showed an ICER below the commonly cited value of £20,000 per QALY.
Recommendations for research
Further modelling of the costs of therapy using Hospital Episode Statistics data is desirable and we plan to
complete this. Further research into the use of ZA (and other bone-targeting therapies) with newer
prostate cancer therapies is desirable.
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Appendix 1 Trial protocol
A randomised phase II / III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone 
plus Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus 
Prednisolone plus Zoledronic acid plus Strontium-89 in Hormone Refractory Prostate Cancer 
metastatic to bone. 
 
 
 
 
 
 
 
 
 
Phase II/III Efficacy and Safety Clinical Trial in Hormone Refractory Prostate Cancer  
Protocol 
Version 11, 17 February 2012 
 
 
 Protocol Number: PR2100 
 EudraCT Number: 2004-002295-41 
 HTA 06/303/205 
 ISRCTN 12808747 
 
 
 
  
T rapeze Taxane Radioisotope Zoledronic acid 
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SUMMARY OF AMENDMENTS 
 
Protocol Version No. 
/Date 
Brief description of previous amendments 
 
Trapeze, Phase II 
Version 4 (01/09/2004) 
Version 5 (23/03/2005) 
 
 
 
• Change to the eligibility criteria to enable patients to enter the study without the 
need for a confirmation prostate biopsy if they have confirmed bone disease with a 
PSA value > 100ng/ml. 
• Change to wording of baseline and post chemotherapy assessment requirements 
will allow centres to take part in the study without the need to perform clinical 
procedures if local facilities are not available. 
 
Version 6 (07/06/2005) 
 
• Safety amendment to clarification of zoledronic acid dose procedures to comply with 
SmPC. 
 
Version 7 (04/05/2007) 
 
 
• Changes to the inclusion criteria clarified patient eligibility regarding abnormal ALT 
and AST levels.  
• The requirement for a confirmed Serum Testosterone blood test was removed from 
the screening procedures.  
• A new entry criteria question was added to ensure that at time of study entry all 
patients were fit enough to receive any of the trial treatments, in the opinion of the 
investigator. 
• Clarification of administration sequence of trial treatments. 
 
Trapeze, Phase III 
Version 8 (24/09/2008) 
 
 
• The majority of the changes related to the transition from a phase II to a phase III 
clinical trial, covering trial infrastructure, data collection procedures and statistical 
considerations. These changes had no direct impact on patient participation or 
safety, but did increase the maximum number of chemotherapy cycles from 6 to10, 
according to NICE guidelines for docetaxel chemotherapy. 
 
Version 9 (12/04/2011) 
 
 
 
• This amendment concerns a statistical redesign of the phase III trial from a 4 arm 
comparison to a 2 by 2 factorial design to assess treatment efficacy. 
• Reduction of target recruitment from 1240 (as per version 8 amendment) to 618 
evaluable patients.  The trial will close to recruitment at the end of February 2012. 
 
Version 10 (25/05/2011) 
 
• This amendment concerns a correction in section 12.2.3 on timing of analysis.  We 
intend to conduct initial analysis once all patients have at least 1 year’s follow-up not 
2 years as previously stated. 
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 Version 11 (17/02/2012) 
 
Substantial amendments :  
• Changing the requirement for both ALT and AST to be tested – only one of them 
needs to have been performed. 
• Change of definition for skeletal related event-free interval and pain progression-free 
interval, and removal of the event of death as a skeletal related event and element 
of pain progression criteria. 
 
Non-substantial amendments :  
• Clarification of prophylactic anti-emetic for nausea/vomiting due to chemotherapy, 
and permission to use local protocols that coincide with off-study practice.  
• Updating of Deputy Clinical Co-ordinators details. 
• Additional safety information for zoledronic acid administration. 
• Various typographical corrections and clarifications of existing text. 
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TRIAL MANAGEMENT GROUP  
Chief Investigator Co-Investigators 
Professor Nicholas James Dr James Wylie, Christie Hospital, Manchester 
CRUK Clinical Trials Unit Dr John Staffurth, Oncologist, Cardiff  
University of Birmingham Dr Christopher Parker, Royal Marsden  
Edgbaston    Dr Duncan McLaren, Edinburgh 
Birmingham     B15 2TT Dr J M O’Sullivan, Belfast 
Tel:   
Fax:  Co-Investigator and Analytical Lead 
Email: Professor Lucinda Billingham, CRUK Clinical Trials Unit, 
University of Birmingham 
  J.D.Alonzo@bham.ac.uk  
 Biostatisticians 
Tel: Miss Sarah Pirrie  
Fax:  Dr Stuart Collins 
Email:  
  Health Economist 
  Vacant 
Clinical Co-ordinator  
Professor Nicholas James   
(Contact as above)  
 Research Nurse 
Deputy Clinical Co-ordinator Sr Helen Jones, Welcome Trust QE, Birmingham 
Dr Emilio Porfiri  
CRUK Clinical Trials Unit Trial Pharmacist 
University of Birmingham Andrew Stanley, Pharmacist, Birmingham 
Edgbaston, Birmingham      B15 2TT  
Tel:  Trial Co-ordinator 
Fax:    Dr Ann M Pope 
Email:  University of Birmingham  
  Tel:  
Deputy Clinical Co-ordinator Fax:  
Dr Syed Hussain  Email:  
Clinical Senior Lecturer &  
Consultant Medical Oncology 
 
Dept of Molecular & Clinical Cancer Medicine  
University of Liverpool  
Liverpool   L69 3GA  
Tel:         Fax:   
Email:  
  
Deputy Clinical Co-ordinator  
Dr Daniel Ford  
Consultant Clinical Oncologist  
University Hospitals Birmingham NHS 
Foundation Trust 
 
Queen Elizabeth Hospital  
Birmingham    B15 2TH  
Tel:  
Email:   
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STUDY OFFICE  
  
For randomisation and general queries, supply of trial materials, and collection of data please contact:  
  
Dr Ann M Pope, Trial Co-ordinator  
Trapeze Study Office  
CRCTU  
School of Cancer Sciences  
University of Birmingham   
Edgbaston   
Birmingham  
B15 2TT  
  
Tel:    
Fax:   
E-mail:   
  
RANDOMISATION  
  
CLOSING TO RECRUITMENT AT 5PM ON WED 29 FEBRUARY 2012  
  
Mon-Fri 9.00–5.00  
  
Tel:     or   
  
Fax:     (24hrs) or   
  
CLINICAL QUERIES  
  
  
Clinical queries during office hours should be directed to the Clinical Co-ordinator,   
Professor N James, on Tel:    
or an appropriate member of the Trial Management Group*.  
  
Out of hours, please call Queen Elizabeth Hospital switchboard on Tel:  and ask to bleep  
Professor N James, Clinical Co-ordinator.  
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CHIEF INVESTIGATOR SIGNATURE PAGE 
 
A randomised phase II / III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus 
Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolone plus 
Zoledronic acid plus Strontium-89 in Hormone Refractory Prostate Cancer metastatic to bone. 
 
TRAPEZE 
 
Version 11, 17 February 2012 
This Protocol is approved by : 
 
 
Professor Nicholas James, Chief Investigator 
       
 
Signature :    
 
 
Date :           1st May 2012 
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INVESTIGATOR SIGNATURE PAGE 
 
I have thoroughly read and reviewed the study protocol:  
 
 
A randomised phase II / III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus 
Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolone plus 
Zoledronic acid plus Strontium-89 in Hormone Refractory Prostate Cancer metastatic to bone. 
 
TRAPEZE 
 
I have read and understood the requirements and conditions of the study protocol.  
 
I am aware of my responsibilities as an Investigator under the guidelines of Good Clinical Practice 
(GCP), the Declaration of Helsinki, local regulations and the study protocol and I agree to conduct the 
study according to these guidelines and to appropriately direct and assist the staff under my control who 
will be involved in the study.  
 
I agree to use the study material, including medication, only as specified in the protocol.  
 
I understand that changes to the protocol must be made in the form of an amendment, which has to be 
approved by the relevant Ethics Committee prior to its implementation.  
 
I understand that any violation of the protocol may lead to early termination of the study.  
 
 
Investigator's Name:  
  
Signature:  
  
Date:  
 
The Principal Investigator must sign this page and return a copy to the Trapeze Study Office. 
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PROTOCOL SYNOPSIS 
 
TITLE: A randomised phase II/III study of Docetaxel plus Prednisolone vs. 
Docetaxel plus Prednisolone plus Zoledronic acid vs. Docetaxel plus 
Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolone plus 
Zoledronic acid plus Strontium-89 in Hormone Refractory Prostate 
Cancer metastatic to bone. 
STUDY DESIGN: Randomised Phase II/III clinical trial with 4 different treatment 
combinations 
STUDY OBJECTIVES: Phase II objective:  
To compare the four trial arms with respect to feasibility, tolerability and 
safety 
 
Phase III objective:  
To assess treatments with respect to efficacy within a 2×2 factorial design 
framework i.e. the trial will compare (i) ZA versus no ZA (stratified for 
Sr89 use) and (ii) Sr89 versus no Sr89 (stratified for ZA use). 
 
STUDY POPULATION 
SAMPLE SIZE, INCLUSION 
& EXCLUSION CRITERIA:  
The trial aims to recruit a minimum of 618 evaluable adult male patients 
with Hormone Refractory Prostate Cancer  with: 
 
INCLUSION CRITERIA 
• Histologically/cytologically-proven prostate adenocarcinoma OR 
multiple sclerotic bone metastases with a PSA>100ng/ml without 
histological confirmation. 
• Radiological evidence of metastasis. 
• Fit enough to receive trial treatment. 
• Prior hormonal therapy for prostate cancer. 
• For patients who have received prior hormonal drug therapy: 
• Flutamide, nilutamide, bicalutamide, cyproterone acetate or 
stilboestrol must have stopped at least four weeks prior to 
enrolment and progression must have been demonstrated since 
cessation. 
• Estramustine must have stopped at least four weeks prior to 
enrolment and any adverse events must have been resolved and 
progression demonstrated since cessation. 
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• Documented progression, defined by: 
• Elevated and rising prostate-specific antigen (PSA). 
• And/or progression of any unidimensionally or bidimensionally 
measurable malignant lesion. 
• And/or at least one new lesion identified on bone scan by 
radiological assessment of the bone. 
• Life expectancy ≥ 3 months. 
• ECOG performance status 0-2. 
• Adequate haematological function. 
• Adequate renal and hepatic function. 
• Written informed consent. 
 
 
EXCLUSION CRITERIA 
• Prior cytotoxic chemotherapy for HRPC, other than estramustine 
monotherapy. 
• Prior radiotherapy to more than 25% of the bone marrow or whole 
pelvic irradiation. 
• Prior radionuclide therapy for HRPC. 
• Prior treatment with a bisphosphonate for any reason within the 
previous 2 months. 
• Malignant disease within the previous 5 years, other than adequately 
treated basal cell carcinoma. 
• Known brain or leptomeningeal metastases. 
• Symptomatic peripheral neuropathy ≥ grade 2 (NCI CTC). 
• Concurrent enrolment in any other investigational clinical trial. 
• Treatment with any other investigational compound within the 
previous 30 days. 
• Any condition, which, in the opinion of the investigator, might interfere 
with the safety of the patient or evaluation of the study objectives. 
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1 BACKGROUND 
 
1.1 Hormone-Refractory Prostate cancer 
 
Prostate cancer is the commonest cancer in men in the UK and other industrialised countries and 
one of the leading causes of death. 
 
Although adenocarcinoma of the prostate most often presents as local (stage T1 or T2) disease, in 
which the malignancy is confined to the prostate, a significant proportion of patient’s progress despite 
initial treatment with ablative surgery or radiotherapy, often in combination with hormonal therapy.  
 
Metastatic disease, which is reliably predicted by increasing levels of prostate-specific antigen (PSA), 
is usually treated by androgen-withdrawal, which can be achieved surgically, by bilateral 
orchidectomy (castration), or medically, with LHRH-receptor agonists.  Initial response rates are very 
high, but recurrence is almost inevitable and median survival once androgen ablation has failed is 
typically 12-18 months in the presence of metastatic disease. 
 
Treatment of hormone-refractory prostate cancer (HRPC) is essentially palliative and options include 
further hormone manipulations, systemic chemotherapy, bisphosphonates, radio-isotopes as well as 
traditional palliative therapies such as radiotherapy to symptomatic areas and surgery for obstructive 
symptoms or bone problems such as fracture or spinal cord compression.  There are a large number 
of trials of new agents currently underway in metastatic HRPC (mHRPC) and it is likely that additional 
effective treatments will become available in the coming years, though it is unlikely that they will 
supplant the current options (cf herceptin in metastatic breast cancer).  James et al. published review 
of the management of metastatic HRPC in 20061. 
 
Bone pain is often the most debilitating component of metastatic prostate cancer, occurring in around 
80% of cases of HRPC.  Current systemic treatment strategies include chemotherapy, 
bisphosphonates and bone-seeking radioisotopes, including Sr89 and samarium-153.  Focal 
irradiation to bone pain for solitary, painful bone metastases is an effective palliative strategy and 
may be supplemented by hemibody irradiation for the palliation of widespread metastases.  
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1.2 Use of Docetaxel (Taxotere) In HRPC 
 
Mitozantrone has previously been compared to steroids alone in the palliative treatment of patients 
with symptomatic metastatic HRPC and been shown to improve quality of life and progression-free, 
but not overall, survival2;3.  More recently, taxane-based chemotherapy has been shown to produce 
much higher biochemical response rates than mitozantrone and two landmark trials using docetaxel-
based therapies published in 2004 demonstrated improved overall survival and quality of life 
compared to mitozantrone in two trials using docetaxel-based therapies4;5.  Low numbers of 
treatment-related deaths occurred in both the docetaxel arms and in the mitozantrone control arms 
with no clear or consistent differences between arms.  Generally the docetaxel regimens were 
reasonably well-tolerated and the adverse event profiles were similar to those seen with other 
cytotoxic regimens. 
 
On the basis of these trials, a three-weekly schedule of docetaxel plus prednisolone for up to 10 
cycles has emerged as the standard of care for mHRPC and has been approved by the National 
Institute for Health and Clinical Excellence (NICE) for this purpose in 2006.  In this trial we propose to  
limit initial docetaxel to 6 cycles (the mean number of cycles on the TAX 327 licensing study6 was 7) 
to ensure the feasibility of the delivery of Sr89 (see below).  Patients still responding to docetaxel 
(stable disease or better response to therapy, as determined by the treating clinician) after 6 cycles 
will be eligible to receive a further 4 cycles of chemotherapy. 
 
 
1.3 Use of Bisphosphonates in HRPC 
 
The use of bisphosphonates in oncology has increased over the last decade, although they remain 
the subject of controversy in prostate cancer.  Bisphosphonates inhibit bone catabolism by reducing 
the numbers of functioning osteoclasts and have been an established treatment for osteoporosis and 
similar conditions for many years and more recently have been used to manage bone metastases in 
breast cancer7.  In addition, some bisphosphonates, for example zoledronic acid, but, interestingly, 
not clodronate, arrest cell-proliferation, induce apoptosis, and inhibit the growth-factor stimulation of 
cultured prostate cancer cells8.  
 
A number of bisphosphonates have been examined in prostate cancer including pamidronate, 
clodronate and zoledronate.  Pamidronate failed to show benefit in a randomised study9,   A large 
randomised, placebo controlled study (MRC PR05) reported that clodronate improved the pain-free 
survival period and overall survival period for patients with metastatic prostate cancer compared with 
placebo, although the benefits did not achieve statistical significance (i.e. p>0.05)10.  Further, the 
authors conducting this study reported more gastrointestinal side effects, increased lactose 
dehydrogenase and required more trial dose modifications, although patients in the clodronate group 
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were significantly less likely to experience deterioration in their performance status (HR 0.71, 95% 
confidence interval 0.56 to 0.92, p=0.008).  A trial combining clodronate with mitozantrone failed to 
show any additional palliative benefit from adding this agent to chemotherapy alone11 and we thus felt 
that a further study combining this agent with chemotherapy was unwarranted. 
 
Since the publication of the MRC PR05 study, more potent bisphosphonates have been evaluated in 
mHRPC. The most widely studied has been zoledronate, which has a 40-850 fold higher potency 
than clodronate in preclinical models of bone resorption12.  It has also been shown to be more 
effective than pamidronate (90mg) in controlling malignant hypercalcaemia13.  In addition, 
zoledronate has also demonstrated direct anti-cancer activity, including inhibition of proliferation of 
breast cancer and prostate cancer cells in vitro14.  
 
In randomised studies of mHRPC, zoledronate has been shown to delay, or prevent, skeletal related 
events (SREs: defined as pathological fracture, spinal cord compression, hypercalcaemia, 
radiotherapy for bone pain)15.  However, the drug is administered intravenously every four weeks; this 
has significant resource implications for oncology or urology departments in terms of both drug costs 
and clinical time.  In the UK, use of this agent is patchy and funding is controversial, for example, the 
Scottish Medicines Consortium recommended that zoledronate should not be used in mHRPC 
without further evidence of effectiveness.  Previous studies with another bone-targeting agent, Sr89 
(see below), have suggested that overall healthcare costs are less with use of Sr89 than with 
alternative means of palliation.  As some of the complications of bone disease are catastrophic for 
both the patient and the Health Service (e.g. spinal-cord compression leading to paralysis), a strategy 
of prevention with an expensive agent may well prove to be better than a cheaper alternative in terms 
of  overall quality of life, as well as cheaper overall for the NHS.  However, the use of zoledronate 
requires further evaluation, hence the inclusion of this agent in the trial. 
 
1.4 Strontium-89 (Sr89) 
 
Sr89 is a bone-seeking radionuclide.  It is a pure ß-emitter with a half-life of 50 days, has a high 
uptake in osteoblastic metastases, and remains in tumour sites for up to 100 days.  Palliation of bone 
pain arising from widespread bony metastases may be affected by the intravenous administration of 
radionuclides that target bone metabolism, for example Sr89, samarium-153 and phosphorous-32.  
Of these, Sr89 is the most widely used, providing pain-relief in up to 80% of patients, and complete 
freedom from pain in approximately 10%, for periods that can exceed three months16;17.  In a 
randomised controlled phase III trial, the combination of Sr89 injection and external beam 
radiotherapy improved pain relief, delayed disease-progression and enhanced some quality of life 
measures compared with external beam radiotherapy alone18.  However, another phase III 
randomised controlled trial has suggested that, in some patients, systemic Sr89 may be inferior to 
local field radiotherapy in terms of survival (11.0 versus 7.2 months, p=0.0457)19.  The selection of 
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patients has a significant impact on outcome, response and duration of response to radionuclide 
therapy, as bone pain palliation is reduced in those with widespread metastatic disease or have a 
short life expectancy20;21.  Consequently, the use of radionuclides appears to be optimal at an early 
stage in disease management.  However, their efficacy is reduced or lost with repeated use and over-
treatment can also lead to irreversible pancytopenia.  Both Sr89 and samarium-153 are only available 
to a minority of NHS patients.  There is some evidence that Sr89 may reduce overall health care 
costs compared to standard methods of delivering radiotherapy22. 
 
The benefit of Sr89 in combination with chemotherapy has been evaluated in one small, randomised 
phase II trail in which 103 HRPC patients received induction therapy with ketoconazole and 
doxorubicin alternating with estramustine and vinblastine.  Seventy two patients who were 
responders or clinically stable were then randomised to receive doxorubicin either with or without 
Sr8923.  Median survival was significantly better in the Sr89 arm (27.7 months vs 16.8 months, p = 
0.0014).  This intriguing trial has not been repeated and forms the basis for the docetaxel plus Sr89 
treatment arms in this study.   
 
1.5 Management of Osteoporosis 
 
Patients eligible for the study will be at risk of osteoporosis in view of their previous therapy 
(androgen deprivation, possible steroid exposure, age) as well as from some on-study therapies 
(steroids, docetaxel).  Osteoporosis should be considered in the causality of any skeletal related 
event (SRE) and should be investigated where appropriate.  A bone density ancillary/sub-study forms 
part of this trial.  As the results of this sub-study are determined by planned interim analysis, it is 
possible that further recommendations on the management of osteoporosis in this patient group may 
be made later in the trial.  
 
1.6 Guidelines for Study Design in HRPC 
 
A consensus group of leading investigators in HRPC formulated recommendations for clinical trial 
design, in order to improve the evaluation of new agents and combinations (Bubley et al.,24). The 
recommendations included eligible patient groups and PSA-based response criteria which have been 
adopted in this study.  
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2 RATIONALE 
 
HRPC (Hormone Refractory Prostate Cancer) with metastases is uniformly rapidly fatal and improved 
therapies are desperately needed. Docetaxel (Taxotere®) has been shown to improve survival in 
patients when compared against mitoxantrone in a recent phase III randomised clinical trial in 
patients with HRPC4 and its favourable toxicity profile allows for combination with other agents. 
 
The beneficial effects of bisphosphonates on bone resorption make zoledronic acid a suitable choice 
for combination with docetaxel, leading to fewer SREs and improved palliation in HRPC.  
Furthermore, as bone disease is often the principal cause of morbidity in HRPC, improved bony 
outcomes may also impact overall survival.  
 
Sr89 also has beneficial effects on bone metastases but acts by a different mechanism from 
bisphosphonates, raising the possibility of an additive benefit when the two are co-administered. In 
addition, one small randomised trial23 showed a statistically and clinically significant advantage to the 
addition of Sr89 to chemotherapy in HRPC. 
 
This study therefore seeks to assess whether the addition of Sr89 or zoledronic acid offers a 
significant benefit in combination with docetaxel and prednisolone in HRPC. 
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3 STUDY OBJECTIVES AND OUTCOMES 
 
The trial incorporates both phase II and phase III components, each with specific objectives and 
employing several outcome measures (see Table: section 3.2). 
 
3.1 Study Objectives 
 
3.1.1 Phase II 
The primary objective of the phase II component is to assess the feasibility, tolerability and safety of 
the four treatment arms. 
 
3.1.2 Phase III  
The phase III component of the trial will assess treatments within a 2x2 factorial design framework 
i.e. the trial will compare (i) ZA versus no ZA (stratified for Sr89 use) and (ii) Sr89 versus no Sr89 
(stratified for ZA use). Each of these treatment comparisons will be made in terms of clinical efficacy, 
with primary outcome clinical progression-free survival time, and health economic outcomes. In 
addition, the trial will assess if there is any association between biomarkers and clinical outcomes. 
  
 
3.2 Study Outcomes 
 
Phase Primary  Subsidiary Ancillary measures and 
exploratory outcomes 
II • Feasibility, tolerability 
and safety in terms of 
cycles of docetaxel and 
prednisolone with 
zoledronic acid and/or 
Sr89 received, cycle 
delays, dose 
reductions and toxicity 
• Clinical progression-free 
survival  
• Skeletal-related event- free 
survival 
• Pain progression-free 
survival 
• Overall survival 
• Costs 
• Quality of life 
• Changes in bone mineral 
density (sub-study) 
• Biological profiling for prognostic 
and predictive indicators (sub-
study) 
• PSA-related outcomes 
• Patient-reported pain-related 
outcomes 
III • Clinical  progression-
free survival  
• Cost and cost-
effectiveness 
• Skeletal-related event-free 
survival  
• Pain-progression–free 
survival 
• Overall survival  
• Quality of life 
• Toxicity 
 
• Changes in bone mineral 
density (sub-study) 
• Biological profiling for prognostic 
and predictive indicators (sub-
study) 
• PSA-related outcomes 
• RECIST criteria-related 
outcomes 
• Patient-reported pain-related 
outcomes. 
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4 STUDY DESIGN 
 
4.1 Study Summary 
 
Figure 4.1: Schematic representation of Trapeze study : NB After completion of combined chemotherapy 
& zoledronic acid cycles on Arms B & D, zoledronic acid is to be administered at four-weekly intervals. 
At radiological bone progression or at pain progression the local investigator may choose to continue it. 
  
 
 
Patients are assessed every three weeks during the study treatment period (during chemotherapy 
cycles 1-6 and cycles 7-10).  After treatment, patients receive monthly follow-up visits for the first 
three months, with follow-up visits every three months thereafter, until the patient dies or is withdrawn 
from the study. 
 
All patients will receive a clinical assessment (section 9.3) at the end of cycle 6 (this is the end of the 
Primary Treatment Period), irrespective of treatment arm. 
 
** In Arms C and D a minimum of 28 days between the date of Sr89 administration and day 1 of cycle 
7 of chemotherapy is required.  If cycle 7 (day 1) of chemotherapy is delayed and cannot be 
administered, for any reason, within 8 weeks (56 days) of the date of Sr89 administration then the 
patient is considered to be ‘off–study treatment’.  Thereafter, all additional therapy, including any 
additional docetaxel cycles, will be considered as off-study therapy for the purposes of the trial. 
 
 
R
A
N
D
O
M
I
docetaxel + 
prednisolone
A 
B 
docetaxel + 
prednisolone
strontium – 89 
(Day 28 cycle 6) 
C 
 docetaxel + 
prednisolone +  
D 
docetaxel + 
prednisolone 
strontium – 89 
(Day 28 cycle 6) 
+ 28 Days* 
docetaxel + 
prednisolone + 
+ 28 Days* 
* At least 28 Days 
docetaxel + 
prednisolone + 
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4.2 Study Size 
 
The trial requires 412 events and it is anticipated that a total of 588 patients will need to be recruited 
to observe this number of events at one year follow-up. We aim to recruit a minimum of 618 
evaluable patients which allows for 5% dropout. (see section 12.2 for justification of sample size). 
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5 STUDY POPULATION 
 
5.1 Inclusion Criteria  
 
• Age ≥ 18 years 
• Histologically / cytologically proven prostate adenocarcinoma OR multiple sclerotic bone 
metastases with PSA> 100ng/ml without histological confirmation. 
• Radiological evidence of bone metastasis.  
• Fit enough to receive trial treatment. 
• Prior hormonal therapy for prostate cancer: 
o Bilateral orchidectomy, AND/OR medical castration by LHRH agonist therapy (if 
LHRH agonist therapy alone, this therapy should be continued). 
• For patients who have received prior hormonal drug therapy: 
o Flutamide, nilutamide, bicalutamide, cyproterone acetate or stilboestrol must have 
stopped at least four weeks prior to enrolment and progression must have been 
demonstrated since cessation; 
o Estramustine must have stopped at least four weeks prior to enrolment, any adverse 
events must have been resolved and progression must have been demonstrated 
since cessation.  
• Documented progression, defined by one of the following: 
o Elevated and rising prostate-specific antigen (PSA): 
 PSA > 5ng/ml; 
 Progressive rise in PSA, defined as two consecutive increases in PSA 
documented over a previous reference value (measure 1).  The first increase 
in PSA (measure 2) should occur a minimum of one week from the reference 
value (measure 1).  This increase in PSA should be confirmed (measure 3) 
after a minimum of one week.  If the confirmatory PSA value (measure 3) is 
less than the previous value, the patient will still be eligible for the trial 
provided the next PSA (measure 4) is found to be greater than the second 
PSA (measure 2).  The final sample must have been taken within 28 days of 
enrolment. 
o And/or progression of any uni-dimensionally or bi-dimensionally measurable 
malignant lesion  
o And/or at least one new lesion identified on bone scan. 
• Life expectancy ≥ 3 months. 
• ECOG performance status 0-2. 
• Adequate haematological function: 
o Haemoglobin ≥ 10g/dl 
o Neutrophil count ≥ 1.5 × 109/l 
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o Platelets ≥ 100 × 109/l 
• Adequate renal and hepatic function: 
o Serum creatinine ≤ 1.5 × upper limit of normal 
o Transaminases (ALT, AST or both) ≤ 1.5 × upper limit of normal (unless related to 
hepatic metastatic disease, where patients may be entered after discussion with one 
of the Clinical Co-ordinators) 
o Serum bilirubin ≤ 1.5 × upper limit of normal  
• Written informed consent. 
 
5.2 Exclusion Criteria 
 
• Prior cytotoxic chemotherapy for HRPC, other than estramustine monotherapy. 
• Prior radiotherapy to more than 25% of the bone marrow, or whole pelvic irradiation. 
• Prior radionuclide therapy for HRPC. 
• Prior treatment with a bisphosphonate for any reason within the previous two months.  
• Malignant disease within the previous five years, other than adequately treated basal cell 
carcinoma. 
• Known brain or leptomeningeal metastases. 
• Symptomatic peripheral neuropathy ≥ grade 2 (NCI CTC). 
• Concurrent enrolment in any other investigational clinical trial. 
• Treatment with any other investigational compound within the previous 30 days. 
• Any condition, which, in the opinion of the investigator, might interfere with the safety of the 
patient or the evaluation of the study objectives. 
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6 STUDY TREATMENT  
 
6.1 Study Drug Administration 
 
All four study treatments are IMPs. 
 
6.1.1 Docetaxel  
Docetaxel will be administered by intravenous injection in accordance with the instructions in the 
Summary of Product Characteristics (SmPC) at a dose of 75 mg/m2 (up to a maximum dose of 165 
mg) on day one of the study treatment period and then every three weeks thereafter up to a 
maximum of 10 cycles. 
 
NOTE: Patients with a body surface area (BSA) greater than 2.2m2 should be dosed as though they 
have a BSA of 2.2 m2.  No “ideal” weight should be used for BSA calculations. 
 
6.1.2 Prednisolone 
Prednisolone 10mg daily will be given until the completion of chemotherapy, not being interrupted for 
administration of Sr89.  Additional dexamethasone should be given pre- and post-docetaxel infusion 
to suppress allergic reactions.  At the end of chemotherapy treatment, Prednisolone should be 
tapered off starting 3 weeks from the last administration of docetaxel. 
 
6.1.3 Zoledronic acid  
Zoledronic acid will be administered intravenously as a 15 minute infusion in accordance with the 
instructions in the SmPC at the recommended dose (detailed in the dose table below), every three 
weeks up to the end of chemotherapy and thereafter monthly.  Renal function should be closely 
monitored throughout the zoledronic acid treatment period. 
 
Serum Creatinine measurements: Serum creatinine should be measured at baseline and within 48 
hours prior to every administration of zoledronic acid. 
Serum Electrolytes and FBC: Serum electrolytes including calcium, phosphate and magnesium 
should also be measured prior to each infusion.  
 
Pre-treatment 
Creatinine Clearance 
(ml/min) 
Zoledronic acid  
Recommended Dose 
Volume of concentrate 
solution for infusion 
>60 4.0 mg 5.0 ml 
50-60 3.5 mg 4.4 ml 
40-49 3.3 mg 4.1 ml 
30-39 3.0 mg 3.8 ml 
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Patients must also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D 
daily.  These doses are available as a combination tablet.  When docetaxel and zoledronic acid are 
both administered, the recommended sequence of drug administration is the docetaxel infusion prior 
to zoledronic acid infusion.   
 
Patients must be evaluated prior to and following the administration of the zoledronic acid infusion to 
ensure that they are adequately hydrated. 
 
If the patient is scheduled to receive a dose of Sr89 (as per study arm, or at any time during the post-
study treatment period whilst receiving zoledronic acid), the calcium and vitamin D supplements must  
be discontinued three weeks before and recommenced four weeks after the Sr89 injection.  
 
Prior to treatment with zoledronic acid, dental examination with appropriate preventive dentistry 
should be considered for patients with poor dentition.   While on treatment these patients should 
avoid invasive dental procedures if possible.   For patients requiring dental surgery, for example tooth 
extraction, zoledronic acid should be temporarily discontinued prior to dental work and recommenced 
only when the wound has healed thoroughly.    
 
 
6.1.4 Strontium-89 (Sr89) 
Sr89 will be administered intravenously in accordance with the instructions in the SmPC, as a single 
dose of 150 MBq given at day 28 after day one of cycle 6, subject to satisfactory recovery of marrow 
function.  
 
6.2 Planned Interventions 
 
6.2.1 Arm A: Control – Docetaxel plus prednisolone 
Docetaxel 75 mg/m2 (up to a maximum dose of 165 mg) administered intravenously on day one of 
study treatment plus prednisolone 10mg daily, every three weeks for a maximum of 10 cycles or until 
disease-progression (as defined by the treating clinician), patient withdrawal, or associated treatment 
toxicity.  It is recommended that all 10 cycles of chemotherapy are administered subject to the above; 
however, the local clinician can decide to stop therapy at any time for any reason.  The reason for 
discontinuation of therapy must be recorded on the Case Report Form (CRF). 
 
 
6.2.2 Arm B: Docetaxel plus prednisolone plus zoledronic acid 
Docetaxel 75 mg/m2 (up to a maximum dose of 165 mg) administered intravenously on day one of 
study treatment plus prednisolone 10mg daily.  Zoledronic acid will be administered intravenously at 
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a dose of 4 mg every three weeks on day one of the chemotherapy cycle up to the end of 
chemotherapy, and thereafter every four weeks as clinically indicated, or until disease-progression or 
other discontinuation criteria outlined in Section 8.  Patients treated with zoledronic acid will also 
receive vitamin D and calcium supplements throughout treatment.  
  
6.2.3 Arm C: Docetaxel plus prednisolone plus Sr89 
Docetaxel 75 mg/m2 (up to a maximum dose of 165 mg) administered intravenously on day one of 
study treatment plus prednisolone 10mg daily, every three weeks thereafter for 6 cycles.  At day 28 
after the administration of cycle 6 of docetaxel, subject to satisfactory haematological and clinical 
parameters, Sr89 will be administered as a single dose of 150 MBq.  After at least four weeks (28 
days) and within 56 days after the Sr89 administration (provided bone marrow function has 
adequately recovered), the additional chemotherapy cycles (cycles 7-10) will be given until disease-
progression (as defined by the treating clinician), patient withdrawal or associated treatment toxicity.  
It is recommended that all 10 cycles of chemotherapy are administered subject to the above; 
however the local clinician can decide to stop therapy at any time for any reason. 
 
6.2.4 Arm D: Docetaxel plus prednisolone plus Zoledronic acid plus Sr89 
Docetaxel 75 mg/m2 (up to a maximum dose of 165 mg), prednisolone 10mg daily and Sr89 150 MBq 
will be administered as described above for Treatment Arm C.  In addition, zoledronic acid will be 
administered intravenously at a dose of 4 mg every three weeks up to the end of docetaxel 
chemotherapy, and thereafter every four weeks as clinically indicated or until disease progression (as 
defined by the local clinician).  The zoledronic acid dose on day 28 post-chemotherapy, will be 
omitted and patients will discontinue the calcium and vitamin D tablets for three weeks before and 
four weeks after the Sr89 injection. 
 
6.3 Further off-study treatment 
 
All further off-study treatment, i.e. chemotherapy, bisphosphonate and radioisotope therapy, received 
after study treatment must be captured on the “Concomitant Medication Running Form”.  The choice 
of further treatment is at the discretion of the clinician.  However, if clinically indicated the following 
additional treatments are recommended for all patients: 
 
6.3.1 Zoledronic acid  
On development of radiological bone progression or pain progression (as defined in Section 8), 
patients not randomised to receive zoledronic acid, i.e. treatment arms A and C, should be 
considered to commence this agent.  Patients already on zoledronic acid at radiological bone 
progression or pain progression can continue with this treatment at the investigator’s discretion. 
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6.3.2 Strontium-89 (Sr89) 
On development of radiological bone progression or pain progression, patients not receiving Sr89, 
i.e. arms A and B, can receive Sr89 at the investigator’s discretion.  Patients who have already 
received Sr89, i.e. arms C and D, can receive further Sr89 at the investigator’s discretion, but it is 
recommended, as per the SmPC, that there is at least a 12 week interval between Sr89 
administrations. 
 
 
6.4 Dose Modification in the Event of Toxicity 
 
6.4.1 General rules 
Every effort will be made to administer the full dose regimen to maximise dose-intensity.  If possible, 
toxicities should be managed symptomatically.  If toxicity occurs, the appropriate treatment will be 
used to ameliorate signs and symptoms, including antiemetics for nausea and vomiting, anti-
diarrhoeals for diarrhoea, and antipyretics and/or antihistamines for drug fever. 
 
If a patient experiences several toxicities and there are conflicting recommendations, the most 
conservative dose adjustment will be adopted. 
 
No more than two docetaxel dose reductions will be adopted per patient.  If more than two dose 
reductions are indicated, the patient must go off study.  
 
6.4.2 Docetaxel dose reductions 
Doses must be adjusted according to the following: 
• Standard dose: 75 mg/m² 
• First level dose reduction: 60 mg/m² 
• Second level dose reduction: 45 mg/m² 
 
Doses which have been reduced for toxicity must not be re-escalated. 
 
6.4.3 Docetaxel dose delay 
A treatment delay of four days or more must be reported in the CRF, specifying the reason for the 
delay.  Treatment may be delayed no more than 14 days to allow recovery from acute toxicity.  In 
case of a treatment delay greater than 14 days, the patient must be withdrawn from the trial and a 
Withdrawal CRF completed. 
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6.5 Myelosuppression 
 
6.5.1 Neutropenia and/or its complications  
Adverse event Action to be taken 
- Grade 4 neutropenia* for 7 days or more. 
- Grade 3-4 neutropenia with oral fever >38.5°C 
- Infection* (ie. documented infection with grade 3-4 
neutropenia) 
If the patient develops one of these 
adverse events, the next docetaxel 
infusion must be given with a one-level 
dose reduction. 
* according to NCI-CTCAE  
 
ANC on day of infusion Action to be taken 
≥ 1.5 x 10
9
/L Treat on time: do not reduce the dose 
 
< 1.5 x 10
9
/L Delay maximum 2 weeks 
Blood counts have to be performed until ANC ≥ 1.5 x 
109/L. 
Then treat with a one-level dose reduction. 
If no recovery (ANC still <1.5 x 109/L) after 2 week 
delay: the patient will be discontinued from study. 
 
 
6.5.2 Thrombocytopenia 
In case of grade >3 platelets (NCI-CTCAE), treatment may be delayed for a maximum of 14 days 
until platelets recover to >100 x 109/L, following which treatment will be given with a one-level dose 
reduction. 
 
6.5.3 Allergy (anaphylactic and hypersensitivity reactions) 
Hypersensitivity reactions that occur despite pre-medication are very likely to occur within a few 
minutes of the start of the first or of the second infusion of docetaxel.  Therefore, during the first and 
the second infusions, careful evaluation of the general sense of well-being and of blood-pressure and 
heart-rate monitoring will be performed for at least the first 10 minutes, so that immediate intervention 
can occur in response to symptoms of an untoward reaction. 
 
Facilities and equipment for resuscitation must be immediately available: antihistamine, 
corticosteroids, aminophylline, and epinephrine. 
 
If a reaction occurs, the specific treatment that can be medically-indicated for a given symptom (e.g. 
adrenalin (epinephrine) in case of anaphylactic shock, aminophylline in case of bronchospasm, etc.) 
will be instituted.  In addition, it is recommended to take the measures listed below: 
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Mild symptoms: 
 
Localised cutaneous reaction, such as: 
pruritus, flushing, rash. 
- Consider decreasing the rate of infusion until 
recovery from symptoms, stay at bedside 
- then, complete study-drug infusion at the initial 
planned rate. At subsequent cycles use the pre-
medication outlined in section 6.1.1. 
Moderate symptoms: 
 
Generalised pruritus, more severe flushing or 
rash, mild dyspnoea, hypotension with systolic 
B.P. ≤80 mmHg 
- stop study drug infusion 
- give IV antihistamine and IV corticosteroids (*) 
- resume study-drug infusion after recovery from 
symptoms. At subsequent cycles, antihistamines* 
and steroids* will be given IV, one-hour before 
infusion, in addition to the pre-medication planned 
in section 6.1.1. 
Severe symptoms: 
 
e.g. 
bronchospasm, 
generalised urticaria, 
hypotension with systolic B.P. <80 mmHg, 
angioedema 
- stop study-drug infusion 
- give IV antihistamine and steroids (*). 
 add adrenaline (epinephrine)** or bronchodilators 
and/or IV plasma expanders if indicated. 
-  Once all signs and/or symptoms of hypersensitivity 
reaction disappear, study-drug may be re-infused 
within 24 hours from the interruption, if medically 
appropriate, and whenever possible. 
 Pre-medication regimen as described in section 
6.1.1 is only recommended when study drug is re-
infused more than 3 hours after the interruption. 
 During subsequent cycles, dexamethasone will be 
given at 20mg orally,  24, 18, 13, 7 and 1 hour 
before study-drug infusion.  
 Additionally diphenhydramine (or equivalent) will 
be given at 50mg IV 1 hour before study-drug 
infusion.  
 If a severe reaction recurs, patient will go off 
protocol therapy, , and a Withdrawal CRF 
completed. 
*antihistamines: Chlorpheniramine (*) IV 10-20 mg 
 or promethazine (*) IM 25–50 mg, max-100 mg 
 
 corticosteroids: dexamethasone or equivalent (*) IV  5-10 mg of dexamethasone 
 
** Adrenaline (epinephrine): administer standard dose – 500 µg). 
 
 
6.5.4 Nausea/Vomiting 
A prophylactic anti-emetic treatment should be given to patients from the first cycle.  The use of 
dexamethasone plus a second anti-emetic such as metoclopramide is recommended.  Local 
protocols that coincide with off study practice are permitted.  More aggressive anti-emetic prophylaxis 
(eg. 5-HT3 antagonists) should be given to a patient who has experienced grade ≥3 nausea/vomiting 
in a preceding cycle. 
 
If, despite the appropriate medication, grade ≥3 nausea/vomiting still occurs, reduce the dose of 
docetaxel by one dose level.  Should nausea/vomiting continue or recur at grade ≥3 despite the dose 
reduction, the patient must go off-study, and a Withdrawal CRF completed. 
 
 
6.5.5 Diarrhoea 
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No prophylactic treatment for diarrhoea is recommended from cycle one.  However, following the first 
episode of diarrhoea, the patient should receive symptomatic treatment with loperamide: 
 
• 4 mg following the first episode and then 2 mg following each new episode until recovery of 
diarrhoea (no more than 16 mg daily). 
 
If diarrhoea grade ≥3 still occurs despite the use of loperamide, reduce the dose of study-drug by one 
dose level.  If despite dose reduction, diarrhoea still occurs at grade ≥3, the patient will go off-study, 
and a Withdrawal CRF completed. 
 
6.5.6 Stomatitis 
Grade ≤2: No change, study chemotherapy should be withheld until resolution to grade ≤1.  If grade 3 
stomatitis occurs, study drug must be withheld until resolution to grade ≤1. Treatment may then be 
resumed, but the dose of study drug must be reduced by one dose level for all subsequent doses. 
 
In case of grade 4 stomatitis, the patient will go off study, and a Withdrawal CRF completed. 
 
6.5.7 Peripheral neuropathy 
In case of symptoms or signs experienced by the patient, dose modification should be performed as 
follows: 
• Grade ≤1: no change. 
• Grade 2: re-treat with a one-level dose reduction (no further dose reduction is planned). 
• Grade ≥3: patient will go off study, and a Withdrawal CRF completed. 
 
6.5.8 Skin toxicity 
• Grade 0, 1, 2: No change. 
• Grade ≥3: delay until grade ≤1, maximum 2 weeks then reduce dose of study drug by one 
dose level; if no recovery to grade ≤1 within 2 weeks delay, patient will go off protocol 
therapy, and a Withdrawal CRF completed. 
 
6.5.9 Liver toxicity 
In case of increase of ALT and/or AST to >1.5 x ULN or bilirubin to >ULN, delay study drug treatment  
for up to 2 weeks until ALT and/or AST returned to ≤1.5 x ULN and bilirubin to ≤ ULN. Then re-treat 
at one dose level lower. 
 
In the case of a patient entered into the study with elevated bilirubin levels (serum bilirubin ≥1.5 × 
upper limit of normal) as per the eligibility criteria, the criteria detailed in the above paragraph for 
dose reduction/treatment delay in relation to bilirubin levels for this patient DO NOT apply.  In this 
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case the individual patient’s reading at study entry is considered the normal bilirubin level for that 
individual.  Subsequent dose delays and dose reductions are applied as above, if the individual’s 
bilirubin level increases from baseline after cycle 1 of chemotherapy.  This is because any increase in 
the bilirubin level can be considered toxicity from treatment and not related to the underlying disease 
at baseline.  
 
6.5.10 Docetaxel-induced fluid retention 
In case of fluid retention (peripheral oedema and/or effusions) during the treatment with docetaxel, 
the signs and symptoms should be graded as mild, moderate, severe or life threatening.  
 
NO DOSE REDUCTION IS PLANNED 
 
The patient’s body weight will be recorded and followed as frequently as possible to document any 
weight gain, which could be related to oedema. 
 
Recommended treatment 
Treatment should commence when signs and/or symptoms of fluid retention are observed, including 
weight gain from baseline grade ≥1 not otherwise explained. 
 
Based on the hypothesis of capillary damage due to docetaxel, the following treatment is 
recommended in case fluid retention occurs: frusemide 20 mg orally once daily. 
 
If the symptoms cannot be controlled adequately i.e. worsening of the fluid retention or spread to 
another area, the dose of frusemide should be increased to 40 mg.  The addition of metolazone orally 
at the recommended dose together with potassium ± magnesium supplements may be useful. 
 
The clinical tolerance of the patient, the overall tumour response and the medical judgment of the 
investigator will determine if it is in the patient's best interest to continue or to discontinue the study 
drug.  It is recommended, however, that patients with fluid retention of grade ≥3 severity should be 
withdrawn, and a Withdrawal CRF completed. 
 
In case it is difficult to make a judgment as to whether an effusion is disease-related or study drug-
related, the treatment should be continued until progressive disease in other organs is documented, 
and provided there is no worsening of the effusion during treatment. 
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6.5.11 Docetaxel-induced hyperlacrimation 
The excessive lacrimation (epiphora) seen in some patients receiving docetaxel appears to be 
related to cumulative dose (median ~300 mg/m2) and resolves rapidly after treatment discontinuation. 
Excessive lacrimation seems to be the result of a chemical conjunctivitis and/or chemical 
inflammation (with oedema) of the lachrymal duct epithelium (producing a reversible lachrymal duct 
stenosis).  If epiphora persists patients should be referred to an Ophthalmologist. 
 
In patients experiencing clinically significant hyperlacrimation, the following approach is 
recommended: 
 
NO DOSE REDUCTION PLANNED 
 
Frequent instillation of artificial tears. 
Prescribe a steroid ophthalmic solution (e.g. prednisolone acetate): 2 drops each eyelid for 3 days 
starting the day before docetaxel administration in patients without a history of herpetic eye disease. 
 
6.5.12 Zoledronic acid and renal impairment 
Please refer to section 6.1.3. 
 
6.5.13 Hypersensitivity to zoledronic acid  
If hypersensitivity occurs treatment should be discontinued, or continued with the use of anti-
histamines, at the discretion of the treating clinician.   
 
6.5.14 Osteonecrosis of the jaw and zoledronic acid 
Long-term use (i.e. >24 months) of zoledronic acid use has been linked to osteonecrosis of the jaw 
(ONJ). This is of particular concern in patients who have dental disease.  If a patient develops ONJ 
then their zoledronic acid should be immediately and permanently discontinued. 
 
6.5.15 Strontium-89 (Sr89) 
This should be omitted if there is inadequate marrow reserve (Hb ≤10 g/dL, neutrophils <1.5 x 109/L, 
platelets <100 x 109/L). There will be no dose reduction : Sr89 must be given at full-dose if it is given 
as trial treatment. 
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7 STUDY ORGANISATION 
 
7.1 Duration of Study 
 
It is anticipated that the study will involve up to 50 centres.  At a mean recruitment rate of 
approximately 15 patients per month, accrual should be feasible in the previously estimated 6-year 
time span. The primary treatment period (i.e. the first 6 cycles of chemotherapy) for each patient will 
last 18 weeks in arms A and B (the arms that are not randomised to receive Sr89) and 22 weeks in 
arms C and D  (the arms which are randomised to receive Sr89).  A further 4 cycles of chemotherapy 
may be given to all patients; continuous for patients in arms A and B and following a break of at least 
28 days (and less than 56 days) for those in arms C and D.  Following completion of chemotherapy 
(docetaxel) patients in treatment arms A and C may receive zoledronic acid monthly (every four 
weeks) at the clinician’s discretion.  Follow-up visits will initially occur monthly for three months, and 
subsequently three-monthly until death or withdrawal for any other reason.  Patients withdrawn from 
the study will be followed-up by ONS flagging, which will provide copies of patients’ death certificates. 
For such patients, a withdrawal CRF must be completed.   It is estimated that recruitment of 
participants into the study will be complete by the end of February 2012. 
 
The Trial Management Group (TMG) is responsible for protocol development and initiation of the 
study.  This group forms the basis for the Trial Steering Committee (TSC) who are responsible for 
monitoring study-progress, amending the study-protocol as required, overseeing the trial conduct and 
providing information to the Independent Data Monitoring Committee (IDMC).  The Cancer Research 
UK Clinical Trials Unit (CRCTU), School of Cancer Sciences, (formerly within the Institute for Cancer 
Studies) University of Birmingham, is responsible for the day-to-day running of the study, centre-
initiation, reporting to the TSC and IDMC, analysis, and presentation of results.  Intellectual property 
and access to data arising from this trial will be governed by the TSC. 
 
7.2 Site Responsibilities 
 
The Principal Investigator at each participating centre has overall responsibility for the study and all 
patients entered into the study, but may delegate responsibility to other members of the study team 
as appropriate.  The Principal Investigator must ensure that all staff involved in the trial are 
adequately trained and that their duties have been logged on the Site Responsibilities Sheet.  
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7.3 Study Start-Up and Core Documents 
 
Centres wanting to participate in the study should contact the study office to obtain information.  The 
Principal Investigator should then provide the study office with the following core documents and 
attend an initiation visit or attend an initiation teleconference before the site is activated: 
 
Core Documents: 
• The site contact details. 
• The University of Birmingham Clinical Study Site Agreement. 
• All Investigators and Co-investigators will provide an up-to-date copy of their CV, personally 
signed and dated, prior to the start of the study. The CV should detail the Investigators’ 
education, training and experience relevant to their role in the study.   
• The study-specific Commitment Statement. 
• Site Responsibilities Sheet. 
• Trust approval letters. 
 
It is the Principal Investigator’s responsibility to apply for site-specific assessment for his/her 
individual site.  Once a site has been approved the Principal Investigator will be informed by the Chief 
Investigator (or one of his team) that site-specific approval has been granted. 
 
7.4 Forms And Data Collection 
 
Data collected on each subject will be recorded by the investigator, or his/her designee, as accurately 
and completely as possible as soon as the requested information becomes available.  The 
investigator will be responsible for the timing, completeness, legibility and accuracy of the Case 
Report Form (CRF) and he/she will retain a copy of each completed CRF.  The investigator will 
supply the study office with any required data from such records.  
 
Entries will be made in black ballpoint pen on the CRF provided and must be legible.  Any errors 
should be crossed out with a single stroke, the correction inserted and the change initialled and dated 
by the investigator or his/her designee.  If it is not clear why a change has been made, an explanation 
should be written next to the change.  Typing correction fluid should not be used.  Each patient 
enrolled into the study must have all CRFs completed and signed by the Principal Investigator or 
his/her designee.  This also applies to those patients who failed to complete the study.  Data reported 
on the CRF should be consistent with the source data, or the discrepancies should be explained.  
 
To enable peer review and/or audits from Health Authorities or other regulatory bodies, the 
Investigator must agree to keep records, including the identity of all participating subjects (sufficient 
information to link records, e.g. CRFs and hospital records), all original signed Informed Consent 
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Forms, copies of all CRFs and detailed records of drug disposition.  It is the responsibility of the 
Principal Investigator to ensure that all essential trial documentation and source records (e.g. signed 
Consent Forms, Investigator and Pharmacy Files, patients’ hospital notes, copies of CRFs etc.) at 
their site are securely retained for at least five years after the end of the trial: participating sites will be 
sent a letter specifying the permissible disposal date.  
 
7.5  Quality Of Life Data (Sub-study) 
 
Quality of life (QoL) will be assessed using EuroQol EQ-5D and FACT-P, which are patient-
completed questionnaires (Appendix 3, 4).  Patients will also be asked to complete pain diary sheets 
during their treatment (Appendix 5).  All eligible patients will be asked to consent to both the main trial 
and also to the QoL part of the trial, as taking part in this part of the trial is optional. QoL 
questionnaires will be completed at baseline, on treatment (prior to each dose of docetaxel), and at 
every protocol-defined visit,, including all patient follow-up visits.  The patient should be asked to 
complete the QoL questionnaires prior to consultation with the clinician.  It is the intention that in this 
trial, patients will be asked to complete QoL questionnaires and Pain Diaries from the date of 
randomisation until death or patient refusal.  The completion of these documents is voluntary and 
should continue throughout patient follow-up (pre- and post-clinical progression) irrespective of any 
further therapy that an individual patient may receive.  All additional therapy post-clinical progression 
will be recorded in the relevant page of the CRF. 
 
It is essential to explain to the patient that all parts of the QoL questionnaire should be completed as 
fully as possible.  In order to administer these consistently, the QoL questionnaires will be in order 
and given to the patient in a stapled booklet.   Each centre must identify a named individual 
responsible for administering the QoL questionnaires. 
 
Participation in the QoL sub-study is not compulsory and will not affect the patient’s ability to take part 
in the trial.  
 
7.6 Health Economic Analysis 
 
The economic analysis will be conducted alongside the trial. The main objective of this analysis is to 
assess the costs and cost-effectiveness across different treatments.  The key resource use data will 
be collected through the CRFs and supplemented by a patient-completed resource-use 
questionnaire. Health-related QoL will be assessed using the EQ-5D. The EQ-5D is a widely-used, 
brief, generic utility-based measure of health-related QoL. A utility score will be generated from this 
questionnaire. Quality-adjusted life-years (QALYs) will be calculated using area under the curve 
methods. A cost-effectiveness analysis will be conducted in which outcome will be measured as 
incremental cost per QALY gained within the trial period analysis. 
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The scope for validating data on resource use by using routine NHS administrative system data will 
be explored, including obtaining patient consent.  Modelling will be required to estimate the cost per 
life year and per QALY, for sensitivity analysis and also to explore the implications of generalising 
from the study.  
 
The economic analysis will be undertaken in conjunction with The Health Economics Unit, University 
of Birmingham, who have extensive experience in such work. 
 
7.7 Biomarkers Data (Sub-study) 
 
The CRCTU will request pathological information at the time of randomisation for all patients entered 
into the trial.  This information will include histology number, location of paraffin-embedded tumour 
blocks and reporting consultant pathologist.  Subject to patient consent, collection of this information 
will allow for the prospective collection of tissue blocks, which will be analysed at a later date.  
Immuno-histochemical techniques will be used on tissue sections to test for the presence of 
biological predictive-markers of treatment benefit (e.g. P53, P27, P20, Ki67, Her2/neu, EZH2).  
 
We will also seek patient consent for the collection and storage of repeat blood samples which can 
initially be stored at the local centre but ultimately will be sent to CRCTU for future proteomic analysis  
of known (e.g. PSA, FGS, IGS) and novel protein markers using the expertise within the School of 
Cancer Sciences in Birmingham and other collaborative centres.  
 
7.8 Computerised Records 
 
Create data – Details of centres and participating staff will be recorded during the study. Patient data 
records will be created at randomisation and data entered from CRFs during study participation.  
 
Modify and maintain data – Records of centres and participating staff will be modified to maintain 
accurate details of trial-related personnel and their involvement status.  Data from CRFs will be 
modified to correct any erroneous or missing entries.  The reason for these changes will be recorded 
to facilitate an audit trail. 
 
Archive – At the conclusion of the trial, when all patient data has been collected, and the analysis is 
complete, all the data stored on the computer system will be archived for 15 years.  After trial 
conclusion, if any audit is required, or new analysis to be performed, the data will be retrieved.  
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7.9 Monitoring  
The study is being conducted under the auspices of the CRCTU according to the current guidelines 
for Good Clinical Practice.  Participating centres will be monitored by CRCTU staff to confirm 
compliance with the protocol and the protection of patients’ rights as detailed in the Declaration of 
Helsinki. 
 
Participating centres will be monitored by checking incoming forms for compliance against the 
protocol, consistent data, missing data and timing.  Study staff will be in regular contact with centre 
personnel to check on progress and to deal with any queries they may have. 
 
On-site monitoring will be carried out as required following a study-specific risk assessment and as 
documented in the study-specific monitoring plan. 
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8 STUDY PROCEDURES 
 
8.1 Patient Screening  
 
The investigator will provide patients who appear to meet the criteria for participation in the study with 
information to allow them to make an informed decision regarding their participation.  If informed 
consent is given, the investigator will conduct a full screening evaluation to ensure that the subject 
satisfies all inclusion and exclusion criteria.  If the screening is successful, it is recommended that the 
patient commences trial treatment within two weeks of randomisation. 
 
8.2 Randomisation of Patients  
 
Randomisation will be undertaken by the CRCTU, School of Cancer Sciences, University of 
Birmingham. 
 
8.2.1 Stratification 
Patients will be randomised to treatment arms in a 1:1:1:1 allocation ratio using a computerised 
minimisation algorithm.  Randomisation will be stratified by centre and ECOG performance status 
(0,1,2) to avoid imbalance in the four treatment arms.  
 
8.2.2 Randomising a patient 
To randomise a patient: 
• Obtain the patient’s written informed consent to participate in the study. 
• Complete the Randomisation Form 
• Telephone: 
 
Mon-Fri, 9.00 –5.00 
Tel:     or  
Fax:     (24hrs) 
 
The patient will be allocated their treatment and a trial number, which must be noted on the 
Randomisation CRF.  The investigator should send the patients’ GP a letter and information sheet 
indicating their participation in the study. 
 
8.3 Study Treatment Period 
 
Day 1 of the study treatment period is the day on which the first dose of docetaxel is administered 
and prednisolone commenced.  The first 22 weeks is the primary treatment period: 6 cycles of 
docetaxel +/- Sr89 +/- zoledronic acid, according to the randomisation treatment allocation.  A further 
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4 cycles of docetaxel can then be given according to the details in section 6 of the protocol.  This 
period will be classed as the secondary treatment period.  Prednisolone should be tapered off starting 
3 weeks from the last administration of docetaxel. 
 
If a patient has been randomised to receive zoledronic acid, this will be continued 4 weekly thereafter 
until protocol-defined disease progression, patient or clinician withdrawal (for toxicity), or patient 
choice.  Further treatment (including the use of zoledronic acid) after clinical disease progression will 
be given according to local clinical practice. 
 
8.4 Follow-up Period 
 
The follow-up period begins after the completion of the primary and secondary (if given) treatment 
periods.  Patients are followed-up every month for the first three months and then every three months 
until death or patient withdrawal for any other reason. 
 
8.5 Discontinuation of Study Treatment 
 
Discontinuation of any study medication(s) must be reported by completing the Withdrawal CRF. 
 
8.5.1  Discontinuation of study docetaxel  
A patient should be withdrawn from docetaxel treatment in the event of any of the following: 
• Progression due to either: 
o Pain progression (as defined by the local clinician), or 
o Clinical Disease progression, as defined by the local clinician.  
NOTE: biochemical (PSA) progression alone is NOT a reason to discontinue 
treatment unless the investigator deems it to be in the best interests of the patient. 
• Development of a life-threatening and/or irreversible toxicity not manageable by symptomatic 
care, dose reduction, or dose delay.  A maximum of two docetaxel dose reductions are 
permitted per patient (see Section 6.4.1).  A maximum dose delay of 14 days is permitted on 
each cycle of docetaxel (see Section 6.4.3). 
• Administration of any other anti-tumour chemotherapy, radiotherapy or investigational agent 
during the trial. 
• Development of any condition, or occurrence of any event, which, in the opinion of the 
investigator, justifies discontinuation of treatment. 
• Patient’s decision to discontinue trial treatment or to withdraw (consent) from other aspects of 
the trial, e.g. completion of QoL booklets, participation in tumour-block collection or proteomic 
(blood sample) collection. 
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8.5.2 Discontinuation of study zoledronic acid  
A patient should discontinue on-going zoledronic acid in the event of any of the following: 
• Development of any of the toxicities requiring discontinuation as described in section 6.5.12. 
• Pain progression or clinical disease progression (as defined by the local clinician). NOTE 
zoledronic acid may continue to be given (off-study) at the investigator’s discretion. 
• Development of any condition or occurrence of any event, which, in the opinion of the 
investigator, justifies discontinuation of treatment. 
• Patient’s decision to discontinue trial treatment or to withdraw from the trial. 
 
8.5.3 Omission of study Sr89 
The planned treatment of Sr89 should be omitted in the event of any of the following: 
• Unsatisfactory haematological and clinical parameters as described in section 6.5.14. 
• Failure to complete 6 cycles of study docetaxel.  
• Development of any condition or occurrence of any event, which, in the opinion of the 
investigator, justifies discontinuation of treatment. 
• Patient’s decision to discontinue treatment or to withdraw from the trial. 
 
8.6 Study Completion 
 
A patient will be considered to have completed the study in the event of death or of loss to follow-up.  
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9 STUDY ASSESSMENTS 
 
9.1 Baseline Assessments 
 
The following must have been done not more than 28 days prior to enrolment, with one exception as 
detailed below: 
• Medical history. 
• Physical examination. 
• ECOG performance status 
• Tumour assessment by any or all of: CT scan, MRI scan, bone scan and ultrasound:  
o The trial management team recommend that the tumour assessment is performed 
within 56 days of patient randomisation.  
o The same technique must continue to be used for a given lesion throughout a 
patient’s study course.  
o As per eligibility criteria, radiological evidence of bone metastasis is required for 
study entry.  If a patient has received additional cancer therapy after the radiological 
imaging, but prior to randomisation into the trial, new imaging is required to confirm 
that the patient has continued disease involvement of the bone  
• Chest X-ray (required if no CT scan of chest) or CT scan. 
• Dual energy X-ray absorption scan (DXA) – Bone Density Scan.  
 
(The requirement for a DXA scan may not be required if the participating centre is not taking part 
in the relevant sub-study, or if a patient has declined to participate in this part of the study). 
 
• Proteomic blood sample (subject to individual investigator site participation) 
• Serum PSA. 
• Haematology tests: haemoglobin, WBC count, neutrophil count and platelet count.  
• Clinical chemistry tests: urea, serum creatinine, potassium, sodium, calcium, magnesium, 
aminotransferases (AST, ALT or both), alkaline phosphatase, total bilirubin and blood 
glucose. 
• Pain score and analgesic use (see Section 9.5). Both pain and analgesic-use scores will be 
derived from the record of the week immediately prior to assessment. 
• Questionnaires: QoL using EuroQol EQ-5D and Fact-P questionnaires, the resource-use 
questionnaire. 
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9.2 Assessments During Study Treatment Period (Cycles 1-10 of Chemotherapy) 
 
The following assessments will be carried out at the indicated intervals during the course of the 
study: 
• Tumour assessment as clinically indicated - each lesion to be assessed using the same 
technique as used for that lesion at baseline. 
• Chest X-ray or CT scan – as clinically indicated. 
• Physical examination. 
• Serum PSA: immediately prior to each dose of docetaxel, then every 12 weeks during 
secondary treatment period. 
• Proteomic blood sample at end of cycles 2, 4 and 6 of chemotherapy.  If further 
chemotherapy is given (i.e. cycles 7 to 10) then samples will be taken at the end of cycles 8 
and 10 (subject to individual investigator site participation). 
• Haematology tests (as at baseline): immediately prior to each dose of docetaxel or 
assessment. 
• Clinical chemistry tests (as at baseline): immediately prior to each dose of docetaxel or 
assessment. 
• Pain score and analgesic use: recorded by patient during the week immediately prior to each 
dose of docetaxel or assessment (see section 9.5). 
• QoL using the EuroQol EQ-5D and Fact-P questionnaires, and the resource-use 
questionnaire: immediately prior to each dose of Docetaxel or assessment. 
• ECOG performance status. 
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9.3 End of Primary Treatment Period Chemotherapy Assessments (ALL Patients) 
 
Following completion of the 6th cycle of protocol-defined therapy, all patients should have the 
following assessment completed 21 days after receiving cycle 6 docetaxel.  The CRF form to 
complete is titled ‘Post Cycle 6 Docetaxel Assessment Form’.   This assessment is not required for 
patients who do not complete 6 cycles of chemotherapy, nor is it required after the last cycle if more 
than 6. 
 
For patients not randomised to receive Sr89, the following assessments are the same as those 
normally performed for pre-chemotherapy assessment required for cycle 7 treatment.  It is not 
necessary to repeat any tests for this assessment, only to record it on the above CRF. 
 
            
• Physical examination. 
• ECOG performance status. 
• Imaging required if disease progression is suspected either clinically or biochemically. 
• Proteomic blood sample (subject to individual investigator participation). 
• Haematology tests: (as at baseline). 
• Clinical chemistry tests: (as at baseline) including PSA. 
• Pain score and analgesic-use (see section 9.5). Both pain and analgesic-use scores will be 
derived from the record of the week immediately prior to assessment. 
• Questionnaires: QoL using the EuroQol EQ-5D and Fact-P questionnaires, resource-use 
questionnaire. 
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9.4 Follow-up Assessments 
 
Patients who have clinically progressed, i.e. having pain progressed, date of first skeletal-related 
event, as described in section 10.1.2, should progress to 3 monthly follow-up.    
 
Table : Patient’s pathway post-progression  
Type of progression Discontinue docetaxel 
Increasing PSA No 
Tumour (radiology) Yes 
Pain progression Yes 
1st SRE  Only if disease related 
Death - 
 
Please note that withdrawal from trial treatment due to disease progression must be reported on a 
Disease Progression CRF and not a Withdrawal CRF. 
 
9.4.1 Monthly follow-up, for first three months only 
During follow-up the following assessments will be performed every month for the first 3 months only,  
or until the patient completes or is withdrawn from the trial: 
• Haematology tests (as at baseline). 
• Clinical chemistry tests (as at baseline) including PSA. 
• Pain score and analgesic-use (see section 9.5). 
• QoL using EQ-5D and Fact-P questionnaires, resource-use questionnaire. 
• Imaging as required.  The exact timing of any imaging will be determined by the local 
clinician, and therefore may not occur at one or more follow-up visits. 
• ECOG performance status 
 
9.4.2 Three-monthly follow-up, after first three months: 
During follow-up the following assessments will be performed every three months (after the first 
three-monthly follow-up assessments), until the patient completes, or is withdrawn from, the study: 
• Haematology tests (as at baseline). 
• Clinical chemistry tests (as at baseline) including PSA. 
• Pain score and analgesic-use (see section 9.5). 
• QoL using EQ-5D and Fact-P questionnaires, resource-use questionnaire. 
• Imaging as required.  The exact timing of any imaging will be determined by the local 
clinician, and therefore may not occur at one or more follow-up visits. 
• ECOG performance status. 
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9.5 Patient Pain Diaries 
 
To enable an exploratory analysis of patient-reported pain outcomes, patients will be asked to 
complete pain diaries.  These diaries will provide a daily record of the pain experienced by a patient 
and their analgesic intake for the seven day period prior to every protocol-defined visit. 
 
The first diary must be collected after patient consent and prior to the first docetaxel treatment.  
Thereafter, a diary will be completed for the seven day period prior to the:- 
• Start of each subsequent chemotherapy cycle (day 1). 
• End of the primary treatment period. 
• Follow-up assessment visits, and at every protocol-defined visit thereafter. 
 
The diaries will then be promptly reviewed (ideally with the patient present) for compliance by the 
investigator or nurse.  Any potential problems, i.e. dose of drug missing, will be reviewed and 
amended by the individual patient (if possible) at this time. 
 
It is intended that the pain diaries will be completed by patients throughout the treatment and follow-
up periods of the study, until the occurrence of one of the following: death, loss to follow-up or patient  
refusal.  A patient can decide to stop completing pain diaries at any time without giving a reason.  
Patient participation in the pain diary sub-study is not compulsory and will not affect the patient’s 
ability to take part in the trial.  
 
Pain-scoring will use both the Present Pain Intensity (PPI) six-point scale (0=no pain to 5 = 
excruciating pain) from the McGill-Melzack questionnaire and the analgesic score, calculated by a 
member of the participating centre trial team using the following table : 
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SCORES associated with ANALGESICS TYPE AND DOSES 
Non Narcotic Medications Narcotic Medications 
1 POINT 4 POINTS 
Any route Oral/Rectal IV/IM/SC 
Generic Name Dose 
(mg) 
Generic Name Dose 
(mg) 
Generic Name Dose 
(mg) 
Aceclofenac 100 Anileridine 25   
Acemetacin 90 Buprenorphine 0.8 Buprenorphine 0.8 
Acetaminophen /  
Paracetamol 
325   Butorphanol 1 
Aminophenazone 500 Codeine 60   
Aspirin 325 Dextropropoxyphene 50   
Celecoxib 100 Dihydrocodeine 30   
Diclofenac 25 Fentanyl* 100 
µg 
Fentanyl* 50 µg 
Diflunisal 250 Hydrocodone 10 Hydrocodone 5 
Dipyrone/ 
Metamizole 
500 Hydromorphone 2 Hydromorphone 1 
Etodolac 200 Levorphanol 2 Levorphanol 2 
Fenoprofen 200 Meperidine/ 
Pethidine 
100 Meperidine/ 
Pethidine 
50 
Flurbiprofen 50 Methadone 10   
Ibuprofen 200 Morphine 10 Morphine 5 
Indomethacin 25 Oxycodone 5 Oxycodone 2.5 
Ketoprofen 25 Oxymorphone rectal  2.5   
Ketorolac 10   Papaveretum 15.4 
Mefenamic Acid 250 Pentazocine 50 Pentazocine 30 
Nabumetone 500 Piritramide 15   
Naproxen 250 Propoxyphene 50   
Nefopam 20 Tilidine 50   
Nimesulide 100 Tramadol 50 Tramadol 50 
Piroxicam 10     
Propyphenazone 250     
Rofecoxib 12.5     
Tenoxicam 20 * Fentanyl patch (TTS): 36 points / day for 25µg/hour patch 
 
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
170
9.6 Other Assessments (One Year Post-Randomisation Date) 
 
 
Dual energy X-ray absorption (DXA) scan, bone density scan (1 year post-randomisation date only, 
+/- 3 months) 
 
The DXA scan is only required if the participating centre is participating in the Bone Density sub-
study. 
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9.7 Flow Chart of Trapeze Study Procedures and Assessments 
 
 
Investigations Pre- 
randomisation 
On Treatment 
Primary Treatment  
Period (cycles 1 – 6) 
Post-primary treatment 
period (cycles 1 - 6) 
assessment 
Follow-up 
1. Informed consent     
2. History / physical exam 
(including clinical tumour 
assessment and new 
skeletal events) 
Within 28 days Every 3 weeks 
(prior to docetaxel 
infusion) 
Cycle 6 (Day 21) 
Before Sr89 infusion or 
subsequent treatments 
Clinical tumour assessment: 
Every 3 months 
3. Haematology 1 & clinical 
chemistry tests 2 
Within 28 days Every 3 weeks  
(prior to docetaxel 
infusion) 
Cycle 6 (Day 21) 
Before Sr89 infusion or 
subsequent treatments 
Every month for the first 3 
months, then every 3 
months until study 
completion or patient 
withdrawal 
4. Serum Creatinine Within 28 days Every 3 weeks 
throughout treatment, 
prior to each infusion 
Cycle 6 (Day 21) 
Before Sr89 infusion or 
subsequent treatments 
- 
5. PSA 3 Within 28 days Every 3 weeks 
(day 1 before infusion) 
Cycle 6 (Day 21) 
Before Sr89 infusion or 
subsequent treatments 
At each follow-up 
assessment until disease 
progression 
6. Adverse events reporting / 
collection 4 
Within 28 days AEs logged for all 
treatment period 
 
- 
 
Until 60 days after the last 
study drug administration 
7. *Radiology tumour 
assessment (CT scan/ chest 
x-ray/ bone scan) 
Recommend 
within 56 days  
As clinically indicated If disease progression 
suspected, clinically or 
biochemically 
If disease progression 
suspected, clinically or 
biochemically 
8. CT scan or chest x-ray ** Within 28 days As clinically indicated As clinically indicated As clinically indicated 
9. DXA bone density scan Within 28 days - - 1 year from randomisation 
date 
10. Quality of life & Health 
economics5 
Within 3 days Every 3 weeks 
(prior to docetaxel 
infusion) 
Cycle 6 (Day 21) 
Before SR89 infusion 
or subsequent treatments 
Every visit (until study 
completion or  patient 
withdrawal) 
Pain assessments:  
PPI + Analgesic Score  
Within 3 days, 
averaged over 7 
days 
Every 3 weeks 
(prior to docetaxel 
infusion) averaged over 7 
days 
Cycle 6 (Day 21) 
Before SR89 infusion or 
subsequent treatments 
Every visit (until study 
completion or patient 
withdrawal) 
Proteomic blood sample  Within 28 Days Every 2 Cycles  
Cycle 2,4,6  
Every 2 cycles  
Cycle 8, 10 and end of 
treatment 
- 
1 WBC, neutrophils, platelet, haemoglobin 
2 Urea, serum creatinine, potassium, sodium, calcium, magnesium, AST ALT, alkaline phosphatase, total bilirubin, blood glucose 
3 Refer to inclusion criteria section 5 for rising and elevated PSA assessments  
4 Refer to section 11 for specific adverse event reporting. 
5 Self administered EuroQol & Fact-P questionnaire, plus health problems questionnaire for health economics. QoL questionnaire should be administered before 
randomization or at randomization, but in any case before the patient is informed of the treatment to which he is assigned 
* To ensure comparability, the baseline X-rays/ultrasounds/scans and subsequent X-rays/ultrasounds/scans to assess response must be performed using 
identical techniques (i.e., scans performed immediately following bolus contrast administration using a standard volume of contrast, the identical contrast agent, 
and preferably the same scanner). Each lesion must be followed with the same method throughout the study (from baseline until follow-up). 
** To be performed at baseline:  
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10 MEASUREMENT OF OUTCOME 
 
Table 10.1:  Measurement of Outcome 
 
Phase Primary  Subsidiary Ancillary measures and 
exploratory outcomes 
II • Feasibility, tolerability 
and safety in terms of 
cycles of docetaxel, 
prednisolone, 
zoledronic acid and 
Sr89 received, cycle 
delays, dose 
reductions and toxicity 
• Clinical progression-free 
survival  
• Skeletal-related-event-free 
survival 
• Pain progression-free 
survival 
• Overall survival 
• Costs 
• Quality of life 
• Changes in bone mineral 
density (sub-study) 
• Biological profiling for prognostic 
and predictive indicators (sub-
study) 
• PSA-related outcomes 
• Patient-reported pain-related 
outcomes 
III • Clinical  progression-
free survival  
• Costs and cost-
effectiveness 
• Skeletal-related-event-free 
survival  
• Pain progression-free 
survival 
• Overall survival  
• Quality of life 
• Toxicity 
 
• Changes in bone mineral 
density (sub-study) 
• Biological profiling for prognostic 
and predictive indicators (sub-
study) 
• PSA-related outcomes 
• RECIST criteria-related 
outcomes 
• Patient-reported pain-related 
outcomes 
 
 
10.1 Primary Outcome Measures 
 
10.1.1 Phase II primary outcomes: feasibility, tolerability and safety 
The primary outcomes for the phase II analysis are feasibility, tolerability and safety, and will be 
measured in terms of: 
 
 Treatment Received 
• Mean number of cycles of docetaxel received per patient and the proportion of patients 
receiving 6 cycles. 
• Mean number of cycles of zoledronic acid received per patient and the proportion of patients 
receiving 6 cycles. 
• The proportion of patients who receive Sr89 after receiving 6 cycles of chemotherapy. 
 
Dose Delays and Reductions 
•  Mean number of cycles of docetaxel per patient with dose delay, and proportion of patients 
who experience at least one dose delay. 
•  Mean number of cycles of docetaxel per patient with dose reduction and proportion of 
patients who experience at least one dose reduction. 
 
 
Adverse Events 
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• Proportion of patients with at least one grade 3 or 4 adverse event. 
• Proportion of patients experiencing at least one grade 3 or 4 adverse event for specific 
categories of toxicity, i.e. infection, musculoskeletal or haematological. 
 
Serious Adverse Events (SAEs) 
• Mean number of SAEs per patient, and proportion of patients with at least one SAE. 
• Proportion of patients with at least one Serious Adverse Reaction (SAR). 
• Proportion of patients with at least one Suspected Unexpected Serious Adverse Reaction 
(SUSAR). 
 
10.1.2 Phase III primary outcome: clinical progression-free survival 
The primary outcome for the phase III analysis is clinical progression-free survival (CPFS). CPFS 
time is defined as the time, in whole number of days, between the date of randomisation and the date 
of clinical progression.  Clinical progression is defined as the earliest of the: 
 
• date of occurrence of pain progression; 
• date of occurrence of a skeletal-related event, if disease related; 
• date of death from any cause. 
 
CPFS is a composite endpoint with three component events in the definition, the occurrence of any 
one of which means that the patient has reached clinical progression and must therefore be 
withdrawn from all trial treatments.  For patients who are withdrawn from the study or lost to follow-
up, CPFS time will be censored at the date they were last known to be alive.  For those patients who 
do not experience at least one of these component events during the course of the trial, CPFS time 
will be censored at their last follow-up date. 
 
Pain Progression 
Pain progression is defined as clinical evidence of an increase in pain which, in the opinion of the 
treating clinician, is sufficient to warrant discontinuation of trial treatments and to trigger a change in 
therapy (e.g. to radiotherapy).  The date of pain progression is defined as the date on which the 
decision to discontinue trial treatment is made. 
 
NOTE: Prior to baseline, on the development of pain in an area, which involves a new area of the 
skeleton not present at baseline (randomisation into the clinical trial), we recommend that a 
radiological assessment of the bone should be performed (via CT scan, MRI, plain X-ray or bone 
scan) to assess if there is bone disease progression. 
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Skeletal-Related Event (SREs) 
Any given patient may experience more than one occurrence of an SRE.  All SREs must be 
recorded, but the date of occurrence of the earliest SRE must be used for the purposes of 
determining the date of clinical progression.  Each of the following events constitute an SRE: 
• Symptomatic pathologic bone fractures 
• spinal cord or nerve root compression likely to be related to cancer or to treatment 
• cancer-related surgery to bone (includes procedures to set, or stabilise, pathologic fractures 
or areas of spinal cord compression and procedures to prevent imminent fracture or spinal 
cord compression) 
• radiation therapy to bone (including the use of radioisotopes) 
• change of anti-neoplastic therapy to treat bone pain due to prostate cancer 
• Hypercalcaemia 
• Initiation of bisphosphonate therapy in response to new bone pain symptoms 
 
Death 
Death from any cause will be included as an event. 
 
10.1.3  Phase III Primary Outcome: Health Economics Outcomes 
One of the primary objectives of the trial is to compare treatment arms in terms of costs and cost-
effectiveness. The economic analysis will be carried out from UK NHS and social service 
perspectives. Key resource-use data will be collected; by the CRF and supplemented by patient-
completed resource use questionnaires. This will include primary care consultations, medication and 
use of secondary care services (outpatient visits, A&E visits and, inpatient hospital stays). The 
itemized use of each resource will be weighted by its unit cost to give the aggregate cost per patient.  
Unit costs will be obtained from NHS reference costs and relevant routine sources – PSSRU (Curtis 
and Netten, 2006). QoL will be assessed using the EQ-5D questionnaire. A utility score will be 
generated from this questionnaire. QALYs will be calculated.  A cost-effectiveness analysis will be 
conducted in which outcome will be measured as incremental cost per-QALY gained within the trial.  
 
 
10.2  Subsidiary Outcomes 
 
10.2.1  Skeletal Related Event-Free Interval (SREFI) 
SREs are defined in the section describing clinical progression-free survival.  The skeletal related 
event-free interval (SREFI) is defined as the time in whole number of days between the date of 
randomisation and the date of the first skeletal related event.  For patients who do not experience a 
skeletal related event, SREFI will be censored at either the date of death, date of last follow up or 
date withdrawn consent, whichever is earliest..  
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10.2.2  Pain Progression-Free Interval (PPFI)  
Pain progression is defined in the section describing clinical progression-free survival. Pain 
progression-free interval (PPFI) is defined as the time in whole number of days between the date of 
randomisation and the date of pain progression.  For those patients who do not experience pain 
progression, PPFI will be censored at either the date of death, date of last follow up or date 
withdrawn consent, whichever is earliest.  
 
10.2.3  Overall survival 
Overall survival time is the time in whole number of days between the date of randomisation and the 
date of death, from any cause.  For patients who are withdrawn from the study or who are lost to 
follow-up, survival time will be censored at the date they were last known to be alive.  For patients 
who do not die during the course of the study, survival time will be censored on the date they were 
last known to be alive. 
 
10.2.4  Quality of life 
QoL will be assessed using the EQ-5D and FACT-P and Health Problems questionnaires, which are 
patient completed questionnaires (see appendix 3). The EQ-5D is a generic utility-based measure of 
health-related QoL that has been widely used in economic analyses of healthcare interventions.  It is 
being used in this trial in order that improvements in overall QoL can be estimated and measured in 
terms of the strength of preference for such improvements.  The instrument is designed to be self-
completed and so, where possible, the patient will provide the data.  Patients will also be asked to 
complete pain diary sheets and QoL questionnaire booklets, which include the EQ-5D, FACT-P, and 
study-specific heath-related questionnaires, during their treatment (see appendices 3-5). 
 
10.2.5  Toxicity of treatment 
Toxicity of treatment will be measured in terms of the occurrence, severity, type and causality of 
adverse events during the treatment period. 
 
10.3  Outcomes from Ancillary Biomarker Studies 
 
10.3.1  Bone mineral density changes 
Changes in bone density will be monitored by a DXA scan.  These scans will be done at baseline 
(within 28 days of randomisation) and at 1 year following the date of randomisation.  The results of 
these scans will be analysed along with the recording of any disease in the region of bone density 
measurements.  The regions of the skeleton used for the bone density measurement will be the right 
or left-forearm (non-dominant arm) as well measurements at spine, hip and neck of femur if 
unaffected by metastases.  Patient participation in this part of the study will be voluntary; declining to 
participate will not prevent entry into the main study.  
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10.3.2  Biological profiling for prognostic and predictive indicators 
Blood (serum) samples will be taken at regular intervals during the treatment phase of the study, i.e. 
baseline and end of treatment cycles 2, 4, 6, 8 and 10. Patient consent for the collection of these 
samples will be recorded on the patient consent form.  Patient participation in this part of the study 
will be voluntary; declining to participate will not prevent entry into the main study. 
 
In addition to blood samples, archived diagnostic or other subsequent tissue biopsies from the 
prostate or metastatic sites (paraffin fixed and embedded tissue blocks) from a proportion of patients 
will be collected, subject to patient consent.  These samples will subsequently be sent to the Trapeze 
co-ordinating centre by individual participating centres.  This collection of tissue blocks will only occur 
subject to adequate funding arrangements.  It is proposed that the collection of these samples will 
take place towards the end of the recruitment phase of the trial.  These samples will then be subject 
to biological profiling of prognostic and predictive indicators.  This information will then be collated 
with the clinical data derived from the trial. 
 
10.4 Exploratory Outcomes 
 
Exploratory outcomes will not be used to directly evaluate the treatments being compared in this trial, 
but rather to investigate the extent to which they are associated with other outcomes. 
 
10.4.1  Patient-reported pain events 
The primary analysis of differences in pain-related outcomes between treatment arms will be based 
on clinician-reported pain (see section 10.1.2).  However, further exploratory analyses will also be 
undertaken using the patient-reported pain data recorded in pain diaries (see section 9.1.4), including 
measures of pain response and patient-reported pain progression. 
 
10.4.2  PSA-related events 
PSA will be measured at every study assessment and protocol-defined patient visit. Exploratory 
analyses of several conventional PSA-related events will be undertaken. 
 
10.4.3  Number of SREs  
The number of SREs is defined as the number of SREs occurring between the date of randomisation 
and the earliest of: the date of death; and the date of the end of follow-up. 
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10.4.4  RECIST criteria-related events 
Patients will be evaluated with respect to RECIST (version 1.0) criteria, as appropriate (see Appendix 
2). Exploratory analyses of several conventional RECIST criteria related events will be undertaken. 
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11 SAFETY ASSESSMENT  
 
11.1 Definitions 
 
11.1.1 Adverse event  
An Adverse Event (AE) is defined as any untoward medical occurrence in a patient or clinical trial 
subject administered either docetaxel, prednisolone, zoledronic acid or Sr89, either administered 
alone or in combination, and which does not necessarily have a causal relationship with this 
treatment.  
 
Comment: An AE can therefore be any unfavourable and unintended sign (including abnormal 
laboratory findings), symptom or disease temporally associated with the use of an IMP, whether or 
not considered related to the IMP. 
 
11.1.2  Adverse reaction  
An Adverse Reaction (AR) is defined as all untoward and unintended responses to a study drug 
related to any dose administered.  
 
Comment: An AE judged by either the reporting Investigator or Sponsor as having a causal 
relationship to the IMP qualifies as an AR.  The expression causal relationship means to convey in 
general that there is evidence or argument to suggest a causal relationship. 
 
11.1.3 Unexpected adverse reaction  
An Unexpected Adverse Reaction (UAR) is defined as an AR, the nature or severity of which is not 
consistent with the applicable with the current product information. The Summary of manufacturer’s 
Product Characteristics (SmPC) for each of the study drugs (docetaxel, zoledronic acid, prednisolone 
and Sr89) will be used to assess each AE reported as part of a SAE. 
 
Comment: When the outcome of an AR is not consistent with the applicable product information, the 
AR should be considered unexpected.  
 
Severity: The term “severe” is often used to describe the intensity of a specific event.  This is not the 
same as “serious”, which is based on patients/event outcome or action criteria. 
 
11.1.4 Serious adverse event or serious adverse reaction 
A Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) is defined as any untoward 
medical occurrence or affect that at any dose:  
• Results in death 
• Is life-threatening1 
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• Requires inpatient hospitalisation2 or prolongation of existing hospitalisation 
• Results in persistent or significant disability or incapacity  
• Is a congenital anomaly/birth defect3 
 
Comment: Medical judgment should be exercised in deciding whether an AE or AR is serious in other 
situations.  An AE or AR that is not immediately life-threatening or does not result in death or 
hospitalisation but may jeopardise the subject in some way or may require intervention to prevent one 
of the other outcomes listed in the definition above, should be considered serious.  
 
1 Life-threatening in the definition of an SAE or SAR refers to an event in which the patient was at risk 
of death at the time of the event; it does not refer to an event that hypothetically might have caused 
death if it were more severe. 
 
2 Hospitalisation is defined as an inpatient admission, regardless of length of stay, even if the 
hospitalisation is a precautionary measure for continued observation.   
 
3 This will include children of fathers receiving study therapy 
 
11.1.5 Suspected unexpected serious adverse reactions 
A Suspected Unexpected Serious Adverse Reaction (SUSAR) is defined as a SAR that is 
unexpected, i.e. the nature, or severity, of the event is not consistent with the applicable summary of  
product information (SmPC). 
 
A SUSAR should meet the definition of an AR, UAR and SAR as detailed above. 
 
11.1.6 List of expected adverse reactions (SARs) 
For a list of all expected adverse reactions please refer to the relevant SmPC. 
 
11.1.7 SAEs that do not require reporting for Trapeze 
The following reasons for hospitalisation do not require reporting as SAEs for Trapeze unless 
associated with other serious advents: 
• Admissions for study therapy; 
• Admissions for procedures related to the patient’s disease (e.g. placement of an indwelling 
catheter or a planned admission for a blood transfusion for low haemoglobin levels only). 
 
11.1.8 Reporting period 
Details of all SAEs must be documented from the date of consent until 60 days after the last 
administration of study drug.  Patients must be followed-up until resolution of the SAE.  
 
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
180
NB: Zoledronic acid will be considered a study drug only if the drug was assigned during the 
randomisation process (Arms B and D).  If zoledronic acid is prescribed AFTER the patient has 
progressed, as defined by section 8.5.2, the drug will no longer be considered a study drug and will 
not be subject to the SAE reporting procedures.  In such a case zoledronic acid administrations 
should be recorded on the Concomitant Medications Running Log. 
. 
There is no time limit for reporting SAEs thought by the Investigator to meet the definition of a post-
study SUSAR.  
 
11.2 Assessment of Adverse Events 
 
All adverse events (AEs) will be collected for patients with TNOs below 300.  For those with TNOs 
above 300 grades 3 and 4 will be will be collected.  All AEs must be graded according to the NCI 
CTCAE Toxicity Criteria (Version 3).   
 
For adverse events not listed in the toxicity table, severity should be recorded as: 
Mild  does not interfere with subject’s usual functioning 
Moderate  interferes to some extent with subject’s usual functioning 
Severe  interferes significantly with subject’s usual functioning 
 
Life-threatening risk of death, organ damage or disability 
 
Relationship to study therapy will be assessed using the following definitions: 
Unrelated There is no evidence of any causal relationship. 
 
Unlikely to be related There is little evidence to suggest there is a causal relationship (e.g. the 
event did not occur within a reasonable time after administration of the trial 
medication).  There is another reasonable explanation for the event (e.g. 
the patient’s clinical condition, other concomitant event). 
Possibly related  There is some evidence to suggest a causal relationship, e.g. the event 
occurred within what the treating clinician felt was a reasonable period 
following administration of the trial medication.  However, the influence of 
other factors may have contributed to the event, e.g. the patient’s clinical 
condition, other concomitant events. 
Probably related There is evidence to suggest a causal relationship, and the influence of 
other factors is unlikely. 
Definitely related There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. 
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NOTE:  All adverse events considered to be “possibly related”, “probably related”, or “definitely 
related” will be reported as a SAR or SUSAR in all Trapeze-related safety reports.  In line with MHRA  
guidance and CRCTU practice, “unlikely to be related” events will not be reported as SARs or 
SUSARs.    
 
 
11.3 Reporting of Adverse and Serious Adverse Events 
 
11.3.1 Adverse events 
Adverse Events must be recorded on the Adverse Event Running Log of the CRF, including date of 
onset, severity, duration and relationship to study therapy, whether on-going and stop date.   AEs 
which are also SREs must also be recorded on an SRE CRF. 
 
If more than one AE occurs, each one must be recorded separately.  The Investigator should take all 
therapeutic measures necessary for resolution of any AE.  Any medication necessary for the 
treatment of an AE must be recorded on the patient’s Concomitant Medication Running Log. 
 
11.3.2 Serious adverse events 
In the case of an SAE the Investigator must immediately: 
 
Complete a SAE Form – the form can be completed and signed by a member of the site trial-team 
who has been delegated this responsibility by the Investigator, but should be checked and counter 
signed by the local Investigator at a later date. 
 
Send the original SAE form with fax coversheet to the Trials Office once signed by the Investigator; 
Report SAE in accordance with local institutional policy: 
 
Fax form to     (or    , if primary number is unobtainable). 
 
Continue follow-up of the subject until clinical recovery is complete or any sequelae have stabilised; 
Provide follow-up information on a SAE Form on resolution of the event; 
 
On receipt of a SAE CRF, seriousness and causality of the event will be determined independently by 
a Clinical Co-ordinator.  An SAE judged by either the local investigator or Clinical Co-ordinator, or 
both, to have a reasonable causal relationship with the trial medication will be regarded as a SAR.  
The Clinical Co-ordinator will also assess all SARs for expectedness.  If the event meets the 
definition of a SAR that is unexpected in nature it will be classified as a SUSAR. 
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11.4 Reporting of Events to Other Organisations 
 
11.4.1 Regulatory authorities and main research ethics committee 
SUSARs 
The Trials Office will report a minimal data set of all individual events categorised as a fatal or life-
threatening SUSAR, to the Medicines and Healthcare products Agency (MHRA) and main Research 
Ethics Committee (MREC) within seven days. Detailed follow-up information will be provided within 
an additional eight days.  All other events categorised as SUSARs will be reported within 15 days. 
 
SARs 
The Trials Office will report details of all SARs (including SUSARs) to the MHRA and MREC annually, 
from the date of the Clinical Trial Authorisation, in the form of an Annual Safety Report. 
 
AEs 
Details of all reported AEs experienced during chemotherapy (i.e. grades 1-4 for patients 1-300; 
grades 3-4 for patients 301+) will be reported to the MHRA on request. 
 
Other Safety Issues Identified During the Course of the Trial 
The MHRA and main REC will be notified immediately if a significant safety issue is identified during 
the course of the trial. 
 
11.4.2 Investigators 
Details of all SUSARs and any other safety issue which arises during the course of the trial will be 
reported to all Trapeze Investigators. 
 
11.4.3 Independent data monitoring committee 
An Independent Data Monitoring Committee will review all SAEs annually.  
 
11.4.4 Novartis Oncology, Sanofi-Aventis and GE Healthcare 
All SAEs classified as “unlikely to be related”, “possibly related”, “probably related” or “definitely 
related” to docetaxel, zoledronic acid and Sr89, must be reported to Sanofi-Aventis, Novartis 
Pharmaceuticals (UK) Ltd, or GE Healthcare, respectively, within 24 hours by fax. 
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12 STATISTICAL CONSIDERATIONS 
 
12.1 Study Analysis 
The definitive study analysis will be conducted on an intention-to-treat basis.  All tests of statistical 
significance will be conducted at the 5% two-sided significance level. The phase II analysis will 
compare all four treatment arms with respect to feasibility, tolerability and safety whereas the phase 
III analysis will assess treatments with respect to efficacy within a 2x2 factorial design framework, i.e. 
the trial will compare (i) ZA versus no ZA (stratified for Sr89 use) and (ii) Sr89 versus no Sr89 
(stratified for ZA use). 
 
12.1.1 Analysis of outcome measures 
Feasibility, tolerability and safety. In the primary phase II analysis, the feasibility, tolerability and 
safety of each treatment arm will be reported in terms of the measures specified in section 10.1.1.  
The analysis will be purely descriptive and the data on the control arm will act as a benchmark 
against which to assess the experimental treatment arms. Proportions and means will be calculated, 
and 95% confidence intervals constructed as appropriate. 
 
Clinical progression free survival (CPFS). The primary phase III analysis will compare ZA versus 
no ZA (stratified for Sr89 use) and Sr89 versus no Sr89 (stratified for ZA use) in terms of CPFS.  
Treatments will be compared using the Kaplan-Meier method and a log-rank test.  Statistical models 
for time-to event data that account for other factors which are potentially related to outcome, in 
addition to treatment, will also be used.  In particular, Cox regression models will be considered, and 
the possibility of fitting parametric survival models investigated. Time-to-event will be measured 
between date of randomisation and date of first detection of the event, with censoring dealt with 
appropriately (see section 10).  
 
Overall survival. The approach adopted for the analysis of clinical progression-free survival time will 
also be used to analyse overall survival time. 
 
Pain-progression-free survival. The approach adopted for the analysis of clinical progression-free 
survival time will also be used to analyse pain-progression-free survival time. 
 
Skeletal-related event-free survival. The approach adopted for the analysis of clinical progression-
free survival time will also be used to analyse skeletal-related event-free survival time. 
 
Quality of life. Quality of life data will be analysed using longitudinal statistical methods and 
consideration will be given to missing data that occurs due to dropout and death.  The balance 
between quality of life and survival will be analysed by comparing treatments in a quality-adjusted 
survival analysis28.[25] 
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Health economic analysis.  The cost-effectiveness of treatments will be evaluated primarily by 
balancing the healthcare costs on each of the treatment arms during clinical progression-free survival  
time against the measure of clinical effectiveness.  In addition cost-effectiveness (cost-per-life-year 
gained) and cost-utility (cost-per-quality-adjusted life-year) analyses will be undertaken.  Both 
probabilistic and univariate sensitivity analyses will be performed, with results reported using both 
cost-effectiveness planes and cost-effectiveness acceptability curves (plot of CE thresholds against 
the probability that the intervention is cost-effective).  Given the planned long-term follow-up of 
patients in the trial, lifetime costs and effects will largely be observed and so it is not envisaged that 
extrapolation beyond the trial will be required. 
The mean difference in costs across treatment arms and the associated 95% confidence interval will 
be estimated using non-parametric bootstrapping to account for the expected skewed distribution of 
the cost data. An incremental cost-effectiveness analysis will be conducted. The base-case analysis 
will be framed in terms of cost-consequences, reporting data in a disaggregated manner on the 
incremental cost and the important consequences (including data on quality of life, etc.). If this 
identifies a situation of dominance then further analysis will not be required.  If no dominance is found 
then cost-effectiveness analyses (i.e. cost-per-clinical progression-free life-year and cost-per-life-
year) and cost-utility analysis (i.e. cost-per-quality-adjusted life-year) will be employed.  Quality-
adjusted life-years (QALYs) will be calculated using EQ-5D data collected as part of the trial. The 
results of the economic analyses will be presented using cost-effectiveness acceptability curves to 
reflect sampling variation and uncertainties in the appropriate threshold cost-effectiveness value.  We 
will also use both simple and probabilistic sensitivity analyses to explore the robustness of these 
results to plausible variations in key assumptions and variations in the analytical methods used, and 
to consider the broader issue of the ability to generalise the results. 
 
Toxicity. The analysis of toxicity will be purely descriptive.  Proportions and means will be calculated, 
and 95% confidence intervals constructed as appropriate. 
 
Measures from ancillary biomarker studies.  The analysis of changes in bone mineral density will 
be exploratory and entirely descriptive, with summary statistics and their associated 95% confidence 
intervals constructed as appropriate.  It is anticipated that the same approach will be adopted for the 
analysis of prognostic and predictive indicators, but this will be re-examined prior to seeking separate 
funding for these sub-studies. 
 
Exploratory outcomes. The analysis of patient-reported pain outcomes, PSA-related outcomes, and 
RECIST criteria-related outcomes which can be considered time-to-event data will be analysed using 
the approach adopted for the analysis of clinical progression-free survival; outcomes which can be 
treated as repeated measurements will be analysed using methods suitable for longitudinal data. 
Number of skeletal-related events will be analysed using methods appropriate to count data. 
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12.2 SAMPLE SIZE 
 
12.2.1    Phase II  
The analysis of the phase II component of the trial will be entirely descriptive and will not involve any 
statistical hypothesis testing.  The primary outcomes are feasibility, tolerability and safety and these 
will be measured as proportions or means, as appropriate: recruitment of 50 patients into each arm 
will ensure that proportions are estimated with a precision of at least 15%, and provide sufficient data 
to be able to assess the arms in terms of their suitability for progression into the phase III component 
of the trial. 
 
12.2.2    Phase III  
Sample size calculations are based on the primary outcome measure of clinical progression-free 
survival time (CPFS). The calculations are the same for both the comparison of ZA versus no ZA and 
Sr89 compared to no Sr89. The trial aims to detect a hazard ratio of 0.76 (equivalent to 1 year CPFS 
rates of 30% vs 40%, assuming CPFS follows an exponential distribution).   The number of events 
required to detect this difference in each group for either treatment comparison, using a two-sided 5% 
significance level and 80% power, is 206; it is estimated that approximately 294 patients per arm i.e. 
588 patients in total will need to be recruited to observe this number of events. We will aim to recruit 
a minimum of 618 evaluable patients, which allows for 5% dropout.  
 
12.2.3 Timing of analyses 
Interim analysis will be carried out at least once a year for consideration by the independent Data 
Monitoring Committee (DMC), and more often if required.  Final analysis of the phase II data wasl 
presented to the DMC after 200 patients were recruited and followed-up for at least seven months, 
and all relevant data returned to the trial office.  At this point the IDMC determined that the trial 
should continue into phase III.  Final analysis of the phase III trial will take place once all patients 
have been followed up for one year, and all patients have complete data.   
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12.4 Milestones 
 
The target recruitment rate is 15 to 25 patients per month, from a total of up to 50 centres.  It is 
anticipated that 618 evaluable patients will have been recruited by the end of the first quarter of 2012.   
 
The milestones below are guidelines based on predicted future recruitment rates, as well as dates of 
real events which occurred prior to the preparation of this version of the protocol. 
 
Dec 2004   Start randomisation 
Sept 2006  First Report to DMC 
Dec 2007  Second Annual DMC meeting to review safety data and recruitment 
July 2008  DMC Meeting to review safety data and recruitment 
Oct 2008  TSC Meeting to review clinical trial, DMC recommendations and recruitment 
Nov 2008  Accrual of 300 patients reached 
Feb 2009  DMC Meeting to review safety data 
May 2009  Determination of Phase III protocol treatment arms and study numbers (if 
required: a protocol amendment to be submitted to Ethics and MHRA for 
approval). The Milestones after this date to be determined by the exact 
finalised protocol details.  
Sept 2010  DMC Meeting to review safety data and recruitment 
Oct 2010  TSC Meeting to review clinical trial, DMC recommendations and recruitment 
June 2011  DMC Meeting to review requested further data  
Jan 2012  DMC Meeting to review requested further safety and SRE data 
Mar 2012  TSC Meeting to review clinical trial, DMC recommendations and recruitment 
End Feb 2012  Trial closing to recruitment  
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13 TRIAL COMMITTEES 
 
13.1 Trial Management Group  
 
The Trial Management Group (TMG) is comprised of the Chief Investigator, other co-investigators 
and members of the CRCTU as detailed in the front sleeve of the protocol.  The TMG will be 
responsible for the day-to-day running and management of the trial and will meet by teleconference, 
or in person, as required.  See Figure 1 for the relationship between all committees. 
 
13.2 Trial Steering Committee  
 
An independent Trial Steering Committee (TSC) will provide overall supervision for the trial and 
provide advice to the TMG. Membership includes the Chief Investigator or his deputy, and an 
independent oncologist, urologist and statistician.  The ultimate decision regarding continuation of the 
trial lies with the TSC.  The TSC will meet at least once a year or more often if required.  
 
13.3 Independent Data Monitoring Committee 
 
An Independent Data Monitoring Committee (DMC) has been established for this study. The DMC 
will be the only group who see the confidential reports on the data accumulating to the trial.  Their 
main objective will be to advise the TSC as to whether there is any evidence or reason as to why the 
study should be amended or terminated based on the recruitment rate or safety. Reports to the DMC 
will be produced by the CRCTU.  The first meeting of the DMC occurred when 121 patients had been 
randomised into the trial.  Thereafter, the DMC will meet at intervals determined by the DMC (at least 
every year), to monitor recruitment to the trial, protocol compliance, toxicity, and serious adverse 
events.  The DMC may consider discontinuing the trial if the recruitment rate or data quality are 
unacceptable, or if there are cases of excessive toxicity.  The DMC would also stop the trial early if 
the interim analyses showed differences between treatments, which, in their opinion, were deemed to 
be convincing to the clinical community.  Further details of DMC functions and the procedures for 
interim analysis and monitoring are provided in the DMC charter (available on request). 
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Figure 2: Diagram of the Relationship between Committees and the CRCTU Trials Unit 
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14 REGULATORY & ETHICS COMMITTEE (EC) APPROVAL  
 
14.1 Ethical Considerations 
 
This study will be carried out in accordance with the World Medical Association (WMA) Declaration of 
Helsinki (1964) and the Tokyo (1975), Venice (1983), Hong Kong (1989), South Africa (1996) and 
Scotland (2000) amendments. Copies of the declaration may be obtained by contacting the Trapeze 
Study Office, or directly from the WMA website at  http//www.wma.net/e/policy/17-c_e.html.  
 
The protocol has gained ethical approval from the South West MREC.  Before entering patients into the 
study, the Principal Investigator must ensure that the protocol has approval from their local Research 
Ethics Committee and local Research and Development (R&D) Office. 
 
14.2 Informed Consent 
 
It is the responsibility of the investigator to obtain written informed consent from each patient prior to 
entering the trial, in compliance with national requirements.  
 
14.3 Patient Confidentiality 
 
The personal data recorded on all documents will be regarded as strictly confidential. To preserve the 
patient’s anonymity, only their initials, date of birth, and hospital number will be recorded on the case 
report forms.  With the patient’s permission, their name will be collected at randomisation to allow 
flagging with the Office of National Statistics.  The Principle Investigator must ensure the patient’s 
anonymity is maintained.  The Investigator must maintain documents which are not intended for 
submission to the trials office in strict confidence. 
 
The trials office will maintain the confidentiality of all patient data and will not reproduce or disclose any 
information by which patients could be identified.  Patients must be reassured that their confidentiality will 
be respected at all times. 
 
In the case of special problems and/or governmental queries, it will be necessary to have access to the 
complete study records, provided that patient confidentiality is protected.   
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15 INDEMNITY & INSURANCE 
 
This study is a clinician-initiated and clinician-led study with education grants provided by Sanofi-Aventis 
and Novartis Pharmaceuticals (UK) Ltd.  In addition a Health Technology Assessment (HTA) programme 
grant was approved in December 2006.  This grant was activated in April 2007 and will provide funding 
for the study until 2013.  The study is being run by the Cancer Research UK Clinical Trials Unit (CRCTU), 
School of Cancer Sciences (Formerly Institute for Cancer Studies), The University of Birmingham.  The 
University of Birmingham will act as the sponsor for the study.  As sponsor, the University is responsible 
for the general conduct of the study and shall indemnify the Investigation Centre against any claims 
arising from any negligent act or omission by the University in fulfilling the Sponsor role in respect of the 
Study.  The University is under no obligation to indemnify the Investigation Centre against any claims 
arising from the conduct of the Study at the Centre. 
 
In terms of liability, NHS Trust and Non-Trust Hospitals have a duty of care to patients treated by them, 
whether or not the patient is taking part in a clinical trial.  Compensation is therefore only available in the 
event of clinical negligence being proven.  There are no specific arrangements for compensation made in 
respect of any serious adverse events occurring though participation in the study, whether from the side-
effects listed, or others as yet unforeseen. 
 
Novartis Pharmaceuticals (UK), Sanofi-Aventis, and GE Healthcare Ltd are liable, on a no fault basis, for 
the quality and fitness-for-use of their products.  
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16 PUBLICATION POLICY 
 
The main trial results will be published in the name of the trial in a peer-reviewed journal, on behalf of all 
collaborators.  The manuscript will be prepared by a writing group, appointed from amongst the Trapeze 
Trial Steering Committee, Trial Management Group and high-accruing Investigators. The CRCTU and all 
participating centres and Investigators will be acknowledged in this publication.  All presentations and 
publications relating to the trial must be authorised by the Trapeze Trial Steering Committee.   
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17 STUDY COSTS AND RELATIONSHIP WITH PHARMACEUTICAL 
INDUSTRY 
 
Sanofi-Aventis and Novartis provided an educational grant to CRCTU, CRUK, School of Cancer 
Sciences (formerly the Institute for Cancer Studies), University of Birmingham, to conduct the study (first 
300 patients only).  Subsequently, a grant from the Health Technology Assessment (HTA) programme 
was secured in December 2006 to provide funding and support for the expansion of the initial programme 
into a Phase III clinical trial. This funding is secured until April 2013 (subject to conditions).  
 
Sanofi-Aventis and Novartis Pharmaceuticals (UK) Ltd also provided study drugs (Taxotere® (docetaxel) 
and Zometa® (zoledronic acid), respectively) free-of-charge for the first 300 patients recruited into the 
trial.  Docetaxel is now NICE approved and therefore funding is nationally endorsed for this medicine for 
mHRPC patients.  From patient 301 onwards docetaxel will be purchased by individual hospitals at local 
hospital prices.  Sanofi-Aventis continued to support the clinical trial with a £300 grant (paid to the 
national co-ordinating centre) for patients recruited into the trial with trial numbers 301 to 700. 
 
For patients 301 and above, the following other arrangements will apply: 
 
Zoledronic acid (Zometa®) will be supplied to participating centres with a 28.2% discount on the standard 
NHS list price. This means that each 4mg vial will cost £140. 
 
GE Healthcare Limited have extended their trial discount (5%) Metastron® (Sr89), for patients entered 
into Trapeze to receive a single administration of Metastron®, for the period 1 September 2011 until 31 
October 2012.  
  
The trial data, including quality of life information, the health economic study and pathological material 
collected as part of the biological studies, will remain the property of the Trial Management Group.  
  
DOI: 10.3310/hta20530 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 53
© Queen’s Printer and Controller of HMSO 2016. This work was produced by James et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
193
Reference List 
 
1.  James, N. D., Bloomfield, D., and Luscombe, C. The changing pattern of management for 
hormone refractory, metastatic prostate cancer. Prostate Cancer Prostatic.Dis.  2006.  
2.  Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al. Chemotherapy with 
mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate 
cancer: a Canadian randomized trial with palliative end points [see comments]. Journal of Clinical 
Oncology 1996;14:1756-64. 
3.  Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V et al. Hydrocortisone with or 
without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and 
leukemia group B 9182 study.[comment]. Journal of Clinical Oncology 1999;17:2506-13. 
4.  Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone 
or mitoxantrone plus prednisone for advanced prostate cancer. N.Engl.J Med. 2004;351:1502-
12. 
5.  Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME et al. Docetaxel and 
estramustine compared with mitoxantrone and prednisone for advanced refractory prostate 
cancer. N.Engl.J Med. 2004;351:1513-20. 
6.  Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone 
or mitoxantrone plus prednisone for advanced prostate cancer. N.Engl.J Med. 2004;351:1502-
12. 
7.  Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005;16:687-95. 
8.  Green JR. Preclinical pharmacology of zoledronic acid. [Review] [51 refs]. Seminars in Oncology 
2002;29:3-11. 
9.  Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two 
multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of 
bone pain in men with metastatic prostate cancer. J Clin.Oncol 2003;21:4277-84. 
10.  Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC et al. A double-blind, 
placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer 
(MRC PR05 Trial). J Natl.Cancer Inst. 2003;95:1300-11. 
11.  Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ et al. Randomized, double-
blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone 
and placebo in patients with hormone-refractory prostate cancer and pain. Journal of Clinical 
Oncology 2003;21:3335-42. 
12.  Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, 
heterocyclic bisphosphonate compound. Journal of Bone & Mineral Research 1994;9:745-51. 
13.  Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD et al. Zoledronic acid is superior to 
pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two 
randomized, controlled clinical trials. Journal of Clinical Oncology 2001;19:558-67. 
14.  Santini D, Vespasiani GU, Vincenzi B, Picardi A, Vasaturo F, La Cesa A et al. The antineoplastic 
role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14:1468-76. 
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
194
15.  Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term 
efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic 
hormone-refractory prostate cancer. J Natl.Cancer Inst. 2004;96:879-82. 
16.  Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD et al. A comparison of the 
palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. 
Radiother Oncol 1994;31:33-40. 
17.  Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ, Mason MD, Quilty PM et al. Strontium-89 
(Metastron) versus external beam radiotherapy in patients with painful bone metastases 
secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron 
Investigators Group. Seminars in Oncology 1993;20:32-3. 
18.  Porter AT,.McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain 
relief and delays disease progression in advanced prostate cancer: results of a randomized 
controlled trial. Seminars in Oncology 1993;20:38-43. 
19.  Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der MH et al. 
Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped 
prostate cancer: a phase III study of the European Organisation for Research and Treatment of 
Cancer, Genitourinary Group. Eur.Urol 2003;44:519-26. 
20.  Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre 
observational study of radionuclide therapy in patients with painful bone metastases of prostate 
cancer. European Journal of Nuclear Medicine 2001;28:788-98. 
21.  Kraeber-Bodere F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I. Treatment of bone 
metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of 
bone involvement. Eur.J Nucl.Med. 2000;27:1487-93. 
22.  McEwan AJ, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT. A retrospective analysis of 
the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to 
bone. European Urology 1994;26 Suppl 1:26-31. 
23.  Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC et al. Bone-targeted 
therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II 
trial.[comment][erratum appears in Lancet 2001 Apr 14;357(9263):1210]. Lancet 2001;357:336-
41. 
24.  Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M et al. Eligibility and 
response guidelines for phase II clinical trials in androgen-independent prostate cancer: 
recommendations from the Prostate-Specific Antigen Working Group.[erratum appears in J Clin 
Oncol 2000 Jul;18(13):2644]. Journal of Clinical Oncology 1999;17:3461-7. 
25.  Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone 
or mitoxantrone plus prednisone for advanced prostate cancer. N.Engl.J Med. 2004;351:1502-
12. 
26.  Billingham LJ,.Abrams KR. Simultaneous analysis of quality of life and survival data. 
Stat.Methods Med.Res. 2002;11:25-48. 
27.  Makuch RW,.Simon RM. Sample size requirements for comparing time-to-failure among k 
treatment groups. J.Chronic.Dis. 1982;35:861-7. 
DOI: 10.3310/hta20530 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 53
© Queen’s Printer and Controller of HMSO 2016. This work was produced by James et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
195
PROTOCOL APPENDIX 1: ECOG PERFORMANCE STATUS SCALES 
ECOG Performance Status 
 
These scales and criteria are used by doctors and researchers to assess how a patient's disease is 
progressing, assess how the disease affects the daily living abilities of the patient, and to determine 
appropriate treatment and prognosis. They are included here for health care professionals to access.  
 
 
 
 
ECOG PERFORMANCE STATUS* 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry-out any work activities. 
Up-and-about for more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair for more than 50% of 
waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 Dead 
* As published in Am. J. Clin. Oncol.: 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: 
Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-
655, 1982 
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PROTOCOL APPENDIX 2 ; RESPONSE EVALUATION CRITERIA IN SOLID TUMOURS   
 
1.0  Definition of Measurable and Non-Measurable Lesions. 
Measurable disease - the presence of at least one measurable lesion. If the measurable disease is 
restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology. 
 
Measurable lesions - lesions that can be accurately measured in at least one-dimension with longest 
diameter >20 mm using conventional techniques or >10 mm with spiral CT scan. 
 
Non-measurable lesions - all other lesions, including small lesions (longest diameter <20 mm with 
conventional techniques or <10 mm with spiral CT scan), i.e. leptomeningeal disease, ascites, 
pleural/pericardial effusion, inflammatory breast disease, lymphangitis cutis/pulmonis, cystic lesions, and 
also abdominal masses that are not confirmed and followed by imaging techniques. 
 
All measurements should be taken and recorded in metric notation, using a ruler or callipers.  All baseline 
evaluations should be performed as close as possible to the beginning of treatment and never more than 
four weeks before the beginning of the treatment.  
 
2.0  Methods of Measurement  
The same method of assessment and the same technique should be used to characterize each identified 
and reported lesion at baseline and during follow-up. 
 
CT and MRI scans: CT and MRI are the best currently available and reproducible methods to measure 
target lesions selected for response assessment.  Conventional CT and MRI should be performed with 
contiguous cuts of 10 mm or less in slice thickness.  Spiral CT should be performed using a 5 mm 
contiguous reconstruction algorithm; this specification applies to tumours of the chest, abdomen and 
pelvis, while head and neck tumours and those of extremities usually require specific protocols. 
 
Chest X-ray. Lesions on chest X-ray are acceptable as measurable lesions when they are clearly defined 
and surrounded by aerated lung. However, CT is preferable.  
 
Cytology and histology can be used to differentiate between Partial Response and Complete Response 
in rare cases (e.g., after treatment to differentiate between residual benign lesions and residual malignant 
lesions in tumour types such as germ cell tumours). 
 
Clinical examination: Clinically selected lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lymph nodes).  For the case of skin lesions, documentation 
by colour photography- including a ruler to estimate the size of the lesion -is recommended. 
 
3.0  Selection of “Target” and “Non-Target” lesions 
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Target Lesions 
All measurable lesions up to a maximum of five lesions per organ and 10 lesions in total, representative 
of all involved organs, should be identified as target lesions and recorded and measured at baseline.  
Target lesions should be selected on the basis of their size (those with the longest diameter) and their 
suitability for accurate repeated measurements, either by imaging techniques or clinically.  A sum of the 
longest diameter (LD) for all target lesions will be calculated and reported as the baseline sum LD.  The 
baseline sum LD will be used as reference by which to characterise the objective tumour-response. 
 
Non-Target Lesions 
All other lesions (or sites of disease) should be identified as non-target lesions and should also be 
recorded at baseline. Measurements of these lesions are not required, but the presence or absence of 
each should be noted throughout follow-up. 
 
4.0  Response 
Response criteria for this study are defined below 
Evaluation of Target Lesions 
Progressive Disease (PD): at least a 20% increase in the sum of the LD of target lesions, taking as 
reference the smallest sum LD recorded since the treatment started or the appearance of one or more 
new lesions 
Evaluation of Non-Target Lesions 
Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of 
existing non-target lesions  
 
5.0  Overall Responses 
The table below provides overall responses for all possible combinations of tumour responses in target 
and non-target lesions, with or without the appearance of new lesions. 
 
In assessing tumour progression in this study, only the last three shaded rows in the table on the next 
page are relevant. 
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Table of Overall response (taken from RECIST) 
 
Target lesions Non-Target lesions New lesions Overall 
response 
CR CR No CR 
CR Incomplete response/SD No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
 
Patients with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be classified as having “symptomatic 
deterioration”.  Every effort should be made to document the objective progression even after 
discontinuation of treatment.  
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PROTOCOL APPENDIX 3: EUROQOL EQ-5D & FACT-P QUALITY OF LIFE QUESTIONNAIRES   
 
 
Health Questionnaire 
The next few questions are about your general health at present. 
For each of the five sets of statements below, please tick the one box that best describes your own 
health state today. 
1.  Mobility 
I have no problems in walking about . .. ..  
I have some problems in walking about . .. 
I am confined to bed ..  
 
2.  Self-care 
I have no problems with self-care. .  
I have some problems washing and dressing myself. . .. 
I am unable to wash or dress myself. .  
 
3. Usual activities  
(e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities. .   
I have some problems with performing my usual activities.  
I am unable to perform my usual activities. .. 
 
4.  Pain/discomfort 
I have no pain or discomfort. .  
I have moderate pain or discomfort. ..  
I have extreme pain or discomfort.  
 
5.  Anxiety/depression 
I am not anxious or depressed  
I am moderately anxious or depressed. ..  
I am extremely anxious or depressed. .... 
 
EQ-5D
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6.       Health State Scale 
To help people say how good or 
bad their health is, we have drawn 
a scale (rather like a thermometer) 
on which the best health state you 
can imagine is marked 100 and the 
worst health state you can imagine
is marked 0.  
 
Worst Imaginable Health 
State 
10 
0 
20 
30 
40 
50 
60 
80 
 100 
Best Imaginable Health 
State 
5 
15 
25 
35 
45 
55 
65 
75 
85 
90 
95 
70 
Your own 
health state 
today 
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FACT-P QoL 
 
QUALITY OF LIFE QUESTIONNAIRE 
Fact P (Version 4) 
Below is a list of statements that other people with your illness have said are important. By circling one 
(1) number per line, please indicate how true each statement has been for you during the past 7 days. 
 
 PHYSICAL WELL-BEING 
 
Not 
at all 
A little 
bit 
Some
-what 
Quite 
 a bit 
Very 
much 
 
GP1 
I have a lack of energy  
 
0 1 2 3 4 
 
GP2 
I have nausea (I feel sick)   
 
0 1 2 3 4 
 
GP3 
Because of my physical condition, I have trouble  
meeting the needs of my family  
 
0 
 
1 
 
2 
 
3 
 
4 
 
GP4 
I have pain  
 
0 1 2 3 4 
 
GP5 
I am bothered by side effects of treatment  
 
0 1 2 3 4 
 
GP6 
I feel ill  
 
0 1 2 3 4 
 
GP7 
I am forced to spend time in bed  
 
0 1 2 3 4 
 SOCIAL/FAMILY WELL-BEING 
 
Not 
at all 
A little 
bit 
Some
-what 
Quite 
 a bit 
Very 
much 
 
GS1 
I feel close to my friends 
 
0 1 2 3 4 
 
GS2 
I get emotional support from my family  
 
0 1 2 3 4 
 
GS3 
I get support from my friends  
 
0 1 2 3 4 
 
GS4 
My family has accepted my illness  
 
0 1 2 3 4 
 
GS5 
I am satisfied with family communication about my 
illness 
  
 
0 
 
1 
 
2 
 
3 
 
4 
 
GS6 
I feel close to my partner (or the person who is my 
main support)   
 
0 
 
1 
 
2 
 
3 
 
4 
 
Q1 
 
 
Regardless of your current level of sexual activity, please  
answer the following question.  If you prefer not to answer  
it, please check this box           and go to the next section. 
 
 
GS7 
I am satisfied with my sex life  0 1 2 3 4 
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By circling one (1) number per line, please indicate how true each statement has been for you during the 
past 7 days. 
 
 EMOTIONAL WELL-BEING 
 
Not 
at all 
A little 
bit 
Some
-what 
Quite 
 a bit 
Very 
much 
       
 
GE1 
I feel sad  
 
0 1 2 3 4 
 
GE2 
I am satisfied with how I am coping with my illness
  
 
0 1 2 3 4 
 
GE3 
I am losing hope in the fight against my illness  
 
0 1 2 3 4 
 
GE4 
I feel nervous  
 
0 1 2 3 4 
 
GE5 
I worry about dying  
 
0 1 2 3 4 
 
GE6 
I worry that my condition will get worse  
 
0 1 2 3 4 
 
 
 FUNCTIONAL WELL-BEING 
 
Not 
at all 
A little 
bit 
Some
-what 
Quite 
 a bit 
Very 
much 
       
 
GF1 
I am able to work (include work at home)   
 
0 1 2 3 4 
 
GF2 
My work (include work at home) is fulfilling  
 
0 1 2 3 4 
 
GF3 
I am able to enjoy life  
 
0 1 2 3 4 
 
GF4 
I have accepted my illness  
 
0 1 2 3 4 
 
GF5 
I am sleeping well  
 
0 1 2 3 4 
 
GF6 
I am enjoying the things I usually do for fun  
 
0 1 2 3 4 
 
GF7 
I am content with the quality of my life right now  
 
0 1 2 3 4 
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By circling one (1) number per line, please indicate how true each statement has been for you during the 
past 7 days. 
 
 
 ADDITIONAL CONCERNS 
 
Not 
at all 
A little 
bit 
Some
-what 
Quite 
 a bit 
Very 
much 
       
 
C2 
I am losing weight  
 
0 1 2 3 4 
 
C6 
I have a good appetite  
 
0 1 2 3 4 
 
P1 
I have aches and pains that bother me  
 
0 1 2 3 4 
 
P2 
I have certain areas of my body where I experience 
significant pain  
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
P3 
My pain keeps me from doing things I want to do 
 
0 1 2 3 4 
 
P4 
I am satisfied with my current level of physical comfort
  
 
0 1 2 3 4 
 
P5 
I am able to feel like a man  
 
0 1 2 3 4 
 
P6 
I have trouble moving my bowels  
 
0 1 2 3 4 
 
P7 
I have difficulty urinating (passing water)   
 
0 1 2 3 4 
 
BL
2 
I urinate more frequently than usual  
 
0 1 2 3 4 
 
P8 
My problems with urinating limit my activities  
 
0 1 2 3 4 
 
BL
5 
I am able to have and maintain an erection  
 
0 1 2 3 4 
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PROTOCOL APPENDIX 4 – HEALTH ECONOMICS QUESTIONNAIRE 
 
Trapeze health problems questionnaire for patients on study treatment 
 
During the last 3 weeks (i.e. since your last visit to hospital for study treatment) we would like you to tell 
us about any health problems you may have had. Please answer all of the questions yourself by ticking 
the box that best applies to you. 
 
THE INFORMATION YOU PROVIDE WILL BE KEPT STRICTLY CONFIDENTIAL AND USED ONLY 
FOR MEDICAL RESEARCH. 
 
1. Talking to a doctor 
a) During the three weeks ending yesterday, apart from any visit to a hospital, did you talk to a doctor, 
either in person or by telephone? 
 
Yes    No     (if no, go straight to question 2) 
If Yes: 
b) How many times did you talk to a doctor in these two weeks? (please circle) 
 1 2 3 4 5 6 7 8 9 or more 
 
c) Was this consultation 
under the National Health Service,    or paid for privately?  
 
d) Was the doctor  
1   a GP (i.e. a family doctor),  
2 a specialist,  
3 some other kind of doctor?  
 
e) Did you talk to the doctor  
1  by telephone,  
2  at your home,  
3 in the doctor's surgery,  
4 at a health centre,   
5 elsewhere  
 
f) Did the doctor prescribe you any medication (in addition to your study drugs)? 
Yes     No                (If no, please go to question 2) 
If yes, was this prescribed over a short period or permanently? 
Short    Permanently 
Please list prescription medication below: 
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2. Hospital visits  
During the last 3 weeks have you been to hospital for any reason?  
Yes      No                  (if no, please go to question 3)  
  
  
  
If yes, please give details of your attendance or admittance?  
1. Out-patient;   how many times  ______  
2. In patient;   how many days    ______  
3. Casualty;   how many days   _______  
  
   
3. During the last 3 weeks has a nurse visited you at your home for any reason?  
Yes      No      (if no, please go to question 4)  
  
If yes, how many times? _______  
  
4.  During the last 3 weeks has anyone from social services or a voluntary organisation visited you at  
your home for any reason?  
Yes      No      (if no, please go to question 5)  
  
If yes, how many times? _______  
  
  
5.  During the last 3 weeks has a relative or friend taken time off work to look after you?  
Yes      No         
  
If yes, how many days? _______  
  
If yes to any of the above questions 1 - 6, what was the problem?  
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TRAPEZE health problems questionnaire for patients on follow-up 
 
During the last 3 months (i.e. since your last visit to hospital) we would like you to tell us about any health 
problems you may have had. Please answer all the questions yourself by ticking the box that best applies 
to you. 
 
THE INFORMATION YOU PROVIDE WILL BE KEPT STRICTLY CONFIDENTIAL AND USED ONLY 
FOR MEDICAL RESEARCH. 
 
1. Talking to a doctor 
a) During the three months ending yesterday, apart from any visit to a hospital, did you talk to a doctor, 
either in person or by telephone? 
 
Yes    No     (if no, go straight to question 2) 
 
If Yes: 
b) How many times did you talk to a doctor in these three months? (please circle) 
1 2 3 4 5 6 7 8 9 or more 
 
c) Was this consultation 
under the National Health Service,    or paid for privately?  
 
d) Was the doctor  
1   a GP (i.e. a family doctor),  
2 a specialist,  
3 some other kind of doctor?  
 
e) Did you talk to the doctor  
1  by telephone,  
2  at your home,  
3 in the doctor's surgery,  
4 at a health centre,   
5 or elsewhere?  
 
f) Did the doctor prescribe you any medication? 
Yes     No  
 
If yes, was this prescribed for use over a short period or permanently? 
Short    Permanently 
 
Please list the prescribed medication below: 
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2. Hospital visits  
During the last 3 months have you been to hospital for any reason?  
Yes     No    (if no, please go to question 3)  
  
If yes, please give details of your attendance or admittance?  
1. Out-patient;   how many times  _______  
2. In patient;   how many days    ______  
3. Casualty;   how many days   _______  
  
   
3. During the last 3 months has a nurse visited you at your home for any reason?  
  
Yes     No     (if no, please go to question 4)  
  
If yes, how many times? _______  
  
  
4.  During the last 3 months has anyone from social services or a voluntary organisation visited you at  
your home for any reason?  
  
Yes     No     (if no, please go to question 5)  
  
If yes, how many times? _______  
  
  
5.  During the last 3 months has a relative or friend taken time off work to look after you?  
   
Yes     No       
  
If yes, how many days? _______  
  
If yes to any of the above questions 1 - 6, what was the problem?  
  
             
             
APPENDIX 5: PAIN DIARY SHEETS  
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TRAPEZE 
CONFIDENTIAL 
Patient Pain Diary 
 
 
 
 
Patient Initials:   
 
 (First - middle - last) 
 
Patient Number:  
 
 
Centre Name: 
 
Investigator:  
 
 
 
 
This diary should be carried with you at all times. 
 
For the seven-day period prior to your next appointment, please complete one page for each day as 
carefully as possible. 
 
Next appointment: Date:  
 
  Time: 
 
Please take this diary with you when you return to the clinic/hospital: 
 
This patient is in a clinical study. In the event of a medical emergency, please telephone one of the 
following numbers listed below:  
 
1. 
2. 
Patient: please complete the following: 
These questions were answered on:      20 
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   Day of week      Day         Month Year 
Please list the type of pain relief (analgesic) medication that you have taken over the last 24 hours and 
the amount. Only information about pain medication is needed.  Please do not include medication for 
other conditions ,(e.g. heart problems) 
To be completed by the patient These shaded boxes to be completed by the clinical 
Research Nurse/ Associate 
(*refer to analgesic score table in protocol) 
Product name 
(trade name and 
dose) 
Type of dose 
(tablet, injection, 
patch ) 
Number of 
doses in 24 
hours 
Type of analgesic and 
total dose (in 24 hours) 
Total dose / 
analgesic 
dose 
(A) 
Score value 
 
 
(B) 
Total units 
per 24 hours 
 
(A x B) 
 
 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
       Total daily score        (C) 
 
 
 
  
Do you think you have remembered everything you have taken?   Yes       No 
 
 
Present Pain Intensity (PPI) 
 
Please circle the appropriate number according to how much pain you felt on average during 
the past 24 hours. 
 
     0   1  2  3  4  5 
No pain Mild    Discomforting      Distressing          Horrible         Excruciating  
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Appendix 2 Composition of the Data Monitoring
Committee and Trial Steering Committee
Data Monitoring Committee
Professor Mario Eisenberger (Chairperson), Professor of Oncology & Urology, The Blausteine Cancer
Research Building, John Hopkins University, Baltimore, MD, USA.
Professor Fred Saad, Professor of Surgery/Urology, Université de Montréal, Chum/Hôpital Notre-Dame,
Montreal, Québec, Canada.
Mr Matthew Sydes, Senior Medical Statistician, Medical Research Council, MRC Clinical Trials Unit Aviation
House London, UK.
Trial Steering Committee
Professor Richard Gray, Professor of Medical Statistics, Clinical Trial Service Unit and Epidemiological
Studies Unit, Oxford, UK.
Professor Noel Clark, Consultant Oncologist, Christie Hospital NHS Foundation Trust, Manchester UK.
Professor Robert Coleman, Cancer Research Building, School of Medicine & Biomedical Sciences,
Weston Park Hospital, Sheffield, UK.
Mr John Anderson (deceased 2013), Department of Urology, Royal Hallamshire Hospital, Sheffield, UK.
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Appendix 3 Dates of regulatory and ethical
approvals and timelines
TABLE 76 Summary of regulatory and ethical approvals and trial milestones
Event Date
MHRA approval of Phase II stage of trial
MREC approval of Phase II stage of trial
– Protocol V4 & patient and GP Information & consent documents V2
11 November 2004
9 November 2004
First site opened 1 January 2005
Recruitment of first patient 4 February 2005
Protocol V5 amendment April 2005
Protocol V6 amendment June 2005
Protocol V7 amendment June 2007
MHRA approval of Phase III stage of trial
MREC approval of Phase III stage of trial
– Protocol V8 & patient and GP information & consent documents V3
9 January 2009
29 January 2009
MHRA approval of CTA amendment
MREC approval of CTA amendment
(i.e. generic docetaxel and ZA use)
20 January 2011
17 February 2011
Protocol V9 amendment & patient and GP information & consent documents V3 May 2011
Protocol V10 amendment 10 June 2011
Patient information addendum to V3 (for patients randomised to ZA treatment arms) July 2011
Closure to recruitment 29 February 2012
Protocol V11 amendment 17 February 2012
CTA, Clinical Trials Authorisation.
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Appendix 4 Patient information
TRAPEZE
Research Trial Of Treatments For Patients With Bony Metastatic Cancer Of
The Prostate
Patient Information Form
Your Oncologist has explained to you that your prostate cancer is no longer responding to hormonal
treatment. We would like to invite you to take part in a research trial to treat you with chemotherapy.
Before you decide whether to take part it is important for you to understand why the research is being
done and what it will involve. Please take time to read the following information carefully and discuss it
with friends, relatives and your GP if you wish. Ask us if there is anything that is not clear or if you would
like more information. Take time to decide whether or not you wish to take part.
Further information and a summary of the principles of clinical trials can be found on the Cancer Research
UK’s patient website (www.cancerhelp.org.uk) together with information about this trial.
Purpose of the trial
It is believed that chemotherapy may be beneficial in treating your prostate cancer. Chemotherapy is
currently a standard treatment for prostate cancer that has spread to the bone. The main aim of this trial is
test the effects of combining two further known treatments for prostate cancer at different time points,
with chemotherapy. The three treatments involved in this trial are described below:
l Docetaxel is a chemotherapy drug and is approved in the UK for the treatment of advanced breast and
lung cancer. Docetaxel has been approved for use within clinical trials for the treatment of prostate
cancer. Recently published studies (including an international prostate cancer clinical trial called
TAX-327) demonstrate that docetaxel improves symptom control and survival times.
l Zoledronic acid is a bone-strengthening agent approved in the UK for treating cancer affecting
the bone.
l Strontium-89 is a type of radiotherapy (given by an injection), which is also approved in the UK for
treating cancer affecting the bone. Early studies show that it may provide additional pain relief when
combined with chemotherapy and may improve your condition.
The aim of the trial is to assess how effective and safe zoledronic acid or strontium-89 is in treating your
disease when given in combination with chemotherapy.
We aim to recruit 618 evaluable patients with cancer no longer responding to hormone treatment to take
part in this trial. The trial will be open to recruitment for up to 5 years. A patient enrolled onto this trial will
be expected to visit the hospital every 3 weeks for chemotherapy treatment for 32 weeks. After this period
patients will be expected to attend the hospital on a regular basis for a maximum follow-up period of
2 years. This trial may also be known under the shorter title of ‘TRAPEZE’, named after the treatments
involved which include docetaxel, radioisotope and zoledronic acid.
Taking part in the trial
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this
information sheet to keep and be asked to sign a consent form. The original consent form will be stored
by your hospital and a copy of the consent form will be sent to the coordinating centre.
If you decide to take part you are still free to withdraw at any time and without giving a reason. This will
not affect the standard of care you receive.
DOI: 10.3310/hta20530 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 53
© Queen’s Printer and Controller of HMSO 2016. This work was produced by James et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
215
Description of the trial
When we do not know which way of treating patients is best, we need to make comparisons. Everyone
who agrees to take part in this trial will be put into a treatment group.
The treatment you receive will be chosen by a process called randomisation; the treatment is randomly
allocated by computer, which is like making a choice by tossing a coin. This means that you have an equal
chance of being treated with one of the above treatments. You and your Oncologist will know which
treatment you are receiving.
The four treatment groups in this trial are:
(a) Docetaxel
(b) Docetaxel+ zoledronic acid
(c) Docetaxel+ strontium-89
(d) Docetaxel+ zoledronic acid+ strontium-89.
If you agree to take part, your Oncologist will perform a number of tests and examinations before,
during and after the trial. You will also be asked to complete a number of questionnaires. These are
summarised below:
l General medical and physical examinations
l Blood tests
l X-rays, CT and bone scans – to measure your cancer response to treatment
l DXA Scan (bone density scans) – to measure bone density
l Pain diary
l Quality-of-life questionnaires
Docetaxel, zoledronic acid and strontium-89 are given by a drip into a vein in your arm. This is called an
infusion. You will receive one of the following treatments:
(a) Docetaxel 75mg/m2 as a one hour intravenous infusion every 3 weeks for a maximum of 10 cycles.
(b) Docetaxel as a one hour intravenous infusion every 3 weeks for a maximum of 10 cycles with
zoledronic acid every 3 weeks. Zoledronic acid will then continue alone every 4 weeks until you or your
Oncologist wishes to discontinue it.
(c) Docetaxel as a one hour intravenous infusion every 3 weeks for a maximum of 10 cycles and one
treatment of strontium-89 given 28 days after the sixth dose of docetaxel as a short intravenous
injection. Cycles 7–10 will then follow after a 28 day recovery period.
(d) Docetaxel as a 1-hour intravenous infusion every 3 weeks for a maximum of 10 cycles, followed by one
treatment of strontium-89 given 28 days after the sixth dose of docetaxel as a short intravenous
injection. Cycles 7–10 will then follow after a 28 day recovery period. Zoledronic acid will be given
every 3 weeks throughout the treatment, and will then continue alone every 4 weeks until you or your
Oncologist wishes to discontinue it.
You may receive less than 10 cycles of docetaxel chemotherapy cycles. The exact number of cycles that
you will receive will be determined by your Oncologist after consultation with you.
As part of your main treatment you will also be given steroid tablets (prednisolone) to take during your
course of treatment with docetaxel. In addition, you will receive extra steroid tablets (dexamethasone) for a
few days around each infusion of chemotherapy to decrease the potential side-effects of docetaxel (allergic
reactions and fluid retention).
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You will be required to visit the hospital every 3 weeks until the end of therapy. The duration of treatment
will be approximately 35 weeks.
After the end of treatment your Oncologist will see you monthly for 3 months and then every 3 months in
order to assess the status of your disease.
The flow chart below explains the visits you will make to the hospital and at which time.
Restrictions
It is important that you inform your Oncologist of any changes in your health, whether or not you think it
is due to the treatment. You should also tell your Oncologist of any changes to your medicines, either
those prescribed by your GP or those you buy at the chemist.
Other treatments available
Your Oncologist will discuss the different treatment options available to treat your disease.
TABLE 77 Tests and procedures that will be carried out during the trial
Tests and procedures
Before start of
chemotherapy
Before each
administration of
chemotherapy
After
chemotherapy
Follow-up (every month
for 3 months then every
3 months thereafter)
Read information ✓ – – –
Sign consent
Scanning procedures
(CT scan, MRI scan, bone
scan and\or ultrasound)
✓ – – ✓ (as clinically indicated)
DXA bone density scan ✓ ✓ (1 year after start of
treatment)
Other current medication/
side-effect information
collected
✓ ✓ ✓ ✓ (30 days after last
infusion)
Medical history information
collected
✓ – – –
Height measured ✓ – – –
Weight and physical exam
and vital signs
✓ ✓ ✓ ✓
Blood tests including PSA ✓ ✓ ✓ ✓
Pain and quality-of-life
assessments
✓ ✓ ✓ ✓
DXA, dual-energy X-ray absorption scan; MRI, magnetic resonance imaging.
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Potential side effects and risks
As with all medicines of this type there may be some unwanted side-effects. You should discuss these with
your Oncologist. The more common side-effects are listed below; there may also be other side-effects that
we cannot predict. Other medicines will be given to make side-effects less serious and less uncomfortable.
With docetaxel you may experience nausea and/or vomiting, mouth irritation, diarrhoea, fatigue, a pins
and needles sensation in your hands or feet, hair loss, changes in your skin and nails, muscular pain,
decrease in blood cell counts, infection, and swelling due to fluid retention. Your blood pressure may
also fall while the drug is being given, and this will be checked carefully. The infusion of docetaxel may
cause temporary local irritation and bruises if it is given into a small vein. All these side-effects have
been experienced by some patients during previous studies and most of them are reversible. (The items
underlined may not be reversible).
With docetaxel+ zoledronic acid you may experience the same effects as stated for docetaxel above with a
rise in temperature, and flu-like symptoms, consisting of fever and bone pain due to the zoledronic acid.
Zoledronic acid may also affect your kidney function. Blood samples will be taken prior to zoledronic acid
infusion at every trial visit to check that your kidney function has not been affected. Uncommonly,
zoledronic acid can cause breakdown (osteonecrosis) of the jaw. This is associated with long-term use
of zoledronic acid (usually over 24 months) particularly in patients who have dental disease. Zoledronic
acid should be discontinued if you need a tooth extraction.
With docetaxel+ zoledronic acid+ strontium-89 you may experience the same side-effects as stated above
for docetaxel and zoledronic acid. The addition of strontium-89 to docetaxel and zoledronic acid may
cause some bone pain lasting 36 to 72 hours following injection. This can usually be controlled by
analgesics (pain killers). Strontium-89 can also affect your blood counts following injection; these will be
monitored very closely with regular blood tests.
With docetaxel + strontium-89 the addition of strontium-89 to docetaxel may cause some bone pain
lasting 36 to 72 hours following injection. This can usually be controlled by analgesics (pain killers).
Strontium-89 can also affect your blood counts following injection; these will be monitored very closely
with regular blood tests.
As with any chemotherapy it is possible that your treatment could cause problems to an unborn child. You
must take full contraceptive precautions if there is any chance of you fathering a child during and for at
least 2 months after the treatment. If you have a fever or bruising after receiving either of the drug
combinations, it is important that you contact your Oncologist immediately. If you have a fever your
Oncologist will perform some blood tests and may prescribe antibiotics.
For more information about risks and side-effects, ask your Oncologist.
You may require one extra bone scan more than you would if you were not taking part in the trial. You
may require one additional CT scan and will receive two additional bone density scans (DXA scans) more
than you would receive if you were not taking part in the trial. Any potential health risk associated with
these or any of the above scans is considered to be low for a patient with your medical condition.
The radioactive strontium is intended to give a very high radiation dose to any parts of your bones that are
involved in your cancer. The rest of your body gets a lower radiation dose and your Oncologist will explain
possible side-effects with you. Any potential health risk associated with the radiation is considered to be
minimal for a patient with your medical condition.
If you have private medical insurance you may wish to consult your medical insurers before agreeing to
take part in the trial. This is to ensure that you participation will not affect your medical insurance cover.
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What happens when the research trial stops?
At the end of the research trial, or should you withdraw, your Oncologist will assess your symptoms,
discuss your options and prescribe appropriate treatment. Rarely companies sponsoring research studies
may decide to stop the trial before it has finished. If this happens, your Oncologist will explain the reasons
why and arrange appropriate care for you.
Potential benefits
The use of chemotherapy may result in a decrease in pain, improvement in the quality of life and a delay in
the progression of your disease and improved survival times. This may be further improved by combining
chemotherapy with zoledronic acid and/or strontium-89.
The information we get from this trial may help us to treat other patients with cancer more effectively
in future.
Looking at blood serum samples
In addition to your routine blood tests we would also like to take additional blood samples from you
during your regular trial visits for additional analyses. We would like to monitor changes in protein levels in
your blood during treatment to see if it can help us better predict treatment outcomes.
Your participation in this part of the trial is optional and will not affect the treatment that you receive if
you do not consent to providing additional blood samples for these additional tests and research.
Looking at tissue samples
As part of the clinical trial we would like to be allowed to have access to samples of your disease tissue,
which were taken as part of your routine care and disease diagnoses. These samples will have been
collected by your hospital and stored in paraffin fixed wax blocks. If you agree these samples will be
collected and tested for the presence of a number of different chemicals known as biological markers by
the School of Cancer Sciences at The University of Birmingham and other collaborative centres.
Your participation in this part of the trial is optional and will not affect the treatment that you receive if
you do not consent to the research team having access to your stored tissue samples for
additional research.
Your rights regarding tissue/blood samples taken as part of this clinical trial
The results of the analysis of your individual samples will not routinely be given to you unless it is of clinical
significance and of importance to your health. You will not benefit financially if this research leads to the
development of a new treatment or medical test. Any publications resulting from the collection of these
tissue or blood samples will be made available to you, if requested.
Please note that your participation in this part of the trial is optional and will not affect the treatment that
you receive, if you do not consent to providing additional blood samples or for the research team to have
access to your stored tissue samples detailed above.
New information
Sometimes during a trial new information becomes available about the treatment that is being studied.
If this happens your Oncologist will tell you about it and discuss with you whether or not you want to
continue. If you decide to withdraw your Oncologist will ensure the continuation of your care off trial. You
may be asked, if you decide to continue in the trial, to sign a new consent from.
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Voluntary participation and discontinuation
Your participation in this trial is voluntary. If you agree to take part and then change your mind and wish
to withdraw, you may do so at any time without this decision affecting your future care. If you decide not
to take part your Oncologist will discuss your future care with you. Your legal rights will not be affected by
your giving consent to participate.
At the end of the trial your Oncologist will discuss future treatment options. It is not anticipated that
patients will be switched routinely to the alternative treatment in the trial.
Confidentiality and patient rights
If you agree to take part in the trial you will need to sign and date the Informed Consent Form attached.
Your medical notes will need to be seen by authorised members of our research team so they can collect
information needed for this research trial and also to check that it is correct. Your unique registration
number will be used to make sure you cannot be identified outside the trial. All information collected
about you during the course of the research will be treated as strictly confidential. The confidentiality of
your medical records will be respected at all times.
We will continue to contact your hospital in the future to find out how you are getting on. Ideally, we
would like to do this for life, but patients often change address or can lose touch with their hospital. If this
happens we would still like to be able to collect important basic details (e.g. full name, date of birth,
hospital number and NHS number). The Office for National Statistics (ONS) keeps records that can easily
provide the information we need, so we would like your permission to ask ONS to pass on this information
to us. Any information received in this way remains confidential and is used only for the purposes of that
particular trial. Please initial the consent form to indicate you are happy for us to do this. The information
that will be collected from ONS will relate only to the status of your disease and current health. The ONS
system will not be used to collect information such as your home address.
With your consent your GP will be informed that you wish to take part in a clinical trial. Your GP may be
asked to provide information from your records, which are required for the trial.
Anonymised data from the trial may be provided to third parties (e.g. pharmaceutical companies or other
academic institutions) for research, safety monitoring or licensing purposes.
Your legal rights will not be affected by agreeing to take part in or withdrawing from the trial. You are
free to withdraw from the trial at any time without giving a reason. If you decide to withdraw from the
trial, this will not affect the standard of your routine care in any way. Your Oncologist will continue to
treat you with the same level of care.
The trial has been reviewed and approved by the South West Multicentre Research Ethics Committee,
one of 13 national Research Ethics Committees.
You will be informed of any significant new findings that occur during the trial as this may change your
decision to continue.
What if something goes wrong?
You will be closely monitored both during and after therapy and any side effects will be treated
as appropriate.
If you are harmed by taking part in this research project, there are no special compensation arrangements.
If you are harmed due to someone’s negligence, then you may have grounds for legal action but you may
have to pay for legal advice. Regardless of this, if you wish to complain about any aspect of the way you
have been approached or treated during the course of this trial, the normal National Health Service
complaints mechanisms are available to you.
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Results of the trial
At the end of the trial the information collected will be analysed and published in recognised medical
journals. Your Oncologist will be informed of any publications and will be able to supply a copy of these
publications to you on request. The identity of the patients who took part in the trial will remain
confidential. Your Oncologist and trial nurse will also be informed of any results throughout the duration
of the trial.
Organisation and funding of the trial
The research trial is being carried out by the Cancer Research UK, School of Cancer Sciences at The
University of Birmingham. The research is funded by grants from the Health Technology Assessment (HTA)
programme (a governmental funding body which funds clinical research), and pharmaceutical companies
Sanofi-aventis and Novartis Pharmaceuticals UK Ltd. During your involvement in this trial no travel costs
incurred by you or you family will be paid. Your Oncologist or any other members of staff that are involved
in your treatment and care have not been paid for entering you into this clinical trial or receive payment
for conducting the trial.
Time to consider
You should take at least 24 hours to decide if you wish to take part.
Who should you contact with questions?
You will be given a copy of this information sheet and the signed consent form to keep. If you have any
problems or questions about this trial or your rights as a patient in clinical research you should contact:
Oncologist . . . . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. .. Tel No . . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .
Trial Nurse . . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . . .. Tel No . . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .
24 hour contact number: . . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .
The 24 hour contact number can be used out of working hours (9am – 5pm) in the event where you need
you contact a hospital doctor immediately.
We would like to thank you for reading the Patient Information Sheet and for considering taking part in
this Clinical Trial. If you have any further questions please talk to the trial doctor before considering entry
into this clinical trial.
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TRAPEZE 
Research Trial of Treatments for Patients with Bony Metastatic Cancer 
of the Prostate 
 
Patient Consent Form 
 
I have been given a copy of the Patient Information Sheet (version 4, 12-Apr-2011) for this study.   I 
have read and understood it and I have had the opportunity to ask questions and discuss the study. 
   Please initial 
 
If I want to ask any further questions I understand that I may contact the Study Doctor or his/her 
colleagues or staff. 
 
 
I understand that I must tell the Study Doctor (or his/her nominee) if I notice any unusual or unexpected 
effects or if my health changes. 
 
 
I give permission for my GP to be informed of my participation and sent details of the study. 
 
 
I give permission for my name and a copy of this consent form, to be given to the study office when I am 
registered into the study. 
 
 
I understand that my medical records may need to be reviewed by responsible individuals from the trials 
office, or from regulatory authorities where it is relevant to my taking part in research.   I give permission 
for these individuals to have access to my records. However, I understand that I will not be identified by 
name in any reports or publications resulting from this study. 
 
 
I also understand that data collected about me for this study will be held under the provisions of the 1998 
Data Protection Act and will be stored in manual and electronic files in a secure encoded format 
 
 
I understand that I may withdraw from the Study at any time, without giving a reason and without 
affecting any medical treatment I will receive. 
 
 
I give permission for ONS (Office of National Statistics) to pass information on from my records for the 
TRAPEZE trial.  
 
 
I voluntarily agree to participate in the TRAPEZE study      
  
 
 
I give permission for samples of tissue previously taken (Tissue blocks) and tissue left over from 
Surgery and routine investigations to be used for related laboratory research that may be 
conducted in the future. (If the answer to this question is ‘NO’, you may still take part in this study) 
 
 
YES       NO 
I give permission for extra blood samples to be taken and used for additional related 
laboratory studies.  I understand that I am free to withdraw my approval for use of these 
samples at any time without giving a reason and without my medical care and legal rights 
being affected.  (If the answer to this question is ‘NO’, you may still take part in this study)  
 
 
YES       NO 
I have been given a copy of the quality of life Patient Booklet and I agree to take part 
in the quality of life study.  (If the answer to this question is ‘NO’, you may still take part in this study) 
 
YES       NO 
 
                                                     ____________________        ________________  
Name of Patient  Signature   Date  
I certify that I have explained to the above patient the nature and purpose, the potential benefits, and possible risks 
associated with participation in this research study. I have answered all questions that have been raised. 
                                                     ____________________        ________________  
Name of Investigator  Signature   Date  
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A randomised phase II/III trial of Docetaxel plus Prednisolone
vs. Docetaxel plus Prednisolone plus Zoledronic Acid vs.
Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel
plus Prednisolone vs. Docetaxel plus Prednisolone plus
Zoledronic Acid plus Strontium-89 in Hormone-refractory
Prostate Cancer Metastatic to bone
The TRAPEZE Trial
GP Information Sheet
Your patient has been entered into the TRAPEZE trial for the treatment of their hormone-refractory
prostate cancer, which is now metastatic to bone. This is a Phase II/III randomised controlled trial that aims
to recruit 618 evaluable patients over 6 years from approximately up to 50 hospitals throughout the UK.
The trial will close to recruitment at the end of February 2012. The trial is being coordinated by the CR UK
Clinical Trials Unit (CRCTU) at the University of Birmingham. This sheet provides information on the
rationale behind the trial and what it will involve for your patient.
Aim of the trial
The treatment of hormone-refractory disease is problematical. There is evidence that cytotoxic
chemotherapy can help control symptoms and improve survival. As the disease commonly affects the
bones (in around 80% of men) agents targeting bone disease are frequently used. Zoledronic acid has
been shown to delay worsening of bone disease and help control pain. There is also laboratory evidence
suggesting it may kill prostate cancer cells when combined with chemotherapy.
We therefore wish to examine whether the addition of zoledronic acid to chemotherapy will improve
outcomes, including survival, in patients with hormone-refractory disease affecting bone.
Strontium-89 is a radioactive drug which is actively taken up from the blood by bone deposits of the
cancer, resulting in targeted radiotherapy. It has also been shown to slow down bone disease and improve
pain control. A previous small trial has suggested that there may be benefits from combining Strontium-89
with chemotherapy and we wish to verify or refute this in a larger trial with modern chemotherapy.
Treatment allocation
The details of the trial have been discussed with your patient by their clinician and trial nurse and written
informed consent has been obtained. It has been made clear to the patient that they are free to withdraw
from the trial at any time without needing to justify their decision and without affecting their future care.
Patients are randomised via computer randomisation at the CRCTU Birmingham, into one of the four
possible treatment arms below:
(a) Docetaxel 75mg/m2 as a one hour intravenous infusion every 3 weeks for a maximum of 10 cycles.
(b) Docetaxel as above with Zoledronic acid every 3 weeks.
(c) Docetaxel as above and Strontium-89 given 28 days after the Cycle 6 docetaxel, as a short intravenous
injection. Docetaxel may be continued for up to 10 cycles at his clinician’s discretion, restarting at least
one month after the Strontium-89 injection.
(d) Docetaxel plus Zoledronic acid and Strontium-89, administered as above. Docetaxel may be continued
up to 10 cycles, as above.
Patients are allocated a trial number and been informed as to which of the above treatment arms they
have been randomised to.
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Possible side effects
Your patient is likely to experience some side-effects associated with the allocated treatment. The more
common side-effects are listed below, but there may also be others that we cannot predict.
Docetaxel:
l Nausea and/or vomiting
l Myelosuppression – Neutropenia, Thrombocytopenia.
l Allergy (Anaphylactic and Hypersensitivity reactions)
l Diarrhoea
l Stomatitis
l Peripheral neuropathy
l Skin toxicity
l Alopecia
l Liver toxicity
l Fluid retention
l Hyperlacrimation
l Fatigue
Zoledronic acid treatment arms (b+ d): The patient may experience the same effects as stated for
Docetaxel above plus a rise in temperature, and flu-like symptoms, consisting of fever and bone pain due
to the zoledronic acid. Long-term use (i.e. > 24 months) of zoledronic acid use has been linked to
osteonecrosis of the jaw. This is particularly of concern in patients who have dental disease. Zoledronic
acid should be discontinued if a patient requires dental extraction.
Strontium-89 treatment arms (c+ d): The addition of strontium-89 to docetaxel may cause some bone
pain lasting 36 to 72 hours following injection. This will be controlled by analgesics. Strontium-89 may also
affect marrow reserve. Blood counts will be monitored very closely and strontium-89 will be omitted if
there is inadequate marrow reserve.
Your patient has been given a 24 hour contact number to call in the event of suspected neutropenic
sepsis, or any other clinical problems arising while on the trial.
The trial will be monitored by an independent data and safety monitoring committee. The committee will
advise on whether the trial should be continued in respect to patient safety and results arising from the
trial and any other relevant studies.
Quality of life
As part of the TRAPEZE trial, we are also keen to investigate how treatments might affect patients’ quality
of life and general well-being. If your patient has agreed to enter this part of the trial they will be asked to
complete two questionnaires about their quality of life and general health at each trial visit.
Additional pathology studies
The CRCTU is also interested in biological predictive markers of treatment benefit or toxicity. For this
purpose, we have also requested permission from your patient to access a tissue sample from their
surgery/biopsy of their prostate, done as part of routine clinical practice. We have also sought consent
from your patient for the collection and storage of blood samples taken at intervals during the trial for
future proteomic analysis of both known and novel protein markers, using the expertise within the School
of Cancer Sciences at the University of Birmingham and other collaborative centres.
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Patient confidentiality
All information about your patient will be treated in the strictest of confidence and nothing that may
identify them will be revealed to any third parties. Access to your patient’s medical records may be
required by authorised members of our research team, to enable them to retrieve or validate information
needed for the trial. Unless your patient has given permission for their name to be collected, all research
data held centrally at CRCTU about them will be anonymised and identified only by a unique trial number,
initials and data of birth.
Contacts
If you have any further questions regarding your patient’s participation in the TRAPEZE trial please do
not hesitate to contact your patient’s treating clinician, trial nurse or the TRAPEZE trial office on the
numbers below.
Your patient’s clinician is:
Contact number:
24 hour Hospital switchboard number:
TRAPEZE Trial Office: XXXXX (Mon-Fri 08.00 – 16.00 hrs)
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Appendix 5 Results tables and figures
TABLE 78 Patients who have withdrawn full consent
Centre Date of Randomisation TNO Randomised treatment
Queen Elizabeth Hospital 6 January 2006 51 Docetaxel ZA Sr-89
Queen Elizabeth Hospital 27 January 2006 60 Docetaxel Sr-89
Queen Elizabeth Hospital 7 March 2006 70 Docetaxel
Queen Elizabeth Hospital 25 August 2006 115 Docetaxel ZA
Western Infirmary 18 December 2006 140 Docetaxel Sr-89
Western General Hospital 16 August 2007 194 Docetaxel Sr-89
Western General Hospital 6 February 2008 241 Docetaxel Sr-89
Queen Elizabeth Hospital 29 September 2008 289 Docetaxel ZA
Western General Hospital 5 August 2009 389 Docetaxel ZA
Royal Free Hospital 9 November 2009 422 Docetaxel ZA
Queen Elizabeth Hospital 11 June 2010 477 Docetaxel ZA
Queen Elizabeth Hospital 7 July 2010 485 Docetaxel ZA
Huddersfield Royal Infirmary 15 July 2010 488 Docetaxel ZA Sr-89
Western General Hospital 5 October 2010 523 Docetaxel
Weston General Hospital 5 November 2010 545 Docetaxel
Royal Derby Hospital 8 November 2010 546 Docetaxel
Royal Derby Hospital 11 November 2010 551 Docetaxel ZA
Aberdeen Royal Infirmary 19 November 2010 557 Docetaxel ZA Sr-89
Western General Hospital 30 November 2010 561 Docetaxel ZA
Queen Elizabeth Hospital 21 January 2011 579 Docetaxel ZA
Huddersfield Royal Infirmary 5 April 2011 609 Docetaxel
Christie Hospital 5 April 2011 610 Docetaxel ZA
Royal Preston Hospital 11 May 2011 623 Docetaxel Sr-89
Western General Hospital 31 August 2011 679 Docetaxel
St Mary's Hospital 4 January 2012 725 Docetaxel ZA
Huddersfield Royal Infirmary 23 January 2012 740 Docetaxel Sr-89
Bradford Royal Infirmary 2 February 2012 743 Docetaxel ZA
Royal Preston Hospital 13 February 2012 748 Docetaxel ZA
TNO, trial number.
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TABLE 79 Recruitment by centre
Randomisation centre
Docetaxel,
n (N= 191)
Docetaxel+ ZA,
n (N= 188)
Docetaxel+ Sr-89,
n (N= 190)
Docetaxel+ ZA+
Sr-89, n (N= 188)
Overall,
n (N= 757)
Aberdeen Royal Infirmary 5 5 5 6 21
Ayr Hospital 5 6 5 5 21
Bradford Royal Infirmary 3 4 4 2 13
Cheltenham General
Hospital
4 4 4 4 16
Christie Hospital 30 31 30 31 122
Dorset County Hospital 2 1 1 1 5
Forth Valley Royal Hospital 2 1 2 1 6
Gloucester Royal Hospital 0 0 1 0 1
Huddersfield Royal Infirmary 2 2 3 2 9
Ipswich Hospital 5 4 4 4 17
Maidstone Hospital 7 7 7 8 29
Poole Hospital 0 0 0 1 1
Queen Elizabeth Hospital 32 31 32 31 126
Royal Albert Edward
Infirmary
2 1 2 2 7
Royal Bournemouth Hospital 2 1 1 1 5
Royal Derby Hospital 6 6 7 7 26
Royal Free Hospital 3 4 2 3 12
Royal Marsden Hospital
London
1 0 0 0 1
Royal Marsden Hospital
Sutton
7 8 7 8 30
Royal Preston Hospital 9 9 8 8 34
Southampton General
Hospital
4 3 4 3 14
St James’s University Hospital 7 7 7 6 27
Queen Alexandra Hospital 4 5 4 4 17
Velindre Hospital 1 2 2 2 7
Western General Hospital 28 27 28 28 111
Beatson West of Scotland
Cancer Centre
15 15 15 16 61
Weston General Hospital 3 3 4 3 13
Wishaw General Hospital 2 1 1 1 5
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TABLE 80 Ineligible patients
Centre
Date of
randomisation TNO
Randomised
treatment Reason for ineligibility
Queen Elizabeth Hospital 18 May 2005 2 Docetaxel+ ZA+ Sr-89 No proof of progression on
study entry. Patient was referred
from an external hospital and
not all results were here. Please
see principal investigator for
further information
Western General Hospital 10 November 2005 41 Docetaxel+ Sr-89 Baseline BP not recorded
Christie Hospital 4 January 2006 49 Docetaxel+ Sr-89 4 January 2006 – PSA
progression not demonstrated
Western General Hospital 1 February 2006 62 Docetaxel Computed tomography and
bone scan done after
randomisation
Western General Hospital 10 October 2006 129 Docetaxel+ ZA Baseline bloods not within
28 days of randomisation
Beatson West of Scotland
Cancer Centre
23 November 2006 136 Docetaxel Haemoglobin and AST were not
within the levels specified for
entry – waiver not requested
Queen Elizabeth Hospital 25 January 2007 147 Docetaxel+ Sr-89 Patient GP/urologists stopped
Zoladex® (AstraZeneca) prior
study entry. We were not
informed
Western General Hospital 22 February 2008 245 Docetaxel+ ZA Bicalutamide not stopped before
25 January 2008 and no baseline
bloods prior to randomisation
Royal Marsden Hospital
Sutton
19 December 2008 313 Docetaxel+ ZA+ Sr-89 Inadequate haematological
function (Hb< 10 g/dl)
Beatson West of Scotland
Cancer Centre
26 February 2009 334 Docetaxel+ ZA+ Sr-89 On-study bloods more than
14 days before cycle 1
Wishaw General Hospital 3 April 2009 343 Docetaxel+ ZA Stop date of bicalutamide not
known
Royal Marsden Hospital
Sutton
17 April 2009 345 Docetaxel+ Sr-89 Bicalutamide not stopped 4 weeks
before treatment start as clinician
wanted patient to start
chemotherapy earlier as high risk
of developing cord compression
St James’s University
Hospital
21 April 2009 346 Docetaxel+ Sr-89 On-study bloods not within
28-day time frame
Dorset County Hospital 15 July 2009 381 Docetaxel Patient did not discontinue
bicalutamide until 7 July 2009 –
discussed/agreed by Darren
Barton, TC
Western General Hospital 5aug2009 389 Docetaxel+ ZA Haematology not within 28 days
Christie Hospital 20 August 2009 394 Docetaxel+ ZA Patients PSA was only 4.4 on
randomisation and there is no
evidence of new bone mets.
His PSA on his first treatment
cycle was 6.5
Maidstone Hospital 12 January 2010 438 Docetaxel+ ZA BP not done at baseline
Western General Hospital 7 July 2010 486 Docetaxel+ Sr-89 Baseline BP not recorded in error
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TABLE 80 Ineligible patients (continued )
Centre
Date of
randomisation TNO
Randomised
treatment Reason for ineligibility
Bradford Royal Infirmary 13 October 2010 531 Docetaxel+ ZA Prior estramustine therapy –
randomised 5 days short of
4 weeks
St James’s University
Hospital
9 November 2010 547 Docetaxel+ ZA No chest scans at baseline
Huddersfield Royal
Infirmary
17 November 2010 556 Docetaxel+ Sr-89 Patient randomised too early in
error so bicalutamide date is
before 4 weeks; treatment did
not commence until after
4 weeks
Huddersfield Royal
Infirmary
29 November 2010 559 Docetaxel BP not done at baseline
Queen Alexandra Hospital 21 December 2010 569 Docetaxel Not 4 weeks between stopping
bicalutamide – was 4 weeks
before starting treatment
Dorset County Hospital 16 February 2011 589 Docetaxel+ ZA Baseline bloods taken 17 January
2011, randomised 16 February
2011, outside 28-day time-period
Royal Derby Hospital 4 April 2011 607 Docetaxel+ ZA Bicalutamide stop date not
4 weeks
Royal Marsden Hospital
Sutton
23 June 2011 643 Docetaxel+ ZA+ Sr-89 Patient had dental extractions
before first cycle meaning they
were unfit to receive ZA until
cycle 4
Christie Hospital 15 February 2012 749 Docetaxel+ ZA+ Sr-89 Still taking a bisphosphonate
AST, aspartate aminotransferase; BP, blood pressure; GP, general practitioner; TC, trial co-ordinator; TNO, trial number.
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TABLE 81 Sequence of treatment forms returned by randomisation arms
Sequence
Docetaxel
(N= 191)
Docetaxel+ ZA
(N= 188)
Docetaxel+
Sr-89 (N= 190)
Docetaxel+ ZA+
Sr-89 (N= 188)
Overall
(N= 757)
n % n % n % n % n %
0 5 2.6 8 4.3 9 4.7 6 3.2 28 3.7
1 7 3.7 13 6.9 6 3.2 11 5.9 37 4.9
1–2 9 4.7 4 2.1 9 4.7 5 2.7 27 3.6
1–2–3 12 6.3 7 3.7 14 7.4 9 4.8 42 5.5
1–2–3–4 10 5.2 8 4.3 8 4.2 9 4.8 35 4.6
1–2–3–4–5 20 10.5 14 7.4 14 7.4 9 4.8 57 7.5
1–2–3–4–5–6 83 43.5 77 41 81 42.6 88 46.8 329 43.5
1–2–3–4–5–6–7 7 3.7 4 2.1 5 2.6 7 3.7 23 3
1–2–3–4–5–6–7–8 4 2.1 10 5.3 4 2.1 5 2.7 23 3
1–2–3–4–5–6–7–8–9 8 4.2 8 4.3 5 2.6 4 2.1 25 3.3
1–2–3–4–5–6–7–8–9–10 26 13.6 33 17.6 35 18.4 33 17.6 127 16.8
1–2–3–4–5–7–8 0 0 0 0 0 0 1 0.5 1 0.1
1–2–3–4–5–7–8–10 0 0 0 0 0 0 1 0.5 1 0.1
1–2–3–4–5–7–8–9 0 0 1 0.5 0 0 0 0 1 0.1
1–2–3–4–5–7–8–9–10 0 0 1 0.5 0 0 0 0 1 0.1
Total 191 100.0 188 100.0 190 100.0 188 100.0 757 100.0
TABLE 82 Sequence of treatment by comparisons
Sequence
No ZA (N= 381) ZA (N= 376) No Sr-89 (N= 379) Sr-89 (N= 378)
n % n % n % n %
0 14 3.7 14 3.7 13 3.4 15 4
1 13 3.4 24 6.4 20 5.3 17 4.5
1–2 18 4.7 9 2.4 13 3.4 14 3.7
1–2–3 26 6.8 16 4.3 19 5 23 6.1
1–2–3–4 18 4.7 17 4.5 18 4.7 17 4.5
1–2–3–4–5 34 8.9 23 6.1 34 9 23 6.1
1–2–3–4–5–6 164 43 165 43.9 160 42.2 169 44.7
1–2–3–4–5–6–7 12 3.1 11 2.9 11 2.9 12 3.2
1–2–3–4–5–6–7–8 8 2.1 15 4 14 3.7 9 2.4
1–2–3–4–5–6–7–8–9 13 3.4 12 3.2 16 4.2 9 2.4
1–2–3–4–5–6–7–8–9–10 61 16 66 17.6 59 15.6 68 18
1–2–3–4–5–7–8 0 0 1 0.3 0 0 1 0.3
1–2–3–4–5–7–8–10 0 0 1 0.3 0 0 1 0.3
1–2–3–4–5–7–8–9 0 0 1 0.3 1 0.3 0 0
1–2–3–4–5–7–8–9–10 0 0 1 0.3 1 0.3 0 0
Total 381 100 376 100 379 100 378 100
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Second SRE
Median time from SRE 1
2.0 months 
(IQR 0.3–5.6 months)
None, n = 56 (40%)
Surgery, n = 2 (1%)
Primary SRE
Median time
from 
randomisation
8.0 months
(IQR 5.7–12.0 months)
Radiation,
n = 141
60%
Third SRE
Median time from SRE 2
2.3 months 
(IQR 0.8–5.2 months)
Fourth SRE
Median time from SRE 3
3.0 months 
(IQR 1.6–6.0 months)
Fracture, n = 4 (3%)
SCC, n = 6 (4%)
Radiation, n = 1 (100%)
Fracture, n = 1 (100%)
Radiation, n = 2 (100%)
Radiation, n = 4 (67%)
None, n = 2 (33%)
SCC, n = 1 (8%)
None, n = 6 (50%)
Radiation, n = 12 (43%)
Radiation, n = 5 (42%)
None, n = 11 (39%)
Change, n = 3 (11%)
Change, n = 28 (20%)
SCC, n = 2 (7%)
Radiation, n = 2 (67%)
None, n = 1 (33%)
None, n = 15 (50%)
Radiation, n = 12 (40%)
Fracture, n = 1 (3%)
Radiation, n = 30 (67%)
Change, n = 2 (7%)
None, n = 12 (27%)
Change, n = 2 (4%)
Radiation, n = 45 (32%)
Surgery, n = 1 (2%)
Change, n = 1 (50%)
Radiation, n = 1 (50%)
None, n = 1 (25%)
Radiation, n = 1 (25%)
SCC, n = 1 (25%)
Change, n = 1 (25%)
Surgery, n = 1 (25%)
None, n = 2 (50%)
Radiation, n = 1 (25%)
FIGURE 55 Depiction of time between SREs when first event was radiation: no ZA. Dark blue, surgery; mid-blue,
change; dark green, radiation; mid-green, fracture; light green, SCC; white, none.
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Second SRE
Median time from SRE 1
2.3 months 
(IQR 1.0–6.2 months)
None, n = 79 (54%)
Change, n = 1 (3%)
Radiation, n = 39 (26%)
Primary SRE
Median time
from 
randomisation
9.4 months
(IQR 6.8–12.2 months)
Radiation,
n = 148
73%
Third SRE
Median time from SRE 2
2.3 months 
(IQR 0.9–6.6 months)
Fourth SRE
Median time from SRE 3
1.7 months 
(IQR 0.7–3.0 months)
Fracture, n = 3 (2%)
SCC, n = 6 (4%)
Radiation, n = 2 (100%)
Radiation, n = 1 (100%)
SCC, n = 2 (5%)
Change, n = 1 (100%)Change, n = 1 (5%)
None, n = 20 (51%)
Radiation, n = 3 (50%)
None, n = 3 (50%)
Radiation, n = 9 (56%)
SCC, n = 2 (13%)
None, n = 5 (31%)
Radiation, n = 16 (41%)
Change, n = 1 (33%)
SCC, n = 1 (33%)
None, n = 1 (33%)
Change, n = 21 (14%)
Fracture, n = 1 (5%)
None, n = 8 (38%)
Radiation, n = 2 (18%)
Change, n = 2 (18%)
SCC, n = 1 (9%)
None, n = 6 (55%)
Radiation, n = 11 (52%)
Radiation, n = 2 (67%)
None, n = 1 (33%)
FIGURE 56 Depiction of time between SREs when first event was radiation: ZA. Mid-blue, change; dark green,
radiation; mid-green, fracture; light green, SCC; white, none.
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Second SRE
Median time from SRE 1
0.3 months
 (IQR 0.1–0.9 months)
None, n = 3 (19%)
Change, n = 2 (50%)
None, n = 2 (50%)
Surgery, n = 5 (31%)
Radiation, n = 4 (25%)
Primary SRE
Median time
from 
randomisation
4.5 months
(IQR 3.1–11.7 months)
Fracture,
n = 16
(7%)
Third SRE
Median time from SRE 2
1.1 months 
(IQR 0.7–2.3 months)
Fourth SRE
Median time from SRE 3
1.5 months 
(IQR 0.6–3.3 months)
Radiation, n = 1 (100%)SCC, n = 1 (6%)
Surgery, n = 1 (33%)
Radiation, n = 2 (100%)
Change, n = 1 (33%)
None, n = 1 (33%)Fracture, n = 1 (20%)
Radiation, n = 3 (60%)
None, n = 1 (20%)
Radiation, n = 1 (100%)
Radiation, n = 1 (100%)Fracture, n = 1 (6%) Radiation, n = 1 (100%)
Change, n = 1 (50%)
SCC, n = 1 (50%)
Change, n = 2 (13%)
Fracture, n = 1 (100%)
Radiation, n = 1 (100%)
FIGURE 57 Depiction of time between SREs when first event was fracture: no ZA. Dark blue, surgery; mid-blue,
change; dark green, radiation; mid-green, fracture; light green, SCC; white, none.
Second SRE
Median time from SRE 1
0.0 months 
(IQR 0.0–0.2 months)
None, n = 10 (28%)
SCC, n = 1 (4%)
Change, n = 1 (100%)
None, n = 13 (54%)
Hypercalcaemia, n = 1 (4%)
Radiation, n = 9 (38%)
Radiation, n = 1 (100%)
None, n = 6 (67%)
SCC, n = 2 (22%)
Radiation, n = 1 (11%)
Surgery, n = 2 (5%)
Radiation, n = 24 (67%)
Primary SRE
Median time
from 
randomisation
5.3 months
(IQR 3.7–9.4 months)
SCC,
n = 36
(15%)
Third SRE
Median time from SRE 2
2.6 months 
(IQR 1.5–4.9 months)
Fourth SRE
Median time from SRE 3
0.7 months 
(IQR 0.3–2.1 months)
Radiation, n = 1 (100%)
Radiation, n = 1 (50%)
None, n = 1 (50%)
FIGURE 58 Depiction of time between SREs when first event was SCC: no ZA. Dark blue, surgery; mid-blue, change;
light blue, hypercalcaemia; dark green, radiation; light green, SCC; white, none.
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Second SRE
Median time from SRE 1
0.5 months 
(IQR 0.1–2.9 months)
None, n = 1 (14%)
Radiation, n = 1 (100%)
Radiation, n = 2 (67%)
Radiation, n = 1 (50%)
None, n = 1 (33%)
None, n = 1 (50%)
Surgery, n = 1 (50%)
None, n = 1 (50%)
Fracture, n = 1 (14%)
Surgery, n = 3 (43%)
Change, n = 2 (29%)
Primary SRE
Median time
from 
randomisation
2.9 months
(IQR 0.5–4.1 months)
Fracture,
n = 7
(4%)
Third SRE
Median time from SRE 2
6.1 months 
(IQR 2.7–11.3 months)
Fourth SRE
Median time from SRE 3
0.5 months 
(IQR 0.5–0.5 months)
FIGURE 59 Depiction of time between SREs when first event was fracture: ZA. Dark blue, surgery; mid-blue,
change; dark green, radiation; mid-green, fracture; white, none.
Second SRE
Median time from SRE 1
0.1 months 
(IQR 0.0–0.7 months)
None, n = 4 (23%)
Radiation, n = 5 (50%)
Change, n = 2 (20%)
None, n = 3 (30%)
Radiation, n = 10 (59%)
Primary SRE
Median time
from 
randomisation
11.0 months
(IQR 3.4–15.0 months)
SCC,
n = 17
(8%)
Third SRE
Median time from SRE 2
0.4 months 
(IQR 0.1–3.9 months)
Fourth SRE
Median time from SRE 3
4.9 months 
(IQR  0.9–8.9 months)
Radiation, n = 1 (100%)SCC, n = 1 (6%)
Radiation, n = 1 (100%)Change, n = 1 (6%)
Radiation, n = 1 (100%)Surgery, n = 1 (6%)
Radiation, n = 1 (20%)
Change, n = 1 (20%)
None, n = 3 (60%)
FIGURE 60 Depiction of time between SREs when first event was SCC: ZA. Dark blue, surgery; mid-blue, change;
dark green, radiation; light green, SCC; white, none.
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Second SRE
Median time from SRE 1
2.8 months 
(IQR 1.1–7.6 months)
None, n = 10 (26%)
Change, n = 1 (6%)
Radiation, n = 17 (43%)
Primary SRE
Median time
from 
randomisation
8.4 months
(IQR 5.8–13.0 months)
Change,
n = 39
(17%)
Third SRE
Median time from SRE 2
1.9 months 
(IQR 1.1–5.8 months)
Fourth SRE
Median time from SRE 3
2.1 months 
(IQR 0.3–5.7 months)
Surgery, n = 1 (100%)Fracture, n = 1 (3%)
SCC, n = 4 (10%)
Radiation, n = 1 (100%)
Surgery, n = 1 (6%)
Radiation, n = 6 (35%)
Radiation, n = 3 (100%)SCC, n = 1 (6%)
None, n = 8 (47%) Radiation, n = 1 (33%)
SCC, n = 1 (33%)
None, n = 1 (33%)
Radiation, n = 3 (50%)
None, n = 3 (50%)
Radiation, n = 3 (75%)
None, n = 1 (25%)
Change, n = 7 (18%)
Change, n = 1 (14%) Change, n = 1 (100%)
SCC, n = 1 (14%)
Radiation, n = 2 (29%)
Surgery, n = 1 (100%)
Surgery, n = 1 (100%)
Fracture, n = 1 (14%)
None, n = 2 (29%)
Radiation, n = 1 (50%)
None, n = 1 (50%)
FIGURE 61 Depiction of time between SREs when first event was change in therapy: no ZA. Dark blue, surgery;
mid-blue, change; dark green, radiation; mid-green, fracture; light green, SCC; white, none.
Primary SRE
Median time from 
randomisation
6.7 months
Second SRE
Median time from SRE 1
7.2 months
Third SRE
Median time from SRE 2
4.7 months
Surgery, n = 1
(0.5%)
Radiation, n = 1 (100%) Radiation, n = 1 (100%)
FIGURE 62 Depiction of time between SREs when first event was surgery: no ZA. Dark blue, surgery; dark
green, radiation.
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Hypercalcaemia, n = 1
(0.5%)
Primary SRE
Median time from randomisation
5.9 months
FIGURE 63 Depiction of time between SREs when first event was hypercalcaemia: no ZA. Light
blue, hypercalcaemia.
Second SRE
Median time from SRE 1
3.3 months 
(IQR 1.1–4.0 months)
None, n = 16 (52%)
SCC, n = 1 (8%)
None, n = 6 (50%)
Change, n = 1 (8%)
Radiation, n = 1 (%)
Radiation, n = 4 (34%)
Change, n = 1 (100%)
None, n = 2 (%)
Radiation, n = 12 (39%)
Change, n = 3 (9%)
Primary SRE
Median time
from 
randomisation
9.9 months
(IQR 6.8–12.8 months)
Change,
n = 31
(15%)
Third SRE
Median time from SRE 2
1.9 months 
(IQR 1.1–5.8 months)
Fourth SRE
Median time from SRE 3
1.4 months 
(IQR 0.6–10.6 months)
Radiation, n = 1 (100%)
None, n = 2 (50%)
Radiation, n = 1 (25%)
Change, n = 1 (25%)
FIGURE 64 Depiction of time between SREs when first event was change in therapy: ZA. Mid-blue, change;
dark green, radiation; light green, SCC; white, none.
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Second SRE
Median time from SRE 1
2.3 months 
(IQR 0.9–6.4 months)
None, n = 67 (45%)
Surgery, n = 1 (1%)
Primary SRE
Median time
from 
randomisation
8.4 months
(IQR 6.1–12.0 months)
Radiation,
n = 149
(67%)
Third SRE
Median time from SRE 2
2.3 months 
(IQR 0.9–7.6 months)
Fourth SRE
Median time from SRE 3
2.6 months 
(IQR 1.1–4.4 months)
Fracture, n = 2 (1%)
SCC, n = 6 (4%)
Radiation, n = 51 (34%)
Radiation, n = 1 (100%)
Radiation, n = 4 (66%)
None, n = 2 (33%)
Surgery, n = 1 (50%)
None, n = 1 (50%)
Radiation, n = 3 (75%)
None, n = 1 (25%)
Radiation, n = 4 (45%)
SCC, n = 2 (22%)
None, n = 2 (22%)
Radiation, n = 9 (41%)
Change, n = 1 (11%)
Radiation, n = 1 (100%)SCC, n = 1 (2%)
None, n = 18 (35%)
Change, n = 2 (9%)
Change, n = 22 (15%)
None, n = 11 (50%)
Change, n = 1 (50%)
None, n = 1 (50%)
Radiation, n = 12 (42%)
SCC, n = 1 (3%)
Fracture, n = 1 (3%)
None, n = 14 (49%)
Radiation, n = 29 (57%)
Change, n = 1 (3%)
Change, n = 2 (4%)
Surgery, n = 1 (2%)
Change, n = 1 (50%)
Radiation, n = 1 (50%)
FIGURE 65 Depiction of time between SREs when first event was radiation: no Sr-89. Dark blue, surgery; mid-blue,
change; dark green, radiation; mid-green, fracture; light green, SCC; white, none.
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Second SRE
Median time from SRE 1
2.1 months 
(IQR 0.8–5.5 months)
None, n = 68 (49%)
Change, n = 1 (3%)
Radiation, n = 34 (24%)
Surgery, n = 1 (1%)
Primary SRE
Median time
from 
randomisation
9.1 months
(IQR 6.4–12.3 months)
Radiation,
n = 140
(65%)
Third SRE
Median time from SRE 2
2.3 months 
(IQR 0.9–4.4 months)
Fourth SRE
Median time from SRE 3
2.5 months 
(IQR 0.8–7.2 months)
Fracture, n = 4 (3%)
SCC, n = 6 (4%)
Radiation, n = 1 (100%)
Radiation, n = 1 (100%)
Fracture, n = 1 (100%)
Surgery, n = 1 (3%)
SCC, n = 1 (3%)
None, n = 14 (41%)
Radiation, n = 3 (50%)
None, n = 3 (50%)
Radiation, n = 9 (53%)
SCC, n = 1 (6%)
None, n = 6 (35%)
Radiation, n = 17 (50%)
Change, n = 1 (6%)
Radiation, n = 1 (25%)
SCC, n = 1 (25%)
None, n = 1 (25%)
Change, n = 1 (25%)
Change, n = 2 (7%)
Change, n = 27 (19%)
Radiation, n = 2 (100%)
Radiation, n = 2 (100%)
SCC, n = 2 (7%)
Fracture, n = 1 (4%)
None, n = 8 (30%)
Change, n = 1 (8%)
Radiation, n = 3 (21%)
None, n = 10 (71%)
Radiation, n = 14 (52%)
Change, n = 1 (33%)
SCC, n = 1 (33%)
None, n = 1 (33%)
FIGURE 66 Depiction of time between SREs when first event was radiation: Sr-89. Dark blue, surgery; mid-blue,
change; dark green, radiation; mid-green, fracture; light green, SCC; white, none.
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Second SRE
Median time from SRE 1
0.5 months 
(IQR 0.0–1.9 months)
None, n = 3 (30%)
Radiation, n = 1 (100%)
Radiation, n = 1 (33%)
Change, n = 2 (66%)
None, n = 2 (66%)
Surgery, n = 1 (100%)
None, n = 1 (33%)
Fracture, n = 1 (10%)
Surgery, n = 3 (30%)
Radiation, n = 3 (30%)
Primary SRE
Median time
from 
randomisation
3.8 months
(IQR 2.5–8.7 months)
Fracture,
n = 10
(5%)
Third SRE
Median time from SRE 2
0.9 months 
(IQR 0.4–4.0 months)
Fourth SRE
Median time from SRE 3
0.9 months 
(IQR 0.5–11.0 months)
Radiation, n = 2 (100%)
FIGURE 67 Depiction of time between SREs when first event was fracture: no Sr-89. Dark blue, surgery; mid-blue,
change; dark green, radiation; mid-green, fracture; white, none.
Second SRE
Median time from SRE 1
0.0 months 
(IQR 0.0–0.1 months)
None, n = 5 (%)
Radiation, n = 1 (100%)
Radiation, n = 1 (50%)
Radiation, n = 9 (38%)
Change, n = 1 (1%)
None, n = 1 (50%)
None, n = 6 (%)
SCC, n = 1 (%)
Surgery, n = 2 (%)
Radiation, n = 24 (67%)
Primary SRE
Median time
from 
randomisation
5.0 months
(IQR 4.2–9.9 months)
SCC,
n = 23
(10%)
Third SRE
Median time from SRE 2
1.4 months 
(IQR 0.2–3.2 months)
Fourth SRE
Median time from SRE 3
2.1 months 
(IQR 0.8–13.4 months)
SCC, n = 2 (%)
Radiation, n = 1 (%)
None, n = 5 (%)
FIGURE 68 Depiction of time between SREs when first event was SCC: no Sr-89. Dark blue, surgery; mid-blue,
change; dark green, radiation; light green, SCC; white, none.
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Second SRE
Median time from SRE 1
0.3 months 
(IQR 0.1–1.9 months)
None, n = 1 (8%)
Radiation, n = 1 (100%)
Radiation, n = 4 (80%)
SCC, n = 1 (25%)
Radiation, n = 1 (25%)
Change, n = 1 (25%)
Radiation, n = 1 (100%)
Fracture, n = 1 (100%)
Fracture, n = 1 (20%)
None, n = 1 (25%)
Fracture, n = 1 (8%)
Surgery, n = 5 (38%)
Radiation, n = 1 (8%)
Change, n = 4 (30%)
Primary SRE
Median time
from 
randomisation
3.6 months
(IQR 2.9–9.7 months)
Fracture,
n = 13
(6%)
Third SRE
Median time from SRE 2
1.8 months 
(IQR 0.7–5.3 months)
Fourth SRE
Median time from SRE 3
1.5 months 
(IQR 0.3–3.1 months)
Surgery, n = 1 (25%)
Change, n = 1 (25%)
Radiation, n = 1 (100%)
Radiation, n = 1 (100%)SCC, n = 1 (8%) Radiation, n = 1 (100%)
None, n = 2 (50%)
FIGURE 69 Depiction of time between SREs when first event was fracture: Sr-89. Dark blue, surgery; mid-blue,
change; dark green, radiation; mid-green, fracture; light green, SCC; white, none.
Second SRE
Median time from SRE 1
0.0 months 
(IQR 0.0–0.1 months)
None, n = 9 (30%)
Radiation, n = 1 (100%)
SCC, n = 1 (5%)
Radiation, n = 1 (100%)
None, n = 10 (53%)
Change, n = 1 (5%)
Hypercalcaemia, n = 1 (5%)
Radiation, n = 6 (32%)
Surgery, n = 1 (3%)
Radiation, n = 19 (64%)
Change, n = 1 (3%)
Primary SRE
Median time
from 
randomisation
7.5 months
(IQR 3.3–11.8 months)
SCC,
n = 30
(14%)
Third SRE
Median time from SRE 2
3.0 months 
(IQR 0.5–6.4 months)
Fourth SRE
Median time from SRE 3
0.6 months 
(IQR 0.3–0.9 months)
Radiation, n = 1 (16%)
Radiation, n = 1 (100%)
Change, n = 1 (16%)
Change, n = 1 (100%)
None, n = 4 (67%)
Radiation, n = 1 (100%)
FIGURE 70 Depiction of time between SREs when first event was SCC: Sr-89. Dark blue, surgery; mid-blue, change;
light blue, hypercalcaemia; dark green, radiation; light green, SCC; white, none.
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Second SRE
Median time from SRE 1
2.7 months 
(IQR 1.1–5.8 months)
None, n = 15 (38%)
Surgery, n = 1 (100%)
SCC, n = 2 (13%)
None, n = 7 (44%)
Change, n = 1 (33%)
Radiation, n = 2 (66%)
Change, n = 1 (6%)
Radiation, n = 6 (37%)
Fracture, n = 1 (3%)
Radiation, n = 16 (41%)
Change, n = 3 (8%)
Primary SRE
Median time
from 
randomisation
8.6 months
(IQR 6.3–11.6 months)
Change,
n = 39
(18%)
Third SRE
Median time from SRE 2
2.0 months 
(IQR 1.0–5.1 months)
Fourth SRE
Median time from SRE 3
1.6 months 
(IQR 0.4–4.5 months)
Radiation, n = 2 (%)
Radiation, n = 1 (100%)
Change, n = 1 (25%)
None, n = 3 (%)
SCC, n = 1 (33%)
Radiation, n = 1 (33%)
None, n = 1 (33%)
Radiation, n = 2 (100%)
Radiation, n = 3 (75%)
None, n = 1 (25%)
SCC, n = 4 (10%)
Change, n = 1 (100%)
FIGURE 71 Depiction of time between SREs when first event was change in antineoplastic therapy: no Sr-89.
Dark blue, surgery; mid-blue, change; dark green, radiation; mid-green, fracture; light green, SCC; white, none.
Primary SRE
Median time from 
randomisation
6.7 months
Second SRE
Median time from SRE 1
7.2 months
Third SRE
Median time from SRE 2
4.7 months
Surgery, n = 1
(%)
Radiation, n = 1 (100%) Radiation, n = 1 (100%)
FIGURE 72 Depiction of time between SREs when first event was surgery: no Sr-89. Dark blue, surgery; dark
green, radiation.
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Hypercalcaemia, n = 1
(%)
Primary SRE
Median time from randomisation
5.9 months
Second SRE
None, n = 1 (100%)
FIGURE 73 Depiction of time between SREs when first event was hypercalcaemia: Sr-89. Light blue,
hypercalcaemia; white, none.
Second SRE
Median time from SRE 1
3.5 months 
(IQR 1.6–7.9 months)
None, n = 11 (%)
Fracture, n = 1 (14%)
SCC, n = 1 (14%)
Radiation, n = 1 (%)
Surgery, n = 1 (100%)
Surgery, n = 1 (100%)
Radiation, n = 1 (50%)
None, n = 4 (%)
Change, n = 3 (9%)
Primary SRE
Median time
from 
randomisation
9.5 months
(IQR 6.7–13.0 months)
Change,
n = 31
(14%)
Third SRE
Median time from SRE 2
3.0 months 
(IQR 1.8–5.8 months)
Fourth SRE
Median time from SRE 3
3.8 months 
(IQR 0.3–5.7 months)
Surgery, n = 1 (%)
Radiation, n = 4 (%)
Change, n = 1 (8%)
None, n = 7 (%)
Radiation, n = 6 (%)
None, n = 2 (%)
Radiation, n = 2 (%)
Change, n = 1 (100%)
FIGURE 74 Depiction of time between SREs when first event was change in antineoplastic therapy: Sr-89.
Dark blue, surgery; mid-blue, change; dark green, radiation; mid-green, fracture; light green, SCC; white, none.
DOI: 10.3310/hta20530 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 53
© Queen’s Printer and Controller of HMSO 2016. This work was produced by James et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
283

Appendix 6 Resource use tables for
economic evaluation
TABLE 95 Number (percentage) of people who received a treatment and average use for ZA and no ZA
Treatment/service
ZA No ZA
n %
Mean no. of cycles/units
used n %
Mean no. of cycles/units
used
Trial treatments
Docetaxel+ prednisolone 342 98 6.31 349 98 6.11
ZA 342 98 6.13 0 0 0.00
Sr-89 125 36 1.00 120 34 1.00
ZA as follow-up treatment 192 55 5.11 1 0 3.00
Concomitant medications
Radiotherapy 177 51 1.65 204 57 1.95
Abiraterone 56 16 1.00 68 19 1.00
ZA as concomitant medication 73 21 3.77 63 18 1.94
Sr-89 as concomitant medication 15 4 1.00 21 6 1.00
Blood transfusion 31 9 2.10 22 6 2.50
Cabazitaxel 18 5 1.56 12 3 2.33
Docetaxel as concomitant
medication
34 10 2.94 38 11 3.13
Mitoxantrone 23 7 2.30 15 4 1.87
Surgery 18 5 1.20 5 1 1.17
Outpatient appointments and inpatient stay
Hospital outpatient appointment 296 85 5.79 293 82 5.25
Hospital inpatient stay 231 66 8.00 250 70 8.28
GP appointments 311 89 5.03 328 92 5.61
GP, general practitioner.
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TABLE 96 Number (percentage) of people who received a treatment and average use for Sr-89 and no Sr-89
Treatment/service
Sr-89 No Sr-89
n %
Mean no. of cycles/units
used n %
Mean no. of cycles/units
used
Trial treatments
Docetaxel+ prednisolone 345 99 6.23 346 97 6.19
ZA 172 49 6.14 170 48 6.12
Sr-89 245 70 1.00 0 0 0.00
ZA as follow-up treatment 90 26 5.10 103 29 5.10
Concomitant medications
Radiotherapy 184 53 1.67 197 55 1.94
Abiraterone 59 17 1.00 65 18 1.00
ZA as concomitant medication 61 17 2.85 75 21 2.97
Sr-89 as concomitant medication 16 5 1.13 20 6 1.00
Blood transfusion 26 7 2.31 27 8 2.22
Cabazitaxel 19 5 1.84 11 3 1.91
Docetaxel as concomitant
medication
36 10 3.11 36 10 2.97
Mitoxantrone 20 6 2.00 18 5 2.28
Surgery 13 4 1.23 10 3 1.10
Outpatient appointments and inpatient stay
Hospital outpatient appointment 227 65 5.27 254 71 5.78
Hospital inpatient stay 295 84 8.52 294 82 7.80
GP appointments 311 89 5.10 328 92 5.55
GP, general practitioner.
TABLE 97 Number of instances of radiotherapy
Number of instances of radiotherapy No ZA ZA Total
0 153 173 326
1 108 114 222
2 42 39 81
3 29 10 39
4 12 8 20
5 9 3 12
6 3 1 4
8 1 1 2
9 0 1 1
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TABLE 98 Total number of instances of radiotherapy
Number of instances of radiotherapy No ZA ZA
Total number of instances of radiotherapy 398 292
TABLE 99 Number of instances of radiotherapy
Number of instances of radiotherapy No Sr-89 Sr-89 Total
0 160 166 326
1 111 111 222
2 36 45 81
3 25 14 39
4 12 8 20
5 8 4 12
6 2 2 4
8 2 0 2
9 1 0 1
TABLE 100 Total number of instances of radiotherapy
Number of instances of radiotherapy No Sr-89 Sr-89
Total number of instances of radiotherapy 383 307
TABLE 101 Average number of instances of radiotherapy: no ZA
Average number of instances of radiotherapy No ZA ZA
For patients who had radiotherapy 1.95 1.65
For all patients in the group 1.11 0.83
TABLE 102 Average number of instances of radiotherapy: no Sr-89
Average number of instances of radiotherapy No Sr-89 Sr-89
For patients who had radiotherapy 1.94 1.67
For all patients in the group 1.07 0.88
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